0001558370-23-009262.txt : 20230511 0001558370-23-009262.hdr.sgml : 20230511 20230511073046 ACCESSION NUMBER: 0001558370-23-009262 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 95 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230511 DATE AS OF CHANGE: 20230511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Century Therapeutics, Inc. CENTRAL INDEX KEY: 0001850119 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 842040295 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-40498 FILM NUMBER: 23908836 BUSINESS ADDRESS: STREET 1: 3675 MARKET STREET CITY: PHILADELPHIA STATE: PA ZIP: 19104 BUSINESS PHONE: 215-981-4000 MAIL ADDRESS: STREET 1: 3675 MARKET STREET CITY: PHILADELPHIA STATE: PA ZIP: 19104 10-Q 1 ipsc-20230331x10q.htm 10-Q
0.530.665861037557051539http://www.centurytx.com/20230331#AccruedExpensesAndOtherLiabilitiesCurrent58610375570515390001850119false--12-312023Q10058473660591067840P12Y950000P5Yhttp://www.centurytx.com/20230331#AccruedExpensesAndOtherLiabilitiesCurrent0.530.66P4Y0001850119us-gaap:RetainedEarningsMember2023-03-310001850119us-gaap:AdditionalPaidInCapitalMember2023-03-310001850119us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001850119us-gaap:RetainedEarningsMember2022-12-310001850119us-gaap:AdditionalPaidInCapitalMember2022-12-310001850119us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001850119us-gaap:RetainedEarningsMember2022-03-310001850119us-gaap:AdditionalPaidInCapitalMember2022-03-310001850119us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001850119us-gaap:RetainedEarningsMember2021-12-310001850119us-gaap:AdditionalPaidInCapitalMember2021-12-310001850119us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001850119us-gaap:CommonStockMember2023-03-310001850119us-gaap:CommonStockMember2022-12-310001850119us-gaap:CommonStockMember2022-03-310001850119us-gaap:CommonStockMember2021-12-310001850119us-gaap:EmployeeStockOptionMember2022-12-310001850119us-gaap:EmployeeStockOptionMemberipsc:IncentivePlan2021Member2023-01-012023-03-310001850119us-gaap:EmployeeStockOptionMember2023-03-310001850119ipsc:EmployeeStockPurchasePlan2021Member2023-03-310001850119ipsc:IncentivePlan2021Member2022-12-310001850119ipsc:EmployeeStockPurchasePlan2021Member2022-12-310001850119us-gaap:EmployeeStockOptionMemberipsc:IncentivePlan2021Member2021-06-170001850119us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001850119ipsc:UnvestedRestrictedStockWithTimeBasedVestingMember2022-12-310001850119us-gaap:RestrictedStockUnitsRSUMemberipsc:IncentivePlan2021Member2023-01-012023-03-310001850119us-gaap:EmployeeSeveranceMember2023-03-310001850119us-gaap:ResearchAndDevelopmentExpenseMemberipsc:ConsultingArrangementsMemberipsc:ShareholdersOfEquityMethodInvestorMember2023-01-012023-03-310001850119us-gaap:ResearchAndDevelopmentExpenseMemberipsc:ConsultingArrangementsMemberipsc:ShareholdersOfEquityMethodInvestorMember2022-01-012022-03-310001850119ipsc:TermLoanAgreementWithHerculesCapitalIncMemberus-gaap:SubsequentEventMember2023-05-012023-05-010001850119us-gaap:SoftwareDevelopmentMember2023-03-310001850119us-gaap:LeaseholdImprovementsMember2023-03-310001850119us-gaap:FurnitureAndFixturesMember2023-03-310001850119us-gaap:ConstructionInProgressMember2023-03-310001850119ipsc:LabEquipmentMember2023-03-310001850119us-gaap:SoftwareDevelopmentMember2022-12-310001850119us-gaap:LeaseholdImprovementsMember2022-12-310001850119us-gaap:FurnitureAndFixturesMember2022-12-310001850119us-gaap:ConstructionInProgressMember2022-12-310001850119ipsc:LabEquipmentMember2022-12-310001850119us-gaap:EmployeeSeveranceMember2023-01-012023-03-310001850119us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001850119us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001850119ipsc:AccruedExpensesAndOtherLiabilitiesCurrentMemberipsc:DistributedBioMasterServiceAgreementMember2023-03-310001850119ipsc:AccruedExpensesAndOtherLiabilitiesCurrentMemberipsc:DistributedBioMasterServiceAgreementMember2022-12-310001850119us-gaap:RetainedEarningsMember2023-01-012023-03-310001850119us-gaap:RetainedEarningsMember2022-01-012022-03-310001850119srt:MinimumMember2023-03-310001850119srt:MaximumMember2023-03-310001850119ipsc:FcdiCollaborationAgreementMember2023-01-012023-03-310001850119ipsc:FcdiCollaborationAgreementMember2022-01-012022-03-310001850119ipsc:AccruedExpensesAndOtherLiabilitiesCurrentMember2023-03-310001850119ipsc:AccruedExpensesAndOtherLiabilitiesCurrentMember2022-12-310001850119us-gaap:ForeignCountryMemberus-gaap:CanadaRevenueAgencyMember2023-01-012023-03-310001850119us-gaap:InProcessResearchAndDevelopmentMemberipsc:EmpiricaAgreementMember2020-06-090001850119ipsc:TimeBasedVestingMember2023-03-310001850119ipsc:UnvestedRestrictedStockWithTimeBasedVestingMember2023-01-012023-03-310001850119ipsc:TimeBasedVestingMember2023-01-012023-03-310001850119us-gaap:RestrictedStockUnitsRSUMember2023-03-310001850119ipsc:FujifilmCellularDynamicsInc.Member2023-03-310001850119us-gaap:AccruedLiabilitiesMemberipsc:ConsultingArrangementsMemberipsc:ShareholdersOfEquityMethodInvestorMember2023-03-310001850119ipsc:FcdiCollaborationAgreementMember2023-03-310001850119us-gaap:AccruedLiabilitiesMemberipsc:ConsultingArrangementsMemberipsc:ShareholdersOfEquityMethodInvestorMember2022-12-310001850119ipsc:UnvestedRestrictedStockWithTimeBasedVestingMember2023-03-310001850119ipsc:Next2OfParticipatingEmployeeContributionsMember2023-01-012023-03-310001850119ipsc:First3OfParticipatingEmployeeContributionsMember2023-01-012023-03-310001850119ipsc:ResearchAndDevelopmentServicesMemberipsc:TransactionPriceMember2023-03-310001850119ipsc:OptionRightsMemberipsc:TransactionPriceMember2023-03-310001850119ipsc:TransactionPriceMember2023-03-310001850119ipsc:ResearchAndDevelopmentServicesMember2023-03-310001850119ipsc:OptionRightsMember2023-03-310001850119ipsc:ResearchAndDevelopmentServicesMemberipsc:TransactionPriceMember2022-12-310001850119ipsc:OptionRightsMemberipsc:TransactionPriceMember2022-12-310001850119ipsc:TransactionPriceMember2022-12-310001850119ipsc:ResearchAndDevelopmentServicesMember2022-12-310001850119ipsc:OptionRightsMember2022-12-310001850119ipsc:TermLoanAgreementWithHerculesCapitalIncMember2023-01-012023-03-310001850119srt:MinimumMemberipsc:TermLoanAgreementWithHerculesCapitalIncMemberus-gaap:PrimeRateMember2020-09-142020-09-140001850119ipsc:Tranche3AdvancesMember2023-03-310001850119ipsc:Tranche2AdvancesMember2023-03-310001850119ipsc:Tranche1AdvancesMember2020-09-140001850119ipsc:TermLoanAgreementWithHerculesCapitalIncMember2020-09-140001850119ipsc:ResearchAndDevelopmentServicesMemberipsc:CumulativeCollaborationRevenueRecognizedMember2023-01-012023-03-310001850119ipsc:CumulativeCollaborationRevenueRecognizedMember2023-01-012023-03-310001850119ipsc:ResearchAndDevelopmentServicesMemberipsc:CumulativeCollaborationRevenueRecognizedMember2022-01-012022-12-310001850119ipsc:CumulativeCollaborationRevenueRecognizedMember2022-01-012022-12-310001850119us-gaap:EmployeeStockMemberipsc:IncentivePlan2021Member2023-03-310001850119ipsc:IncentivePlan2021Member2023-03-3100018501192022-03-3100018501192021-12-310001850119us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2023-03-310001850119us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2023-03-310001850119us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2022-12-310001850119us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2022-12-310001850119us-gaap:USTreasurySecuritiesMember2023-03-310001850119us-gaap:USTreasurySecuritiesMember2022-12-310001850119us-gaap:CorporateBondSecuritiesMember2023-03-310001850119us-gaap:CorporateBondSecuritiesMember2022-12-310001850119us-gaap:FairValueInputsLevel2Member2023-03-310001850119us-gaap:FairValueInputsLevel1Member2023-03-310001850119us-gaap:FairValueInputsLevel2Member2022-12-310001850119us-gaap:FairValueInputsLevel1Member2022-12-310001850119us-gaap:InProcessResearchAndDevelopmentMemberipsc:EmpiricaAgreementMember2020-06-092020-06-090001850119us-gaap:WarrantMember2023-01-012023-03-310001850119us-gaap:StockOptionMember2023-01-012023-03-310001850119us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001850119us-gaap:RestrictedStockMember2023-01-012023-03-310001850119ipsc:EarlyExercisedStockOptionsSubjectToFutureVestingMember2023-01-012023-03-310001850119us-gaap:WarrantMember2022-01-012022-03-310001850119us-gaap:StockOptionMember2022-01-012022-03-310001850119us-gaap:RestrictedStockMember2022-01-012022-03-310001850119ipsc:EarlyExercisedStockOptionsSubjectToFutureVestingMember2022-01-012022-03-310001850119us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001850119us-gaap:RestrictedStockMember2023-01-012023-03-310001850119us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001850119us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-03-310001850119us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001850119us-gaap:EmployeeStockMember2023-01-012023-03-310001850119us-gaap:RestrictedStockMember2022-01-012022-03-310001850119us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310001850119us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-03-310001850119us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001850119ipsc:FcdiCollaborationAgreementMember2022-12-3100018501192023-01-012023-01-310001850119us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001850119us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001850119us-gaap:CommonStockMember2023-01-012023-03-310001850119us-gaap:CommonStockMember2022-01-012022-03-3100018501192022-01-012022-12-310001850119ipsc:EmployeeStockOptionsAndRestrictedStockUnitsMemberipsc:IncentivePlan2021Member2023-03-310001850119us-gaap:InProcessResearchAndDevelopmentMemberipsc:EmpiricaAgreementMember2023-02-012023-02-280001850119us-gaap:InProcessResearchAndDevelopmentMemberipsc:EmpiricaAgreementMember2022-06-012022-06-300001850119us-gaap:InProcessResearchAndDevelopmentMemberipsc:EmpiricaAgreementMember2021-07-012021-07-310001850119ipsc:ConsultingArrangementsMemberipsc:ShareholdersOfEquityMethodInvestorMember2019-01-012019-12-310001850119ipsc:ConsultingArrangementsMemberipsc:ShareholdersOfEquityMethodInvestorMember2019-12-310001850119ipsc:IncentivePlan2021Member2023-01-012023-03-310001850119ipsc:IncentivePlan2021Member2022-01-012022-12-310001850119ipsc:EmployeeStockPurchasePlan2021Member2022-01-012022-12-310001850119ipsc:IncentivePlan2021Member2021-01-012021-12-3100018501192022-01-012022-03-310001850119ipsc:IcellInc.SublicenseAgreementMember2020-03-310001850119ipsc:TermLoanAgreementWithHerculesCapitalIncMember2020-09-142020-09-140001850119ipsc:LoanAmountsPrepaidDuringInterestOnlyPeriodMemberipsc:TermLoanAgreementWithHerculesCapitalIncMember2020-09-142020-09-140001850119ipsc:LoanAmountsPrepaidAfterInterestOnlyPeriodMemberipsc:TermLoanAgreementWithHerculesCapitalIncMember2020-09-142020-09-140001850119srt:MinimumMemberipsc:TermLoanAgreementWithHerculesCapitalIncMember2020-09-142020-09-140001850119ipsc:BristolMyersSquibbCompanyCollaborationAgreementMember2022-01-072022-01-070001850119srt:MaximumMemberipsc:IcellInc.SublicenseAgreementMember2020-03-310001850119ipsc:DistributedBioMasterServiceAgreementMember2019-06-240001850119ipsc:DistributedBioMasterServiceAgreementMember2023-03-310001850119ipsc:IcellInc.SublicenseAgreementMember2022-12-310001850119ipsc:IcellInc.SublicenseAgreementMember2021-12-310001850119ipsc:FcdiCollaborationAgreementMemberipsc:BristolMyersSquibbCompanyCollaborationAgreementMember2022-01-070001850119ipsc:BristolMyersSquibbCompanyCollaborationAgreementMember2022-01-0700018501192020-09-1400018501192023-03-310001850119ipsc:AccruedExpensesAndOtherLiabilitiesCurrentMemberus-gaap:InProcessResearchAndDevelopmentMemberipsc:EmpiricaAgreementMember2023-03-310001850119ipsc:AccruedExpensesAndOtherLiabilitiesCurrentMemberus-gaap:InProcessResearchAndDevelopmentMemberipsc:EmpiricaAgreementMember2022-12-3100018501192022-12-3100018501192023-05-0100018501192023-01-012023-03-31xbrli:sharesiso4217:USDipsc:Programiso4217:USDxbrli:sharesxbrli:pureipsc:itemipsc:segment

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2023

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______                      

Commission File Number: 001-40498

Century Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware

    

84-2040295

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

3675 Market Street
Philadelphia, Pennsylvania
(Address of principal executive offices)

19104
(Zip Code)

(267) 817-5790

(Registrant’s telephone number, including area code)

Not applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

    

Trading
Symbol(s)

    

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

IPSC

The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer           

Accelerated filer                  

Non-accelerated filer             

Smaller reporting company

Emerging growth company   

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes   No 

As of May 1, 2023 the registrant had 59,580,817 shares of common stock, $0.0001 par value per share, outstanding.

Table of Contents

 

 

Page

PART I.

FINANCIAL INFORMATION

6

Item 1.

Financial Statements:

6

Consolidated Balance Sheets as of March 31, 2023 (unaudited) and December 31, 2022

6

Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2023 and 2022 (unaudited)

7

Consolidated Statements of Changes in Stockholders’ Equity for the three months ended March 31, 2023 and 2022 (unaudited)

8

Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and 2022 (unaudited)

9

Notes to Unaudited Consolidated Financial Statements

10

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

32

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

43

Item 4.

Controls and Procedures

43

PART II.

OTHER INFORMATION

45

Item 1.

Legal Proceedings

45

Item 1A.

Risk Factors

45

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

45

Item 3.

Defaults Upon Senior Securities

45

Item 4.

Mine Safety Disclosures

45

Item 5.

Other Information

45

Item 6.

Exhibits

46

Signatures

47

2

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q and the documents incorporated by reference herein contain forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this Quarterly Report on Form 10-Q or the documents incorporated by reference herein regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” “would,” “could,” “should,” “potential,” “seek,” “evaluate,” “pursue,” “continue,” “design,” “impact,” “affect,” “forecast,” “target,” “outlook,” “initiative,” “objective,” “designed,” “priorities,” “goal,” or the negative of such terms and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are based on assumptions and expectations that may not be realized and are inherently subject to risks, uncertainties and other factors, many of which cannot be predicted with accuracy and some of which might not even be anticipated.

The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:

our ability to raise additional capital to fund our operations and continue the development of our current and future product candidates;
the preclinical and early clinical nature of our business and our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials;
our ability to generate revenue from future product sales and our ability to achieve and maintain profitability;
the accuracy of our projections and estimates regarding our expenses, capital requirements, cash utilization, and need for additional financing;
the extent to which the COVID-19 pandemic, or any other pandemic or global health crises may impact our business, including development activities, preclinical studies, clinical trials, supply chain and labor force;
our dependence on the success of our lead product candidate, CNTY-101;
the novelty of our approach to immuno-oncology treatment of cancer, utilizing iPSC-derived natural killer cells, or iNK cells, and iPSC-derived T cells, or iT cells, and the challenges we will face due to the novel nature of such technology;
the success of competing therapies that are or become available;
our reliance on the maintenance of our collaborative relationship with FUJIFILM Cellular Dynamics Inc., or FCDI, for access to key differentiation and reprogramming technology for the manufacturing and development of our product candidates;
the initiation, progress, success, cost, and timing of our development activities, preclinical studies and future clinical trials;
the timing of future investigational new drug, or IND, applications and the likelihood of, and our ability to obtain and maintain, regulatory clearance of such IND applications for our product candidates;
the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates;

3

our reliance on FCDI to be the exclusive manufacturer of certain product candidates, and our ability to manufacture our own product candidates in the future, and the timing and costs of such manufacturing activities;
our reliance on the maintenance of our collaborative relationship with Bristol-Myers Squibb Company, or Bristol-Myers Squibb, in connection with the furtherance of our collaboration programs;
the performance of third parties in connection with the development of our product candidates, including third parties conducting our current and future clinical trials as well as third-party suppliers and manufacturers;
our ability to attract and retain strategic collaborators with development, regulatory, and commercialization expertise;
the public opinion and scrutiny of cell-based immuno-oncology therapies for treating cancer and its potential impact on public perception of our company and product candidates;
our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved;
the size and growth of the potential markets for our product candidates and our ability to serve those markets;
regulatory developments and approval pathways in the United States and foreign countries for our product candidates;
the potential scope and value of our intellectual property and proprietary rights;
our ability, and the ability of our licensors, to obtain, maintain, defend, and enforce intellectual property and proprietary rights protecting our product candidates, and our ability to develop and commercialize our product candidates without infringing, misappropriating, or otherwise violating the intellectual property or proprietary rights of third parties;
our ability to recruit and retain key members of management and other clinical and scientific personnel;
the volatility of capital markets and other macroeconomic factors, including due to inflationary pressures, banking instability geopolitical tensions or the outbreak of hostilities or war;
developments relating to our competitors and our industry; and
other risks and uncertainties, including those described under the caption “Risk factors” in our Annual Report on Form 10-K for the year ended December 31, 2022.

We have based these forward-looking statements largely on our current expectations, estimates, forecasts, and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report on Form 10-Q, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. You should refer to the section titled “Risk Factors” set forth in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2022 for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be

4

material. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

You should read this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. We intend the forward-looking statements contained in this Quarterly Report on Form 10-Q to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act.

5

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

CENTURY THERAPEUTICS, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share amounts)

March 31, 2023

December 31, 2022

    

(unaudited)

    

Assets

Current assets

Cash and cash equivalents

$

86,832

$

84,265

Short-term investments

 

164,637

 

231,233

Escrow deposits, current

 

 

220

Prepaid expenses and other current assets

 

4,465

 

4,003

Total current assets

 

255,934

 

319,721

Property and equipment, net

 

85,842

 

82,785

Operating lease right-of-use assets

28,207

28,945

Restricted cash

1,979

1,979

Long-term investments

 

83,316

 

51,854

Security deposits

 

950

 

1,260

Total assets

$

456,228

$

486,544

Liabilities and stockholders’ equity

 

  

 

  

Current liabilities

 

 

  

Accounts payable

$

3,475

$

5,454

Accrued expenses and other liabilities

 

6,531

 

9,841

Deposit liability

881

866

Long-term debt, current

10,297

6,502

Deferred revenue, current

6,500

7,154

Total current liabilities

 

27,684

 

29,817

Operating lease liability, long term

 

41,168

 

38,698

Deposit liability, non-current

433

718

Deferred revenue, non-current

109,768

110,834

Long-term debt, net

 

 

3,739

Total liabilities

 

179,053

 

183,806

Commitments and contingencies (Note 11)

 

  

 

  

Stockholders' equity:

Preferred stock, $ 0.0001 par value, 10,000,000 shares authorized and 0 shares issued and outstanding at March 31, 2023 and December 31, 2022

Common stock, $0.0001 par value, 125,236,190 shares authorized; 59,106,784 and 58,473,660 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively

6

6

Additional paid-in capital

 

828,806

 

824,292

Accumulated deficit

(550,362)

(519,098)

Accumulated other comprehensive loss

(1,275)

(2,462)

Total stockholders’ equity

277,175

302,738

Total liabilities and stockholders’ equity

$

456,228

$

486,544

See accompanying notes to the consolidated financial statements.

6

CENTURY THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(In thousands, except share and per share amounts)

Three Months Ended

Three Months Ended

March 31, 2023

March 31, 2022

Collaboration revenue

$

1,720

$

1,058

Operating expenses

Research and development

24,899

21,196

General and administrative

 

8,902

 

7,298

In-process research and development

 

-

 

10,000

Total operating expenses

 

33,801

 

38,494

Loss from operations

 

(32,081)

 

(37,436)

Interest expense

 

(404)

 

(314)

Interest income

2,623

253

Other expense, net

 

(194)

 

Total other income (expense)

2,025

(61)

Loss before provision for income taxes

(30,056)

(37,497)

Provision for income taxes

(1,208)

(16)

Net loss

$

(31,264)

$

(37,513)

Net loss per common share
Basic and Diluted

(0.53)

(0.66)

Weighted average common shares outstanding
Basic and Diluted

58,610,375

57,051,539

Other comprehensive loss

Net loss

$

(31,264)

$

(37,513)

Unrealized gain (loss) on investments

1,196

(1,986)

Foreign currency translation

(9)

(6)

Comprehensive loss

$

(30,077)

$

(39,505)

See accompanying notes to the consolidated financial statements.

7

CENTURY THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(Unaudited)

(In thousands, except share amounts)

Accumulated

Additional

Other

Total

Common Stock

Paid-in

Accumulated

Comprehensive

Stockholders’

  

Shares

  

Amount

  

Capital

  

Deficit

  

Loss

  

Equity

Balance, December 31, 2022

58,473,660

$

6

$

824,292

$

(519,098)

$

(2,462)

$

302,738

Issuance of common stock upon the exercise of stock options

452,102

448

448

Vesting of restricted stock

95,877

Vesting of early exercise stock options

85,145

269

269

Unrealized gain on short-term investments

1,196

1,196

Foreign currency translation

(9)

(9)

Stock based compensation

3,797

3,797

Net loss

(31,264)

(31,264)

Balance, March 31, 2023

59,106,784

$

6

$

828,806

$

(550,362)

$

(1,275)

 

$

277,175

Accumulated

Additional

 Other 

Total

Common Stock

Paid-in

Accumulated

Comprehensive

Stockholders’

    

Shares

  

Amount

  

Capital

  

Deficit

  

Loss

    

Equity

Balance, December 31, 2021

55,005,523

$

5

$

785,049

$

(388,166)

$

(650)

$

396,238

Issuance of stock to collaboration partner

2,160,760

1

26,812

26,813

Issuance of common stock upon the exercise of stock options

85,396

65

65

Vesting of restricted stock

161,159

 

 

 

 

 

Vesting of early exercise stock options

173,192

673

673

Stock based compensation

2,380

2,380

Unrealized loss on investments

(1,986)

(1,986)

Foreign currency translation

(6)

(6)

Net loss

(37,513)

(37,513)

Balance, March 31, 2022

57,586,030

$

6

$

814,979

$

(425,679)

$

(2,642)

 

$

386,664

See accompanying notes to the consolidated financial statements.

8

CENTURY THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(in thousands)

Three Months Ended

Three Months Ended

March 31, 2023

March 31, 2022

    

(unaudited)

    

(unaudited)

Cash flows from operating activities

 

  

 

  

 

Net loss

$

(31,264)

$

(37,513)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

Depreciation

 

2,908

 

1,160

Amortization of deferred financing cost

56

76

Non-cash operating lease expense

(738)

188

Stock based compensation

 

3,797

 

2,380

Change in operating assets and liabilities:

 

 

Escrow deposit

 

220

 

125

Prepaid expenses and other assets

 

(160)

 

1,033

Operating lease liability

3,842

(152)

Deferred revenue

(1,720)

122,129

Accounts payable

 

(2,954)

 

(1,503)

Accrued expenses and other liabilities

 

(3,206)

 

(1,170)

Net cash (used in) provided by operating activities

 

(29,219)

 

86,753

Cash flows from investing activities

 

  

 

  

Acquisition of property and equipment

 

(4,991)

 

(4,067)

Acquisition of fixed maturity securities, available for sale

 

(42,829)

 

(103,060)

Sale of fixed maturity securities, available for sale

 

79,158

 

63,090

Net cash provided by (used in) investing activities

 

31,338

 

(44,037)

Cash flows from financing activities

 

  

 

  

Proceeds from issuance of common stock

448

65

Proceeds from issuance of shares to collaboration partner

26,813

Net cash provided by financing activities

 

448

 

26,878

Net increase in cash, cash equivalents, and restricted cash

 

2,567

 

69,594

Cash, cash equivalents and restricted cash, beginning of period

 

86,244

 

58,162

Cash, cash equivalents and restricted cash, end of period

$

88,811

$

127,756

Supplemental disclosure of cash and non-cash operating activities:

Cash paid for interest

$

345

$

238

Supplemental disclosure of non-cash investing and financing activities:

  

 

  

Purchase of property and equipment, accrued and unpaid

$

975

$

3,796

See accompanying notes to the consolidated financial statements.

9

CENTURY THERAPEUTICS, INC.

NOTES TO FINANCIAL STATEMENTS

(Unaudited)

(in thousands, except share and per share amounts)

Note 1—Organization and description of the business

Century Therapeutics, Inc. (the “Company”) is an innovative biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. Since inception, the Company has devoted substantially all of its time and efforts to performing research and development activities, building infrastructure and raising capital. The Company is incorporated in the state of Delaware.

Century Therapeutics Canada ULC (“Century Canada”) is the Company’s wholly owned subsidiary performing research and development activities in Canada.

Principles of Consolidation

The consolidated financial statements include the consolidated financial position and consolidated results of operations of the Company and Century Canada. All intercompany balances and transactions have been eliminated in consolidation.

Liquidity

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has limited operating history and its prospects are subject to risks, expenses, and uncertainties frequently encountered by companies in the biotechnology and pharmaceutical industries. These risks include, but are not limited to, the uncertainty of availability of additional financing and the uncertainty of achieving future profitability.

Since inception, the Company has incurred net losses. During the three months ended March 31, 2023, the Company incurred a net loss of $31,264. During the three months ended March 31, 2023, the Company used $29,219 of cash from operations. Cash and cash equivalents and investments were $334,785 at March 31, 2023. Management expects to incur additional losses in the future to fund its operations and conduct product research and preclinical and clinical development and recognizes the need to raise additional capital to fully implement its business plan. The Company believes it has adequate cash and financial resources to operate for at least the next 12 months from the date of issuance of these consolidated financial statements.

Reduction in force

In January 2023, the Company's Board of Directors approved, and management implemented a new portfolio prioritization and capital allocation strategy. The resulting changes include pausing investment in CNTY-103 for glioblastoma as well as a discovery program in hematologic malignancies. The Company will focus on CNTY-101 and will accelerate key programs, including one follow-on candidate for lymphoma, CNTY-102, and CNTY-107 for Nectin-4+ solid tumors. In addition, the Company will continue its partnered programs with Bristol Myers Squibb. The restructuring plan resulted in a reduction in the Company's workforce of approximately 25%. In addition, lab operations in Seattle and Hamilton, Ontario were closed and research activities were consolidated in Philadelphia.

10

Note 2—Summary of significant accounting policies and basis of presentation

Basis of presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the interim period reporting requirements of Form 10-Q and Article 10 of Regulation S-X. The consolidated balance sheet as of March 31, 2023, the consolidated statements of operations and comprehensive loss, and consolidated statements of changes in stockholders’ equity for the three months ended March 31, 2023 and 2022, and the consolidated statements of cash flows for the three months ended March 31, 2023 and 2022 are unaudited, but, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.  The results for any interim period are not necessarily indicative of results for the year ending December 31, 2023 or for any other subsequent interim period.  The consolidated balance sheet at December 31, 2022 has been derived from the Company’s audited consolidated financial statements.

Certain prior year information has been reclassified to conform to the fiscal year 2023 presentation.

Segment information

Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages the business as one operating segment.

Use of estimates

The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuations supporting stock compensation, the estimation of the incremental borrowing rate for operating leases and standalone selling prices of performance obligations in collaboration agreements. If actual results differ from the Company’s estimates, or to the extent these estimates are adjusted in future periods, the Company’s results of operations could either benefit from, or be adversely affected by, any such change in estimate.

Concentration of credit risk and other risks and uncertainties

Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist of cash, cash equivalents, U.S. Treasury bills and bonds, as well as corporate bonds. Cash and cash equivalents, as well as short and long-term investments include a checking account and asset management accounts held by a limited number of financial institutions. At times, such deposits may be in excess of insured limits. As of March 31, 2023 and December 31, 2022, the Company has not experienced any losses on its deposits of cash and cash equivalents.

The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, uncertainty of market acceptance of its products, competition from substitute products and larger companies, protection of proprietary technology, strategic relationships, and dependence on key individuals.

Products developed by the Company require clearances from the U.S. Food and Drug Administration (the “FDA”) or other international regulatory agencies prior to commercial sales. There can be no assurance the Company’s future products will receive the necessary clearances. If the Company was denied clearance,

11

clearance was delayed, or if the Company was unable to maintain clearance, it could have a material adverse impact on the Company.

Fair value of financial instruments

The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:

Level 1

Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date;

Level 2

Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly, including inputs in markets that are not considered to be active;

Level 3

Inputs are unobservable in which there is little or no market data available, which require the reporting entity to develop its own assumptions that are unobservable.

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.

Cash and cash equivalents

Management considers all highly liquid investments with an insignificant interest rate risk and original maturities of three months or less to be cash equivalents.

Restricted cash

As of March 31, 2023 and December 31, 2022, the Company had $1,979 in cash on deposit to secure certain lease commitments. Restricted cash is recorded separately in the Company’s consolidated balance sheets.

The following provides a reconciliation of the Company’s cash, cash equivalents, and restricted cash as reported in the consolidated balance sheets to the amounts reported in the consolidated statements of cash flows:

    

March 31, 2023

    

December 31, 2022

Cash and cash equivalents

$

86,832

$

84,265

Restricted cash

1,979

1,979

Cash, cash equivalents, and restricted cash

$

88,811

$

86,244

Investments

The Company invests in fixed maturity securities including U.S. Treasury bills and bonds as well as corporate bonds. The investments are classified as available-for-sale and reported at fair value. Unrealized gains or losses are determined by comparing the fair market value of the securities with their cost or amortized cost. Realized gains and losses on investments are recorded on the trade date and are included in the statement of operations. Unrealized gains and losses on investments are recorded in other comprehensive income (loss) on the consolidated statements of operations and comprehensive loss. The cost of securities sold is based on the specified identification method. Investment income is recognized as earned and discounts or premiums arising from the purchase of debt securities are recognized in investment income using the interest

12

method over the remaining term of the security. Securities with an original maturity date greater than three months that mature within one year of the balance sheet date are classified as short-term, while investments with a maturity date greater than one year are classified as long-term.

Property and equipment, net

Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which is generally five years. Leasehold improvements are amortized over the shorter of the asset’s useful life or the remaining term of the lease. Construction in progress includes direct cost related to the construction of leasehold improvements and is stated at original cost. Such costs are not depreciated until the asset is completed and placed into service. Once the asset is placed into service, these capitalized costs will be allocated to leasehold improvements and will be depreciated over the shorter of the asset’s useful life or the remaining term of the lease. Computer software and equipment includes implementation costs for cloud-based software and network equipment.

Expenditures for major additions and improvements are capitalized, while minor replacements, maintenance, and repairs are charged to expense as incurred. When property is retired or otherwise disposed of, the costs and accumulated depreciation are removed from the respective accounts, with any resulting gain or loss recognized concurrently.

Research and development expenses

Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, stock compensation, materials, supplies, rent, depreciation on and maintenance of research equipment with alternative future use, and the cost of services provided by outside contractors. All costs associated with research and development are expensed as incurred.

Clinical trial costs are a component of research and development expenses. The company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.

Stock-based compensation

Employees, consultants and members of the board of directors of the Company have received stock options and restricted stock of the Company. The Company recognizes the cost of the stock-based compensation incurred as its employees and board members vest in the awards. The Company accounts for stock-based compensation arrangements in accordance with provisions of Accounting Standards Codification (“ASC”) 718, Compensation—Stock Compensation. ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The Company uses the Black-Scholes option-pricing model (“Black Scholes”) to determine the fair value of options granted. The Company’s stock-based awards are subject to service-based vesting conditions and performance-based vesting conditions. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. For performance-based awards, the Company reassesses at each reporting date whether achievement of the performance condition is probable and accrues compensation expense if and when achievement of the performance condition is probable.

Black-Scholes requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. Due to

13

the lack of a public market for the Company’s common stock prior to its initial public offering (“IPO”) and lack of company-specific historical and implied volatility data, the Company based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. Forfeitures are recognized as they occur.

Warrants

The Company has issued warrants that have been recognized as equity, and the fair value is recorded into additional paid-in capital in the accompanying consolidated balance sheets. Warrants are accounted for in accordance with applicable accounting guidance provided in ASC Topic 815, Derivatives and Hedging—Contracts in Entity’s Own Equity, as either derivative liabilities or as equity instruments depending on the specific terms of the warrant agreement. The Company’s warrants issued are in connection with its long-term debt and in connection with services provided by consultants, and are equity classified on the accompanying consolidated balance sheets. Equity classified warrants are accounted for at fair value on the issuance date, using Black Scholes, with no changes in fair value recognized after the issuance date.

Foreign currency translation

The reporting currency of the Company is the U.S. dollar. The functional currency of Century Canada is the Canadian dollar. Assets and liabilities of Century Canada are translated into U.S. dollars based on exchange rates at the end of each reporting period. Expenses are translated at average exchange rates during the reporting period. Gains and losses arising from the translation of assets and liabilities are included as a component of accumulated other comprehensive loss or income on the company’s consolidated balance sheets. Gains and losses resulting from foreign currency transactions are reflected within the Company’s consolidated statements of operations and comprehensive loss. The Company has not utilized any foreign currency hedging strategies to mitigate the effect of its foreign currency exposure.

Intercompany payables and receivables are considered to be long-term in nature and any change in balance due to foreign currency fluctuation is included as a component of the Company’s consolidated comprehensive loss and accumulated other comprehensive loss within the Company’s consolidated balance sheets.

Basic and diluted net loss per common shares

Basic net loss per common share is computed by dividing net loss applicable to common shareholders by the weighted-average number of common shares outstanding during the period. The Company computes diluted net loss per common share by dividing the net loss applicable to common shareholders by the sum of the weighted- average number of common shares outstanding during the period plus the potential dilutive effects of its warrants, restricted stock and stock options to purchase common shares, but such items are excluded if their effect is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there were no differences between the Company’s basic and diluted net loss per common share for the three months ended March 31, 2023 and 2022.

Early exercised options

The Company allowed certain of its employees and its consultants to exercise options granted under the 2018 Stock Option and Grant Plan (the “2018 Incentive Plan”) (Note 16) prior to vesting and prior to its IPO. The shares related to early exercised stock options are subject to the Company’s repurchase right upon termination of employment or services at the lesser of the original purchase price or fair market value at the time of repurchase. In order to vest, the holders are required to provide continued service to the Company. The early exercise by an employee or consultant of a stock option is not considered to be a substantive

14

exercise for accounting purposes, and therefore, the payment received by the employer for the exercise price is recognized as a liability. For accounting purposes, unvested early exercised shares are not considered issued and outstanding and therefore not reflected as issued and outstanding in the accompanying consolidated balance sheets or the consolidated statements of changes in stockholders’ equity (deficit) until the awards vest. The deposits received are initially recorded in deposit liability. The liabilities are reclassified to common stock and additional paid-in-capital as the repurchase right lapses. At March 31, 2023 and December 31, 2022, there were $1,314 and $1,584, respectively, recorded in deposit liability related to shares held by employees and nonemployees that were subject to repurchase.

All shares that were early exercised by the executives of the Company are considered legally issued, however, for accounting purposes, only vested shares are considered issued. Below is a reconciliation of shares issued and outstanding:

    

March 31, 2023

    

December 31, 2022

Total shares legally outstanding

59,541,904

59,137,491

Less: unvested early exercised shares

(385,655)

(470,800)

Less: unvested restricted stock awards (Note 16)

(49,465)

(193,031)

Total shares issued and outstanding

59,106,784

58,473,660

Income taxes

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations and comprehensive loss. As of March 31, 2023 and December 31, 2022, no accrued interest or penalties are included on the related tax liability line in the consolidated balance sheet.

Collaboration revenue

The Company may enter into collaboration and licensing agreements with strategic partners for research and development, manufacturing, and commercialization of its product candidates. Payments under these arrangements may include non-refundable, upfront fees; reimbursement of certain costs; customer option fees for additional goods or services; payments upon the achievement of development, regulatory, and commercial milestones; sales of product at certain agreed-upon amounts; and royalties on product sales.

The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers, or ASC 606. This standard applies to all contracts with customers. When an agreement falls under the scope of other standards, such as ASC Topic 808, Collaborative Arrangements, or ASC 808, the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the

15

performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606 is recorded as collaboration revenue on the statements of operations.

Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under a collaboration agreement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations on a relative stand-alone selling price basis; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.

As part of the accounting for these arrangements, the Company must use its judgment to determine the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price. The estimation of the stand-alone selling price may include such estimates as forecasted revenues and costs, development timelines, discount rates, and probabilities of regulatory and commercial success. The Company also applies significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining when performance obligations have been met, assessing the recognition and future reversal of variable consideration and determining and applying appropriate methods of measuring progress for performance obligations satisfied over time. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, current. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, non-current.

If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are not determined to represent a material right, no transaction price is allocated to these options and the Company will account for these options at that time they are exercised. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement.

The obligations under the Company’s collaboration agreements may include research and development services to be performed by the Company for or on behalf of the customer. Amounts allocated to these performance obligations are recognized as the Company performs these obligations, and revenue is measured based on an inputs method of costs incurred to date of budgeted costs. Under certain circumstances, the Company may be reimbursed for certain expenses incurred under the research and development services.

At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the statements of operations in the period of adjustment.

16

Recent accounting pronouncements

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses of Financial Instruments (ASC 326). The guidance is effective for the Company beginning January 1, 2023 and it changes how entities account for credit losses on the financial assets and other instruments that are not measured at fair value through net income, including available-for-sale debt securities. The adoption of ASC 326 did not have a material impact on the consolidated financial statements.

Note 3—Reduction in force

During the three months ended March 31,2023, the Company incurred $2,032 of cash-based expenses related to employee severances, benefits and related costs. In addition, the Company recorded non-cash stock-based compensation charge of $581 related to modification of equity awards for employees impacted by the restructuring during the quarter ended March 31, 2023. There were no remaining outstanding liabilities related to the reduction in force during the quarter ended March 31, 2023.

Note 4—Asset purchase by Century Therapeutics Canada ULC

On June 9, 2020, Century Canada and the Company entered into an agreement with Empirica Therapeutics, Inc. (“Empirica”), a company focused on the development of adoptive immunotherapies against aggressive and treatment-resistant forms of cancers, including glioblastoma and brain metastasis. Under the terms of the Empirica Agreement, the Company acquired an IPR&D asset. Cash of $4,519 was paid at closing and transaction expenses totaled $203. The Company also deposited $1,506 in escrow (the “Escrow Deposit”). Release of the Escrow Deposit is subject to the terms of a promissory note, which provides for the funds to be released in equal annual installments over a three-year period related to continuing services by certain Empirica shareholders. In July 2021, the first annual installment of $523 was released from the Escrow Deposit. In June 2022, the second annual installment of $517 was released from the Escrow Deposit. In February 2023, the third installment of $494 was released from Escrow Deposit. As of March 31, 2023 and December 31, 2022, accrued compensation expense on the promissory note was $0 and $220, which is presented within escrow deposits on the consolidated balance sheets.

Note 5—Financial instruments and fair value measurements

The following table sets forth the Company’s assets that were measured at fair value as of March 31, 2023 by level within the fair value hierarchy:

    

Level 1

    

Level 2

    

Level 3

    

Total

Cash equivalents

$

83,187

$

83,187

U.S. Treasury

 

65,197

 

 

 

65,197

Corporate bonds

 

 

182,756

 

 

182,756

Total

$

148,384

$

182,756

$

$

331,140

17

The following table sets forth the Company’s assets that were measured at fair value as of December 31, 2022, by level within the fair value hierarchy:

    

Level 1

    

Level 2

    

Level 3

    

Total

Cash equivalents

$

77,736

$

77,736

U.S. Treasury

 

86,475

 

 

 

86,475

Corporate bonds

 

 

196,603

 

 

196,603

Total

$

164,211

$

196,603

$

$

360,814

There were no transfers between levels during the period ended March 31, 2023. The Company uses the services of its investment manager, which uses widely accepted models for assumptions in valuing securities with inputs from major third-party data providers.

The Company classifies all of its investments in fixed maturity debt securities as available-for-sale and, accordingly, are carried at estimated fair value.

The amortized cost, gross unrealized gains and losses, and fair value of investments in fixed maturity securities are as follows as of March 31, 2023:

    

    

Gross 

    

Gross

    

Unrealized

 Unrealized 

Amortized Cost

 Gains

Losses

Fair Value

U.S. Treasury

$

65,807

$

$

(610)

$

65,197

Corporate bonds

 

183,329

 

87

 

(660)

 

182,756

Total

$

249,136

$

87

$

(1,271)

$

247,953

The amortized cost, gross unrealized gains and losses, and fair value of investments in fixed maturity securities are as follows as of December 31, 2022:

    

Gross 

    

Gross 

    

Unrealized

Unrealized

    

Amortized Cost

 Gains

 Losses

Fair Value

U.S. Treasury

$

87,798

$

$

(1,323)

$

86,475

Corporate bonds

 

197,668

 

2

 

(1,067)

 

196,603

Total

$

285,466

$

2

$

(2,390)

$

283,078

The following table provides the maturities of our fixed maturity available-for-sale securities:

     

March 31, 2023

     

December 31, 2022

Less than one year

$

164,637

$

231,224

One to five years

 

83,316

 

51,854

$

247,953

$

283,078

The Company has evaluated the unrealized losses on the fixed maturity securities and determined that they are not attributable to credit risk factors. For fixed maturity securities, losses in fair value are viewed as temporary if the fixed maturity security can be held to maturity and it is reasonable to assume that the issuer will be able to service the debt, both as to principal and interest.

At March 31, 2023 and December 31, 2022, respectively, the Company had 32 and 42 available-for-sale investment debt securities in an unrealized loss position without an allowance for credit losses. Unrealized losses on corporate debt securities have not been recognized into income because the issuers’ bonds are of high credit quality (rated BBB+ or higher) and the decline in fair value is largely due to market conditions and or changes in interest rates. Management does not intend to sell and it is likely that management will not be required to sell the securities prior to the anticipated recovery of their amortized cost basis. The issuers

18

continue to make timely payments on the bonds. The fair value is expected to recover as the bond approach maturity.

As of March 31, 2023 and December 31, 2022, accrued interest receivable on available-for-sale investment debt securities totaling $855 and $0, respectively, is excluded from the estimate of credit losses and is included in prepaid expenses and other current assets.

Note 6—Prepaid expenses and other current assets

The following is a summary of prepaid expenses and other current assets:

     

March 31, 2023

    

December 31, 2022

Research and development

$

$

110

Prepaid clinical trial related costs

791

Insurance

 

884

 

1,454

Software licenses and other

 

1,123

 

1,417

Reimbursement receivable

610

780

Warranties

 

202

 

242

Accrued interest receivable

 

855

 

Total prepaid expenses and other current assets

$

4,465

$

4,003

Note 7—Property and equipment, net

The following is a summary of property and equipment, net:

     

March 31, 2023

    

December 31, 2022

Lab equipment

$

28,787

$

28,811

Leasehold improvements

 

49,180

 

48,951

Construction in progress

 

19,758

 

13,998

Computer software and equipment

 

3,132

 

3,132

Furniture and fixtures

 

1,548

 

1,548

Total

102,405

96,440

Less: Accumulated depreciation

 

(16,563)

 

(13,655)

Property and equipment, net

$

85,842

$

82,785

Depreciation expense was $2,908 and $1,160 for the three months ended March 31, 2023 and 2022, respectively.

Note 8—Accrued expenses and other liabilities

The following is a summary of accrued expenses:

     

March 31, 2023

    

December 31, 2022

Payroll and bonuses

$

3,139

    

$

7,062

Interest

 

122

 

117

Accrued clinical trial related costs

314

Professional and legal fees

 

2,432

 

1,637

Operating lease liability, current

579

475

Other

 

259

 

236

Total accrued expenses and other liabilities

$

6,531

$

9,841

19

Note 9—Long-term debt

The following is a summary of the Company’s indebtedness:

     

March 31, 2023

    

December 31, 2022

Principal

$

10,000

$

10,000

Plus: End of term fee

395

395

Less: Debt discount attributable to warrants, net of accretion

 

(8)

 

(8)

Less: Unamortized deferred financing cost and end of term fee, net of accretion

 

(90)

 

(146)

Long-term debt, net

$

10,297

$

10,241

On September 14, 2020, the Company entered into a $10,000 Term Loan Agreement (as amended, the “Loan Agreement”) with Hercules Capital, Inc. (“Hercules”). Pursuant to the terms of the Loan Agreement, the Company borrowed $10,000 (the “Tranche 1 Advance”) from the lenders at closing. Beginning January 1, 2021 and upon the achievement of certain development milestones and continuing through September 30, 2021 the Company may borrow an additional $10,000 (the “Tranche 2 Advance”). The remaining $10,000 tranche (“Tranche 3 Advance”) is subject to Hercules’ investment committee’s sole discretion.

The Loan Agreement has a four-year term and an interest-only period of up to 30 months. The Company was in compliance with all provisions of the Loan Agreement as of March 31, 2023. Amounts borrowed under the Loan Agreement accrue interest at a floating rate per annum (based on a year of 360 days) equal to (i) the sum of (a) the greater of 6.30% plus (b) the prime rate as reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue or (ii) 9.55%. The interest rate as of March 31, 2023 was 14.3%.

The Company incurred $410 in deferred financing costs. The Company is also required to pay the lenders an end of term fee of 3.95% of loan proceeds upon repayment or prepayment of any loans made under the Loan Agreement. The end of term fee is being recognized as interest expense and accreted over the term of the Loan Agreement using the effective interest method. The Company is also required to pay Hercules a prepayment charge equal to 2.00% of the loan amounts prepaid during the interest-only period and 1.00% thereafter on any loans made under the Loan Agreement.

The Company granted Hercules a lien on substantially all of the Company’s assets, excluding intellectual property.

The Company issued to Hercules warrants to purchase up to an aggregate of 16,112 shares of common stock. The warrants are exercisable for a period of ten years from the date of the issuance of each warrant at a per share exercise price equal to $13.96, subject to certain adjustments as specified in the warrants. The fair value of the warrants at issuance was $46. The Company accounted for the warrants as equity, and the fair value is recorded in additional paid-in capital. The warrant value is also recorded as a debt discount and classified as a contra- liability on the consolidated balance sheet and amortized to interest expense. If the Company borrows on the remaining two tranche advances outlined above, the Company will be required to issue warrants to Hercules equal to 2.25% of the aggregate amount funded.

Interest expense of the Loan Agreement is as follows:

For the Three Months Ended

For the Three Months Ended

    

March 31, 2023

    

March 31, 2022

Interest expense

$

348

$

238

Amortization of debt issuance costs, including end of term fee accretion

 

56

 

76

$

404

$

314

20

Included in accrued expenses in the accompanying consolidated balance sheets as of March 31, 2023 and December 31, 2022 was $122 and $117 of accrued interest, respectively.

Future principal payments due (including the end of term fee) under the Loan Agreement are as follows (in thousands):

    

Principal Payments

2023

$

10,395

Total future payments

$

10,395

On May 1, 2023, the Company repaid the loan in its entirety. See Note 18.

Note 10 – Bristol-Myers Squibb Collaboration

On January 7, 2022, the Company entered into the Collaboration Agreement with Bristol-Myers Squibb to collaborate on the research, development and commercialization of iNK and iT cell programs for hematologic malignancies and solid tumors (“Collaboration Program,” and each product candidate a “Development Candidate”). The Collaboration Agreement is within the scope of ASC 808, Collaborative Arrangements as both parties are active participants in the arrangement and are exposed to significant risks and rewards. While this arrangement is in the scope of ASC 808, the Company analogizes to ASC 606 for the accounting for the Collaboration Agreement, including for the delivery of goods and services (i.e., units of account). Revenue recognized by analogizing to ASC 606 is recorded as collaboration revenue in the statements of operations.

Pursuant to the Collaboration Agreement, the Company and Bristol-Myers Squibb will initially collaborate on two Collaboration Programs focused on acute myeloid leukemia (“AML”) and multiple myeloma (“MM”), and Bristol-Myers Squibb has the option to add up to two additional Collaboration Programs for an additional fee. The Company is responsible for generating Development Candidates for each Collaboration Program, and Bristol-Myers Squibb has the option to elect to exclusively license the Development Candidates for pre-clinical development, clinical development and commercialization on a worldwide basis (“License Option”). Following Bristol-Myers Squibb’s exercise of the License Option, the Company will be responsible for performing IND-enabling studies, supporting Bristol-Myers Squibb’s preparation and submission of an IND, and manufacturing of clinical supplies until completion of a proof of concept clinical trial. Bristol-Myers Squibb will be responsible for all regulatory, clinical, manufacturing (after the proof of concept clinical trial) and commercialization activities for such Development Candidates worldwide. The Company has the option to co-promote Development Candidates generated from certain specified Collaboration Programs.

Under the terms of the Collaboration Agreement, Bristol-Myers Squibb made a non-refundable, upfront cash payment of $100,000 and will pay an exercise fee upon the exercise of the License Option (“Licensed Program” and product candidates developed under a Licensed Program, “Licensed Products”). For each Licensed Program, Bristol-Myers Squibb will pay up to $235,000 in milestone payments upon the first achievement of certain development and regulatory milestones and will pay up to $500,000 per Licensed Product in net sales-based milestone payments. Bristol-Myers Squibb will also pay the Company tiered royalties per Licensed Product as a percentage of net sales in the high-single digits to low-teens, subject to reduction for biosimilar competition, compulsory licensing and certain third party license costs. If Century exercises its co-promote option, such royalty percentage will be increased to low-teens to high-teens in respect of the sales of the co-promoted Licensed Products in the United States. The royalty term shall terminate on a Licensed Product-by-Licensed Product and country-by-country basis on the latest of (i) the twelve (12) year anniversary of the first commercial sale of such Licensed Product in such country, (ii) the expiration of any regulatory exclusivity period that covers such Licensed Product in such country, and (iii) the expiration of the last-to-expire licensed patent of the Company or a jointly owned patent that covers such the Licensed Product in such country. After expiration of the applicable royalty term for a Licensed Product in a

21

country, all licenses granted by the Company to Bristol-Myers Squibb for such Licensed Product in such country will be fully paid-up, royalty- free, perpetual and irrevocable.

In connection with the Collaboration Agreement, Bristol-Myers Squibb purchased 2,160,760 shares of the Company’s common stock at a price per share of $23.14, for an aggregate purchase price of $50,000. In determining the fair value of the common stock issued to Bristol-Myers Squibb, the Company considered the closing price of the common stock on the date of the transaction and included a lack of marketability discount because the shares are subject to certain restrictions. The Company determined the common stock purchase represented a premium of $7.82 per share, or $23,200 in the aggregate (“Equity Premium”), and the remaining $26,800 was recorded as issuance of common stock in stockholders’ equity.

The Company identified the following commitments under the arrangement: (i) research and development services (“R&D Services”) under each of the two initial Collaboration Programs and (ii) Bristol-Myers Squibb’s License Option to elect to exclusively license the Development Candidates for each of the two initial Collaboration Programs. The Company determined that these four commitments represent distinct performance obligations for purposes of recognizing revenue and will recognize revenue as the Company fulfills each performance obligation.

The Company determined that the upfront payment and Equity Premium constitute the transaction price at the inception of the Collaboration Agreement. The future potential development and regulatory milestone payments were fully constrained at contract inception as the risk of significant revenue reversal related to these amounts has not yet been resolved. The achievement of the future potential milestones is not within the Company’s control and is subject to certain research and development success and therefore carries significant uncertainty. The Company will reevaluate the likelihood of achieving these milestones at the end of each reporting period and adjust the transaction price in the period the risk is resolved. In addition, the Company will recognize any consideration related to sales-based milestones and royalties when the subsequent sales occur.

At March 31, 2023, the total transaction price of $123,187 is allocated to the performance obligations based on their estimated standalone selling price. The stand-alone selling price of the research and development services was estimated using the expected cost-plus margin approach, and the stand-alone selling price of the License Options was based on a discounted cash flow approach and considered several factors including, but not limited to, discount rate, development timeline, regulatory risks, estimated market demand, and future revenue potential using an adjusted market approach. The allocated transaction price is recognized as revenue in one of two ways:

Research and development services: The Company recognizes the portion of the transaction price allocated to each of the research and development performance obligations as the research and development services are provided, using an inputs method, in proportion to costs incurred to date for each research development target as compared to total costs incurred and expected to be incurred in the future to satisfy the underlying obligation related to each research and development target. The transfer of control occurs over this period and, in management’s judgment, is the best measure of progress towards satisfying the performance obligation.
License option rights: The transaction price allocated to the license options rights, which are considered material rights to license and commercialize the underlying research and development target, are deferred until the period that Bristol-Myers Squibb elects to exercise or elects to not exercise its option or when the option to exercise expires.

22

The following table summarizes the allocation of the total transaction price to the identified performance obligations under the arrangement, and the amount of the transaction price unsatisfied as of March 31, 2023:

Cumulative collaboration

Deferred

Performance obligations:

Transaction price

revenue recognized

collaboration revenue

Option rights

$

109,164

$

-

$

109,164

Research and development services

14,023

(6,919)

7,104

Total

123,187

(6,919)

116,268

Less current portion of deferred revenue

-

-

(6,500)

Total long-term deferred revenue

$

123,187

$

(6,919)

$

109,768

The following table summarizes the allocation of the total transaction price to the identified performance obligations under the arrangement, and the amount of the transaction price unsatisfied as of December 31, 2022:

Cumulative collaboration

Deferred

Performance obligations:

Transaction price

revenue recognized

collaboration revenue

Option rights

$

109,164

$

-

$

109,164

Research and development services

14,023

(5,199)

8,824

Total

123,187

(5,199)

117,988

Less current portion of deferred revenue

-

-

(7,154)

Total long-term deferred revenue

$

123,187

$

(5,199)

$

110,834

As a direct result of the execution of the Collaboration Agreement, the Company incurred $10,000 in fees to amend the FCDI agreement to gain access to the territory rights of Japan. This is recorded as in-process research and development expenses in the consolidated statement of operations and comprehensive loss for the three months ended March 31, 2022.

Note 11—Commitments and contingencies

From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when future expenditures are probable and such expenditures can be reasonably estimated.

Distributed Bio Master Service Agreement

On July 24, 2019, the Company entered into a Master Service Agreement with Distributed Bio, Inc (“DBio”), whereby DBio will screen for protein binders that bind to specific therapeutic targets. The Company pays for such services according to a payment schedule, and if the Company brings the protein binders into the clinic for further development, DBio will receive milestone payments of up to $16,100 in total for each product as the products move through the clinical development and regulatory approval processes. No milestone payments were due since the inception of the agreement.

The Company had $27 within accounts payable as of March 31, 2023 and $110 as of December 31, 2022, in its consolidated balance sheets related to the Master Service Agreement.

iCELL Inc. Sublicense Agreement

In March 2020, the Company entered into a Sublicense Agreement with iCELL Inc (“iCELL”) whereby iCELL granted the Company a license of certain patents and technology. The Company will pay iCELL royalties in the low single digits on net sales of the licensed product. In addition to the earned royalties, the Company will pay sales milestones, not to exceed $70,000, for the sales of the licensed product. iCELL is also eligible to

23

receive payments of up to $4,250 in development and regulatory approval milestone payments. No milestones or royalties were due in 2022 or 2021.

Note 12—Leases

The Company has commitments under operating leases for certain facilities used in its operations. The Company maintains security deposits on certain leases in the amounts of $950 and $1,260 within security deposits in its consolidated balance sheets at March 31, 2023 and December 31, 2022, respectively. The Company’s leases have initial lease terms ranging from 5 to 16 years. Certain lease agreements contain provisions for future rent increases.

The following table reflects the components of lease expense:

For the Three Months Ended

For the Three Months Ended

March 31, 2023

March 31, 2022

Operating lease expense:

    

  

Fixed lease cost

$

1,395

$

597

Variable lease cost

 

125

 

297

Short term lease expense

594

649

Total operating lease expense

$

2,114

$

1,543

The following table reflects supplemental balance sheet information related to leases:

    

As of

As of

    

    

March 31, 

    

December 31, 

Location in Balance Sheet

2023

2022

Operating lease right-of-use asset, net

 

Operating lease right-of-use assets

$

28,207

$

28,945

Operating lease liability, current

 

Accrued expenses and other liabilities

$

579

$

475

Operating lease liability, long-term

 

Operating lease liability, long-term

 

41,168

 

38,698

Total operating lease liability

 

  

$

41,747

$

39,173

The following table reflects supplement lease term and discount rate information related to leases:

    

As of March 31, 2023

     

As of December 31, 2022

 

Weighted-average remaining lease terms - operating leases

 

9.1 years

9.4 years

Weighted-average discount rate - operating leases

 

9.0

%

9.0

%

The following table reflects supplemental cash flow information related to leases as of the periods indicated:

For the Three Months Ended

For the Three Months Ended

     

March 31, 2023

     

March 31, 2022

Cash paid for amounts included in the measurement of lease liabilities

 

  

 

  

Operating cash flows from operating leases

$

(31)

$

(152)

24

The following table reflects future minimum lease payments under noncancelable leases as of March 31, 2023:

    

Operating Leases

2023

$

4,306

2024

 

8,079

2025

 

8,588

2026

 

8,727

2027

 

8,905

Thereafter

 

53,073

Total lease payments

 

91,678

Less: Imputed interest

 

(46,097)

Less: Tenant incentive receivable

(3,834)

Total

$

41,747

Note 13—Income taxes

During the three months ended March 31, 2023, the Company recorded income tax expense of $1,208, which includes a tax provision of $13 related to its income tax obligations of its operating company in Canada. The Company is projecting taxable income for tax year 2023, due primarily to revenue recognition for tax purposes from the Company's Research Collaboration and Collaboration Agreement entered into with Bristol-Myers Squibb Company in 2022.

The Company’s tax provision and the resulting effective tax rate for interim periods is determined based upon its estimated annual effective tax rate (“AETR”), adjusted for the effect of discrete items arising in that quarter. The impact of such inclusions could result in a higher or lower effective tax rate during a particular quarter, based upon the mix and timing of actual earnings or losses versus annual projections. In each quarter, the Company updates its estimate of the annual effective tax rate, and if the estimated annual tax rate changes, a cumulative adjustment is made in that quarter.

The Company has evaluated the positive and negative evidence bearing upon its ability to realize its deferred tax assets, which primarily consist of net operating loss carryforwards. While the Company anticipates utilizing a portion of its existing net operating loss carryforwards during tax year 2023, the Company has considered its history of cumulative net losses in the U.S., estimated future taxable income and prudent and feasible tax planning strategies and has concluded that it is more likely than not that the Company will not realize the benefits of its U.S. deferred tax assets. As a result, as of March 31, 2023, the Company has recorded a full valuation allowance against its net deferred tax assets in the U.S.

Note 14—Basic and diluted net loss per common share

Basic and diluted net loss per common share is calculated as follows:

Three Months Ended

Three Months Ended

March 31, 

March 31, 

    

2023

    

2022

Numerator

 

  

 

  

Net loss

 

$

(31,264)

$

(37,513)

Denominator

 

  

 

  

Weighted-average common shares for basic and diluted net loss per share

 

58,610,375

 

57,051,539

Basic and diluted net loss per common share

$

(0.53)

$

(0.66)

25

The Company’s potentially dilutive securities, which include restricted stock, warrants, early exercised stock options and stock options to purchase shares of the Company’s common stock, have been excluded from the computation of dilutive net loss per share as the effect would be antidilutive. Therefore, the weighted- average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential shares of common stock presented based on amounts outstanding at each stated period end, from the computation of diluted net loss per share for the three months ended March 31, 2023 and 2022 because including them would have had an anti-dilutive effect.

Three Months Ended

Three Months Ended

March 31, 

March 31, 

    

2023

    

2022

Stock options to purchase common stock

10,370,402

 

7,424,538

Early exercised stock options subject to future vesting

385,655

 

773,394

Restricted stock award subject to future vesting

49,465

 

520,630

Unvested restricted stock units

 

544,650

 

Warrants

32,009

32,009

Total

 

11,382,181

 

8,750,571

Note 15—Defined contribution plan

The Company has a 401(k) Employee Savings Plan (“401(k) Plan”) that is available to all employees of the Company. The Company has elected a Safe-Harbor provision for the 401(k) Plan in which participants are always fully vested in their employer contributions. The Company matches 100% of the first 3% of participating employee contributions and 50% of the next 2% of participating employee contributions. Contributions are made in cash. Contributions were approximately $384 and $158 for the three months ended March 31, 2023 and 2022, respectively. Such contribution expense has been recognized in the consolidated statement of operations for each period.

Note 16—Stock-based compensation

On June 17, 2021, the Company adopted the Century Therapeutics, Inc. 2021 Equity Incentive Plan (the “2021 Incentive Plan”) which superseded the 2018 Incentive Plan and from that date forward all issuances of incentive awards will be governed by the 2021 Incentive Plan.

The 2021 Incentive Plan provides for the Company to sell or issue common stock or restricted common stock, restricted stock units (“RSU”), or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the Board of Directors, and consultants of the Company under terms and provisions established by the Board of Directors. Under the terms of the 2021 Incentive Plan, options may be granted at an exercise price not less than fair market value.

Upon adoption of the 2021 Incentive Plan, the Company was authorized to issue 5,481,735 shares of Common Stock under the 2021 Incentive Plan (which represents 5,640,711 shares of Common Stock initially available for grant under the 2021 Incentive Plan less 158,976 shares of Common Stock reserved for issuance upon the exercise of previously granted stock options that remain outstanding under the 2018 Incentive Plan). The number of shares of common stock initially reserved for issuance under the 2021 Incentive Plan shall be increased, upon approval by the board of directors, on January 1, 2022 and each January 1 thereafter, in an amount equal to the least of, (i) five percent (5%) of the outstanding common stock on the immediately preceding December 31, or (ii) such number of common stock determined by the board of directors no later than the immediately preceding December 31. For 2022, the 2021 Incentive Plan reserved shares were increased under clause (i) by 2,750,276 shares, effective as of January 1, 2022. For 2023, the 2021 Incentive Plan reserved shares were increased under clause (i) by 2,954,788 shares, effective as of January 1, 2023. As of March 31, 2023, there were 4,863,670 shares available for issuance under the 2021 Incentive Plan.

26

The Company’s stock-based awards are subject to service-based vesting conditions. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Stock awards granted typically vest over a four-year period but may be granted with different vesting terms. The Company may also issue awards with performance-based vesting conditions. For performance-based awards, the Company would reassess at each reporting date whether achievement of the performance condition is probable and accrue compensation expense if and when the achievement of the performance condition is probable.

The Company recognizes the costs of the stock-based payments as the employees vest in the awards.

As of March 31, 2023, the Company had reserved shares of common stock for issuance as follows:

    

Shares

Options and RSUs issued and outstanding

10,915,052

Shares available for future stock option and RSU grants

4,863,670

Shares available for employee stock purchase plan

1,114,126

Total

16,892,848

The shares of Common Stock available under the 2021 Incentive Plan as of March 31, 2023 are as follows

    

Shares

Balance, December 31, 2022

5,786,358

Shares reserved for issuance

2,954,788

Options granted

(3,770,399)

RSU’s granted

(546,795)

Options and RSUs forfeited / cancelled

439,718

Balance March 31, 2023

4,863,670

Stock Options

The following table summarizes stock option activity for the three month period ended March 31, 2023:

Weighted Average 

Remaining

Aggregate

Contractual

Intrinsic

Term

Value

    

Shares

    

Exercise Price

    

(years)

(in thousands)

Outstanding January 1, 2023

 

7,489,678

$

7.77

 

7.84

$

8,991

Granted

 

3,770,399

 

4.66

 

 

Exercised

 

(452,102)

 

0.99

 

 

Forfeited

 

(437,573)

 

10.39

 

 

Outstanding, March 31, 2023

 

10,370,402

$

5.28

 

4.55

$

3,952

Exercisable at March 31, 2023

3,145,362

$

6.45

6.93

$

3,262

The weighted average grant date fair value of awards for options granted during the three months ended March 31, 2023 was $4.65. As of March 31, 2023, there was $38,428 of total unrecognized compensation expense related to unvested stock options with time-based vesting terms, which is expected to be recognized over a weighted average period of 3.13 years.

The Company estimates the fair value of its option awards to employees and directors using Black-Scholes. Due to the lack of substantial company-specific historical and implied volatility data of its common stock, the Company has based its estimate of expected volatility on the historical volatility of a group of similar public

27

companies. The Company has never paid dividends and does not expect to in the foreseeable future. The expected term of the options granted to employees is derived from the “simplified” method as described in Staff Accounting Bulletin 107 relating to stock-based compensation. The risk-free interest rates for periods within the expected term of the option are based on the U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company will account for actual forfeitures as they occur.

The weighted-average assumptions used to calculate the fair value of stock options granted are as follows:

March 31, 2022

December 31, 2022

 

Expected dividend rate

 

Expected option term (years)

6.08

 

6.09

Expected volatility

79.15

%  

69.73

%

Risk-free interest rate

3.65

%  

1.08

%

Stock-based compensation expense recorded under ASC 718 related to stock options granted and common stock issued under the 2021 Employee Stock Purchase Plan (the “ESPP”) were allocated to research and development and general and administrative expense as follows:

Three Months Ended

Three Months Ended

March 31, 

March 31, 

2023

2022

Research and development

$

2,112

$

1,309

General and administrative

1,685

1,071

Total stock-based compensation

$

3,797

$

2,380

Stock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:

Three Months Ended

Three Months Ended

March 31, 

March 31, 

2023

2022

Stock options

$

3,546

$

2,108

Restricted stock units

97

Restricted stock awards

93

272

Employee stock purchase plan

61

Total stock-based compensation

$

3,797

$

2,380

Restricted Stock Units

The following table summarizes RSU activity for the quarter ended March 31, 2023:

    

    

Weighted Average

Shares

Grant Date Fair Value

Total Unvested December 31, 2022

 

$

Granted

546,795

4.64

Forfeited

(2,145)

4.64

Total Unvested March 31, 2023

 

544,650

$

4.64

28

As of March 31, 2023, there was $2,428 of total unrecognized compensation expense related to the unvested restricted stock with time-based vesting terms, which is expected to be recognized over a weighted average period of 3.85 years. All restricted stock units vest over a four-year period.

Restricted Stock Awards

The following table summarizes restricted stock activity as of March 31, 2023 and December 31, 2022:

    

    

Weighted Average

Shares

Grant Date Fair Value

Total Unvested December 31, 2022

 

193,031

$

8.41

Granted

Forfeited

(47,689)

Vested

 

(95,877)

 

2.50

Total Unvested March 31, 2023

 

49,465

$

7.27

Pursuant to certain stock purchase agreements containing vesting and other provisions, the Company has the right to repurchase unvested shares.

As of March 31, 2023, there was $356 of total unrecognized compensation expense related to the unvested restricted stock with time-based vesting terms, which is expected to be recognized over a weighted average period of 1.98 years. All restricted stock vests over a four-year period.

Early-Exercise of Unvested Equity Awards

Certain equity award holders early exercised unvested equity awards. The cash received upon early exercise of options of $1,314 was recorded as a deposit liability on the Company’s balance sheet as of March 31, 2023.

Employee Stock Purchase Plan

The ESPP was adopted by the Board of Directors in May 2021. A total of 564,071 shares of common stock were initially reserved for issuance under this plan, which shall be increased, upon approval by the board of directors, on January 1, 2022 and each January 1 thereafter, to the lesser of (i) one percent (1%) of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (ii) an amount determined by the board of directors no later than the last day of the immediately preceding fiscal year. For 2022, the ESPP reserved shares were increased under clause (i) by 550,055 shares, effective as of January 1, 2022. For 2023, the board waived the annual increase to the shares reserved under the ESPP. As of March 31, 2023, there were 1,114,126 shares available for issuance, under the ESPP.

Note 17—Related party transactions

License Agreements and Collaborative Agreements with Shareholder

The Company owns licenses and other contracts with FUJIFILM Cellular Dynamics, Inc. (“FCDI”). FCDI is a shareholder of Century. The acquired licenses and other contracts with FCDI are as follows:

FCDI Licenses

The Company owns a non-exclusive license agreement with FCDI. The license provides the Company with certain patents and know-how related to the reprogramming of human somatic cells to induce pluripotent stem cells (“iPSCs”) (“License Agreement”). Under this agreement, the Company is required to make certain developmental and regulatory milestone payments as well as royalty payments upon commercialization. Royalties are in the low single digits on the sale of all licensed products.

29

The Company also owns an exclusive license agreement with FCDI. The license provides the Company with patents and know-how related to human iPSC exclusively manufactured by FCDI.

The potential development and regulatory milestone payments to be paid by the Company to FCDI are $6,000.

FCDI Collaboration Agreement

In October 2019, the Company entered into the Master Collaboration Agreement with FCDI, whereby FCDI will provide certain services to the Company to develop and manufacture iPSCs and immune cells derived therefrom. FCDI will provide services in accordance with the approved research plan and related research budget. The initial research plan covers the period from October 2019 through March 31, 2022. On July 29, 2022 the Company amended it’s Master Collaboration Agreement to extend the term through September 30, 2025.

On March 23, 2021, the Company entered into a Manufacturing Agreement with FCDI, or the Manufacturing Agreement, pursuant to which FCDI will provide certain agreed upon technology transfer, process development, analytical testing and cGMP manufacturing services to the company.

On January 7, 2022, the Company and FCDI entered into a letter agreement (the “Letter Agreement”), which amends each of the FCDI agreements pursuant to the Company’s Research Collaboration and License Agreement with Bristol-Myers Squibb. Pursuant to the Letter Agreement, and in consideration for amending the FCDI Agreements, the Company will pay to FCDI (i) an upfront payment of $10,000, (ii) a percentage of any milestone payments received by the Company under the FCDI Collaboration Agreement in respect of achievement of development or regulatory milestones specific to Japan, and (iii) a percentage of all royalties received by the Company under the FCDI Collaboration Agreement in respect of sales of products in Japan.

During the three months ended March 31, 2023, the Company made payments of $12 and incurred research and development expenses of $32 and legal fees of $33, recorded within general and administrative expenses in its consolidated statements of operations and comprehensive loss. As of March 31, 2023, there was $21 in accrued expenses related to this agreement on the consolidated balance sheets. As of December 31, 2022, there was $0 in accrued expenses on the consolidated balance sheets.

During the three months ended March 31, 2022, the Company made payments of $3,003 and incurred research and development expenses of $1,445, and legal fees of $30, recorded within general and administrative expenses in its consolidated statements of operations and comprehensive loss.

Bayer Option Agreement

Bayer Health, LLC (“Bayer”) has the right of first refusal to acquire certain products researched and developed by the Company. Subject to certain exceptions, Bayer’s right of first refusal is exercisable with respect to up to four products and may only exercise these option rights in a non-sequential and alternating manner, and such rights are subject to additional limitations.

Consulting Arrangements with Shareholders

In 2019, the Company entered into arrangements with two shareholders of the Company, wherein the shareholders provide consulting services to the Company. As compensation for the consulting services, the shareholders are entitled to an annual retainer fee of $125 payable quarterly, along with payment of reasonable expenses associated with providing the consulting services. The Company incurred $0 related to these consulting arrangements that were included in research and development expenses in the consolidated statements of operations and comprehensive loss for the three  months ended March 31, 2023. The Company incurred $19 related to these consulting arrangements that were included in research and development expenses in the consolidated statements of operations and comprehensive loss for the three months ended March 31, 2022. As of March 31, 2023 and December 31, 2022, there was $0 in accrued

30

expenses related to this agreement on the consolidated balance sheets. This agreement was terminated in January 2023.

Note 18—Subsequent Events

The Company has evaluated subsequent events through the filing of this Quarterly Report on Form 10-Q, and determined that there have been no events that have occurred that would require adjustments to our disclosures in the consolidated financial statements.

On May 1, 2023 the Company repaid the Loan Agreement with Hercules in full. The total repayment was $10,617, which included principal, interest, and end of term and prepayment charge.

31

Item 2. Management’s discussion and analysis of financial condition and results of operations

The following discussion and analysis should be read in conjunction with our financial statements and accompanying notes included in this Quarterly Report on Form 10-Q and the financial statements and accompanying notes thereto for the fiscal year ended December 31, 2022 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, which are contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 16, 2023 (the “Annual Report”). This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). Such forward-looking statements, which represent our intent, belief, or current expectations, involve risks and uncertainties and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terms such as “may,” “will,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “predict,” “potential,” “believe,” “should” and similar expressions. Factors that could cause or contribute to differences in results include, but are not limited to, those set forth under “Risk Factors” in our Annual Report. Except as required by law, we undertake no obligation to update these forward-looking statements to reflect events or circumstances after the date of this report or to reflect actual outcomes.

Overview

We are an innovative biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. We have created a comprehensive allogeneic cell therapy platform that includes industry-leading induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows us to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, our proprietary Allo-EvasionTM technology intended to prevent rejection of our cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. We believe that these vertically integrated capabilities will allow us to further expand our existing pipeline and develop therapeutics from iPSC-derived natural killer cells, or iNK cells, or iNK, and iPSC-derived T cells, or iT cells, or iT, that may provide enhanced clinical outcomes compared to available therapeutic options. Our vision is to become a premier fully integrated biotechnology company by developing and ultimately commercializing off-the-shelf allogeneic cell therapies that dramatically and positively transform the lives of patients suffering from life-threatening cancers. To achieve our vision, we have assembled a world-class team whose members collectively have decades of experience in cell therapy and drug development, manufacturing, and commercialization.

Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, conducting discovery and research activities, filing patent applications, identifying potential product candidates and preparing to initiate and conduct clinical trials, undertaking preclinical studies and in-licensing intellectual property. All of our programs are currently in the development stage, and we do not have any products approved for sale. Since our inception, we have incurred net losses each year. We had an accumulated deficit of $550.4 million as of March 31, 2023. Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs, the acquisition of in-process research and development and from general and administrative costs associated with our operations. Included in our accumulated deficit, as noted above, is a non-cash expense of $225.9 million related to the fair value of the in-process research and development.

In August 2022, the FDA notified us that our ELiPSE-1 clinical trial may proceed to assess CNTY-101 in patients with relapsed or refractory CD19 positive B-cell malignancies. The phase 1 trial, ELiPSE-1, is intended to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CNTY-101 in patients with relapsed or refractory CD19-positive B-cell malignancies. We initiated our phase 1 trial and in February 2023, we began dosing patients in ELiPSE-1, evaluating CNTY-101.

32

In June 2021, we completed our initial public offering, or IPO, in which we issued and sold 12,132,500 shares of our common stock, at a public offering price of $20.00 per share. We received net proceeds of $221.4 million after deducting underwriting discounts, commissions, and other offering costs of $21.2 million in the aggregate. To date, we have funded our operations from the issuance and sale of our equity securities and the receipt of payments from Bristol-Myers Squibb, in connection with our collaborations as described below, and have not generated any revenues. Since our inception, we have raised approximately $591 million in net proceeds from sales of our equity securities. As of March 31, 2023, we had cash and cash equivalents of $86.8 million and investments of $248.0 million.

In January 2023, we announced a strategic internal portfolio prioritization through which, among other discovery efforts, CNTY-103, a CAR-iNK product targeting CD133 and a discovery program for hematological malignancies, was de-prioritized, allowing us to further prioritize our CNTY-102 and CNTY-107 product candidates, which we believe have a higher probability of technical success and greater market potential. As a result of the operational restructuring, lab operations in Seattle and Hamilton, Ontario, have been closed and research activities have been consolidated in Philadelphia.

Based on our current business plans and the January 2023 strategic reprioritization, we believe, our cash, cash equivalents and investments as of March 31, 2023, will be sufficient for us to fund our operating expenses and capital expenditures requirements into 2026. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. We anticipate that our expenses and operating losses will increase substantially over the foreseeable future. The expected increase in expenses will be driven in large part by our ongoing activities, if and as we:

continue to advance our iPSC cell therapy platforms;
progress clinical development of CNTY-101 and continue preclinical development of our other product candidates;
seek to discover and develop additional product candidates;
expand and validate our own clinical-scale current good manufacturing practices, or cGMP, facilities;
seek regulatory approvals for any of our product candidates that successfully complete clinical trials;
maintain, expand, protect, and enforce our intellectual property portfolio;
acquire or in-license other product candidates and technologies; and
increase our employee headcount and related expenses to support these activities.

We are also investing early in building our capabilities in key areas of manufacturing sciences and operations, including development of our iPSC cell therapy platforms, product characterization, and process analytics from the time product candidates are in early research phases. Our investments also include scaled research solutions, scaled infrastructure, and novel technologies intended to improve efficiency, characterization, and scalability of manufacturing.

We anticipate that we will need to raise additional financing in the future to fund our operations, including funding for preclinical studies, clinical trials and the commercialization of any approved product candidates. We intend to use the proceeds from such financings to, among other uses, fund research and development of our product candidates and development programs, including our pre-clinical and clinical development of CNTY-101, CNTY-102, and CNTY-107, as well as CNTY-104 and CNTY-106 in collaboration with Bristol-Myers Squibb. Until such time, if ever, as we can generate significant product revenue, we expect to finance our operations with our existing cash and cash equivalents, investments, any future equity or debt financings, and upfront and milestone and royalties payments, if any, received under future licenses or collaborations. We may not be able to raise additional capital on terms acceptable to us or at all. If we are unable to raise

33

additional capital when desired, our business, results of operations, and financial condition would be adversely affected. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability.

While the COVID-19 pandemic has stabilized within many global regions, it may cyclically continue to adversely affect our business, financial condition and results of operations. Although the Department of Health and Human Services announced that the federal public health emergency for COVID-19 ended on May 11, 2023, we expect the trends that emerged as a result of the pandemic may continue to result in disruptions to the global economy, as well as businesses and capital markets around the world. We experienced modest delays in our discovery and development activities as a result of the COVID-19 pandemic, primarily due to temporary and partial shutdowns at certain of our CROs and academic institutions that have since resumed operations, and due to governmental responses to the pandemic. We implemented a mandatory vaccination policy for all employees and have taken other precautionary measures, including testing of any employees displaying symptoms of COVID-19. While the vaccines have proven effective in reducing the severity and mortality of COVID-19 including the variants that have evolved to date, the emergence of new variants, which could prove resistant to existing vaccines, could again result in major disruptions to businesses and markets worldwide. The extent to which the outbreak may affect our preclinical studies, clinical trials, business, financial condition, and results of operations will depend on future developments, which are uncertain and cannot be predicted at this time.

License and collaboration agreements

Bristol-Myers Squibb

On January 7, 2022, we entered into the Research, Collaboration and License Agreement, with Bristol-Myers Squibb, or the Collaboration Agreement, to collaborate on the research, development and commercialization of iNK and iT cell programs for hematologic malignancies and solid tumors, or the Collaboration Program, and each product candidate, a Development Candidate. We and Bristol-Myers Squibb will initially collaborate on two Collaboration Programs focused on acute myeloid leukemia, or AML, and multiple myeloma, or MM, and Bristol-Myers Squibb has the option to add up to two additional Collaboration Programs for an additional fee. We are responsible for generating Development Candidates for each Collaboration Program, and Bristol-Myers Squibb has the option to elect to exclusively license the Development Candidates for pre-clinical development, clinical development and commercialization on a worldwide basis, or the License Option. Following Bristol-Myers Squibb’s exercise of the License Option, we will be responsible for performing IND-enabling studies, supporting Bristol-Myers Squibb’s preparation and submission of an IND, and manufacturing of clinical supplies until completion of a proof of concept clinical trial. Bristol-Myers Squibb will be responsible for all regulatory, clinical, manufacturing (after the proof of concept clinical trial) and commercialization activities for such Development Candidates worldwide. We have the option to co-promote Development Candidates generated from certain specified Collaboration Programs.

Under the terms of the Collaboration Agreement, Bristol-Myers Squibb made a non-refundable, upfront cash payment of $100 million and will pay an exercise fee upon the exercise of the License Option, or the Licensed Program, and product candidates developed under a Licensed Program, the Licensed Products. For each Licensed Program, Bristol-Myers Squibb will pay up to $235 million in milestone payments upon the first achievement of certain development and regulatory milestones and will pay up to $500 million per Licensed Product in net sales-based milestone payments. Bristol-Myers Squibb will also pay us tiered royalties per Licensed Product as a percentage of net sales in the high-single digits to low-teens, subject to certain adjustments.

In connection with the Collaboration Agreement, Bristol-Myers Squibb purchased 2,160,760 shares of our common stock at a price per share of $23.14, for an aggregate purchase price of $50 million. We determined the common stock purchase represented a premium of $7.82 per share, or $23.2 million in the aggregate, and the remaining $26.8 million was recorded as issuance of common stock in stockholders’ equity.

34

We identified the following commitments under the arrangement: (i) research and development services under each of the two initial Collaboration Programs and (ii) License Option to elect to exclusively license the Development Candidates for each of the two initial Collaboration Programs. We determined that these four commitments represent distinct performance obligations for purposes of recognizing revenue and will recognize revenue as we fulfill each performance obligation.

Fujifilm Cellular Dynamics, Inc. (FCDI)

On September 18, 2018, we entered into a license agreement, or the Differentiation License, with FCDI. The Differentiation License, as amended, provides us with an exclusive license under certain patents and know-how related to human iPSC consisting of cells that are or are modifications of NK cells, T cells, dendritic cells and macrophages derived from human iPSC. In consideration for the Differentiation License, FCDI received 2,980,803 shares of common stock in connection with the Reorganization.

Also on September 18, 2018, we entered into the non-exclusive license, or the Reprogramming License, with FCDI. The Reprogramming License, as amended, provides us with a non-exclusive license under certain patents and know- how related to the reprogramming of human somatic cells to iPSCs and provide us access to iPSC lines for clinical use. Under the Reprogramming License, we are required to make certain developmental and regulatory milestone payments as well as royalty payments upon commercialization in the low single digits. The potential development and regulatory milestone payments to be paid by us to FCDI are approximately $6 million per licensed product. In connection with the Reprogramming License, we entered into a collaboration agreement, or the FCDI Collaboration Agreement, with FCDI pursuant to which we agreed to fund research and development work at FCDI pursuant to a research plan.

On October 21, 2019, we entered into the FCDI Collaboration Agreement with FCDI, whereby FCDI provides certain services to us to develop and manufacture iPSCs and immune cells derived therefrom. Under the terms of the FCDI Collaboration Agreement, as amended, FCDI will provide services in accordance with the approved research plan and related research budget. The initial research plan covers the period from the date of execution of the FCDI Collaboration Agreement through March 31, 2022. On July 29, 2022, we amended the FCDI Collaboration Agreement to extend the term through September 30, 2025.

On January 7, 2022, we and FCDI entered into a letter agreement, or the Letter Agreement, which amends each of the FCDI agreements as further discussed in Note 10 to our consolidated financial statements. Pursuant to the Letter Agreement, and in consideration for amending the FCDI Agreements, we agreed to pay to FCDI (i) an upfront payment of $10 million, (ii) a percentage of any milestone payments received by us under the Collaboration Agreement, in respect of achievement of development or regulatory milestones specific to Japan, and (iii) a percentage of all royalties received by us under the Collaboration Agreement in respect of sales of products in Japan.

During the three months ended March 31, 2023, the Company made payments of $12 thousand and incurred research and development expenses of $33 thousand and legal fees of $31 thousand, recorded within general and administrative expenses in its consolidated statements of operations and comprehensive loss.

During the three months ended March 31, 2022, the Company made payments of $0.8 million and incurred research and development expenses of $0.3 million, and legal fees of $21 thousand, recorded within general and administrative expenses in its consolidated statements of operations and comprehensive loss.

From inception of the FCDI Collaboration Agreement through March 31, 2023, we incurred $36.1 million of expenses under the FCDI Collaboration Agreement.

35

Components of operating results

Collaboration Revenue

We have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products for the foreseeable future. Our revenues to date have been generated through our collaboration, option and license agreement with Bristol-Myers Squibb. We recognize revenue over the expected performance period under this agreement. We expect that our revenue for the next several years will be derived primarily from this agreement and any additional collaborations that we may enter into in the future. To date, we have not received any royalties under any of our existing collaboration agreements.

Operating expenses

Research and development

To date, research and development expenses have related primarily to discovery and development of our iPSC cell therapy platform technology and product candidates and acquired in-process research and development. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are recorded as prepaid expenses until the goods or services are received.

Research and development expenses consist of personnel-related costs, including salaries, and benefits, stock compensation expense, external research and development expenses incurred under arrangements with third parties, laboratory supplies, costs to acquire and license technologies facility and other allocated expenses, including rent, depreciation, and allocated overhead costs, and other research and development expenses.

We deploy our employee and infrastructure resources across multiple research and development programs for developing our iPSC cell therapy platforms, identifying and developing product candidates, and establishing manufacturing capabilities. Due to the number of ongoing projects and our ability to use resources across several projects, the vast majority of our research and development costs are not recorded on a program-specific basis. These include costs for personnel, laboratory, and other indirect facility and operating costs.

Research and development activities account for a significant portion of our operating expenses. We anticipate that our research and development expenses will increase for the foreseeable future as we expand our research and development efforts including expanding the capabilities of our iPSC cell therapy platforms, identifying product candidates, progressing preclinical studies and clinical trials, including for our first clinical product candidate CNTY-101, seeking regulatory approval of our product candidates, and incurring costs to acquire and license technologies aligned with our goal of translating iPSCs to therapies. A change in the outcome of any of these variables could mean a significant change in the costs and timing associated with the development of our product candidates.

General and administrative

General and administrative expenses consist of personnel-related costs, including salaries, benefits, and non-cash stock-based compensation, for our employees in executive, legal, finance, human resources, information technology, and other administrative functions, legal fees, consulting fees, recruiting costs, and facility costs not otherwise included in research and development expenses. Legal fees include those related to corporate and patent matters.

We anticipate that our general and administrative expenses will increase over the foreseeable future to support our continued research and development activities, operations generally, future business development opportunities, consulting fees, as well as due to the increased costs of operating as a public company.

36

In-process research and development

As a direct result of the execution of the Collaboration Agreement with Bristol-Myers Squibb, we incurred $10 million in fees to amend the FCDI agreement to gain access to the territory rights of Japan. See Note 10 to our consolidated financial statements.

Interest expense

Interest expense relates to interest incurred on the Loan Agreement we entered into with Hercules Capital, Inc., or Hercules, in 2020, as well as amortization of the related deferred financing cost. See Note 9 to our consolidated financial statements.

Other income, net

Interest income, net consists of interest earned on our cash, cash equivalents and investment balances.

Income taxes

We have incurred losses and recorded a full valuation allowance on all of our net deferred tax assets. For the three months ended March 31, 2023, the Company recorded $1.2 million in provisions for income taxes in the accompanying consolidated financial statements. The main drivers of the tax provision during the quarter ended March 31, 2023 are taxable revenue related to the Collaboration Agreement with Bristol-Myers Squibb and the limitation of deductions for research and development under Section 174 of the Internal Revenue Code.

Results of operations

Comparison of the three months ended March 31, 2023 and 2022

The following table summarizes our results of operations for the periods presented:

Three Months Ended

Three Months Ended

March 31, 2023

March 31, 2022

Change

(in thousands)

Collaboration revenue

$

1,720

$

1,058

$

662

Operating expenses:

 

 

Research and development

    

24,899

    

21,196

3,703

General and administrative

 

8,902

 

7,298

 

1,604

Write off of in-process research and development asset

 

 

10,000

 

(10,000)

Total operating expenses

 

33,801

 

38,494

 

(4,693)

Loss from operations

 

(32,081)

 

(37,436)

 

5,355

Other income (expense):

Interest expense

 

(404)

 

(314)

 

(90)

Interest income

2,623

253

2,370

Other income, net

 

(194)

 

 

(194)

Total other income (expense)

2,025

(61)

2,086

Loss before provision for income taxes

(30,056)

(37,497)

7,441

Provision for income taxes

(1,208)

(16)

(1,192)

Net loss

$

(31,264)

$

(37,513)

$

6,249

Collaboration revenue

During the three months ended March 31, 2023 and 2022, we recognized revenue of $1.7 and $1.1 million under our collaboration agreement with Bristol-Myers Squibb, respectively.

37

Research and development expenses

The following table summarizes the components of our research and development expenses for the periods presented:

Three Months Ended

Three Months Ended

March 31, 2023

March 31, 2022

Change

(in thousands)

Personnel and related costs

$

12,469

    

$

9,595

    

$

2,874

Facility and other allocated costs

 

5,814

 

2,641

 

3,173

Research and laboratory

 

6,124

 

5,804

 

320

Collaborations

 

254

 

2,385

 

(2,131)

Consulting

 

238

 

609

 

(371)

Other

 

-

 

162

 

(162)

Total research and development expense

$

24,899

$

21,196

$

3,703

Research and development expenses were $24.9 million and $21.2 million for the three months ended March 31, 2023 and 2022. The increase of $3.7 million was primarily due to:

an increase in personnel-related expenses of $2.9 million, including an increase of severance pay of $1.7, which was related to the reduction in force in January of 2023; an increase of $0.2 million in payroll tax expense; and an increase of $0.8 million in stock-based compensation.
an increase of $3.2 million of facility and other allocated costs, including an increase of rent and allocated overhead costs of $1.4 million and an increase in depreciation expense of $1.8 million as a result of an expansion of our geographic footprint for office and lab space;
a decrease of $2.1 million related to our collaboration with FCDI. The decline was due to in process development work being completed in 2022 as the scope of work with FCDI has narrowed down to primarily manufacturing CNTY-101 clinical supply for us.

General and administrative expenses

General and administrative expenses were $8.9 million for the three months ended March 31, 2023 and $7.3 million for three months ended March 31, 2022. The increase of $1.6 million was primarily due to increased personnel-related expenses of $0.8 million, and an increase of stock-based compensation of $0.6 million primarily attributable to an increase in headcount to build our infrastructure, increased information technology and facility costs, including rent, of $0.8 million, partially offset by a decrease in directors’ and officers’ insurance expense of $0.2 million, and decrease in professional development of $0.3 million.

Interest expense

Interest expense was $0.4 million and $0.3 million for the three months ended March 31, 2023 and 2022, respectively, which related to our Loan Agreement with Hercules. On May 1, 2023, we repaid the loan in its entirety and thus expect our interest expenses to decrease accordingly in subsequent periods.

Interest income

Interest income was $2.6 million and $0.3 million for the three months ended March 31, 2023 and 2022, respectively, which related to interest earned on our cash, cash equivalents, and investment balances. The increase in our interest income was due to higher interest rates earned on average balances of cash, cash equivalents and investments.

38

Liquidity, capital resources, and capital requirements

Sources of liquidity

To date, we have funded our operations from the issuance and sale of our equity securities, debt financing and collaboration revenues. Since our inception, we have raised approximately $591 million in net proceeds from the sales of our equity securities. As of March 31, 2023, we had cash, and cash equivalents of $86.8 million and investments of $248.0 million. Based on our research and development plans, we believe our existing cash, cash equivalents and investments, will be sufficient to fund our operating expenses and capital expenditures requirements into 2026. Since our inception, we have incurred significant operating losses. We have not yet commercialized any products and we do not expect to generate revenue from sales of any product candidates for a number of years, if ever. We had an accumulated deficit of $550.4 million as of March 31, 2023.

In July 2022, we entered into a Sales Agreement, or the Sales Agreement, with Cowen and Company, LLC, or Cowen, under which we may offer and sell, from time to time in our sole discretion, shares of our common stock, having an aggregate offering price of up to $150 million through Cowen as sales agent. No sales have been made under the Sales Agreement since its inception.

Future funding requirements

We expect to incur additional losses in the foreseeable future as we conduct and expand our research and development efforts, including conducting preclinical studies and clinical trials, developing new product candidates, establishing internal and external manufacturing capabilities, and funding our operations generally. We anticipate that we will need to raise additional financing in the future to fund our operations, including the commercialization of any approved product candidates. We are subject to the risks typically related to the development of new products, and we may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect our business.

Our future capital requirements will depend on many factors, including:

the scope, timing, progress, costs, and results of discovery, preclinical development, and clinical trials for our current and future product candidates;
the number of clinical trials required for regulatory approval of our current and future product candidates;
the costs, timing, and outcome of regulatory review of any of our current and future product candidates;
the cost of manufacturing clinical and commercial supplies of our current and future product candidates;
the costs and timing of future commercialization activities, including manufacturing, marketing, sales, and distribution, for any of our product candidates for which we receive marketing approval;
the costs and timing of preparing, filing, and prosecuting patent applications, obtaining, maintaining, protecting, and enforcing our intellectual property rights, and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon, misappropriating, or violating their intellectual property rights;
our ability to maintain existing, and establish new, strategic collaborations, licensing, or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty, or other payments due under any such agreement;
the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;
expenses to attract, hire and retain, skilled personnel;

39

our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate reimbursement from third-party and government payors;
the effect of competing technological and market developments; and
the extent to which we acquire or invest in businesses, products, and technologies.

Until and unless we can generate substantial product revenue, we expect to finance our cash needs through the proceeds from a combination of equity offerings and debt financings, and potentially through additional license and development agreements or strategic partnerships or collaborations with third parties. Financing may not be available in sufficient amounts or on reasonable terms. In addition, market volatility resulting from the COVID-19 pandemic, inflationary pressures, disruptions of financial institutions, political unrest and hostilities, war or other factors could adversely impact our ability to access capital as and when needed. We have no commitments for any additional financing and will likely be required to raise such financing through the sale of additional securities, which, in the case of equity securities, may occur at prices lower than the offering price of our common stock. If we sell equity or equity-linked securities, our current stockholders, may be diluted, and the terms may include liquidation or other preferences that are senior to or otherwise adversely affect the rights of our stockholders. Moreover, if we issue debt, we may need to dedicate a substantial portion of our operating cash flow to paying principal and interest on such debt and we may need to comply with operating restrictions, such as limitations on incurring additional debt, which could impair our ability to acquire, sell or license intellectual property rights which could impede our ability to conduct our business.

Cash flows

The following table summarizes our cash flows for the periods indicated:

Three months ended

 

Three months ended

March 31, 2023

     

March 31, 2022

Change

Net cash provided by (used in):

Operating activities

$

(29,219)

$

86,753

    

$

(115,972)

Investing activities

 

31,338

 

(44,037)

 

75,375

Financing activities

 

448

 

26,878

 

(26,430)

Net increase in cash, cash equivalents, and restricted cash

$

2,567

$

69,594

$

(67,027)

Operating activities

Net cash used in operating activities was $29.2 million for the three months ended March 31, 2023. Net cash used in operating activities during the three months ended March 31, 2023 consisted primarily of our net loss of $31.3 million. The non-cash charges of $6.0 million consisted primarily of $2.9 million for depreciation expense, non-cash stock-based compensation expense of $3.8 million, and non-cash operating lease expense of $0.7 million. and net cash outflows from decreases in our accounts payable of $3.0 million and accrued expenses and other liabilities of $3.2 million.

Net cash provided by operating activities was $86.8 million for the three months ended March 31, 2022. Net cash provided by operating activities during the three months ended March 31, 2022 consisted primarily of our deferred revenue of $122.1 million from our collaboration agreement with Bristol-Myers Squibb partially offset by our net loss of $37.5 million and net cash outflows from decreases in our accounts payable of $1.5 million, and accrued expenses and other liabilities of $1.2 million.

Investing activities

Net cash provided by investing activities was $31.3 million for the three months ended March 31, 2023. Cash provided by investing activities for the three months ended March 31, 2023 consisted primarily of the sale of

40

fixed maturity securities, available for sale of $79.2 million, which was partially offset by purchases of fixed maturity securities of $42.8 million and acquisition of property and equipment of $5.0 million.

Cash used in investing activities was $44.0 million for the three months ended March 31, 2022. Cash used in investing activities for the three months ended March 31, 2022 consisted primarily of net purchases of fixed maturity securities of $103.1 million and purchases of property and equipment of $4.1 million.

Financing activities

Net cash provided by financing activities was $0.4 million for the three months ended March 31, 2023. Cash provided by financing activities consisted of $0.4 million from issuance of our common stock from equity incentive plans pursuant to the exercise of employee stock options.

Net cash provided by financing activities was $26.9 million for the three months ended March 31, 2022. Cash provided by financing activities consisted primarily of net proceeds of $26.8 million from Bristol-Myers Squibb for the purchase of our common stock, and cash of $0.1 million from issuance of our common stock from equity incentive plans pursuant to the exercise of employee stock options.

Contractual obligations and commitments

The following table summarizes our significant contractual obligations and commitments as of March 31, 2023:

Payments Due by Period

1 Year

1 to 3 Years

3 to 5 Years

More than 5 Years

Total

(in thousands)

Operating leases

    

$

6,317

    

$

16,829

    

$

17,721

    

$

50,811

    

$

91,678

Long-term debt

10,395

10,395

Interest on long-term debt (1)

122

122

(1) Reflects minimum interest payable under the Loan Agreement. Payment herein subject to variable rate debt have been estimated.

Other than as disclosed in the table above, the payment obligations under our license, collaboration, and acquisition agreements as of March 31, 2023 are contingent upon future events such as our achievement of pre- specified development, regulatory, and commercial milestones, or royalties on net product sales. As of March 31, 2023, the timing and likelihood of achieving the milestones and success payments and generating future product sales are uncertain and therefore, any related payments are not included in the table above. We have commitments under operating leases for certain facilities used in our operations.

We also enter into agreements in the normal course of business for sponsored research, preclinical studies, contract manufacturing, and other services and products for operating purposes, which are generally cancelable upon written notice. These obligations and commitments are not included in the table above. See Note 11 to our unaudited consolidated financial statements for additional information.

We have entered into a $10.0 million Term Loan Agreement with Hercules. Amounts borrowed under the Loan Agreement have an interest-only period of up to 24 months and a maturity date of April 1, 2024. On May 1, 2023, the Company repaid the loan in its entirety See Note 9 to our unaudited consolidated financial statements for additional information.

JOBS Act accounting election

As a company with less than $1.235 billion in revenue during our last fiscal year, we qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. An emerging growth company may take advantage of specified reduced reporting requirements that are

41

otherwise generally applicable to public companies. As such, we may take advantage of reduced disclosure and other requirements otherwise generally applicable to public companies, including:

not being required to have our registered independent public accounting firm attest to management’s assessment of our internal control over financial reporting;
presenting reduced disclosure about our executive compensation arrangements;
an exemption from compliance with any requirement that the Public Company Accounting Oversight Board may adopt regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements;
not being required to hold non-binding advisory votes on executive compensation or golden parachute arrangements; and
extended transition periods for complying with new or revised accounting standards.

The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards until those standards would otherwise apply to private companies. We have elected to use the extended transition period to enable us to comply with new or revised accounting standards and, therefore, we will adopt new or revised accounting standards at the time private companies adopt the new or revised accounting standard and will do so until such time that we either (i) irrevocably elect to “opt out” of such extended transition period or (ii) no longer qualify as an emerging growth company.

We will remain an emerging growth company until the earliest of (i) December 31, 2026, (ii) the last day of the fiscal year in which we have total annual gross revenue of at least $1.235 billion, (iii) the last day of the fiscal year in which we are deemed to be a “large accelerated filer” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, which would occur if the market value of our common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such year or (iv) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.

We are also a “smaller reporting company,” meaning that the market value of our stock held by non-affiliates is less than $700.0 million and our annual revenue is less than $100.0 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250.0 million or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700.0 million as of the last business day of the second fiscal quarter of such year. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.

Critical accounting policies and significant judgments and estimates

Refer to Note 2, Summary of Significant Accounting Policies, included in Part I, Item 1 of this Quarterly Report on Form 10-Q for a discussion of our critical accounting policies.

During the three months ended March 31, 2023, there were no material changes to our critical accounting policies from those described in our audited financial statements for the year ended December 31, 2022

42

included in the our Annual Report on Form 10-K filed with the SEC on March 16, 2023, except as noted below.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. We do not currently have any material exposure to foreign currency fluctuations and do not engage in any hedging activities as part of our normal course of business.

Interest rate risk

We had cash, cash equivalents, and restricted cash of $86.0 million as of March 31, 2023, which consisted of bank deposits and money market funds. We also had investments of $248.8 million as of March 31, 2023. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. However, because of the low risk profile of the instruments in our portfolio, a change in market interest rates would not have a material impact on our financial condition and/or results of operations. Additionally, we had the $10.0 million borrowing related to the Loan Agreement in September 2020 with a floating interest rate per annum (based on a year of 360 days) equal to (i) the sum of (a) the greater of 6.30% plus (b) the prime rate as reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue, or (ii) 9.55%. We are therefore exposed to changes in variable United States interest rates on borrowings under our Loan Agreement. A hypothetical 1% increase in interest rates would not result in a material impact to our business.

Banking Instability

Future disruptions of financial institutions where we bank or have credit arrangements, or disruptions of the financial services industry in general, could adversely affect our ability to access our cash and cash equivalents.

Effects of Inflation

Inflation generally affects us by increasing our cost of labor and laboratory consumables. We believe that inflation has not had a material effect on our financial statements.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosures controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of March 31, 2023. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March 31, 2023, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at a reasonable assurance level.

43

Changes in Internal Control over Financial Reporting

Management determined that, as of March 31, 2023, there were no changes in our internal control over financial reporting that occurred during the three months then ended that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

44

PART II—OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which would have a material adverse effect on our results of operations, financial condition or cash flows.

Item 1A. Risk Factors

There have been no material changes in our risk factors from those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Use of Proceeds

On June 22, 2021, we completed our IPO. Our registration statement on Form S-1 (File No. 333- 256648) relating to the IPO was declared effective by the SEC on June 17, 2021. We issued an aggregate of 12,132,500 shares of our common stock at a price of $20.00 per share for aggregate net cash proceeds of $221.4 million, after deducting approximately $17.0 million in underwriting discounts and commissions and approximately $4.0 million in other offering costs. None of the expenses associated with the IPO were paid to directors, officers, persons owning 10% or more of any class of equity securities, or to their associates, or to our affiliates.

The sale and issuance of 12,132,500 shares in the IPO closed on June 22, 2021. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler acted as joint book-running managers for the IPO.

There has been no material change in the planned use of proceeds from the IPO from that described in the prospectus filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act on June 21, 2021.

Dividends

Our ability to pay cash dividends is currently restricted by the terms of our Loan and Security Agreement with Hercules Capital, Inc., as discussed in Note 9 - “Long term debt” in the notes to our consolidated financial statements.

Repurchase of Shares of Company Equity Securities

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

45

Item 6. Exhibits.

Exhibit

Number

    

10.1

Executive Employment Agreement, by and between the Company and Hyam Levitsky, M.D., dated April 15, 2023

10.2

Separation Agreement and Release by and between the Company and Hyam Levitsky, M.D., dated January 23, 2023

31.1

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2

Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1*

Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2*

Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS

Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)

101.SCH

Inline XBRL Taxonomy Extension Schema

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase

104

The cover page from Century Therapeutics, Inc. Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, formatted in Inline XBRL and contained in Exhibit 101

*

This certification is being furnished solely to accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

● Indicates management contract or compensatory plan

46

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned thereunto duly authorized.

Century Therapeutics, Inc.

Date: May 11, 2023

By:

/s/ Gregory Russotti, Ph.D.

Gregory Russotti, Ph.D.

interim President and Chief Executive Officer

(Principal Executive Officer)

Date: May 11, 2023

By:

/s/ Michael Diem, M.D.

Michael Diem, M.D.

Chief Financial Officer

(Principal Financial Officer)

47

EX-10.1 2 ipsc-20230331xex10d1.htm EX-10.1

Exhibit 10.1

EXECUTIVE EMPLOYMENT AGREEMENT

This Executive Employment Agreement (the “Agreement”), dated April 15, 2023, is made and entered into by and between CENTURY THERAPEUTICS, INC., a Delaware corporation (the “Company”) and HYAM LEVITSKY (“Executive”), and will become effective as of April 12, 2023 (the “Effective Date”).

Introduction

WHEREAS, the Company desires to employ Executive on the terms and conditions set forth herein; and

WHEREAS, Executive desires to be employed by the Company on such terms and conditions.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the parties agree as follows:

1.Position. Executive will serve as the President of Research and Development of the Company and will report directly to the Chief Executive Officer of the Company or his or her delegate. In addition to performing the duties and responsibilities associated with that position, from time to time the Company may assign to Executive other duties and responsibilities reasonable and consistent with such position. Executive agrees to devote his full business time and best efforts to the performance of his duties and to the furtherance of the Company’s interests. Executive also agrees that during his employment with the Company, he will not engage in any other employment, consulting or business services without the written consent of the Company; provided, however, that without such consent, Executive may engage in (i) charitable or public service and (ii) the activities described on Schedule 1, so long as such activities do not interfere with the performance of his duties and obligations to the Company.

2.Term. Executive’s employment pursuant to this Agreement will commence on the Effective Date and will continue until terminated in accordance with Section 8 hereof.

3.Place of Performance. Executive will perform services hereunder at the principal executive offices of the Company in a location to be determined by the board of directors of the Company (the “Board”); provided, however, that Executive may be required to travel from time to time for business purposes.

4.Salary. This is a frill-time exempt position. The Company will pay Executive a salary at an annual rate of $430,700 (“Base Salary”), payable in accordance with the Company’s standard payroll schedule and subject to applicable deductions and withholdings. The Base Salary shall be reviewed on an annual basis by the Compensation Committee of the Board (the “Committee”) and may be adjusted from time to time by the Committee.

5.Annual Bonus. For each calendar year ending during his employment, Executive will have the opportunity to earn an annual bonus with a target amount of 40% of the Base Salary in effect at the end of the applicable year (the “Target Bonus”). The actual bonus payable to Executive, if


any, with respect to any year may be more or less than the Target Bonus and will be determined by the Committee, in its sole discretion, based on the achievement of corporate and/or personal objectives established by the Committee. Except as otherwise provided herein or determined by the Committee, payment of any otherwise earned bonus will be conditioned on Executive’s continued service through the date that annual bonuses are paid to the Company’s executive officers generally with respect to the applicable year.

6.Equity Incentives. As soon as practicable after the Effective Date, the Company will recommend to the Board that Executive receive a one-time grant of, as elected by Executive, either (i) stock options to purchase 131,250 shares of the Company’s common stock (as such term is defined in the Equity Documents) or (ii) stock options to purchase 98,437 shares of the Company’s common stock and restricted stock units covering 32,813 shares of the Company’s common stock. The Executive’s eligibility for and other rights with respect to the options and restricted stock units will be governed by the 2021 Equity Incentive Plan and the associated equity grant agreements required to be entered into by Executive and the Company (the “Equity Documents”). To the extent this Agreement conflicts with the Equity Documents, the Equity Documents shall control. Executive may receive additional equity awards, at times and on terms determined by the Committee in its discretion.

7.Benefits; Business Expenses.

(a)Executive shall be entitled to participate in Company benefit plans that are generally available to other employees of the Company of similar rank and tenure, in accordance with and subject to the terms and conditions of such plans, as in effect from time to time.

(b)The Company will pay or reimburse Executive for all reasonable business expenses incurred or paid by Executive in the performance of his duties and responsibilities for the Company in accordance with the expense reimbursement policies of the Company, as may be amended from time to time.

8.Termination.

(a)Executive’s employment hereunder shall terminate on the earliest of: (i) on the date set forth in a written notice to Executive from the Board that Executive’s employment with the Company has been or will be terminated, (ii) on the date not less than 30 days following written notice from Executive to the Company that Executive is resigning from the Company, (iii) on the date of Executive’s death, or (iv) on the date set forth in a written notice to Executive from the Board that Executive’s employment is terminated on account of Executive’s Disability, as determined by the Board. Notwithstanding the foregoing, in the event that Executive gives notice of termination to the Company, the Company may unilaterally accelerate the date of termination and such acceleration shall not constitute a termination by the Company for purposes of this Agreement.

(b)Upon cessation of Executive’s employment for any reason, unless otherwise consented to in writing by the Board, Executive will resign immediately from any and all officer, director and other positions Executive then holds with the Company and its affiliates and agrees to execute such documents as may be requested by the Company to confirm that resignation.


(c)Upon any cessation of Executive’s employment with the Company, Executive will be entitled only to such compensation and benefits as described in Section 9 below.

(d)Executive agrees that, following any cessation of his employment and subject to reimbursement of his reasonable expenses, he will cooperate with the Company and its counsel with respect to any matter (including litigation, investigations, or governmental proceedings) in which Executive was in any way involved during his employment with the Company. Executive agrees to render such cooperation in a timely manner on reasonable notice from the Company, provided the Company exercises reasonable efforts to limit and schedule the need for Executive’s cooperation so as not to materially interfere with his other professional obligations.

(e)Executive agrees that, upon any cessation of his employment, he will deliver to the Company (and will not retain in his possession or control, or deliver to anyone else) all property and equipment of the Company, including without limitation (i) all keys, books, records, computer hardware, software, cellphones, access cards, credit cards and identification, and (ii) all other Company materials (including copies thereof), including without limitation any records, data, notes, reports, proposals, lists or correspondence.

9.Rights Upon Termination.

(a)Termination without Cause or Resignation for Good Reason. If Executive’s employment by the Company ceases due to a termination by the Company without Cause (as defined below) or a resignation by Executive for Good Reason (as defined below):

(i)the Company shall pay to Executive all accrued and unpaid Base Salary through the date of such cessation of employment at the time such Base Salary would otherwise be paid according to the Company’s usual payroll practices;

(ii)to the extent then unpaid, the Company shall pay to Executive the annual bonus (if any) earned with respect to the fiscal year ended immediately prior to the cessation of Executive’s employment;

(iii)the Company shall make monthly severance payments equal to one-twelfth of Executive’s Base Salary as in effect immediately prior to such cessation of employment (or, if such cessation is due to the Good Reason described in clause (ii) of that definition, the Base Salary in effect immediately prior to such material diminution) for a period equal to the Severance Period;

(iv)if Executive validly elects to receive continuation coverage under the Company’s group health plan (if any) pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”), the Company shall reimburse Executive the applicable premium otherwise payable for COBRA continuation coverage for himself and his eligible dependents for the Severance Period, to the extent such premium exceeds the monthly amount charged to active similarly-situated employees of the Company for the same coverage; and

(v)to the extent such cessation of employment occurs within three (3) months prior to or twelve (12) months following a Change in Control (as defined below), (x) the Company shall pay to Executive an amount equal to the Target Bonus, and (y) all outstanding equity awards that are subject to vesting solely based on the passage of time and Executive’s continued


employment shall become vested upon the later of the date of Executive’s cessation of employment and the Change in Control.

Except as otherwise provided in this Section 9(a), all compensation and benefits will cease at the time of Executive’s cessation of employment and the Company will have no further liability or obligation by reason of such cessation of employment. The payments and benefits described in this Section 9(a) are in lieu of, and not in addition to, any other severance arrangement maintained by the Company. Notwithstanding any provision of this Agreement, the payments and benefits described in Section 9(a)(ii) - 9(a)(v) are conditioned on Executive’s execution and delivery to the Company and the expiration of all applicable statutory revocation periods, by the 60th day following the effective date of Executive’s cessation of employment, of a general release of claims against the Company and its affiliates (which shall have customary exclusions relating to Executive’s equity in the Company, any claims that Executive may have relating to accrued vested benefits under the Company’s benefit plans, subject to the terms and conditions of such plans, and any claims for indemnification in Executive’s role as an officer and director of the Company) in a form and manner satisfactory to the Company (the “Release”) and on Executive’s continued compliance with the provisions of the Proprietary Information and Assignment Agreement (defined below).

Subject to Section 10 below (to the extent applicable) and provided the Release requirement described above has been timely satisfied: (x) the payment described in Section 9(a)(ii) will be paid on the later of the sixty-fifth (65th) day following Executive’s cessation of employment (the “Settlement Date”)and the date such annual bonus would have otherwise been paid, absent Executive’s cessation of employment; (y) the payments described in Section 9(a)(iii) and 9(a)(iv) will commence to be paid on the Settlement Date, provided that the initial payment will include any payments that, but for the above-described timing rule, would have otherwise been paid since the date of Executive’s cessation of employment; and (z) the payment of an amount equal to the Target Bonus described in Section 9(a)(v) will be paid on the later of the Settlement Date or the tenth (10th) day following the Change in Control.

(b)Other Terminations. If Executive’s employment with the Company ceases for any reason other than as described in Section 9(a) above (including but not limited to (i) termination by the Company for Cause, (ii) resignation by Executive without Good Reason, (iii) termination as a result of Executive’s Disability, or (iv) Executive’s death), then the Company’s obligation to Executive will be limited solely to the payment of accrued and unpaid Base Salary through the date of such cessation of employment. All compensation and benefits will cease at the time of such cessation of employment and, except as otherwise provided by COBRA, the Company will have no further liability or obligation by reason of such termination. The foregoing will not be construed to limit Executive’s right to payment or reimbursement for claims incurred prior to the date of such termination under any insurance contract funding an employee benefit plan, policy or arrangement of the Company in accordance with the terms of such insurance contract.

10.Section 409A.

(a)The parties intend for this Agreement to comply with or be exempt from Section 409A of the Code, and all provisions of this Agreement will be interpreted and applied


accordingly. Nonetheless, the Company does not guaranty the tax treatment of any compensation payable to Executive.

(b)Notwithstanding anything to the contrary in this Agreement, no portion of the benefits or payments to be made under Section 9(a) above will be payable until Executive has a “separation from service” from the Company within the meaning of Section 409A of the Code. In addition, to the extent compliance with the requirements of Treas. Reg. § 1.409A-3(i)(2) (or any successor provision) is necessary to avoid the application of an additional tax under Section 409A of the Code to payments due to Executive upon or following his “separation from service,” then notwithstanding any other provision of this Agreement (or any otherwise applicable plan, policy, agreement or arrangement), any such payments that are otherwise due within six months following Executive’s “separation from service” (taking into account the preceding sentence of this paragraph) will be deferred without interest and paid to Executive in a lump sum immediately following that six month period. This paragraph should not be construed to prevent the application of Treas. Reg. § 1.409A-l(b)(9)(iii) (or any successor provision) to amounts payable hereunder. For purposes of the application of Section 409A of the Code, each payment in a series of payments will be deemed a separate payment.

(c)Notwithstanding anything in this Agreement to the contrary, to the extent an expense, reimbursement or in-kind benefit provided to Executive pursuant to this Agreement or otherwise constitutes a “deferral of compensation” within the meaning of Section 409A of the Code: (i) the amount of expenses eligible for reimbursement or in-kind benefits provided to Executive during any calendar year will not affect the amount of expenses eligible for reimbursement or in-kind benefits provided to Executive in any other calendar year, (ii) the reimbursements for expenses for which Executive is entitled to be reimbursed shall be made on or before the last day of the calendar year following the calendar year in which the applicable expense is incurred, and (iii) the right to payment or reimbursement or in-kind benefits hereunder may not be liquidated or exchanged for any other benefit.

11.Section 280G. Notwithstanding any contrary provision of this Agreement (or any plan, policy, agreement or other arrangement covering Executive), if any payment, right or benefit paid, provided or due to Executive, whether pursuant to this Agreement or otherwise (each, a “Payment,” and collectively, the “Total Payments”), would subject Executive to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then the Total Payments will be reduced to the minimum extent necessary to avoid the imposition of the Excise Tax, but only if (i) the amount of such Total Payments, as so reduced, is greater than or equal to (ii) the amount of such Total Payments without reduction (in each case, determined on an after-tax basis). Any reduction of the Total Payments required by this paragraph will be implemented by determining the Parachute Ratio (as defined below) for each Payment and then by reducing the Payments in order, beginning with the Payment with the highest Parachute Ratio. For Payments with the same Parachute Ratio, later Payments will be reduced before earlier Payments. For Payments with the same Parachute Ratio and the same time of payment, each Payment will be reduced proportionately. For purposes of this paragraph, “Parachute Ratio” means a fraction, (x) the numerator of which is the value of the applicable Payment, as calculated for purposes of Section 280G of the Code, and (y) the denominator of which is the economic value of the applicable Payment.


12.Certain Definitions. For purposes of this Agreement:

(a)Cause” means (i) conduct by Executive constituting a material act of misconduct in connection with the performance of Executive’s duties, including, without limitation, a material misappropriation of funds or property of the Company or any of its subsidiaries or affiliates; (ii) the commission by Executive of any felony or a misdemeanor involving moral turpitude, deceit, dishonesty or fraud, or any conduct by Executive that would reasonably be expected to result in material injury or reputational harm to the Company or any of its subsidiaries and affiliates; (iii) continued material non-performance by Executive of his duties hereunder (other than by reason of Executive’s physical or mental illness, incapacity or disability) which has continued for more than 10 days following written notice of such non­performance from the Board; (iv) a material breach by Executive of the Proprietary Information and Assignment Agreement (defined below), any other agreement with the Company or its affiliates, or of any duty owed to the Company or its affiliates, which breach is not cured (if curable) within 10 days after the delivery of written notice thereof; (v) a material violation by Executive of the Company’s written employment policies, including policies prohibiting sexual harassment, which violation is not cured (if curable) within 10 days after the delivery of written notice thereof; (vi) alcohol abuse or use of controlled substances (other than prescription drugs taken in accordance with a physician’s prescription); or (vii) failure to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Company to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigation. For avoidance of doubt, a termination of Executive’s employment due to his Disability will not constitute a termination without Cause.

(b)Change in Control” shall mean the occurrence of a “change in control event” with respect to the Company, within the meaning of Treas. Reg. § 1.409A-3(i)(5)(i).

(c)Code” means the Internal Revenue Code of 1986, as amended.

(d)Disability” means a condition entitling Executive to benefits under the Company’s long term disability plan, policy or arrangement; provided, however, that if no such plan, policy or arrangement is then maintained by the Company and applicable to Executive, “Disability” will mean Executive’s inability to perform his duties under this Agreement due to a mental or physical condition (other than alcohol or substance abuse) that can be expected to result in death or that can be expected to last (or has already lasted) for a continuous period of 90 days or more, or for 120 days in any 180 consecutive-day period. Termination as a result of a Disability will not be construed as a termination by the Company “without Cause.”

(e)Good Reason” means: (i) a material diminution in Executive’s title, responsibilities, authority or duties; (ii) a material diminution in Executive’s Base Salary, except for across-the-board salary reductions similarly affecting all or substantially all C-level executives of the Company; (iii) a change of more than 50 miles in the geographic location at which Executive provide services to the Company; or (iv) the material breach of this Agreement by the Company; provided, however, that no such event will constitute Good Reason unless (x) Executive provides the Company with written objection to such event within 60 days after the initial occurrence thereof, (y) such event is not reversed or corrected by the Company within 30 days of its receipt


of such written objection, and (z) Executive separates from service within 60 days following the expiration of that cure period.

(f)Severance Period” means nine (9) months. Notwithstanding the foregoing, with respect to a cessation of employment due to a termination by the Company without Cause or resignation by Executive for Good Reason that occurs (in either case) within three (3) months prior to a Change in Control or twelve (12) months following a Change in Control, “Severance Period” shall mean twelve (12) months.

13.Company Policies. Executive will comply with all policies of the Company in effect from time to time, including (without limitation) policies regarding ethics, personal conduct, stock ownership, securities trading, clawback and hedging and pledging of securities.

14.Indemnification. In addition to any rights to indemnification to which Executive may be entitled under the Company’s governing documents, the Company shall obtain and maintain an appropriate level of Directors and Officers Liability insurance coverage for Executive’s benefit on the same terms as applicable to other directors and C-level executives of the Company.

15.Proprietary Information and Assignment Agreement. On the same date this Agreement is executed, Executive will execute the Proprietary Information and Assignment Agreement attached hereto as Exhibit A (the “Proprietary Information and Assignment Agreement”).

16.No Conflicting Agreements. Executive represents and warrants that he is not a party to or otherwise bound by any agreement or restriction that could conflict with, or be violated by, the performance of his duties to the Company or his obligations under this Agreement. Executive will not use or misappropriate any intellectual property, trade secrets or confidential information belonging to any third party.

17.Taxes. All compensation payable to Executive are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law. Executive hereby acknowledges that the Company does not have a duty to design its compensation policies in a manner that minimizes Executive’s tax liabilities, and Executive not make any claim against the Company or its board of directors related to tax liabilities arising from his compensation.

18.Entire Agreement; Assignment; Amendment.

(a)This Agreement, together with the Proprietary Information and Assignment Agreement, constitute the final and entire agreement of the parties with respect to the matters covered hereby and replace and supersede all prior agreements, discussions, negotiations, representations or understandings (whether written, oral or implied) relating to Executive’s employment by the Company, including without limitation the Prior Agreement.

(b)The rights and obligations of Executive hereunder are personal and may not be assigned. The Company may assign this Agreement, and its rights and obligations hereunder, to any entity to which the Company transfers substantially all of its assets (or an affiliate thereof). Notwithstanding any other provision of this Agreement, any such assignment of this Agreement by the Company will not entitle Executive to severance benefits under Section 9(a) or otherwise, whether or not Executive accepts employment with the assignee.


(c)This Agreement may be amended or modified only by a written instrument signed by a duly authorized officer of the Company and Executive.

19.Governing Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware, without regard to its choice of law provisions.

20.Arbitration. In the event of any dispute under the provisions of this Agreement or otherwise regarding Executive’s employment or compensation (other than a dispute in which the primary relief sought is an injunction or other equitable remedy, such as an action to enforce compliance with the Proprietary Information and Assignment Agreement), the parties shall be required to have the dispute, controversy or claim settled by arbitration in Philadelphia County, Commonwealth of Pennsylvania, in accordance with the National Rules for the Resolution of Employment Disputes then in effect of the American Arbitration Association (“AAA”), by one arbitrator mutually agreed upon by the parties (or, if no agreement can be reached within 30 days after names of potential arbitrators have been proposed by the AAA, then by one arbitrator having relevant experience who is chosen by the AAA). Any award or finding will be confidential. The arbitrator may not award attorneys’ fees to either party unless a statute or contract at issue specifically authorizes such an award. Any award entered by the arbitrators will be final, binding and non-appealable and judgment may be entered thereon by either party in accordance with applicable law in any court of competent jurisdiction. This arbitration provision will be specifically enforceable. Each party will be responsible for its own expenses relating to the conduct of the arbitration (including reasonable attorneys’ fees and expenses) and will share equally the fees of the arbitrator.

21.Headings. The headings of the sections of this Agreement are inserted for convenience only and shall not the meaning of this Agreement.

22.Notices. All notices, demands or other communications hereunder shall be in writing and shall be deemed to have been duly given if delivered in person, by e-mail or fax, by United States mail, certified or registered with return receipt requested, or by a nationally recognized overnight courier service, or otherwise actually delivered: (a) if to Executive, at the most recent address contained in the Company’s personnel files; (b) if to the Company, to the attention of its Legal Department at the address of its principal executive office; or (c) or at such other address as may have been furnished by such person in writing to the other party. Any such notice, demand or communication shall be deemed given on the date given, if delivered in person, e-mailed or faxed, on the date received, if given by registered or certified mail, return receipt requested or by overnight delivery service, or three days after the date mailed, if otherwise given by first class mail, postage prepaid.

23.Counterparts. This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement.

[Signature Page Follows]


This Agreement has been executed and delivered on the date first above written.

CENTURY THERAPEUTICS, INC.

By:

/s/ Gregory Russotti, Ph.D.

Name:

Gregory Russotti, Ph.D.

Title:

Interim President and Chief Executive Officer

EXECUTIVE

Hyam Levitsky, M.D.

By:

/s/ Hyam Levitsky, M.D.

Name:

Hyam Levitsky, M.D.

[Signature Page to Employment Agreement]


EX-10.2 3 ipsc-20230331xex10d2.htm EX-10.2

Exhibit 10.2

SEPARATION AGREEMENT AND RELEASE

THIS SEPARATION AGREEMENT AND RELEASE is made by and between HYAM LEVITSKY, M.D. (“Employee”) and CENTURY THERAPEUTICS, INC. (the “Company”) as of the last date signed below.

RECITALS

WHEREAS, Employee is presently employed by the Company as its President of Research and Development;

WHEREAS, on May 26, 2021, Employee entered into an Employee Confidentiality, Restrictive Covenant and Assignment Agreement (the “Confidentiality Agreement”) and an Executive Employment Agreement with the Company (the “Employment Agreement”);

WHEREAS, on January 5, 2023, Employee provided the Company with written notice of his intention to resign from employment with “Good Reason” (as that term is used in the Employment Agreement);

WHEREAS, the Company and Employee desire to enter into this Separation Agreement and Release to set forth the terms and conditions of Employee’s remaining period of employment and Employee’s entitlements in connection with the cessation of his employment; and

NOW THEREFORE, in consideration of the mutual promises made herein, intending to be legally bound, the Company and Employee hereby agree as follows:

1.Transition Period; Cessation of Employment.

a.The Company agrees to continue to employ Employee, and Employee agrees to remain in employment with the Company, until the earliest of (i) January 31, 2023 (the “Termination Date”), (ii) the date of Employee’s death or Disability, or (iii) the date Employee’s employment is terminated by the Company with Cause, at which time Employee’s employment by the Company will cease. For the purposes of this Separation Agreement and Release, “Cause” and “Disability” have the meaning set forth in the Employment Agreement.

b.During the period between the date hereof and the date his employment ceases (the “Transition Period”), Employee agrees to devote his reasonable best efforts and full business time to the performance of his duties for the Company and its affiliates (collectively, the “Company Group”), including, but not limited to, conducting an orderly transition of his duties to other Company Group personnel.

c.Employee hereby resigns all offices, titles and positions with the Company Group, effective as of the date his employment ceases, and agrees to execute such further documents as the Company Group may reasonably request to confirm such resignation. Employee further agrees that no compensation or other amounts are payable

-1-


in connection with the cessation of his employment and service, except as expressly provided in this Separation Agreement and Release.

2.Compensation During the Transition Period. During the Transition Period, Employee will continue to be paid his base salary at the current rate, but will not be eligible for a 2023 bonus or any additional equity incentive awards.

3.Compensation Upon Cessation of Employment.

a.In the event of Employee’s cessation of employment prior to the Termination Date due to his death, Disability, or a termination by the Company for Cause, the consequences of such termination shall be as set forth in the Employment Agreement. If Employee resigns from employment with the Company prior to the Termination Date or otherwise fails to comply with paragraph 1 of this Separation Agreement and Release, the consequences of such termination shall be as described in the Employment Agreement with respect to a resignation with Good Reason.

b.Provided that Employee remains employed with the Company until the Termination Date in accordance with this Separation Agreement and Release, executes this Separation Agreement and Release within 21 days of the date it was delivered to him and does not revoke this Separation Agreement and Release, executes the Subsequent Release attached hereto as Exhibit A and does not revoke such Subsequent Release such that it becomes irrevocable within 60 days following the Termination Date, and complies with the Confidentiality Agreement, the Company:

(i)waives its right to “cure” such Good Reason basis and agrees that Employee’s cessation of employment on the Termination Date will be a resignation with Good Reason;

(ii)will provide Employee with the severance payments, rights and benefits described in Section 9(a) of the Employment Agreement, at the time(s) and in the manner therein specified;

(iii)will cause the restricted stock award issued to Employee by the Company on September 18, 2019 to become fully vested as of the Termination Date; and

(iv)will cause each vested Company stock option held by Employee on the Termination Date to remain exercisable until the date that is six months following the Termination Date (subject to earlier termination only if provided in the applicable equity plan or award agreement in connection with a change in control of the Company or similar event or transaction).

c.Employee acknowledges and agrees that Employee will not be entitled to any severance benefits from the Company Group if he does not fulfill the conditions described above in paragraph 3(b) of this Separation Agreement and Release. Employee acknowledges that the severance payments, rights and benefits described above in paragraph 3(b) constitute consideration to which Employee would not be entitled without

-2-


timely signing and not revoking this Separation Agreement and Release and the Subsequent Release.

4.Employee’s Release. Employee hereby generally releases and discharges the Company, together with each and every of its predecessors, successors (by merger or otherwise), parents, subsidiaries, affiliates, divisions, directors, officers, employees and agents, whether present or former (collectively the “Releasees”), from any and all suits, causes of action, complaints, obligations, demands, or claims of any kind, whether in law or in equity, direct or indirect, known or unknown, suspected or unsuspected (hereinafter “claims”), which Employee ever had or now has against the Releasees, or any one of them, arising out of or relating to any matter, thing or event occurring up to and including the date of this Separation Agreement and Release. Employee’s release specifically includes, but is not limited to:

a.any and all claims for wages and benefits including, without limitation, salary, stock, options, commissions, royalties, license fees, health and welfare benefits, separation pay, vacation pay, and bonuses;

b.any and all claims for wrongful discharge, breach of contract (whether express or implied), or for breach of the implied covenant of good faith and fair dealing;

c.any and all claims for alleged employment discrimination, harassment or retaliation on the basis of race, color, religion, sex, sexual orientation, national origin, age, ancestry, veteran or military status, genetic information, disability and/or handicap, familial status, marital status, gender identity, and any and all other claims in violation of any federal, state or local statute, ordinance, judicial precedent or executive order, including but not limited to claims under the following statutes: Title VII of the Civil Rights Act of 1964, 42 U.S.C. §§ 2000e et seq., the Civil Rights Act of 1866, 42 U.S.C. § 1981, the Age Discrimination in Employment Act, 29 U.S.C. §§ 621 et seq., the Older Workers Benefit Protection Act, 29 U.S.C. § 626(f), the Uniformed Services Employment and Reemployment Rights Act, 38 U.S.C. §§ 4301 et seq., the Americans with Disabilities Act, 42 U.S.C. §§ 12101 et seq., the National Labor Relations Act, 29 U.S.C. §§ 151 et seq., the Worker Adjustment and Retraining Notification Act, 29 U.S.C. §§ 2101 et seq., the Genetic Information Nondiscrimination Act, 42 U.S.C. §§ 2000ff et seq., the Rehabilitation Act of 1973, 29 U.S.C. §§ 701 et seq., the Family and Medical Leave Act, 29 U.S.C. §§ 2601 et seq., the Employee Retirement and Income Security Act of 1974, 29 U.S.C. §§ 1001 et seq., the Pennsylvania Human Relations Act, the Pennsylvania Whistleblower Law, the Philadelphia Fair Practices Ordinance, the Washington Industrial Welfare Act, the Washington Minimum Wage Act, the Washington Wage Payment Act and Wage Rebate Act, the Washington Law Against Discrimination, Washington leave laws (including the Paid Sick Leave Act, the Family Care Act, the Domestic Violence Leave Act, and the Military Family Leave Act), and any comparable statute of any other state, country or locality.

d.any and all claims in tort (including but not limited to any claims for wrongful termination, misrepresentation, defamation, interference with contract

-3-


or prospective economic advantage, intentional or negligent infliction of emotional distress, duress, loss of consortium, invasion of privacy and negligence);

e.any and all claims under any federal, state or local statute or law;

f.any and all claims for damages of any kind, including compensatory and punitive damages; and

g.any and all claims for attorneys’ fees and costs.

The foregoing notwithstanding, this paragraph 4 will not release Employee’s rights (i) under paragraph 3(b) of this Separation Agreement and Release, (ii) under the Company Group’s welfare benefit plans (other than severance benefit plans) and 401 (k) plan, subject to the terms and conditions of those plans, or (iii) to indemnification for his acts or omissions as an employee or officer of the Company or any of its affiliates, or for the benefit of any applicable D&O insurance, to the extent contemplated by the Employment Agreement or the Company’s governing documents.

5.Acknowledgment. Employee understands that Employee’s release extends to all of the aforementioned claims and potential claims which arose on or before the date of this Separation Agreement and Release, whether now known or unknown, suspected or unsuspected, and that this constitutes an essential term of this Separation Agreement and Release. Employee further understands and acknowledges the significance and consequence of this Separation Agreement and Release and of each specific release and waiver, and expressly consents that this Separation Agreement and Release shall be given full force and effect according to each and all of its express terms and provisions, including those relating to unknown and unsuspected claims, demands, obligations, and causes of action, if any, as well as those relating to any other claims, demands, obligations or causes of action herein above-specified.

6.Return of Company Property.

a.As used in this Separation Agreement and Release, the term “Company Property” includes, without limitation: (i) all materials (including all copies thereof) containing any Confidential Information (as defined in the Employee Confidentiality Agreement), including, without limitation, drawings, tapes, disks, codes, descriptions or other papers, documents or other materials; (ii) all computer hardware, computer software, cell phones, smart phones, business equipment, drawings, designs, specifications, tapes, drives, disks, codes, notes, files, documents, memoranda or data created by Employee, or made available or furnished to Employee by the Company or any affiliated company (including all copies thereof), whether or not they contain Confidential Information; (iii) all other materials containing any information pertaining to the business of the Company or any affiliated company, or any of their employees, consultants, or business associates, that were acquired by Employee in the course of employment with the Company; and (iv) any passwords to any electronically stored documents on Employee’s mobile phone or computer.

-4-


b.Employee represents that, not later than the Termination Date, Employee will return all Company Property to the Company, and delete all copies of any Company documents, emails, files, data, software, code, business processes and procedures, and/or any Confidential Information that Employee has stored on any personally owned computer, smartphone, network, or computer system. Employee agrees that the Company may demand proof of deletion and that Employee will provide such proof upon request.

7.Covenant Not to Sue. Employee affirms that no charge, complaint or action exists in any forum brought by or on behalf of Employee against the Releasees, and that Employee has not assigned any existing or potential claim to any third party. Further, Employee (for Employee and for Employee’s family members, heirs, executors, administrators, successors, and assigns) covenants that Employee will not at any time hereafter commence, maintain, or in any way cause, or advise to be commenced or prosecuted, or permit to be filed by any other person on Employee’s behalf, any grievance, charge, action (including any class action), suit, or proceeding (judicial or administrative) against the Releasees, except as such waiver is specifically prohibited by law or as provided in paragraph 8 below. Although Employee is not waiving the right to file a charge with the Equal Employment Opportunity Commission or similar state agency, Employee waives any right to personal relief, including reinstatement and money damages.

8.Permitted Conduct. Nothing in this Separation Agreement and Release restricts or prohibits Employee from initiating communications directly with, responding to any inquiries from, providing testimony before, providing Confidential Information to, reporting possible violations of law or regulation to, or assisting with an investigation directly with any governmental agency or entity or self-regulatory authority, including but not limited to the Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Department of Justice, the Securities and Exchange Commission, the Congress, and any agency Inspector General (collectively, the “Regulators”), or from making other disclosures that are protected under the whistleblower provisions of state or federal law or regulation. Employee is not required to notify the Company that Employee has engaged in such communications, responded to such inquiries or made such reports or disclosures.

9.No Legal Violations. Employee agrees and covenants that during Employee’s employment with the Company, Employee did not violate any federal, state or local law, statute or regulation, or Company policy while acting within the scope of Employee’s employment with the Company. While the Company is not currently aware of any facts giving rise to a potential claim against Employee, Employee acknowledges and understands that if the Company should discover any such violation after execution of this Separation Agreement and Release, it will be considered a material breach of this Separation Agreement and Release, all of the Company’s obligations to Employee hereunder (including the obligation to provide the severance benefits described in Section 9(a) of the Employment Agreement) will become immediately null and void, and the Company will have the ability to pursue all claims to enforce its rights. Employee further agrees and covenants that during Employee’s employment with the Company, Employee did not witness and fail to report any violation of federal, state, or local law, statute or

-5-


regulation, nor did Employee witness and fail to report any violation of any Company policy.

10.Duty of Cooperation. Employee acknowledges that his obligation under Section 8(d) of Employment Agreement to cooperate with the Company and its counsel will survive the cessation of his employment and he hereby reaffirms such obligation.

11.Remedies. Ail remedies at law or in equity shall be available to the Releasees for the enforcement of this Separation Agreement and Release. This Separation Agreement and Release may be pleaded as a full bar to the enforcement of any claim that Employee may assert against the Releasees.

12.No Admissions. Neither the execution of this Separation Agreement and Release by the Company, nor the terms hereof, constitute an admission by the Company of liability to Employee.

13.Non-Disparagement. Employee agrees to refrain from making disparaging comments about the Releasees, and from taking any action or making any statements that would harm the professional or business reputation of any of the Releasees, including on social media. Employee is permitted to discuss his employment history at the Company in general terms, provided that in doing so, he does not disparage the Company or make any statements that are misrepresentative or inaccurate, and does not reveal any of the Company’s confidential information. Employee will direct any requests for a reference to Shane Williams, Chief People Officer (shane@centurytx.com). Dr. Williams will only provide Employee’s title and dates of employment.

14.Confidentiality. Employee shall not discuss, disclose or publicize the terms or fact of this Separation Agreement and Release, directly or indirectly, to any person or entity, except to Employee’s accountant, attorney, spouse, and to others as required by law. Employee further understands and agrees that such information may be disclosed to the aforementioned individuals only on the condition that such individuals in turn agree to keep such information completely confidential, and not to disclose it to others. A breach of this provision by any of these persons shall constitute a breach by Employee.

15.No Assistance. Employee shall not solicit or assist current, future or former employees or temporary workers of the Company in preparing, commencing or prosecuting any action or proceeding against the Company, including but not limited to, any administrative agency claims, claims in arbitration, charges or complaints and/or lawsuits against the Company and will not participate voluntarily or cooperate in any such action or proceeding, except when such waiver is specifically prohibited by law, unless ordered by a Court of competent jurisdiction or as provided in paragraph 8. Nothing in this paragraph shall prevent Employee from testifying truthfully in response to a bona fide subpoena or Court Order. Employee agrees that if Employee receives a subpoena or Court Order requiring Employee to testify or participate in any action or proceeding against the Company, Employee will notify Osvaldo Flores, Chief Executive Officer (or his successor or designee), and will make no disclosure until the Company has had fifteen (15) days from receipt of notice to contest the right of the requesting person or entity to such disclosure.

-6-


16.Confidentiality Agreement. Employee acknowledges and agrees that his obligations under the Confidentiality Agreement will survive his cessation of employment. Employee further acknowledges and agrees that he received adequate consideration for entering into the Confidentiality Agreement and hereby reaffirms his obligations thereunder.

17.Essential Terms. Employee understands and acknowledges that Employee’s promises in paragraphs 6, 7, 10, 13, 14, 15 and 16 of this Separation Agreement and Release are a material inducement for the Company to enter into this Separation Agreement and Release and are of the essence of this Separation Agreement and Release. Employee therefore agrees that if a Court determines that Employee has breached any of the provisions of the aforementioned paragraphs, then in addition to any other equitable or legal remedies available to the Company, (a) Employee will be obligated to return to the Company the severance payments, rights and benefits described in paragraph 3(b) of this Separation Agreement and Release; and (b) the Company will be relieved from any obligation to provide any further severance benefits.

18.Fees and Costs. The parties shall bear their own attorneys’ fees and costs.

19.Entire Agreement. This Separation Agreement and Release, together with the Confidentiality Agreement and Subsequent Release, contain the entire agreement of the parties with respect to the subject matter hereof, supersede any prior agreements or understandings with respect to the subject matter hereof, and shall be binding upon their respective heirs, executors, administrators, successors and assigns.

20.Severability. If any term or provision of this Separation Agreement and Release shall be held to be invalid or unenforceable for any reason, the validity or enforceability of the remaining terms or provisions shall not be affected, and such term or provision shall be deemed modified to the extent necessary to make it enforceable.

21.Review of Agreement/Advice of Counsel.

a.Employee is hereby advised to seek the advice of counsel.

b.Employee acknowledges that Employee is acting of Employee’s own free will, that Employee has been afforded a reasonable time to read and review the terms of the Separation Agreement and Release, and that Employee is voluntarily entering into this Separation Agreement and Release with full knowledge of its provisions and effects. Employee intends that this Separation Agreement and Release shall not be subject to any claim for duress.

c.Employee further acknowledges that Employee has been given at least 21 days within which to consider this Separation Agreement and Release and that if Employee decides to execute this Separation Agreement and Release before the 21 day period has expired, Employee does so voluntarily and waives the opportunity to use the full review period. Employee agrees that changes to this Separation Agreement and Release, whether or not material, will not restart the review period. If Employee chooses

-7-


to accept this Separation Agreement and Release, Employee should send a signed copy to Shane Williams via email at shane@centurytx.com.

d.Employee has seven (7) days after signing to revoke Employee’s acceptance of this Separation Agreement and Release, and this Separation Agreement and Release will not become effective or enforceable until the seven-day period has expired. If Employee chooses to revoke Employee’s acceptance of this Separation Agreement and Release, Employee should send written notice to Shane Williams via email at shaiie@centurytx.com.

22.Amendments. Neither this Separation Agreement and Release nor any term hereof may be orally changed, waived, discharged, or terminated, and may be amended only by a written agreement between the parties hereto.

23.Governing Law. This Separation Agreement and Release shall be governed by the laws of the Commonwealth of Pennsylvania, without regard to the conflict of law principles of any jurisdiction.

24.Counterparts. This Separation Agreement and Release may be executed in one or more counterparts, including by a scanned version of a manual signature, each of which shall be deemed an original, and all of which together shall be deemed to be one and the same instrument.

25.Legally Binding. The terms of this Separation Agreement and Release contained herein are contractual, and not a mere recital.

[signature page follows]

-8-


IN WITNESS WHEREOF, the parties, acknowledging that they are acting of their own free will, have caused the execution of this Separation Agreement and Release on the day and year written below, respectively.

HYAM LEVITSKY, M.D.

/s/ Hyam Levitsky, M.D.

Date:

1/22/2023

CENTURY THERAPEUTICS, INC

/s/ Shane Williams

By: Shane Williams

Title: Title: Chief People Officer

Date:

1/23/2023

-9-


A-1


EX-31.1 4 ipsc-20230331xex31d1.htm EX-31.1

Exhibit 31.1

CERTIFICATION

I, Gregory Russotti, certify that:

1.

I have reviewed this Quarterly Report of Century Therapeutics, Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and have:

(a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 11, 2023

/s/ Gregory Russotti, Ph.D.

Gregory Russotti, Ph.D.

Interim President and Chief Executive Officer

(Principal Executive Officer)


EX-31.2 5 ipsc-20230331xex31d2.htm EX-31.2

Exhibit 31.2

CERTIFICATION

I, Michael Diem, certify that:

1.

I have reviewed this Quarterly Report of Century Therapeutics, Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and have:

(a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 11, 2023

/s/ Michael Diem, M.D.

Michael Diem, M.D.

Chief Financial Officer

(Principal Financial Officer)


EX-32.1 6 ipsc-20230331xex32d1.htm EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Century Therapeutics, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to such officer’s knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 11, 2023

/s/ Gregory Russotti, Ph.D.

Gregory Russotti, Ph.D.

Interim President and Chief Executive Officer

(Principal Executive Officer)


EX-32.2 7 ipsc-20230331xex32d2.htm EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Century Therapeutics, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to such officer’s knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 11, 2023

/s/ Michael Diem, M.D.

Michael Diem, M.D.

Chief Financial Officer

(Principal Financial Officer)


EX-101.SCH 8 ipsc-20230331.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 00100 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Summary of significant accounting policies and basis of presentation - Restricted cash (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Financial instruments and fair value measurements - Assets measured at fair value (Details) link:presentationLink link:calculationLink link:definitionLink 40503 - Disclosure - Financial instruments and fair value measurements - Investments in fixed maturity securities (Details) link:presentationLink link:calculationLink link:definitionLink 40504 - Disclosure - Financial instruments and fair value measurements - Maturities of fixed maturity available-for-sale securities (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Prepaid expenses and other current assets - Summary of prepaid expenses and other current assets (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Property and equipment, net (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Accrued expenses and other liabilities - Summary of accrued expenses (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Long-term debt (Details) link:presentationLink link:calculationLink link:definitionLink 40903 - Disclosure - Long-term debt - Interest Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 40904 - Disclosure - Long-term debt - Future principal payments due (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - Bristol-Myers Squibb Collaboration - Total transaction price (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Leases - Components of lease expenses (Details) link:presentationLink link:calculationLink link:definitionLink 41202 - Disclosure - Leases - Other information (Details) link:presentationLink link:calculationLink link:definitionLink 41205 - Disclosure - Leases - Future minimum lease payments (Details) link:presentationLink link:calculationLink link:definitionLink 41205 - Disclosure - Leases - Future minimum lease payments (Details) - calc 2 link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of significant accounting policies and basis of presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 31603 - Disclosure - Stock based compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Organization and description of the business - Going concern and liquidity (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Reduction in force (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Asset purchase by Century Therapeutics Canada ULC (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Long-term debt - Term Loan Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Bristol-Myers Squibb Collaboration (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 41402 - Disclosure - Basic and diluted net loss per common share - Schedule of potential shares of common stock excluded from computation (Details) link:presentationLink link:calculationLink link:definitionLink 41501 - Disclosure - Defined contribution plan (Details) link:presentationLink link:calculationLink link:definitionLink 41601 - Disclosure - Stock based compensation (Details) link:presentationLink link:calculationLink link:definitionLink 41602 - Disclosure - Stock based compensation - Reserved shares of common stock (Details) link:presentationLink link:calculationLink link:definitionLink 41603 - Disclosure - Stock based compensation - Common stock available under 2021 Incentive Plan (Details) link:presentationLink link:calculationLink link:definitionLink 41604 - Disclosure - Stock based compensation - Stock option activity (Details) link:presentationLink link:calculationLink link:definitionLink 41605 - Disclosure - Stock based compensation - Stock option weighted-average assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 41606 - Disclosure - Stock based compensation - Stock-based compensation expense and by award type (Details) link:presentationLink link:calculationLink link:definitionLink 41607 - Disclosure - Stock based compensation - Restricted stock (Details) link:presentationLink link:calculationLink link:definitionLink 41608 - Disclosure - Stock based compensation - Employee Stock Purchase Plan (Details) link:presentationLink link:calculationLink link:definitionLink 41701 - Disclosure - Related party transactions (Details) link:presentationLink link:calculationLink link:definitionLink 41801 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Organization and description of the business link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of significant accounting policies and basis of presentation link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Reduction in force link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Asset purchase by Century Therapeutics Canada ULC link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Financial instruments and fair value measurements link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Prepaid expenses and other current assets link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Property and equipment, net link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Accrued expenses and other liabilities link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Long-term debt link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Bristol-Myers Squibb Collaboration link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Income taxes link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Basic and diluted net loss per common share link:presentationLink link:calculationLink link:definitionLink 11501 - Disclosure - Defined contribution plan link:presentationLink link:calculationLink link:definitionLink 11601 - Disclosure - Stock based compensation link:presentationLink link:calculationLink link:definitionLink 11701 - Disclosure - Related party transactions link:presentationLink link:calculationLink link:definitionLink 11801 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Summary of significant accounting policies and basis of presentation (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Financial instruments and fair value measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Prepaid expenses and other current assets (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Property and equipment, net (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Accrued expenses and other liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Long-term debt (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Bristol-Myers Squibb Collaboration (Tables) link:presentationLink link:calculationLink link:definitionLink 31203 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 31403 - Disclosure - Basic and diluted net loss per common share (Tables) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of significant accounting policies and basis of presentation (Details) link:presentationLink link:calculationLink link:definitionLink 40203 - Disclosure - Summary of significant accounting policies and basis of presentation - Property and equipment and Stock-based compensation (Details) link:presentationLink link:calculationLink link:definitionLink 40204 - Disclosure - Summary of significant accounting policies and basis of presentation - Early exercised options (Details) link:presentationLink link:calculationLink link:definitionLink 40205 - Disclosure - Summary of significant accounting policies and basis of presentation - Income taxes (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Financial instruments and fair value measurements - Transfers between levels (Details) link:presentationLink link:calculationLink link:definitionLink 41203 - Disclosure - Leases - Operating lease - Other information (Details) link:presentationLink link:calculationLink link:definitionLink 41204 - Disclosure - Leases - Supplemental cash flow information (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - Basic and diluted net loss per common share (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 ipsc-20230331_cal.xml EX-101.CAL EX-101.DEF 10 ipsc-20230331_def.xml EX-101.DEF EX-101.LAB 11 ipsc-20230331_lab.xml EX-101.LAB EX-101.PRE 12 ipsc-20230331_pre.xml EX-101.PRE XML 13 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2023
May 01, 2023
Document and Entity Information [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2023  
Document Transition Report false  
Entity File Number 001-40498  
Entity Registrant Name Century Therapeutics, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 84-2040295  
Entity Address State Or Province PA  
Entity Address, Address Line One 3675 Market Street  
Entity Address, City or Town Philadelphia  
Entity Address, Postal Zip Code 19104  
City Area Code 267  
Local Phone Number 817-5790  
Title of 12(b) Security Common Stock, $0.0001 par value per share  
Trading Symbol IPSC  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   59,580,817
Entity Central Index Key 0001850119  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q1  
Amendment Flag false  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED BALANCE SHEETS - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Current assets    
Cash and cash equivalents $ 86,832,000 $ 84,265,000
Short-term investments 164,637,000 231,233,000
Escrow deposits, current   220,000
Prepaid expenses and other current assets 4,465,000 4,003,000
Total current assets 255,934,000 319,721,000
Property and equipment, net 85,842,000 82,785,000
Operating lease right-of-use assets 28,207,000 28,945,000
Restricted cash 1,979,000 1,979,000
Long-term investments 83,316,000 51,854,000
Security deposits 950,000 1,260,000
Total assets 456,228,000 486,544,000
Current liabilities    
Accounts payable 3,475,000 5,454,000
Accrued expenses and other liabilities 6,531,000 9,841,000
Deposit liability 881,000 866,000
Long-term debt, current 10,297,000 6,502,000
Deferred revenue, current 6,500,000 7,154,000
Total current liabilities 27,684,000 29,817,000
Operating lease liability, long term 41,168,000 38,698,000
Deposit liability, non-current 433,000 718,000
Deferred revenue, non-current 109,768,000 110,834,000
Long-term debt, net   3,739,000
Total liabilities 179,053,000 183,806,000
Commitments and contingencies (Note 11)
Stockholders' equity:    
Preferred stock, $ 0.0001 par value, 10,000,000 shares authorized and 0 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively
Common stock, $0.0001 par value, 125,236,190 shares authorized; 59,106,784 and 58,473,660 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively 6,000 6,000
Additional paid-in capital 828,806,000 824,292,000
Accumulated deficit (550,362,000) (519,098,000)
Accumulated other comprehensive loss (1,275,000) (2,462,000)
Total stockholders' equity 277,175,000 302,738,000
Total liabilities and stockholders' equity $ 456,228,000 $ 486,544,000
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares
Mar. 31, 2023
Dec. 31, 2022
CONSOLIDATED BALANCE SHEETS    
Preferred Stock, Par or Stated Value Per Share $ 0.0001 $ 0.0001
Preferred Stock, Shares Authorized 10,000,000 10,000,000
Preferred Stock, Shares Issued 0 0
Preferred Stock, Shares Outstanding 0 0
Common Stock, Par or Stated Value Per Share $ 0.0001 $ 0.0001
Common Stock, Shares Authorized 125,236,190 125,236,190
Common Stock, Shares, Issued 59,106,784 58,473,660
Common Stock, Shares, Outstanding 59,106,784 58,473,660
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS    
Collaboration revenue $ 1,720 $ 1,058
Operating expenses    
Research and development 24,899 21,196
General and administrative 8,902 7,298
In-process research and development   10,000
Total operating expenses 33,801 38,494
Loss from operations (32,081) (37,436)
Interest expense (404) (314)
Interest income 2,623 253
Other expense, net (194)  
Total other income (expense) 2,025 (61)
Loss before provision for income taxes (30,056) (37,497)
Provision for income taxes (1,208) (16)
Net loss $ (31,264) $ (37,513)
Net loss per common share Basic (in dollars per share) $ (0.53) $ (0.66)
Net loss per common share Diluted (in dollars per share) $ (0.53) $ (0.66)
Weighted average common shares outstanding Basic (in shares) 58,610,375 57,051,539
Weighted average common shares outstanding Diluted (in shares) 58,610,375 57,051,539
Other comprehensive loss    
Net loss $ (31,264) $ (37,513)
Unrealized gain (loss) on investments 1,196 (1,986)
Foreign currency translation (9) (6)
Comprehensive loss $ (30,077) $ (39,505)
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Total
Beginning balance at Dec. 31, 2021 $ 5 $ 785,049 $ (388,166) $ (650) $ 396,238
Beginning Balance (in shares) at Dec. 31, 2021 55,005,523        
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of stock to collaboration partner $ 1 26,812     26,813
Issuance of stock to collaboration partner (in shares) 2,160,760        
Issuance of common stock upon the exercise of stock options   65     65
Issuance of common stock upon the exercise of stock options (in shares) 85,396        
Vesting of restricted stock (in shares) 161,159        
Vesting of early exercise stock options   673     673
Vesting of early exercise stock options (in shares) 173,192        
Unrealized gain on short-term investments       (1,986) (1,986)
Foreign currency translation       (6) (6)
Stock based compensation   2,380     2,380
Net loss     (37,513)   (37,513)
Ending balance at Mar. 31, 2022 $ 6 814,979 (425,679) (2,642) 386,664
Ending Balance (in shares) at Mar. 31, 2022 57,586,030        
Beginning balance at Dec. 31, 2022 $ 6 824,292 (519,098) (2,462) 302,738
Beginning Balance (in shares) at Dec. 31, 2022 58,473,660        
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon the exercise of stock options   448     448
Issuance of common stock upon the exercise of stock options (in shares) 452,102        
Vesting of restricted stock (in shares) 95,877        
Vesting of early exercise stock options   269     269
Vesting of early exercise stock options (in shares) 85,145        
Unrealized gain on short-term investments       1,196 1,196
Foreign currency translation       (9) (9)
Stock based compensation   3,797     3,797
Net loss     (31,264)   (31,264)
Ending balance at Mar. 31, 2023 $ 6 $ 828,806 $ (550,362) $ (1,275) $ 277,175
Ending Balance (in shares) at Mar. 31, 2023 59,106,784        
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Cash flows from operating activities    
Net loss $ (31,264) $ (37,513)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 2,908 1,160
Amortization of deferred financing cost 56 76
Non-cash operating lease expense (738) 188
Stock based compensation 3,797 2,380
Change in operating assets and liabilities:    
Escrow deposit 220 125
Prepaid expenses and other assets (160) 1,033
Operating lease liability 3,842 (152)
Deferred revenue (1,720) 122,129
Accounts payable (2,954) (1,503)
Accrued expenses and other liabilities (3,206) (1,170)
Net cash (used in) provided by operating activities (29,219) 86,753
Cash flows from investing activities    
Acquisition of property and equipment (4,991) (4,067)
Acquisition of fixed maturity securities, available for sale (42,829) (103,060)
Sale of fixed maturity securities, available for sale 79,158 63,090
Net cash provided by (used in) investing activities 31,338 (44,037)
Cash flows from financing activities    
Proceeds from issuance of common stock 448 65
Proceeds from issuance of shares to collaboration partner   26,813
Net cash provided by financing activities 448 26,878
Net increase in cash, cash equivalents, and restricted cash 2,567 69,594
Cash, cash equivalents and restricted cash, beginning of period 86,244 58,162
Cash, cash equivalents and restricted cash, end of period 88,811 127,756
Supplemental disclosure of cash and non-cash operating activities:    
Cash paid for interest 345 238
Supplemental disclosure of non-cash investing and financing activities:    
Purchase of property and equipment, accrued and unpaid $ 975 $ 3,796
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Organization and description of the business
3 Months Ended
Mar. 31, 2023
Organization and description of the business  
Organization and description of the business

CENTURY THERAPEUTICS, INC.

NOTES TO FINANCIAL STATEMENTS

(Unaudited)

(in thousands, except share and per share amounts)

Note 1—Organization and description of the business

Century Therapeutics, Inc. (the “Company”) is an innovative biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. Since inception, the Company has devoted substantially all of its time and efforts to performing research and development activities, building infrastructure and raising capital. The Company is incorporated in the state of Delaware.

Century Therapeutics Canada ULC (“Century Canada”) is the Company’s wholly owned subsidiary performing research and development activities in Canada.

Principles of Consolidation

The consolidated financial statements include the consolidated financial position and consolidated results of operations of the Company and Century Canada. All intercompany balances and transactions have been eliminated in consolidation.

Liquidity

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has limited operating history and its prospects are subject to risks, expenses, and uncertainties frequently encountered by companies in the biotechnology and pharmaceutical industries. These risks include, but are not limited to, the uncertainty of availability of additional financing and the uncertainty of achieving future profitability.

Since inception, the Company has incurred net losses. During the three months ended March 31, 2023, the Company incurred a net loss of $31,264. During the three months ended March 31, 2023, the Company used $29,219 of cash from operations. Cash and cash equivalents and investments were $334,785 at March 31, 2023. Management expects to incur additional losses in the future to fund its operations and conduct product research and preclinical and clinical development and recognizes the need to raise additional capital to fully implement its business plan. The Company believes it has adequate cash and financial resources to operate for at least the next 12 months from the date of issuance of these consolidated financial statements.

Reduction in force

In January 2023, the Company's Board of Directors approved, and management implemented a new portfolio prioritization and capital allocation strategy. The resulting changes include pausing investment in CNTY-103 for glioblastoma as well as a discovery program in hematologic malignancies. The Company will focus on CNTY-101 and will accelerate key programs, including one follow-on candidate for lymphoma, CNTY-102, and CNTY-107 for Nectin-4+ solid tumors. In addition, the Company will continue its partnered programs with Bristol Myers Squibb. The restructuring plan resulted in a reduction in the Company's workforce of approximately 25%. In addition, lab operations in Seattle and Hamilton, Ontario were closed and research activities were consolidated in Philadelphia.

XML 20 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of significant accounting policies and basis of presentation
3 Months Ended
Mar. 31, 2023
Summary of significant accounting policies and basis of presentation  
Summary of significant accounting policies and basis of presentation

Note 2—Summary of significant accounting policies and basis of presentation

Basis of presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the interim period reporting requirements of Form 10-Q and Article 10 of Regulation S-X. The consolidated balance sheet as of March 31, 2023, the consolidated statements of operations and comprehensive loss, and consolidated statements of changes in stockholders’ equity for the three months ended March 31, 2023 and 2022, and the consolidated statements of cash flows for the three months ended March 31, 2023 and 2022 are unaudited, but, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.  The results for any interim period are not necessarily indicative of results for the year ending December 31, 2023 or for any other subsequent interim period.  The consolidated balance sheet at December 31, 2022 has been derived from the Company’s audited consolidated financial statements.

Certain prior year information has been reclassified to conform to the fiscal year 2023 presentation.

Segment information

Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages the business as one operating segment.

Use of estimates

The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuations supporting stock compensation, the estimation of the incremental borrowing rate for operating leases and standalone selling prices of performance obligations in collaboration agreements. If actual results differ from the Company’s estimates, or to the extent these estimates are adjusted in future periods, the Company’s results of operations could either benefit from, or be adversely affected by, any such change in estimate.

Concentration of credit risk and other risks and uncertainties

Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist of cash, cash equivalents, U.S. Treasury bills and bonds, as well as corporate bonds. Cash and cash equivalents, as well as short and long-term investments include a checking account and asset management accounts held by a limited number of financial institutions. At times, such deposits may be in excess of insured limits. As of March 31, 2023 and December 31, 2022, the Company has not experienced any losses on its deposits of cash and cash equivalents.

The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, uncertainty of market acceptance of its products, competition from substitute products and larger companies, protection of proprietary technology, strategic relationships, and dependence on key individuals.

Products developed by the Company require clearances from the U.S. Food and Drug Administration (the “FDA”) or other international regulatory agencies prior to commercial sales. There can be no assurance the Company’s future products will receive the necessary clearances. If the Company was denied clearance,

clearance was delayed, or if the Company was unable to maintain clearance, it could have a material adverse impact on the Company.

Fair value of financial instruments

The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:

Level 1

Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date;

Level 2

Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly, including inputs in markets that are not considered to be active;

Level 3

Inputs are unobservable in which there is little or no market data available, which require the reporting entity to develop its own assumptions that are unobservable.

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.

Cash and cash equivalents

Management considers all highly liquid investments with an insignificant interest rate risk and original maturities of three months or less to be cash equivalents.

Restricted cash

As of March 31, 2023 and December 31, 2022, the Company had $1,979 in cash on deposit to secure certain lease commitments. Restricted cash is recorded separately in the Company’s consolidated balance sheets.

The following provides a reconciliation of the Company’s cash, cash equivalents, and restricted cash as reported in the consolidated balance sheets to the amounts reported in the consolidated statements of cash flows:

    

March 31, 2023

    

December 31, 2022

Cash and cash equivalents

$

86,832

$

84,265

Restricted cash

1,979

1,979

Cash, cash equivalents, and restricted cash

$

88,811

$

86,244

Investments

The Company invests in fixed maturity securities including U.S. Treasury bills and bonds as well as corporate bonds. The investments are classified as available-for-sale and reported at fair value. Unrealized gains or losses are determined by comparing the fair market value of the securities with their cost or amortized cost. Realized gains and losses on investments are recorded on the trade date and are included in the statement of operations. Unrealized gains and losses on investments are recorded in other comprehensive income (loss) on the consolidated statements of operations and comprehensive loss. The cost of securities sold is based on the specified identification method. Investment income is recognized as earned and discounts or premiums arising from the purchase of debt securities are recognized in investment income using the interest

method over the remaining term of the security. Securities with an original maturity date greater than three months that mature within one year of the balance sheet date are classified as short-term, while investments with a maturity date greater than one year are classified as long-term.

Property and equipment, net

Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which is generally five years. Leasehold improvements are amortized over the shorter of the asset’s useful life or the remaining term of the lease. Construction in progress includes direct cost related to the construction of leasehold improvements and is stated at original cost. Such costs are not depreciated until the asset is completed and placed into service. Once the asset is placed into service, these capitalized costs will be allocated to leasehold improvements and will be depreciated over the shorter of the asset’s useful life or the remaining term of the lease. Computer software and equipment includes implementation costs for cloud-based software and network equipment.

Expenditures for major additions and improvements are capitalized, while minor replacements, maintenance, and repairs are charged to expense as incurred. When property is retired or otherwise disposed of, the costs and accumulated depreciation are removed from the respective accounts, with any resulting gain or loss recognized concurrently.

Research and development expenses

Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, stock compensation, materials, supplies, rent, depreciation on and maintenance of research equipment with alternative future use, and the cost of services provided by outside contractors. All costs associated with research and development are expensed as incurred.

Clinical trial costs are a component of research and development expenses. The company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.

Stock-based compensation

Employees, consultants and members of the board of directors of the Company have received stock options and restricted stock of the Company. The Company recognizes the cost of the stock-based compensation incurred as its employees and board members vest in the awards. The Company accounts for stock-based compensation arrangements in accordance with provisions of Accounting Standards Codification (“ASC”) 718, Compensation—Stock Compensation. ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The Company uses the Black-Scholes option-pricing model (“Black Scholes”) to determine the fair value of options granted. The Company’s stock-based awards are subject to service-based vesting conditions and performance-based vesting conditions. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. For performance-based awards, the Company reassesses at each reporting date whether achievement of the performance condition is probable and accrues compensation expense if and when achievement of the performance condition is probable.

Black-Scholes requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. Due to

the lack of a public market for the Company’s common stock prior to its initial public offering (“IPO”) and lack of company-specific historical and implied volatility data, the Company based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. Forfeitures are recognized as they occur.

Warrants

The Company has issued warrants that have been recognized as equity, and the fair value is recorded into additional paid-in capital in the accompanying consolidated balance sheets. Warrants are accounted for in accordance with applicable accounting guidance provided in ASC Topic 815, Derivatives and Hedging—Contracts in Entity’s Own Equity, as either derivative liabilities or as equity instruments depending on the specific terms of the warrant agreement. The Company’s warrants issued are in connection with its long-term debt and in connection with services provided by consultants, and are equity classified on the accompanying consolidated balance sheets. Equity classified warrants are accounted for at fair value on the issuance date, using Black Scholes, with no changes in fair value recognized after the issuance date.

Foreign currency translation

The reporting currency of the Company is the U.S. dollar. The functional currency of Century Canada is the Canadian dollar. Assets and liabilities of Century Canada are translated into U.S. dollars based on exchange rates at the end of each reporting period. Expenses are translated at average exchange rates during the reporting period. Gains and losses arising from the translation of assets and liabilities are included as a component of accumulated other comprehensive loss or income on the company’s consolidated balance sheets. Gains and losses resulting from foreign currency transactions are reflected within the Company’s consolidated statements of operations and comprehensive loss. The Company has not utilized any foreign currency hedging strategies to mitigate the effect of its foreign currency exposure.

Intercompany payables and receivables are considered to be long-term in nature and any change in balance due to foreign currency fluctuation is included as a component of the Company’s consolidated comprehensive loss and accumulated other comprehensive loss within the Company’s consolidated balance sheets.

Basic and diluted net loss per common shares

Basic net loss per common share is computed by dividing net loss applicable to common shareholders by the weighted-average number of common shares outstanding during the period. The Company computes diluted net loss per common share by dividing the net loss applicable to common shareholders by the sum of the weighted- average number of common shares outstanding during the period plus the potential dilutive effects of its warrants, restricted stock and stock options to purchase common shares, but such items are excluded if their effect is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there were no differences between the Company’s basic and diluted net loss per common share for the three months ended March 31, 2023 and 2022.

Early exercised options

The Company allowed certain of its employees and its consultants to exercise options granted under the 2018 Stock Option and Grant Plan (the “2018 Incentive Plan”) (Note 16) prior to vesting and prior to its IPO. The shares related to early exercised stock options are subject to the Company’s repurchase right upon termination of employment or services at the lesser of the original purchase price or fair market value at the time of repurchase. In order to vest, the holders are required to provide continued service to the Company. The early exercise by an employee or consultant of a stock option is not considered to be a substantive

exercise for accounting purposes, and therefore, the payment received by the employer for the exercise price is recognized as a liability. For accounting purposes, unvested early exercised shares are not considered issued and outstanding and therefore not reflected as issued and outstanding in the accompanying consolidated balance sheets or the consolidated statements of changes in stockholders’ equity (deficit) until the awards vest. The deposits received are initially recorded in deposit liability. The liabilities are reclassified to common stock and additional paid-in-capital as the repurchase right lapses. At March 31, 2023 and December 31, 2022, there were $1,314 and $1,584, respectively, recorded in deposit liability related to shares held by employees and nonemployees that were subject to repurchase.

All shares that were early exercised by the executives of the Company are considered legally issued, however, for accounting purposes, only vested shares are considered issued. Below is a reconciliation of shares issued and outstanding:

    

March 31, 2023

    

December 31, 2022

Total shares legally outstanding

59,541,904

59,137,491

Less: unvested early exercised shares

(385,655)

(470,800)

Less: unvested restricted stock awards (Note 16)

(49,465)

(193,031)

Total shares issued and outstanding

59,106,784

58,473,660

Income taxes

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations and comprehensive loss. As of March 31, 2023 and December 31, 2022, no accrued interest or penalties are included on the related tax liability line in the consolidated balance sheet.

Collaboration revenue

The Company may enter into collaboration and licensing agreements with strategic partners for research and development, manufacturing, and commercialization of its product candidates. Payments under these arrangements may include non-refundable, upfront fees; reimbursement of certain costs; customer option fees for additional goods or services; payments upon the achievement of development, regulatory, and commercial milestones; sales of product at certain agreed-upon amounts; and royalties on product sales.

The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers, or ASC 606. This standard applies to all contracts with customers. When an agreement falls under the scope of other standards, such as ASC Topic 808, Collaborative Arrangements, or ASC 808, the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the

performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606 is recorded as collaboration revenue on the statements of operations.

Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under a collaboration agreement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations on a relative stand-alone selling price basis; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.

As part of the accounting for these arrangements, the Company must use its judgment to determine the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price. The estimation of the stand-alone selling price may include such estimates as forecasted revenues and costs, development timelines, discount rates, and probabilities of regulatory and commercial success. The Company also applies significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining when performance obligations have been met, assessing the recognition and future reversal of variable consideration and determining and applying appropriate methods of measuring progress for performance obligations satisfied over time. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, current. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, non-current.

If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are not determined to represent a material right, no transaction price is allocated to these options and the Company will account for these options at that time they are exercised. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement.

The obligations under the Company’s collaboration agreements may include research and development services to be performed by the Company for or on behalf of the customer. Amounts allocated to these performance obligations are recognized as the Company performs these obligations, and revenue is measured based on an inputs method of costs incurred to date of budgeted costs. Under certain circumstances, the Company may be reimbursed for certain expenses incurred under the research and development services.

At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the statements of operations in the period of adjustment.

Recent accounting pronouncements

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses of Financial Instruments (ASC 326). The guidance is effective for the Company beginning January 1, 2023 and it changes how entities account for credit losses on the financial assets and other instruments that are not measured at fair value through net income, including available-for-sale debt securities. The adoption of ASC 326 did not have a material impact on the consolidated financial statements.

XML 21 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Reduction in force
3 Months Ended
Mar. 31, 2023
Reduction in force  
Reduction in force

Note 3—Reduction in force

During the three months ended March 31,2023, the Company incurred $2,032 of cash-based expenses related to employee severances, benefits and related costs. In addition, the Company recorded non-cash stock-based compensation charge of $581 related to modification of equity awards for employees impacted by the restructuring during the quarter ended March 31, 2023. There were no remaining outstanding liabilities related to the reduction in force during the quarter ended March 31, 2023.

XML 22 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Asset purchase by Century Therapeutics Canada ULC
3 Months Ended
Mar. 31, 2023
Asset purchase by Century Therapeutics Canada ULC  
Asset purchase by Century Therapeutics Canada ULC

Note 4—Asset purchase by Century Therapeutics Canada ULC

On June 9, 2020, Century Canada and the Company entered into an agreement with Empirica Therapeutics, Inc. (“Empirica”), a company focused on the development of adoptive immunotherapies against aggressive and treatment-resistant forms of cancers, including glioblastoma and brain metastasis. Under the terms of the Empirica Agreement, the Company acquired an IPR&D asset. Cash of $4,519 was paid at closing and transaction expenses totaled $203. The Company also deposited $1,506 in escrow (the “Escrow Deposit”). Release of the Escrow Deposit is subject to the terms of a promissory note, which provides for the funds to be released in equal annual installments over a three-year period related to continuing services by certain Empirica shareholders. In July 2021, the first annual installment of $523 was released from the Escrow Deposit. In June 2022, the second annual installment of $517 was released from the Escrow Deposit. In February 2023, the third installment of $494 was released from Escrow Deposit. As of March 31, 2023 and December 31, 2022, accrued compensation expense on the promissory note was $0 and $220, which is presented within escrow deposits on the consolidated balance sheets.

XML 23 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Financial instruments and fair value measurements
3 Months Ended
Mar. 31, 2023
Financial instruments and fair value measurements  
Financial instruments and fair value measurements

Note 5—Financial instruments and fair value measurements

The following table sets forth the Company’s assets that were measured at fair value as of March 31, 2023 by level within the fair value hierarchy:

    

Level 1

    

Level 2

    

Level 3

    

Total

Cash equivalents

$

83,187

$

83,187

U.S. Treasury

 

65,197

 

 

 

65,197

Corporate bonds

 

 

182,756

 

 

182,756

Total

$

148,384

$

182,756

$

$

331,140

The following table sets forth the Company’s assets that were measured at fair value as of December 31, 2022, by level within the fair value hierarchy:

    

Level 1

    

Level 2

    

Level 3

    

Total

Cash equivalents

$

77,736

$

77,736

U.S. Treasury

 

86,475

 

 

 

86,475

Corporate bonds

 

 

196,603

 

 

196,603

Total

$

164,211

$

196,603

$

$

360,814

There were no transfers between levels during the period ended March 31, 2023. The Company uses the services of its investment manager, which uses widely accepted models for assumptions in valuing securities with inputs from major third-party data providers.

The Company classifies all of its investments in fixed maturity debt securities as available-for-sale and, accordingly, are carried at estimated fair value.

The amortized cost, gross unrealized gains and losses, and fair value of investments in fixed maturity securities are as follows as of March 31, 2023:

    

    

Gross 

    

Gross

    

Unrealized

 Unrealized 

Amortized Cost

 Gains

Losses

Fair Value

U.S. Treasury

$

65,807

$

$

(610)

$

65,197

Corporate bonds

 

183,329

 

87

 

(660)

 

182,756

Total

$

249,136

$

87

$

(1,271)

$

247,953

The amortized cost, gross unrealized gains and losses, and fair value of investments in fixed maturity securities are as follows as of December 31, 2022:

    

Gross 

    

Gross 

    

Unrealized

Unrealized

    

Amortized Cost

 Gains

 Losses

Fair Value

U.S. Treasury

$

87,798

$

$

(1,323)

$

86,475

Corporate bonds

 

197,668

 

2

 

(1,067)

 

196,603

Total

$

285,466

$

2

$

(2,390)

$

283,078

The following table provides the maturities of our fixed maturity available-for-sale securities:

     

March 31, 2023

     

December 31, 2022

Less than one year

$

164,637

$

231,224

One to five years

 

83,316

 

51,854

$

247,953

$

283,078

The Company has evaluated the unrealized losses on the fixed maturity securities and determined that they are not attributable to credit risk factors. For fixed maturity securities, losses in fair value are viewed as temporary if the fixed maturity security can be held to maturity and it is reasonable to assume that the issuer will be able to service the debt, both as to principal and interest.

At March 31, 2023 and December 31, 2022, respectively, the Company had 32 and 42 available-for-sale investment debt securities in an unrealized loss position without an allowance for credit losses. Unrealized losses on corporate debt securities have not been recognized into income because the issuers’ bonds are of high credit quality (rated BBB+ or higher) and the decline in fair value is largely due to market conditions and or changes in interest rates. Management does not intend to sell and it is likely that management will not be required to sell the securities prior to the anticipated recovery of their amortized cost basis. The issuers

continue to make timely payments on the bonds. The fair value is expected to recover as the bond approach maturity.

As of March 31, 2023 and December 31, 2022, accrued interest receivable on available-for-sale investment debt securities totaling $855 and $0, respectively, is excluded from the estimate of credit losses and is included in prepaid expenses and other current assets.

XML 24 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Prepaid expenses and other current assets
3 Months Ended
Mar. 31, 2023
Prepaid expenses and other current assets.  
Prepaid expenses and other current assets

Note 6—Prepaid expenses and other current assets

The following is a summary of prepaid expenses and other current assets:

     

March 31, 2023

    

December 31, 2022

Research and development

$

$

110

Prepaid clinical trial related costs

791

Insurance

 

884

 

1,454

Software licenses and other

 

1,123

 

1,417

Reimbursement receivable

610

780

Warranties

 

202

 

242

Accrued interest receivable

 

855

 

Total prepaid expenses and other current assets

$

4,465

$

4,003

XML 25 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Property and equipment, net
3 Months Ended
Mar. 31, 2023
Property and equipment, net  
Property and equipment, net

Note 7—Property and equipment, net

The following is a summary of property and equipment, net:

     

March 31, 2023

    

December 31, 2022

Lab equipment

$

28,787

$

28,811

Leasehold improvements

 

49,180

 

48,951

Construction in progress

 

19,758

 

13,998

Computer software and equipment

 

3,132

 

3,132

Furniture and fixtures

 

1,548

 

1,548

Total

102,405

96,440

Less: Accumulated depreciation

 

(16,563)

 

(13,655)

Property and equipment, net

$

85,842

$

82,785

Depreciation expense was $2,908 and $1,160 for the three months ended March 31, 2023 and 2022, respectively.

XML 26 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Accrued expenses and other liabilities
3 Months Ended
Mar. 31, 2023
Accrued expenses and other liabilities.  
Accrued expenses and other liabilities

Note 8—Accrued expenses and other liabilities

The following is a summary of accrued expenses:

     

March 31, 2023

    

December 31, 2022

Payroll and bonuses

$

3,139

    

$

7,062

Interest

 

122

 

117

Accrued clinical trial related costs

314

Professional and legal fees

 

2,432

 

1,637

Operating lease liability, current

579

475

Other

 

259

 

236

Total accrued expenses and other liabilities

$

6,531

$

9,841

XML 27 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Long-term debt
3 Months Ended
Mar. 31, 2023
Long-term debt  
Long-term debt

Note 9—Long-term debt

The following is a summary of the Company’s indebtedness:

     

March 31, 2023

    

December 31, 2022

Principal

$

10,000

$

10,000

Plus: End of term fee

395

395

Less: Debt discount attributable to warrants, net of accretion

 

(8)

 

(8)

Less: Unamortized deferred financing cost and end of term fee, net of accretion

 

(90)

 

(146)

Long-term debt, net

$

10,297

$

10,241

On September 14, 2020, the Company entered into a $10,000 Term Loan Agreement (as amended, the “Loan Agreement”) with Hercules Capital, Inc. (“Hercules”). Pursuant to the terms of the Loan Agreement, the Company borrowed $10,000 (the “Tranche 1 Advance”) from the lenders at closing. Beginning January 1, 2021 and upon the achievement of certain development milestones and continuing through September 30, 2021 the Company may borrow an additional $10,000 (the “Tranche 2 Advance”). The remaining $10,000 tranche (“Tranche 3 Advance”) is subject to Hercules’ investment committee’s sole discretion.

The Loan Agreement has a four-year term and an interest-only period of up to 30 months. The Company was in compliance with all provisions of the Loan Agreement as of March 31, 2023. Amounts borrowed under the Loan Agreement accrue interest at a floating rate per annum (based on a year of 360 days) equal to (i) the sum of (a) the greater of 6.30% plus (b) the prime rate as reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue or (ii) 9.55%. The interest rate as of March 31, 2023 was 14.3%.

The Company incurred $410 in deferred financing costs. The Company is also required to pay the lenders an end of term fee of 3.95% of loan proceeds upon repayment or prepayment of any loans made under the Loan Agreement. The end of term fee is being recognized as interest expense and accreted over the term of the Loan Agreement using the effective interest method. The Company is also required to pay Hercules a prepayment charge equal to 2.00% of the loan amounts prepaid during the interest-only period and 1.00% thereafter on any loans made under the Loan Agreement.

The Company granted Hercules a lien on substantially all of the Company’s assets, excluding intellectual property.

The Company issued to Hercules warrants to purchase up to an aggregate of 16,112 shares of common stock. The warrants are exercisable for a period of ten years from the date of the issuance of each warrant at a per share exercise price equal to $13.96, subject to certain adjustments as specified in the warrants. The fair value of the warrants at issuance was $46. The Company accounted for the warrants as equity, and the fair value is recorded in additional paid-in capital. The warrant value is also recorded as a debt discount and classified as a contra- liability on the consolidated balance sheet and amortized to interest expense. If the Company borrows on the remaining two tranche advances outlined above, the Company will be required to issue warrants to Hercules equal to 2.25% of the aggregate amount funded.

Interest expense of the Loan Agreement is as follows:

For the Three Months Ended

For the Three Months Ended

    

March 31, 2023

    

March 31, 2022

Interest expense

$

348

$

238

Amortization of debt issuance costs, including end of term fee accretion

 

56

 

76

$

404

$

314

Included in accrued expenses in the accompanying consolidated balance sheets as of March 31, 2023 and December 31, 2022 was $122 and $117 of accrued interest, respectively.

Future principal payments due (including the end of term fee) under the Loan Agreement are as follows (in thousands):

    

Principal Payments

2023

$

10,395

Total future payments

$

10,395

On May 1, 2023, the Company repaid the loan in its entirety. See Note 18.

XML 28 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Bristol-Myers Squibb Collaboration
3 Months Ended
Mar. 31, 2023
Bristol-Myers Squibb Collaboration  
Bristol-Myers Squibb Collaboration

Note 10 – Bristol-Myers Squibb Collaboration

On January 7, 2022, the Company entered into the Collaboration Agreement with Bristol-Myers Squibb to collaborate on the research, development and commercialization of iNK and iT cell programs for hematologic malignancies and solid tumors (“Collaboration Program,” and each product candidate a “Development Candidate”). The Collaboration Agreement is within the scope of ASC 808, Collaborative Arrangements as both parties are active participants in the arrangement and are exposed to significant risks and rewards. While this arrangement is in the scope of ASC 808, the Company analogizes to ASC 606 for the accounting for the Collaboration Agreement, including for the delivery of goods and services (i.e., units of account). Revenue recognized by analogizing to ASC 606 is recorded as collaboration revenue in the statements of operations.

Pursuant to the Collaboration Agreement, the Company and Bristol-Myers Squibb will initially collaborate on two Collaboration Programs focused on acute myeloid leukemia (“AML”) and multiple myeloma (“MM”), and Bristol-Myers Squibb has the option to add up to two additional Collaboration Programs for an additional fee. The Company is responsible for generating Development Candidates for each Collaboration Program, and Bristol-Myers Squibb has the option to elect to exclusively license the Development Candidates for pre-clinical development, clinical development and commercialization on a worldwide basis (“License Option”). Following Bristol-Myers Squibb’s exercise of the License Option, the Company will be responsible for performing IND-enabling studies, supporting Bristol-Myers Squibb’s preparation and submission of an IND, and manufacturing of clinical supplies until completion of a proof of concept clinical trial. Bristol-Myers Squibb will be responsible for all regulatory, clinical, manufacturing (after the proof of concept clinical trial) and commercialization activities for such Development Candidates worldwide. The Company has the option to co-promote Development Candidates generated from certain specified Collaboration Programs.

Under the terms of the Collaboration Agreement, Bristol-Myers Squibb made a non-refundable, upfront cash payment of $100,000 and will pay an exercise fee upon the exercise of the License Option (“Licensed Program” and product candidates developed under a Licensed Program, “Licensed Products”). For each Licensed Program, Bristol-Myers Squibb will pay up to $235,000 in milestone payments upon the first achievement of certain development and regulatory milestones and will pay up to $500,000 per Licensed Product in net sales-based milestone payments. Bristol-Myers Squibb will also pay the Company tiered royalties per Licensed Product as a percentage of net sales in the high-single digits to low-teens, subject to reduction for biosimilar competition, compulsory licensing and certain third party license costs. If Century exercises its co-promote option, such royalty percentage will be increased to low-teens to high-teens in respect of the sales of the co-promoted Licensed Products in the United States. The royalty term shall terminate on a Licensed Product-by-Licensed Product and country-by-country basis on the latest of (i) the twelve (12) year anniversary of the first commercial sale of such Licensed Product in such country, (ii) the expiration of any regulatory exclusivity period that covers such Licensed Product in such country, and (iii) the expiration of the last-to-expire licensed patent of the Company or a jointly owned patent that covers such the Licensed Product in such country. After expiration of the applicable royalty term for a Licensed Product in a

country, all licenses granted by the Company to Bristol-Myers Squibb for such Licensed Product in such country will be fully paid-up, royalty- free, perpetual and irrevocable.

In connection with the Collaboration Agreement, Bristol-Myers Squibb purchased 2,160,760 shares of the Company’s common stock at a price per share of $23.14, for an aggregate purchase price of $50,000. In determining the fair value of the common stock issued to Bristol-Myers Squibb, the Company considered the closing price of the common stock on the date of the transaction and included a lack of marketability discount because the shares are subject to certain restrictions. The Company determined the common stock purchase represented a premium of $7.82 per share, or $23,200 in the aggregate (“Equity Premium”), and the remaining $26,800 was recorded as issuance of common stock in stockholders’ equity.

The Company identified the following commitments under the arrangement: (i) research and development services (“R&D Services”) under each of the two initial Collaboration Programs and (ii) Bristol-Myers Squibb’s License Option to elect to exclusively license the Development Candidates for each of the two initial Collaboration Programs. The Company determined that these four commitments represent distinct performance obligations for purposes of recognizing revenue and will recognize revenue as the Company fulfills each performance obligation.

The Company determined that the upfront payment and Equity Premium constitute the transaction price at the inception of the Collaboration Agreement. The future potential development and regulatory milestone payments were fully constrained at contract inception as the risk of significant revenue reversal related to these amounts has not yet been resolved. The achievement of the future potential milestones is not within the Company’s control and is subject to certain research and development success and therefore carries significant uncertainty. The Company will reevaluate the likelihood of achieving these milestones at the end of each reporting period and adjust the transaction price in the period the risk is resolved. In addition, the Company will recognize any consideration related to sales-based milestones and royalties when the subsequent sales occur.

At March 31, 2023, the total transaction price of $123,187 is allocated to the performance obligations based on their estimated standalone selling price. The stand-alone selling price of the research and development services was estimated using the expected cost-plus margin approach, and the stand-alone selling price of the License Options was based on a discounted cash flow approach and considered several factors including, but not limited to, discount rate, development timeline, regulatory risks, estimated market demand, and future revenue potential using an adjusted market approach. The allocated transaction price is recognized as revenue in one of two ways:

Research and development services: The Company recognizes the portion of the transaction price allocated to each of the research and development performance obligations as the research and development services are provided, using an inputs method, in proportion to costs incurred to date for each research development target as compared to total costs incurred and expected to be incurred in the future to satisfy the underlying obligation related to each research and development target. The transfer of control occurs over this period and, in management’s judgment, is the best measure of progress towards satisfying the performance obligation.
License option rights: The transaction price allocated to the license options rights, which are considered material rights to license and commercialize the underlying research and development target, are deferred until the period that Bristol-Myers Squibb elects to exercise or elects to not exercise its option or when the option to exercise expires.

The following table summarizes the allocation of the total transaction price to the identified performance obligations under the arrangement, and the amount of the transaction price unsatisfied as of March 31, 2023:

Cumulative collaboration

Deferred

Performance obligations:

Transaction price

revenue recognized

collaboration revenue

Option rights

$

109,164

$

-

$

109,164

Research and development services

14,023

(6,919)

7,104

Total

123,187

(6,919)

116,268

Less current portion of deferred revenue

-

-

(6,500)

Total long-term deferred revenue

$

123,187

$

(6,919)

$

109,768

The following table summarizes the allocation of the total transaction price to the identified performance obligations under the arrangement, and the amount of the transaction price unsatisfied as of December 31, 2022:

Cumulative collaboration

Deferred

Performance obligations:

Transaction price

revenue recognized

collaboration revenue

Option rights

$

109,164

$

-

$

109,164

Research and development services

14,023

(5,199)

8,824

Total

123,187

(5,199)

117,988

Less current portion of deferred revenue

-

-

(7,154)

Total long-term deferred revenue

$

123,187

$

(5,199)

$

110,834

As a direct result of the execution of the Collaboration Agreement, the Company incurred $10,000 in fees to amend the FCDI agreement to gain access to the territory rights of Japan. This is recorded as in-process research and development expenses in the consolidated statement of operations and comprehensive loss for the three months ended March 31, 2022.

XML 29 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2023
Commitments and Contingencies.  
Commitments and Contingencies

Note 11—Commitments and contingencies

From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when future expenditures are probable and such expenditures can be reasonably estimated.

Distributed Bio Master Service Agreement

On July 24, 2019, the Company entered into a Master Service Agreement with Distributed Bio, Inc (“DBio”), whereby DBio will screen for protein binders that bind to specific therapeutic targets. The Company pays for such services according to a payment schedule, and if the Company brings the protein binders into the clinic for further development, DBio will receive milestone payments of up to $16,100 in total for each product as the products move through the clinical development and regulatory approval processes. No milestone payments were due since the inception of the agreement.

The Company had $27 within accounts payable as of March 31, 2023 and $110 as of December 31, 2022, in its consolidated balance sheets related to the Master Service Agreement.

iCELL Inc. Sublicense Agreement

In March 2020, the Company entered into a Sublicense Agreement with iCELL Inc (“iCELL”) whereby iCELL granted the Company a license of certain patents and technology. The Company will pay iCELL royalties in the low single digits on net sales of the licensed product. In addition to the earned royalties, the Company will pay sales milestones, not to exceed $70,000, for the sales of the licensed product. iCELL is also eligible to

receive payments of up to $4,250 in development and regulatory approval milestone payments. No milestones or royalties were due in 2022 or 2021.

XML 30 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Leases
3 Months Ended
Mar. 31, 2023
Leases  
Leases

Note 12—Leases

The Company has commitments under operating leases for certain facilities used in its operations. The Company maintains security deposits on certain leases in the amounts of $950 and $1,260 within security deposits in its consolidated balance sheets at March 31, 2023 and December 31, 2022, respectively. The Company’s leases have initial lease terms ranging from 5 to 16 years. Certain lease agreements contain provisions for future rent increases.

The following table reflects the components of lease expense:

For the Three Months Ended

For the Three Months Ended

March 31, 2023

March 31, 2022

Operating lease expense:

    

  

Fixed lease cost

$

1,395

$

597

Variable lease cost

 

125

 

297

Short term lease expense

594

649

Total operating lease expense

$

2,114

$

1,543

The following table reflects supplemental balance sheet information related to leases:

    

As of

As of

    

    

March 31, 

    

December 31, 

Location in Balance Sheet

2023

2022

Operating lease right-of-use asset, net

 

Operating lease right-of-use assets

$

28,207

$

28,945

Operating lease liability, current

 

Accrued expenses and other liabilities

$

579

$

475

Operating lease liability, long-term

 

Operating lease liability, long-term

 

41,168

 

38,698

Total operating lease liability

 

  

$

41,747

$

39,173

The following table reflects supplement lease term and discount rate information related to leases:

    

As of March 31, 2023

     

As of December 31, 2022

 

Weighted-average remaining lease terms - operating leases

 

9.1 years

9.4 years

Weighted-average discount rate - operating leases

 

9.0

%

9.0

%

The following table reflects supplemental cash flow information related to leases as of the periods indicated:

For the Three Months Ended

For the Three Months Ended

     

March 31, 2023

     

March 31, 2022

Cash paid for amounts included in the measurement of lease liabilities

 

  

 

  

Operating cash flows from operating leases

$

(31)

$

(152)

The following table reflects future minimum lease payments under noncancelable leases as of March 31, 2023:

    

Operating Leases

2023

$

4,306

2024

 

8,079

2025

 

8,588

2026

 

8,727

2027

 

8,905

Thereafter

 

53,073

Total lease payments

 

91,678

Less: Imputed interest

 

(46,097)

Less: Tenant incentive receivable

(3,834)

Total

$

41,747

XML 31 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Income taxes
3 Months Ended
Mar. 31, 2023
Income taxes  
Income taxes

Note 13—Income taxes

During the three months ended March 31, 2023, the Company recorded income tax expense of $1,208, which includes a tax provision of $13 related to its income tax obligations of its operating company in Canada. The Company is projecting taxable income for tax year 2023, due primarily to revenue recognition for tax purposes from the Company's Research Collaboration and Collaboration Agreement entered into with Bristol-Myers Squibb Company in 2022.

The Company’s tax provision and the resulting effective tax rate for interim periods is determined based upon its estimated annual effective tax rate (“AETR”), adjusted for the effect of discrete items arising in that quarter. The impact of such inclusions could result in a higher or lower effective tax rate during a particular quarter, based upon the mix and timing of actual earnings or losses versus annual projections. In each quarter, the Company updates its estimate of the annual effective tax rate, and if the estimated annual tax rate changes, a cumulative adjustment is made in that quarter.

The Company has evaluated the positive and negative evidence bearing upon its ability to realize its deferred tax assets, which primarily consist of net operating loss carryforwards. While the Company anticipates utilizing a portion of its existing net operating loss carryforwards during tax year 2023, the Company has considered its history of cumulative net losses in the U.S., estimated future taxable income and prudent and feasible tax planning strategies and has concluded that it is more likely than not that the Company will not realize the benefits of its U.S. deferred tax assets. As a result, as of March 31, 2023, the Company has recorded a full valuation allowance against its net deferred tax assets in the U.S.

XML 32 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Basic and diluted net loss per common share
3 Months Ended
Mar. 31, 2023
Basic and diluted net loss per common share  
Basic and diluted net loss per common share

Note 14—Basic and diluted net loss per common share

Basic and diluted net loss per common share is calculated as follows:

Three Months Ended

Three Months Ended

March 31, 

March 31, 

    

2023

    

2022

Numerator

 

  

 

  

Net loss

 

$

(31,264)

$

(37,513)

Denominator

 

  

 

  

Weighted-average common shares for basic and diluted net loss per share

 

58,610,375

 

57,051,539

Basic and diluted net loss per common share

$

(0.53)

$

(0.66)

The Company’s potentially dilutive securities, which include restricted stock, warrants, early exercised stock options and stock options to purchase shares of the Company’s common stock, have been excluded from the computation of dilutive net loss per share as the effect would be antidilutive. Therefore, the weighted- average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential shares of common stock presented based on amounts outstanding at each stated period end, from the computation of diluted net loss per share for the three months ended March 31, 2023 and 2022 because including them would have had an anti-dilutive effect.

Three Months Ended

Three Months Ended

March 31, 

March 31, 

    

2023

    

2022

Stock options to purchase common stock

10,370,402

 

7,424,538

Early exercised stock options subject to future vesting

385,655

 

773,394

Restricted stock award subject to future vesting

49,465

 

520,630

Unvested restricted stock units

 

544,650

 

Warrants

32,009

32,009

Total

 

11,382,181

 

8,750,571

XML 33 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Defined contribution plan
3 Months Ended
Mar. 31, 2023
Defined contribution plan  
Defined contribution plan

Note 15—Defined contribution plan

The Company has a 401(k) Employee Savings Plan (“401(k) Plan”) that is available to all employees of the Company. The Company has elected a Safe-Harbor provision for the 401(k) Plan in which participants are always fully vested in their employer contributions. The Company matches 100% of the first 3% of participating employee contributions and 50% of the next 2% of participating employee contributions. Contributions are made in cash. Contributions were approximately $384 and $158 for the three months ended March 31, 2023 and 2022, respectively. Such contribution expense has been recognized in the consolidated statement of operations for each period.

XML 34 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Stock based compensation
3 Months Ended
Mar. 31, 2023
Stock based compensation  
Stock based compensation

Note 16—Stock-based compensation

On June 17, 2021, the Company adopted the Century Therapeutics, Inc. 2021 Equity Incentive Plan (the “2021 Incentive Plan”) which superseded the 2018 Incentive Plan and from that date forward all issuances of incentive awards will be governed by the 2021 Incentive Plan.

The 2021 Incentive Plan provides for the Company to sell or issue common stock or restricted common stock, restricted stock units (“RSU”), or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the Board of Directors, and consultants of the Company under terms and provisions established by the Board of Directors. Under the terms of the 2021 Incentive Plan, options may be granted at an exercise price not less than fair market value.

Upon adoption of the 2021 Incentive Plan, the Company was authorized to issue 5,481,735 shares of Common Stock under the 2021 Incentive Plan (which represents 5,640,711 shares of Common Stock initially available for grant under the 2021 Incentive Plan less 158,976 shares of Common Stock reserved for issuance upon the exercise of previously granted stock options that remain outstanding under the 2018 Incentive Plan). The number of shares of common stock initially reserved for issuance under the 2021 Incentive Plan shall be increased, upon approval by the board of directors, on January 1, 2022 and each January 1 thereafter, in an amount equal to the least of, (i) five percent (5%) of the outstanding common stock on the immediately preceding December 31, or (ii) such number of common stock determined by the board of directors no later than the immediately preceding December 31. For 2022, the 2021 Incentive Plan reserved shares were increased under clause (i) by 2,750,276 shares, effective as of January 1, 2022. For 2023, the 2021 Incentive Plan reserved shares were increased under clause (i) by 2,954,788 shares, effective as of January 1, 2023. As of March 31, 2023, there were 4,863,670 shares available for issuance under the 2021 Incentive Plan.

The Company’s stock-based awards are subject to service-based vesting conditions. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Stock awards granted typically vest over a four-year period but may be granted with different vesting terms. The Company may also issue awards with performance-based vesting conditions. For performance-based awards, the Company would reassess at each reporting date whether achievement of the performance condition is probable and accrue compensation expense if and when the achievement of the performance condition is probable.

The Company recognizes the costs of the stock-based payments as the employees vest in the awards.

As of March 31, 2023, the Company had reserved shares of common stock for issuance as follows:

    

Shares

Options and RSUs issued and outstanding

10,915,052

Shares available for future stock option and RSU grants

4,863,670

Shares available for employee stock purchase plan

1,114,126

Total

16,892,848

The shares of Common Stock available under the 2021 Incentive Plan as of March 31, 2023 are as follows

    

Shares

Balance, December 31, 2022

5,786,358

Shares reserved for issuance

2,954,788

Options granted

(3,770,399)

RSU’s granted

(546,795)

Options and RSUs forfeited / cancelled

439,718

Balance March 31, 2023

4,863,670

Stock Options

The following table summarizes stock option activity for the three month period ended March 31, 2023:

Weighted Average 

Remaining

Aggregate

Contractual

Intrinsic

Term

Value

    

Shares

    

Exercise Price

    

(years)

(in thousands)

Outstanding January 1, 2023

 

7,489,678

$

7.77

 

7.84

$

8,991

Granted

 

3,770,399

 

4.66

 

 

Exercised

 

(452,102)

 

0.99

 

 

Forfeited

 

(437,573)

 

10.39

 

 

Outstanding, March 31, 2023

 

10,370,402

$

5.28

 

4.55

$

3,952

Exercisable at March 31, 2023

3,145,362

$

6.45

6.93

$

3,262

The weighted average grant date fair value of awards for options granted during the three months ended March 31, 2023 was $4.65. As of March 31, 2023, there was $38,428 of total unrecognized compensation expense related to unvested stock options with time-based vesting terms, which is expected to be recognized over a weighted average period of 3.13 years.

The Company estimates the fair value of its option awards to employees and directors using Black-Scholes. Due to the lack of substantial company-specific historical and implied volatility data of its common stock, the Company has based its estimate of expected volatility on the historical volatility of a group of similar public

companies. The Company has never paid dividends and does not expect to in the foreseeable future. The expected term of the options granted to employees is derived from the “simplified” method as described in Staff Accounting Bulletin 107 relating to stock-based compensation. The risk-free interest rates for periods within the expected term of the option are based on the U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company will account for actual forfeitures as they occur.

The weighted-average assumptions used to calculate the fair value of stock options granted are as follows:

March 31, 2022

December 31, 2022

 

Expected dividend rate

 

Expected option term (years)

6.08

 

6.09

Expected volatility

79.15

%  

69.73

%

Risk-free interest rate

3.65

%  

1.08

%

Stock-based compensation expense recorded under ASC 718 related to stock options granted and common stock issued under the 2021 Employee Stock Purchase Plan (the “ESPP”) were allocated to research and development and general and administrative expense as follows:

Three Months Ended

Three Months Ended

March 31, 

March 31, 

2023

2022

Research and development

$

2,112

$

1,309

General and administrative

1,685

1,071

Total stock-based compensation

$

3,797

$

2,380

Stock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:

Three Months Ended

Three Months Ended

March 31, 

March 31, 

2023

2022

Stock options

$

3,546

$

2,108

Restricted stock units

97

Restricted stock awards

93

272

Employee stock purchase plan

61

Total stock-based compensation

$

3,797

$

2,380

Restricted Stock Units

The following table summarizes RSU activity for the quarter ended March 31, 2023:

    

    

Weighted Average

Shares

Grant Date Fair Value

Total Unvested December 31, 2022

 

$

Granted

546,795

4.64

Forfeited

(2,145)

4.64

Total Unvested March 31, 2023

 

544,650

$

4.64

As of March 31, 2023, there was $2,428 of total unrecognized compensation expense related to the unvested restricted stock with time-based vesting terms, which is expected to be recognized over a weighted average period of 3.85 years. All restricted stock units vest over a four-year period.

Restricted Stock Awards

The following table summarizes restricted stock activity as of March 31, 2023 and December 31, 2022:

    

    

Weighted Average

Shares

Grant Date Fair Value

Total Unvested December 31, 2022

 

193,031

$

8.41

Granted

Forfeited

(47,689)

Vested

 

(95,877)

 

2.50

Total Unvested March 31, 2023

 

49,465

$

7.27

Pursuant to certain stock purchase agreements containing vesting and other provisions, the Company has the right to repurchase unvested shares.

As of March 31, 2023, there was $356 of total unrecognized compensation expense related to the unvested restricted stock with time-based vesting terms, which is expected to be recognized over a weighted average period of 1.98 years. All restricted stock vests over a four-year period.

Early-Exercise of Unvested Equity Awards

Certain equity award holders early exercised unvested equity awards. The cash received upon early exercise of options of $1,314 was recorded as a deposit liability on the Company’s balance sheet as of March 31, 2023.

Employee Stock Purchase Plan

The ESPP was adopted by the Board of Directors in May 2021. A total of 564,071 shares of common stock were initially reserved for issuance under this plan, which shall be increased, upon approval by the board of directors, on January 1, 2022 and each January 1 thereafter, to the lesser of (i) one percent (1%) of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (ii) an amount determined by the board of directors no later than the last day of the immediately preceding fiscal year. For 2022, the ESPP reserved shares were increased under clause (i) by 550,055 shares, effective as of January 1, 2022. For 2023, the board waived the annual increase to the shares reserved under the ESPP. As of March 31, 2023, there were 1,114,126 shares available for issuance, under the ESPP.

XML 35 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Related party transactions
3 Months Ended
Mar. 31, 2023
Related party transactions  
Related party transactions

Note 17—Related party transactions

License Agreements and Collaborative Agreements with Shareholder

The Company owns licenses and other contracts with FUJIFILM Cellular Dynamics, Inc. (“FCDI”). FCDI is a shareholder of Century. The acquired licenses and other contracts with FCDI are as follows:

FCDI Licenses

The Company owns a non-exclusive license agreement with FCDI. The license provides the Company with certain patents and know-how related to the reprogramming of human somatic cells to induce pluripotent stem cells (“iPSCs”) (“License Agreement”). Under this agreement, the Company is required to make certain developmental and regulatory milestone payments as well as royalty payments upon commercialization. Royalties are in the low single digits on the sale of all licensed products.

The Company also owns an exclusive license agreement with FCDI. The license provides the Company with patents and know-how related to human iPSC exclusively manufactured by FCDI.

The potential development and regulatory milestone payments to be paid by the Company to FCDI are $6,000.

FCDI Collaboration Agreement

In October 2019, the Company entered into the Master Collaboration Agreement with FCDI, whereby FCDI will provide certain services to the Company to develop and manufacture iPSCs and immune cells derived therefrom. FCDI will provide services in accordance with the approved research plan and related research budget. The initial research plan covers the period from October 2019 through March 31, 2022. On July 29, 2022 the Company amended it’s Master Collaboration Agreement to extend the term through September 30, 2025.

On March 23, 2021, the Company entered into a Manufacturing Agreement with FCDI, or the Manufacturing Agreement, pursuant to which FCDI will provide certain agreed upon technology transfer, process development, analytical testing and cGMP manufacturing services to the company.

On January 7, 2022, the Company and FCDI entered into a letter agreement (the “Letter Agreement”), which amends each of the FCDI agreements pursuant to the Company’s Research Collaboration and License Agreement with Bristol-Myers Squibb. Pursuant to the Letter Agreement, and in consideration for amending the FCDI Agreements, the Company will pay to FCDI (i) an upfront payment of $10,000, (ii) a percentage of any milestone payments received by the Company under the FCDI Collaboration Agreement in respect of achievement of development or regulatory milestones specific to Japan, and (iii) a percentage of all royalties received by the Company under the FCDI Collaboration Agreement in respect of sales of products in Japan.

During the three months ended March 31, 2023, the Company made payments of $12 and incurred research and development expenses of $32 and legal fees of $33, recorded within general and administrative expenses in its consolidated statements of operations and comprehensive loss. As of March 31, 2023, there was $21 in accrued expenses related to this agreement on the consolidated balance sheets. As of December 31, 2022, there was $0 in accrued expenses on the consolidated balance sheets.

During the three months ended March 31, 2022, the Company made payments of $3,003 and incurred research and development expenses of $1,445, and legal fees of $30, recorded within general and administrative expenses in its consolidated statements of operations and comprehensive loss.

Bayer Option Agreement

Bayer Health, LLC (“Bayer”) has the right of first refusal to acquire certain products researched and developed by the Company. Subject to certain exceptions, Bayer’s right of first refusal is exercisable with respect to up to four products and may only exercise these option rights in a non-sequential and alternating manner, and such rights are subject to additional limitations.

Consulting Arrangements with Shareholders

In 2019, the Company entered into arrangements with two shareholders of the Company, wherein the shareholders provide consulting services to the Company. As compensation for the consulting services, the shareholders are entitled to an annual retainer fee of $125 payable quarterly, along with payment of reasonable expenses associated with providing the consulting services. The Company incurred $0 related to these consulting arrangements that were included in research and development expenses in the consolidated statements of operations and comprehensive loss for the three  months ended March 31, 2023. The Company incurred $19 related to these consulting arrangements that were included in research and development expenses in the consolidated statements of operations and comprehensive loss for the three months ended March 31, 2022. As of March 31, 2023 and December 31, 2022, there was $0 in accrued

expenses related to this agreement on the consolidated balance sheets. This agreement was terminated in January 2023.

XML 36 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Events
3 Months Ended
Mar. 31, 2023
Subsequent Events  
Subsequent Events

Note 18—Subsequent Events

The Company has evaluated subsequent events through the filing of this Quarterly Report on Form 10-Q, and determined that there have been no events that have occurred that would require adjustments to our disclosures in the consolidated financial statements.

On May 1, 2023 the Company repaid the Loan Agreement with Hercules in full. The total repayment was $10,617, which included principal, interest, and end of term and prepayment charge.

XML 37 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of significant accounting policies and basis of presentation (Policies)
3 Months Ended
Mar. 31, 2023
Basis of presentation

Basis of presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the interim period reporting requirements of Form 10-Q and Article 10 of Regulation S-X. The consolidated balance sheet as of March 31, 2023, the consolidated statements of operations and comprehensive loss, and consolidated statements of changes in stockholders’ equity for the three months ended March 31, 2023 and 2022, and the consolidated statements of cash flows for the three months ended March 31, 2023 and 2022 are unaudited, but, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.  The results for any interim period are not necessarily indicative of results for the year ending December 31, 2023 or for any other subsequent interim period.  The consolidated balance sheet at December 31, 2022 has been derived from the Company’s audited consolidated financial statements.

Certain prior year information has been reclassified to conform to the fiscal year 2023 presentation.

Segment information

Segment information

Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages the business as one operating segment.

Use of estimates

Use of estimates

The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuations supporting stock compensation, the estimation of the incremental borrowing rate for operating leases and standalone selling prices of performance obligations in collaboration agreements. If actual results differ from the Company’s estimates, or to the extent these estimates are adjusted in future periods, the Company’s results of operations could either benefit from, or be adversely affected by, any such change in estimate.

Concentration of credit risk and other risks and uncertainties

Concentration of credit risk and other risks and uncertainties

Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist of cash, cash equivalents, U.S. Treasury bills and bonds, as well as corporate bonds. Cash and cash equivalents, as well as short and long-term investments include a checking account and asset management accounts held by a limited number of financial institutions. At times, such deposits may be in excess of insured limits. As of March 31, 2023 and December 31, 2022, the Company has not experienced any losses on its deposits of cash and cash equivalents.

The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, uncertainty of market acceptance of its products, competition from substitute products and larger companies, protection of proprietary technology, strategic relationships, and dependence on key individuals.

Products developed by the Company require clearances from the U.S. Food and Drug Administration (the “FDA”) or other international regulatory agencies prior to commercial sales. There can be no assurance the Company’s future products will receive the necessary clearances. If the Company was denied clearance,

clearance was delayed, or if the Company was unable to maintain clearance, it could have a material adverse impact on the Company.

Fair value of financial instruments

Fair value of financial instruments

The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:

Level 1

Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date;

Level 2

Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly, including inputs in markets that are not considered to be active;

Level 3

Inputs are unobservable in which there is little or no market data available, which require the reporting entity to develop its own assumptions that are unobservable.

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.

Cash and cash equivalents

Cash and cash equivalents

Management considers all highly liquid investments with an insignificant interest rate risk and original maturities of three months or less to be cash equivalents.

Restricted cash

Restricted cash

As of March 31, 2023 and December 31, 2022, the Company had $1,979 in cash on deposit to secure certain lease commitments. Restricted cash is recorded separately in the Company’s consolidated balance sheets.

The following provides a reconciliation of the Company’s cash, cash equivalents, and restricted cash as reported in the consolidated balance sheets to the amounts reported in the consolidated statements of cash flows:

    

March 31, 2023

    

December 31, 2022

Cash and cash equivalents

$

86,832

$

84,265

Restricted cash

1,979

1,979

Cash, cash equivalents, and restricted cash

$

88,811

$

86,244

Investments

Investments

The Company invests in fixed maturity securities including U.S. Treasury bills and bonds as well as corporate bonds. The investments are classified as available-for-sale and reported at fair value. Unrealized gains or losses are determined by comparing the fair market value of the securities with their cost or amortized cost. Realized gains and losses on investments are recorded on the trade date and are included in the statement of operations. Unrealized gains and losses on investments are recorded in other comprehensive income (loss) on the consolidated statements of operations and comprehensive loss. The cost of securities sold is based on the specified identification method. Investment income is recognized as earned and discounts or premiums arising from the purchase of debt securities are recognized in investment income using the interest

method over the remaining term of the security. Securities with an original maturity date greater than three months that mature within one year of the balance sheet date are classified as short-term, while investments with a maturity date greater than one year are classified as long-term.

Property and equipment, net

Property and equipment, net

Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which is generally five years. Leasehold improvements are amortized over the shorter of the asset’s useful life or the remaining term of the lease. Construction in progress includes direct cost related to the construction of leasehold improvements and is stated at original cost. Such costs are not depreciated until the asset is completed and placed into service. Once the asset is placed into service, these capitalized costs will be allocated to leasehold improvements and will be depreciated over the shorter of the asset’s useful life or the remaining term of the lease. Computer software and equipment includes implementation costs for cloud-based software and network equipment.

Expenditures for major additions and improvements are capitalized, while minor replacements, maintenance, and repairs are charged to expense as incurred. When property is retired or otherwise disposed of, the costs and accumulated depreciation are removed from the respective accounts, with any resulting gain or loss recognized concurrently.

Research and development expenses

Research and development expenses

Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, stock compensation, materials, supplies, rent, depreciation on and maintenance of research equipment with alternative future use, and the cost of services provided by outside contractors. All costs associated with research and development are expensed as incurred.

Clinical trial costs are a component of research and development expenses. The company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.

Stock based compensation

Stock-based compensation

Employees, consultants and members of the board of directors of the Company have received stock options and restricted stock of the Company. The Company recognizes the cost of the stock-based compensation incurred as its employees and board members vest in the awards. The Company accounts for stock-based compensation arrangements in accordance with provisions of Accounting Standards Codification (“ASC”) 718, Compensation—Stock Compensation. ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The Company uses the Black-Scholes option-pricing model (“Black Scholes”) to determine the fair value of options granted. The Company’s stock-based awards are subject to service-based vesting conditions and performance-based vesting conditions. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. For performance-based awards, the Company reassesses at each reporting date whether achievement of the performance condition is probable and accrues compensation expense if and when achievement of the performance condition is probable.

Black-Scholes requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. Due to

the lack of a public market for the Company’s common stock prior to its initial public offering (“IPO”) and lack of company-specific historical and implied volatility data, the Company based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. Forfeitures are recognized as they occur.

Warrants

Warrants

The Company has issued warrants that have been recognized as equity, and the fair value is recorded into additional paid-in capital in the accompanying consolidated balance sheets. Warrants are accounted for in accordance with applicable accounting guidance provided in ASC Topic 815, Derivatives and Hedging—Contracts in Entity’s Own Equity, as either derivative liabilities or as equity instruments depending on the specific terms of the warrant agreement. The Company’s warrants issued are in connection with its long-term debt and in connection with services provided by consultants, and are equity classified on the accompanying consolidated balance sheets. Equity classified warrants are accounted for at fair value on the issuance date, using Black Scholes, with no changes in fair value recognized after the issuance date.

Foreign currency translation

Foreign currency translation

The reporting currency of the Company is the U.S. dollar. The functional currency of Century Canada is the Canadian dollar. Assets and liabilities of Century Canada are translated into U.S. dollars based on exchange rates at the end of each reporting period. Expenses are translated at average exchange rates during the reporting period. Gains and losses arising from the translation of assets and liabilities are included as a component of accumulated other comprehensive loss or income on the company’s consolidated balance sheets. Gains and losses resulting from foreign currency transactions are reflected within the Company’s consolidated statements of operations and comprehensive loss. The Company has not utilized any foreign currency hedging strategies to mitigate the effect of its foreign currency exposure.

Intercompany payables and receivables are considered to be long-term in nature and any change in balance due to foreign currency fluctuation is included as a component of the Company’s consolidated comprehensive loss and accumulated other comprehensive loss within the Company’s consolidated balance sheets.

Basic and diluted net loss per common shares

Basic and diluted net loss per common shares

Basic net loss per common share is computed by dividing net loss applicable to common shareholders by the weighted-average number of common shares outstanding during the period. The Company computes diluted net loss per common share by dividing the net loss applicable to common shareholders by the sum of the weighted- average number of common shares outstanding during the period plus the potential dilutive effects of its warrants, restricted stock and stock options to purchase common shares, but such items are excluded if their effect is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there were no differences between the Company’s basic and diluted net loss per common share for the three months ended March 31, 2023 and 2022.

Income taxes

Income taxes

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations and comprehensive loss. As of March 31, 2023 and December 31, 2022, no accrued interest or penalties are included on the related tax liability line in the consolidated balance sheet.

Collaboration Revenue

Collaboration revenue

The Company may enter into collaboration and licensing agreements with strategic partners for research and development, manufacturing, and commercialization of its product candidates. Payments under these arrangements may include non-refundable, upfront fees; reimbursement of certain costs; customer option fees for additional goods or services; payments upon the achievement of development, regulatory, and commercial milestones; sales of product at certain agreed-upon amounts; and royalties on product sales.

The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers, or ASC 606. This standard applies to all contracts with customers. When an agreement falls under the scope of other standards, such as ASC Topic 808, Collaborative Arrangements, or ASC 808, the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the

performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606 is recorded as collaboration revenue on the statements of operations.

Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under a collaboration agreement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations on a relative stand-alone selling price basis; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.

As part of the accounting for these arrangements, the Company must use its judgment to determine the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price. The estimation of the stand-alone selling price may include such estimates as forecasted revenues and costs, development timelines, discount rates, and probabilities of regulatory and commercial success. The Company also applies significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining when performance obligations have been met, assessing the recognition and future reversal of variable consideration and determining and applying appropriate methods of measuring progress for performance obligations satisfied over time. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, current. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, non-current.

If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are not determined to represent a material right, no transaction price is allocated to these options and the Company will account for these options at that time they are exercised. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement.

The obligations under the Company’s collaboration agreements may include research and development services to be performed by the Company for or on behalf of the customer. Amounts allocated to these performance obligations are recognized as the Company performs these obligations, and revenue is measured based on an inputs method of costs incurred to date of budgeted costs. Under certain circumstances, the Company may be reimbursed for certain expenses incurred under the research and development services.

At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the statements of operations in the period of adjustment.

Recent accounting pronouncements

Recent accounting pronouncements

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses of Financial Instruments (ASC 326). The guidance is effective for the Company beginning January 1, 2023 and it changes how entities account for credit losses on the financial assets and other instruments that are not measured at fair value through net income, including available-for-sale debt securities. The adoption of ASC 326 did not have a material impact on the consolidated financial statements.

Stock Options  
Stock based compensation

Early exercised options

The Company allowed certain of its employees and its consultants to exercise options granted under the 2018 Stock Option and Grant Plan (the “2018 Incentive Plan”) (Note 16) prior to vesting and prior to its IPO. The shares related to early exercised stock options are subject to the Company’s repurchase right upon termination of employment or services at the lesser of the original purchase price or fair market value at the time of repurchase. In order to vest, the holders are required to provide continued service to the Company. The early exercise by an employee or consultant of a stock option is not considered to be a substantive

exercise for accounting purposes, and therefore, the payment received by the employer for the exercise price is recognized as a liability. For accounting purposes, unvested early exercised shares are not considered issued and outstanding and therefore not reflected as issued and outstanding in the accompanying consolidated balance sheets or the consolidated statements of changes in stockholders’ equity (deficit) until the awards vest. The deposits received are initially recorded in deposit liability. The liabilities are reclassified to common stock and additional paid-in-capital as the repurchase right lapses. At March 31, 2023 and December 31, 2022, there were $1,314 and $1,584, respectively, recorded in deposit liability related to shares held by employees and nonemployees that were subject to repurchase.

All shares that were early exercised by the executives of the Company are considered legally issued, however, for accounting purposes, only vested shares are considered issued. Below is a reconciliation of shares issued and outstanding:

    

March 31, 2023

    

December 31, 2022

Total shares legally outstanding

59,541,904

59,137,491

Less: unvested early exercised shares

(385,655)

(470,800)

Less: unvested restricted stock awards (Note 16)

(49,465)

(193,031)

Total shares issued and outstanding

59,106,784

58,473,660

XML 38 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of significant accounting policies and basis of presentation (Tables)
3 Months Ended
Mar. 31, 2023
Summary of significant accounting policies and basis of presentation  
Schedule of reconciliation of the Company's cash, cash equivalents, and restricted cash

    

March 31, 2023

    

December 31, 2022

Cash and cash equivalents

$

86,832

$

84,265

Restricted cash

1,979

1,979

Cash, cash equivalents, and restricted cash

$

88,811

$

86,244

Reconciliation of shares issued and outstanding

    

March 31, 2023

    

December 31, 2022

Total shares legally outstanding

59,541,904

59,137,491

Less: unvested early exercised shares

(385,655)

(470,800)

Less: unvested restricted stock awards (Note 16)

(49,465)

(193,031)

Total shares issued and outstanding

59,106,784

58,473,660

XML 39 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Financial instruments and fair value measurements (Tables)
3 Months Ended
Mar. 31, 2023
Financial instruments and fair value measurements  
Schedule of assets measured at fair value by level within the fair value hierarchy

    

Level 1

    

Level 2

    

Level 3

    

Total

Cash equivalents

$

83,187

$

83,187

U.S. Treasury

 

65,197

 

 

 

65,197

Corporate bonds

 

 

182,756

 

 

182,756

Total

$

148,384

$

182,756

$

$

331,140

    

Level 1

    

Level 2

    

Level 3

    

Total

Cash equivalents

$

77,736

$

77,736

U.S. Treasury

 

86,475

 

 

 

86,475

Corporate bonds

 

 

196,603

 

 

196,603

Total

$

164,211

$

196,603

$

$

360,814

Schedule of investments in fixed maturity securities

    

    

Gross 

    

Gross

    

Unrealized

 Unrealized 

Amortized Cost

 Gains

Losses

Fair Value

U.S. Treasury

$

65,807

$

$

(610)

$

65,197

Corporate bonds

 

183,329

 

87

 

(660)

 

182,756

Total

$

249,136

$

87

$

(1,271)

$

247,953

    

Gross 

    

Gross 

    

Unrealized

Unrealized

    

Amortized Cost

 Gains

 Losses

Fair Value

U.S. Treasury

$

87,798

$

$

(1,323)

$

86,475

Corporate bonds

 

197,668

 

2

 

(1,067)

 

196,603

Total

$

285,466

$

2

$

(2,390)

$

283,078

Schedule of maturities of fixed maturity available-for-sale securities

     

March 31, 2023

     

December 31, 2022

Less than one year

$

164,637

$

231,224

One to five years

 

83,316

 

51,854

$

247,953

$

283,078

XML 40 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Prepaid expenses and other current assets (Tables)
3 Months Ended
Mar. 31, 2023
Prepaid expenses and other current assets.  
Schedule of summary of prepaid expenses and other current assets

     

March 31, 2023

    

December 31, 2022

Research and development

$

$

110

Prepaid clinical trial related costs

791

Insurance

 

884

 

1,454

Software licenses and other

 

1,123

 

1,417

Reimbursement receivable

610

780

Warranties

 

202

 

242

Accrued interest receivable

 

855

 

Total prepaid expenses and other current assets

$

4,465

$

4,003

XML 41 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Property and equipment, net (Tables)
3 Months Ended
Mar. 31, 2023
Property and equipment, net  
Schedule of summary of property and equipment, net

     

March 31, 2023

    

December 31, 2022

Lab equipment

$

28,787

$

28,811

Leasehold improvements

 

49,180

 

48,951

Construction in progress

 

19,758

 

13,998

Computer software and equipment

 

3,132

 

3,132

Furniture and fixtures

 

1,548

 

1,548

Total

102,405

96,440

Less: Accumulated depreciation

 

(16,563)

 

(13,655)

Property and equipment, net

$

85,842

$

82,785

XML 42 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Accrued expenses and other liabilities (Tables)
3 Months Ended
Mar. 31, 2023
Accrued expenses and other liabilities.  
Schedule of summary of accrued expenses

     

March 31, 2023

    

December 31, 2022

Payroll and bonuses

$

3,139

    

$

7,062

Interest

 

122

 

117

Accrued clinical trial related costs

314

Professional and legal fees

 

2,432

 

1,637

Operating lease liability, current

579

475

Other

 

259

 

236

Total accrued expenses and other liabilities

$

6,531

$

9,841

XML 43 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Long-term debt (Tables)
3 Months Ended
Mar. 31, 2023
Long-term debt  
Summary of the Company's indebtedness

     

March 31, 2023

    

December 31, 2022

Principal

$

10,000

$

10,000

Plus: End of term fee

395

395

Less: Debt discount attributable to warrants, net of accretion

 

(8)

 

(8)

Less: Unamortized deferred financing cost and end of term fee, net of accretion

 

(90)

 

(146)

Long-term debt, net

$

10,297

$

10,241

Schedule of interest expense of the Loan Agreement

For the Three Months Ended

For the Three Months Ended

    

March 31, 2023

    

March 31, 2022

Interest expense

$

348

$

238

Amortization of debt issuance costs, including end of term fee accretion

 

56

 

76

$

404

$

314

Schedule of future principal payments due

Future principal payments due (including the end of term fee) under the Loan Agreement are as follows (in thousands):

    

Principal Payments

2023

$

10,395

Total future payments

$

10,395

XML 44 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Bristol-Myers Squibb Collaboration (Tables)
3 Months Ended
Mar. 31, 2023
Bristol-Myers Squibb Collaboration  
Schedule of transaction price unsatisfied

Cumulative collaboration

Deferred

Performance obligations:

Transaction price

revenue recognized

collaboration revenue

Option rights

$

109,164

$

-

$

109,164

Research and development services

14,023

(6,919)

7,104

Total

123,187

(6,919)

116,268

Less current portion of deferred revenue

-

-

(6,500)

Total long-term deferred revenue

$

123,187

$

(6,919)

$

109,768

XML 45 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Leases (Tables)
3 Months Ended
Mar. 31, 2023
Leases  
Schedule of components of lease expenses

For the Three Months Ended

For the Three Months Ended

March 31, 2023

March 31, 2022

Operating lease expense:

    

  

Fixed lease cost

$

1,395

$

597

Variable lease cost

 

125

 

297

Short term lease expense

594

649

Total operating lease expense

$

2,114

$

1,543

Schedule of Supplemental Balance Sheet Information related to leases

The following table reflects supplemental balance sheet information related to leases:

    

As of

As of

    

    

March 31, 

    

December 31, 

Location in Balance Sheet

2023

2022

Operating lease right-of-use asset, net

 

Operating lease right-of-use assets

$

28,207

$

28,945

Operating lease liability, current

 

Accrued expenses and other liabilities

$

579

$

475

Operating lease liability, long-term

 

Operating lease liability, long-term

 

41,168

 

38,698

Total operating lease liability

 

  

$

41,747

$

39,173

Schedule of supplemental lease term and discount rate information related to leases

The following table reflects supplement lease term and discount rate information related to leases:

    

As of March 31, 2023

     

As of December 31, 2022

 

Weighted-average remaining lease terms - operating leases

 

9.1 years

9.4 years

Weighted-average discount rate - operating leases

 

9.0

%

9.0

%

Schedule of supplemental cash flow information related to leases

The following table reflects supplemental cash flow information related to leases as of the periods indicated:

For the Three Months Ended

For the Three Months Ended

     

March 31, 2023

     

March 31, 2022

Cash paid for amounts included in the measurement of lease liabilities

 

  

 

  

Operating cash flows from operating leases

$

(31)

$

(152)

Schedule of Future minimum lease payments of operating leases

    

Operating Leases

2023

$

4,306

2024

 

8,079

2025

 

8,588

2026

 

8,727

2027

 

8,905

Thereafter

 

53,073

Total lease payments

 

91,678

Less: Imputed interest

 

(46,097)

Less: Tenant incentive receivable

(3,834)

Total

$

41,747

XML 46 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Basic and diluted net loss per common share (Tables)
3 Months Ended
Mar. 31, 2023
Basic and diluted net loss per common share  
Schedule of basic and diluted net loss per shares of common stock

Three Months Ended

Three Months Ended

March 31, 

March 31, 

    

2023

    

2022

Numerator

 

  

 

  

Net loss

 

$

(31,264)

$

(37,513)

Denominator

 

  

 

  

Weighted-average common shares for basic and diluted net loss per share

 

58,610,375

 

57,051,539

Basic and diluted net loss per common share

$

(0.53)

$

(0.66)

Schedule of potential shares of common stock excluded

Three Months Ended

Three Months Ended

March 31, 

March 31, 

    

2023

    

2022

Stock options to purchase common stock

10,370,402

 

7,424,538

Early exercised stock options subject to future vesting

385,655

 

773,394

Restricted stock award subject to future vesting

49,465

 

520,630

Unvested restricted stock units

 

544,650

 

Warrants

32,009

32,009

Total

 

11,382,181

 

8,750,571

XML 47 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Stock based compensation (Tables)
3 Months Ended
Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Schedule of reserved shares of common stock

    

Shares

Options and RSUs issued and outstanding

10,915,052

Shares available for future stock option and RSU grants

4,863,670

Shares available for employee stock purchase plan

1,114,126

Total

16,892,848

Schedule of common stock available under 2021 Incentive Plan

    

Shares

Balance, December 31, 2022

5,786,358

Shares reserved for issuance

2,954,788

Options granted

(3,770,399)

RSU’s granted

(546,795)

Options and RSUs forfeited / cancelled

439,718

Balance March 31, 2023

4,863,670

Schedule of stock option activity

Weighted Average 

Remaining

Aggregate

Contractual

Intrinsic

Term

Value

    

Shares

    

Exercise Price

    

(years)

(in thousands)

Outstanding January 1, 2023

 

7,489,678

$

7.77

 

7.84

$

8,991

Granted

 

3,770,399

 

4.66

 

 

Exercised

 

(452,102)

 

0.99

 

 

Forfeited

 

(437,573)

 

10.39

 

 

Outstanding, March 31, 2023

 

10,370,402

$

5.28

 

4.55

$

3,952

Exercisable at March 31, 2023

3,145,362

$

6.45

6.93

$

3,262

Schedule of weighted-average assumptions

March 31, 2022

December 31, 2022

 

Expected dividend rate

 

Expected option term (years)

6.08

 

6.09

Expected volatility

79.15

%  

69.73

%

Risk-free interest rate

3.65

%  

1.08

%

Schedule of stock-based compensation expense and by award type

Three Months Ended

Three Months Ended

March 31, 

March 31, 

2023

2022

Research and development

$

2,112

$

1,309

General and administrative

1,685

1,071

Total stock-based compensation

$

3,797

$

2,380

Stock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:

Three Months Ended

Three Months Ended

March 31, 

March 31, 

2023

2022

Stock options

$

3,546

$

2,108

Restricted stock units

97

Restricted stock awards

93

272

Employee stock purchase plan

61

Total stock-based compensation

$

3,797

$

2,380

Restricted stock units  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Schedule of restricted stock activity

    

    

Weighted Average

Shares

Grant Date Fair Value

Total Unvested December 31, 2022

 

$

Granted

546,795

4.64

Forfeited

(2,145)

4.64

Total Unvested March 31, 2023

 

544,650

$

4.64

Restricted stock  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Schedule of restricted stock activity

    

    

Weighted Average

Shares

Grant Date Fair Value

Total Unvested December 31, 2022

 

193,031

$

8.41

Granted

Forfeited

(47,689)

Vested

 

(95,877)

 

2.50

Total Unvested March 31, 2023

 

49,465

$

7.27

XML 48 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Organization and description of the business - Going concern and liquidity (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Jan. 31, 2023
Mar. 31, 2023
Mar. 31, 2022
Organization and description of the business      
Net loss   $ (31,264) $ (37,513)
Cash used in operations   (29,219) $ 86,753
Amount of cash and cash equivalents on short and long term investments   $ 334,785  
Reduction percenatge 25.00%    
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of significant accounting policies and basis of presentation (Details)
3 Months Ended
Mar. 31, 2023
segment
Summary of significant accounting policies and basis of presentation  
Number of operating segment 1
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of significant accounting policies and basis of presentation - Restricted cash (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Mar. 31, 2022
Dec. 31, 2021
Summary of significant accounting policies and basis of presentation        
Cash on deposit $ 1,979 $ 1,979    
Cash and cash equivalents 86,832 84,265    
Restricted cash 1,979 1,979    
Cash, cash equivalents, and restricted cash $ 88,811 $ 86,244 $ 127,756 $ 58,162
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of significant accounting policies and basis of presentation - Property and equipment and Stock-based compensation (Details)
3 Months Ended
Mar. 31, 2023
Summary of significant accounting policies and basis of presentation  
Estimated useful lives of the assets 5 years
Expected dividend rate 0.00%
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of significant accounting policies and basis of presentation - Early exercised options (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Summary of significant accounting policies and basis of presentation    
Amount of deposit liability related to shares held by employees and nonemployees that were subject to repurchase $ 1,314 $ 1,584
Total shares legally outstanding 59,541,904 59,137,491
Less: unvested early exercised shares (385,655) (470,800)
Less: unvested restricted stock awards (Note 16) (49,465) (193,031)
Total shares issued and outstanding 59,106,784 58,473,660
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Summary of significant accounting policies and basis of presentation - Income taxes (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Summary of significant accounting policies and basis of presentation    
Accrued interest or penalties on unrecognized tax benefits $ 0 $ 0
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.23.1
Reduction in force (Details) - Employee Severance [Member]
$ in Thousands
3 Months Ended
Mar. 31, 2023
USD ($)
Reduction in force  
Amount of cash-based expenses $ 2,032
Amount of non-cash stock-based compensation charge 581
Amount of remaining outstanding liabilities related to the reduction $ 0
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.23.1
Asset purchase by Century Therapeutics Canada ULC (Details) - In-process research and development (IPR&D) asset - Empirica Agreement - USD ($)
$ in Thousands
1 Months Ended
Jun. 09, 2020
Feb. 28, 2023
Jun. 30, 2022
Jul. 31, 2021
Mar. 31, 2023
Dec. 31, 2022
Asset Acquisition [Line Items]            
Total consideration transferred $ 4,519          
Buyer transaction expenses 203          
Escrow deposit $ 1,506          
Release of escrow deposit   $ 494 $ 517 $ 523    
Accrued expenses and other liabilities            
Asset Acquisition [Line Items]            
Accrued compensation expense         $ 0 $ 220
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Financial instruments and fair value measurements - Assets measured at fair value (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Financial instruments and fair value measurements    
Cash equivalents $ 83,187 $ 77,736
Debt securities 247,953 283,078
Total assets 331,140 360,814
U.S. Treasury    
Financial instruments and fair value measurements    
Debt securities 65,197 86,475
Corporate bonds    
Financial instruments and fair value measurements    
Debt securities 182,756 196,603
Level 1    
Financial instruments and fair value measurements    
Cash equivalents 83,187 77,736
Total assets 148,384 164,211
Level 1 | U.S. Treasury    
Financial instruments and fair value measurements    
Debt securities 65,197 86,475
Level 2    
Financial instruments and fair value measurements    
Total assets 182,756 196,603
Level 2 | Corporate bonds    
Financial instruments and fair value measurements    
Debt securities $ 182,756 $ 196,603
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Financial instruments and fair value measurements - Transfers between levels (Details)
$ in Thousands
Mar. 31, 2023
USD ($)
Financial instruments and fair value measurements  
Transfer of assets from level 1 to level 2 $ 0
Transfer of assets from level 2 to level 1 $ 0
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Financial instruments and fair value measurements - Investments in fixed maturity securities (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Financial instruments and fair value measurements    
Amortized Cost $ 249,136 $ 285,466
Gross Unrealized Gains 87 2
Gross Unrealized Losses (1,271) (2,390)
Fair Value 247,953 283,078
U.S. Treasury    
Financial instruments and fair value measurements    
Amortized Cost 65,807 87,798
Gross Unrealized Losses (610) (1,323)
Fair Value 65,197 86,475
Corporate bonds    
Financial instruments and fair value measurements    
Amortized Cost 183,329 197,668
Gross Unrealized Gains 87 2
Gross Unrealized Losses (660) (1,067)
Fair Value $ 182,756 $ 196,603
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.23.1
Financial instruments and fair value measurements - Maturities of fixed maturity available-for-sale securities (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2023
USD ($)
item
Dec. 31, 2022
USD ($)
item
Financial instruments and fair value measurements    
Less than one year $ 164,637 $ 231,224
One to five years 83,316 51,854
Fair Value $ 247,953 $ 283,078
Number of available-for-sale investment debt securities | item 32 42
Amount of accrued interest receivable on available-for-sale investment debt securities $ 855 $ 0
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.23.1
Prepaid expenses and other current assets - Summary of prepaid expenses and other current assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Prepaid expenses and other current assets.    
Research and development   $ 110
Prepaid clinical trial related costs $ 791  
Insurance 884 1,454
Software licenses and other 1,123 1,417
Reimbursement receivable 610 780
Warranties 202 242
Accrued interest receivable 855  
Total prepaid expenses and other current assets $ 4,465 $ 4,003
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.23.1
Property and equipment, net (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Property and equipment, net      
Gross total $ 102,405   $ 96,440
Less: Accumulated depreciation (16,563)   (13,655)
Property and equipment, net 85,842   82,785
Depreciation 2,908 $ 1,160  
Lab equipment      
Property and equipment, net      
Gross total 28,787   28,811
Leasehold improvements      
Property and equipment, net      
Gross total 49,180   48,951
Construction in progress      
Property and equipment, net      
Gross total 19,758   13,998
Computer software and equipment      
Property and equipment, net      
Gross total 3,132   3,132
Furniture and fixtures      
Property and equipment, net      
Gross total $ 1,548   $ 1,548
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.23.1
Accrued expenses and other liabilities - Summary of accrued expenses (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Accrued expenses and other liabilities.    
Payroll and bonuses $ 3,139 $ 7,062
Interest 122 117
Accrued clinical trial related costs   314
Professional and legal fees 2,432 1,637
Operating lease liability, current $ 579 $ 475
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Accrued Expenses And Other Liabilities, Current Accrued Expenses And Other Liabilities, Current
Other $ 259 $ 236
Total accrued expenses and other liabilities $ 6,531 $ 9,841
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.23.1
Long-term debt (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Long-term debt    
Principal $ 10,000 $ 10,000
Plus: End of term fee 395 395
Less: Debt discount attributable to warrants, net of accretion (8) (8)
Less: Unamortized deferred financing cost, net of accretion (90) (146)
Long-term debt, net $ 10,297 $ 10,241
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.23.1
Long-term debt - Term Loan Agreement (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Sep. 14, 2020
Mar. 31, 2023
Dec. 31, 2022
Long-term debt      
Deferred financing costs   $ 90 $ 146
Warrants to purchase units 16,112    
Warrants term 10 years    
Warrants exercise price $ 13.96    
Fair value of the warrants at issuance $ 46    
Warrants to be issued percentage 2.25%    
Loan Agreement      
Long-term debt      
Loan amount $ 10,000    
Term 4 years    
Debt interest rate 9.55% 14.30%  
Deferred financing costs $ 410    
Percentage of term fee 3.95%    
Loan Agreement | Loan amounts prepaid during the interest-only period      
Long-term debt      
Prepayment charges percentage 2.00%    
Loan Agreement | Loan amounts prepaid after the interest-only period      
Long-term debt      
Prepayment charges percentage 1.00%    
Loan Agreement | Minimum      
Long-term debt      
Interest only payment period 30 months    
Loan Agreement | Minimum | Prime Rate [Member]      
Long-term debt      
Debt interest rate 6.30%    
Tranche 1      
Long-term debt      
Loan amount $ 10,000    
Tranche 2      
Long-term debt      
Loan amount   $ 10,000  
Tranche 3      
Long-term debt      
Loan amount   $ 10,000  
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.23.1
Long-term debt - Interest Expenses (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Long-term debt      
Interest expense $ 348 $ 238  
Amortization of debt issuance costs, including end of term fee accretion 56 76  
Interest expense 404 $ 314  
Accrued interest 122   $ 117
Accrued expenses and other liabilities      
Long-term debt      
Accrued interest $ 122   $ 117
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.23.1
Long-term debt - Future principal payments due (Details)
$ in Thousands
Mar. 31, 2023
USD ($)
Future principal payments due  
2023 $ 10,395
Total future payments $ 10,395
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.23.1
Bristol-Myers Squibb Collaboration (Details)
3 Months Ended
Jan. 07, 2022
USD ($)
item
Program
$ / shares
shares
Mar. 31, 2023
USD ($)
$ / shares
Mar. 31, 2022
USD ($)
Dec. 31, 2022
$ / shares
Common stock, par value | $ / shares   $ 0.0001   $ 0.0001
Aggregate purchase price   $ 448,000 $ 65,000  
Total transaction price   $ 123,187,000    
Collaboration Agreement        
Number of collaboration programs | Program 2      
Additional number of collaboration programs | Program 2      
Upfront cash payment receivable $ 100,000,000      
Milestone payments receivable upon achievement of certain development and regulatory milestones 235,000,000      
Sales-based milestone payments $ 500,000,000      
Termination of Royalty term 12 years      
Common stock issued | shares 2,160,760      
Common stock, par value | $ / shares $ 23.14      
Aggregate purchase price $ 50,000,000      
Common stock, premium per share | $ / shares $ 7.82      
Premium amount of common stock $ 23,200,000      
Aggregate purchase price excluding premium $ 26,800,000      
Number of Commitments | item 4      
FCDI Collaboration Agreement | Collaboration Agreement        
Upfront cash payment receivable $ 10,000,000      
XML 68 R56.htm IDEA: XBRL DOCUMENT v3.23.1
Bristol-Myers Squibb Collaboration - Total transaction price (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Bristol-Myers Squibb Collaboration    
Total $ 116,268 $ 117,988
Less current portion of deferred revenue (6,500) (7,154)
Total long-term deferred revenue 109,768 110,834
Transaction price    
Bristol-Myers Squibb Collaboration    
Total 123,187 123,187
Total long-term deferred revenue 123,187 123,187
Cumulative collaboration revenue recognized    
Bristol-Myers Squibb Collaboration    
Cumulative collaboration revenue recognized (6,919) (5,199)
Option rights    
Bristol-Myers Squibb Collaboration    
Total 109,164 109,164
Option rights | Transaction price    
Bristol-Myers Squibb Collaboration    
Total 109,164 109,164
Research and development services    
Bristol-Myers Squibb Collaboration    
Total 7,104 8,824
Research and development services | Transaction price    
Bristol-Myers Squibb Collaboration    
Total 14,023 14,023
Research and development services | Cumulative collaboration revenue recognized    
Bristol-Myers Squibb Collaboration    
Cumulative collaboration revenue recognized $ (6,919) $ (5,199)
XML 69 R57.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Mar. 31, 2020
Jun. 24, 2019
Distributed Bio Master Service Agreement          
Commitments and Contingencies          
Milestone payments         $ 16,100
Milestone payments due $ 0        
Distributed Bio Master Service Agreement | Accrued expenses and other liabilities          
Commitments and Contingencies          
Accrued expenses $ 27 $ 110      
ICell Inc. Sublicense Agreement          
Commitments and Contingencies          
Milestone payments due   $ 0 $ 0    
Development and regulatory approval milestone payments       $ 4,250  
ICell Inc. Sublicense Agreement | Maximum          
Commitments and Contingencies          
Milestone payments       $ 70,000  
XML 70 R58.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Components of lease expenses (Details) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Lessee, Lease, Description [Line Items]      
Lease deposit $ 950,000   $ 1,260,000
Operating lease expense:      
Fixed lease cost 1,395,000 $ 597,000  
Variable lease cost 125,000 297,000  
Short term lease expense 594,000 649,000  
Total operating lease expense $ 2,114,000 $ 1,543,000  
Minimum      
Lessee, Lease, Description [Line Items]      
Initial lease terms 5 years    
Maximum      
Lessee, Lease, Description [Line Items]      
Initial lease terms 16 years    
XML 71 R59.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Other information (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Leases    
Operating lease right-of-use asset, net $ 28,207 $ 28,945
Operating lease liability, current $ 579 $ 475
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Accrued Expenses And Other Liabilities, Current Accrued Expenses And Other Liabilities, Current
Operating lease liability, long term $ 41,168 $ 38,698
Total operating lease liability $ 41,747 $ 39,173
XML 72 R60.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Operating lease - Other information (Details)
Mar. 31, 2023
Dec. 31, 2022
Leases    
Weighted-average remaining lease terms (years) - operating leases 9 years 1 month 6 days 9 years 4 months 24 days
Weighted-average discount rate - operating leases 9.00% 9.00%
XML 73 R61.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Supplemental cash flow information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Supplemental cash flow information    
Operating cash flows from operating leases $ (31) $ (152)
XML 74 R62.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Future minimum lease payments (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Operating Leases    
2023 $ 4,306  
2024 8,079  
2025 8,588  
2026 8,727  
2027 8,905  
Thereafter 53,073  
Total lease payments 91,678  
Less: imputed Interest (46,097)  
Less: Tenant incentive receivable (3,834)  
Total $ 41,747 $ 39,173
XML 75 R63.htm IDEA: XBRL DOCUMENT v3.23.1
Income taxes (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Tax    
Income Tax Expense (Benefit) $ 1,208 $ 16
Foreign Tax Authority | Canada Revenue Agency    
Income Tax    
Income Tax Expense (Benefit) $ 13  
XML 76 R64.htm IDEA: XBRL DOCUMENT v3.23.1
Basic and diluted net loss per common share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Numerator    
Net loss $ (31,264) $ (37,513)
Denominator    
Weighted-average common shares for basic net loss per share 58,610,375 57,051,539
Weighted-average common shares for diluted net loss per share 58,610,375 57,051,539
Basic net loss per common share $ (0.53) $ (0.66)
Diluted net loss per common share $ (0.53) $ (0.66)
XML 77 R65.htm IDEA: XBRL DOCUMENT v3.23.1
Basic and diluted net loss per common share - Schedule of potential shares of common stock excluded from computation (Details) - shares
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Basic and diluted net loss per common share    
Securities excluded from the computation of diluted net loss per share 11,382,181 8,750,571
Stock options to purchase common stock    
Basic and diluted net loss per common share    
Securities excluded from the computation of diluted net loss per share 10,370,402 7,424,538
Early exercised stock options subject to future vesting    
Basic and diluted net loss per common share    
Securities excluded from the computation of diluted net loss per share 385,655 773,394
Restricted stock award subject to future vesting    
Basic and diluted net loss per common share    
Securities excluded from the computation of diluted net loss per share 49,465 520,630
Unvested restricted stock units    
Basic and diluted net loss per common share    
Securities excluded from the computation of diluted net loss per share 544,650  
Warrants    
Basic and diluted net loss per common share    
Securities excluded from the computation of diluted net loss per share 32,009 32,009
XML 78 R66.htm IDEA: XBRL DOCUMENT v3.23.1
Defined contribution plan (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Defined contribution plan    
Defined contributions $ 384 $ 158
First 3% of participating employee contributions    
Defined contribution plan    
Employer contribution matching percentage 100.00%  
Employee contribution 3.00%  
Next 2% of participating employee contributions    
Defined contribution plan    
Employer contribution matching percentage 50.00%  
Employee contribution 2.00%  
XML 79 R67.htm IDEA: XBRL DOCUMENT v3.23.1
Stock based compensation (Details) - shares
3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Jun. 17, 2021
Stock Options        
Stock based compensation        
Stock awards vesting period 4 years      
2021 Incentive Plan        
Stock based compensation        
Percentage of common stock outstanding   (5.00%)    
Increase in common stock reserved 2,954,788 2,750,276 2,750,276  
Shares available for grant 4,863,670 5,786,358    
2021 Incentive Plan | Stock Options        
Stock based compensation        
Shares authorized for issuance       5,481,735
Shares available for grant       5,640,711
Stock reserved for issuance upon the exercise of previously granted stock options       158,976
XML 80 R68.htm IDEA: XBRL DOCUMENT v3.23.1
Stock based compensation - Reserved shares of common stock (Details) - 2021 Incentive Plan
Mar. 31, 2023
shares
Stock based compensation  
Reserved shares of common stock for issuance 16,892,848
Options and RSUs  
Stock based compensation  
Options and RSUs issued and outstanding 10,915,052
Reserved shares of common stock for issuance 4,863,670
Employee stock purchase plan  
Stock based compensation  
Reserved shares of common stock for issuance 1,114,126
XML 81 R69.htm IDEA: XBRL DOCUMENT v3.23.1
Stock based compensation - Common stock available under 2021 Incentive Plan (Details) - shares
3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Stock Options      
Stock based compensation      
Options granted (3,770,399)    
Restricted stock units      
Stock based compensation      
RSU's granted (546,795)    
2021 Incentive Plan      
Stock based compensation      
Beginning balance 5,786,358    
Shares reserved for issuance 2,954,788 2,750,276 2,750,276
Options and RSUs forfeited / cancelled 439,718    
Ending balance 4,863,670 5,786,358  
2021 Incentive Plan | Stock Options      
Stock based compensation      
Options granted (3,770,399)    
2021 Incentive Plan | Restricted stock units      
Stock based compensation      
RSU's granted (546,795)    
XML 82 R70.htm IDEA: XBRL DOCUMENT v3.23.1
Stock based compensation - Stock option activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Shares    
Less: unvested early exercised shares (385,655) (470,800)
Stock Options    
Shares    
Outstanding, beginning (in shares) 7,489,678  
Granted 3,770,399  
Exercised - vested (452,102)  
Forfeited (437,573)  
Outstanding, ending (in shares) 10,370,402 7,489,678
Exercisable 3,145,362  
Weighted Average Exercise Price    
Outstanding, beginning $ 7.77  
Granted 4.66  
Exercised - vested 0.99  
Forfeited 10.39  
Outstanding, ending 5.28 $ 7.77
Exercisable $ 6.45  
Weighted Average Remaining Contractual Term (years)    
Outstanding 4 years 6 months 18 days 7 years 10 months 2 days
Exercisable 6 years 11 months 4 days  
Weighted average grant date fair value $ 4.65  
Options granted 3,770,399  
Aggregate Intrinsic Value    
Outstanding, beginning $ 8,991  
Outstanding, ending 3,952 $ 8,991
Exercisable 3,262  
Time Based Vesting    
Weighted Average Remaining Contractual Term (years)    
Unrecognized compensation expense $ 38,428  
Unrecognized compensation expense expected to be recognized over a weighted average period 3 years 1 month 17 days  
XML 83 R71.htm IDEA: XBRL DOCUMENT v3.23.1
Stock based compensation - Stock option weighted-average assumptions (Details)
3 Months Ended 12 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
weighted-average assumptions fair value of stock option granted      
Expected dividend rate 0.00%    
Stock Options      
weighted-average assumptions fair value of stock option granted      
Expected option term (years)   6 years 29 days 6 years 1 month 2 days
Expected volatility   79.15% 69.73%
Risk-free interest rate   3.65% 1.08%
XML 84 R72.htm IDEA: XBRL DOCUMENT v3.23.1
Stock based compensation - Stock-based compensation expense and by award type (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Stock based compensation    
Total stock-based compensation $ 3,797 $ 2,380
Stock options    
Stock based compensation    
Total stock-based compensation 3,546 2,108
Restricted stock units    
Stock based compensation    
Total stock-based compensation 97  
Restricted stock awards    
Stock based compensation    
Total stock-based compensation 93 272
Employee stock purchase plan    
Stock based compensation    
Total stock-based compensation 61  
Research and development expenses    
Stock based compensation    
Total stock-based compensation 2,112 1,309
General and administrative expense    
Stock based compensation    
Total stock-based compensation $ 1,685 $ 1,071
XML 85 R73.htm IDEA: XBRL DOCUMENT v3.23.1
Stock based compensation - Restricted stock (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Shares    
Total Unvested 193,031  
Total Unvested 49,465  
Weighted Average Exercise Price    
Deposit liability $ 881 $ 866
Restricted stock    
Weighted Average Exercise Price    
Restricted stock vesting period 4 years  
Unvested restricted stock with time-based vesting    
Shares    
Total Unvested 193,031  
Forfeited (47,689)  
Vested (95,877)  
Total Unvested 49,465  
Weighted Average Exercise Price    
Total Unvested $ 8.41  
Vested 2.50  
Total Unvested $ 7.27  
Unrecognized compensation expense $ 356  
Unrecognized compensation expense expected to be recognized over a weighted average period 1 year 11 months 23 days  
Deposit liability $ 1,314  
Restricted stock units    
Shares    
Granted 546,795  
Forfeited (2,145)  
Total Unvested 544,650  
Weighted Average Exercise Price    
Granted $ 4.64  
Forfeited 4.64  
Total Unvested $ 4.64  
Unrecognized compensation expense $ 2,428  
Unrecognized compensation expense expected to be recognized over a weighted average period 3 years 10 months 6 days  
Restricted stock vesting period 4 years  
XML 86 R74.htm IDEA: XBRL DOCUMENT v3.23.1
Stock based compensation - Employee Stock Purchase Plan (Details) - Employee Stock Purchase Plan 2021 - shares
12 Months Ended
Dec. 31, 2022
Mar. 31, 2023
Stock based compensation    
Shares authorized for issuance 564,071  
Percentage of common stock outstanding (1.00%)  
Increase in common stock reserved 550,055  
Shares available for grant   1,114,126
XML 87 R75.htm IDEA: XBRL DOCUMENT v3.23.1
Related party transactions (Details)
3 Months Ended 12 Months Ended
Mar. 31, 2023
USD ($)
Mar. 31, 2022
USD ($)
Dec. 31, 2019
USD ($)
item
Dec. 31, 2022
USD ($)
Jan. 07, 2022
USD ($)
Collaboration Agreement          
Related party transactions          
Upfront cash payment receivable         $ 100,000,000
FCDI Collaboration Agreement          
Related party transactions          
Payment to related party $ 12,000 $ 3,003,000      
Research and development 32,000 1,445,000      
Legal fees 33,000 30,000      
Accounts payable       $ 0  
Accrued expenses 21,000        
FCDI Collaboration Agreement | Collaboration Agreement          
Related party transactions          
Upfront cash payment receivable         $ 10,000,000
FUJIFILM Cellular Dynamics, Inc.          
Related party transactions          
Development and regulatory milestone payments 6,000,000        
Shareholders of Equity Method Investor | Consulting Arrangements          
Related party transactions          
Number of related parties | item     2    
Pre payments to related party     $ 125,000    
Shareholders of Equity Method Investor | Consulting Arrangements | Accrued expenses          
Related party transactions          
Accrued expenses 0     $ 0  
Shareholders of Equity Method Investor | Consulting Arrangements | Research and development expenses          
Related party transactions          
Research and development $ 0 $ 19,000      
XML 88 R76.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Events (Details)
$ in Thousands
May 01, 2023
USD ($)
Subsequent Event | Loan Agreement  
Subsequent Events  
Total repayment, principal interest $ 10,617
XML 89 ipsc-20230331x10q_htm.xml IDEA: XBRL DOCUMENT 0001850119 us-gaap:RetainedEarningsMember 2023-03-31 0001850119 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001850119 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001850119 us-gaap:RetainedEarningsMember 2022-12-31 0001850119 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001850119 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001850119 us-gaap:RetainedEarningsMember 2022-03-31 0001850119 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001850119 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001850119 us-gaap:RetainedEarningsMember 2021-12-31 0001850119 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001850119 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001850119 us-gaap:CommonStockMember 2023-03-31 0001850119 us-gaap:CommonStockMember 2022-12-31 0001850119 us-gaap:CommonStockMember 2022-03-31 0001850119 us-gaap:CommonStockMember 2021-12-31 0001850119 us-gaap:EmployeeStockOptionMember 2022-12-31 0001850119 us-gaap:EmployeeStockOptionMember ipsc:IncentivePlan2021Member 2023-01-01 2023-03-31 0001850119 us-gaap:EmployeeStockOptionMember 2023-03-31 0001850119 ipsc:EmployeeStockPurchasePlan2021Member 2023-03-31 0001850119 ipsc:IncentivePlan2021Member 2022-12-31 0001850119 ipsc:EmployeeStockPurchasePlan2021Member 2022-12-31 0001850119 us-gaap:EmployeeStockOptionMember ipsc:IncentivePlan2021Member 2021-06-17 0001850119 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001850119 ipsc:UnvestedRestrictedStockWithTimeBasedVestingMember 2022-12-31 0001850119 us-gaap:RestrictedStockUnitsRSUMember ipsc:IncentivePlan2021Member 2023-01-01 2023-03-31 0001850119 us-gaap:EmployeeSeveranceMember 2023-03-31 0001850119 us-gaap:ResearchAndDevelopmentExpenseMember ipsc:ConsultingArrangementsMember ipsc:ShareholdersOfEquityMethodInvestorMember 2023-01-01 2023-03-31 0001850119 us-gaap:ResearchAndDevelopmentExpenseMember ipsc:ConsultingArrangementsMember ipsc:ShareholdersOfEquityMethodInvestorMember 2022-01-01 2022-03-31 0001850119 ipsc:TermLoanAgreementWithHerculesCapitalIncMember us-gaap:SubsequentEventMember 2023-05-01 2023-05-01 0001850119 us-gaap:SoftwareDevelopmentMember 2023-03-31 0001850119 us-gaap:LeaseholdImprovementsMember 2023-03-31 0001850119 us-gaap:FurnitureAndFixturesMember 2023-03-31 0001850119 us-gaap:ConstructionInProgressMember 2023-03-31 0001850119 ipsc:LabEquipmentMember 2023-03-31 0001850119 us-gaap:SoftwareDevelopmentMember 2022-12-31 0001850119 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001850119 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001850119 us-gaap:ConstructionInProgressMember 2022-12-31 0001850119 ipsc:LabEquipmentMember 2022-12-31 0001850119 us-gaap:EmployeeSeveranceMember 2023-01-01 2023-03-31 0001850119 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001850119 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001850119 ipsc:AccruedExpensesAndOtherLiabilitiesCurrentMember ipsc:DistributedBioMasterServiceAgreementMember 2023-03-31 0001850119 ipsc:AccruedExpensesAndOtherLiabilitiesCurrentMember ipsc:DistributedBioMasterServiceAgreementMember 2022-12-31 0001850119 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001850119 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001850119 srt:MinimumMember 2023-03-31 0001850119 srt:MaximumMember 2023-03-31 0001850119 ipsc:FcdiCollaborationAgreementMember 2023-01-01 2023-03-31 0001850119 ipsc:FcdiCollaborationAgreementMember 2022-01-01 2022-03-31 0001850119 ipsc:AccruedExpensesAndOtherLiabilitiesCurrentMember 2023-03-31 0001850119 ipsc:AccruedExpensesAndOtherLiabilitiesCurrentMember 2022-12-31 0001850119 us-gaap:ForeignCountryMember us-gaap:CanadaRevenueAgencyMember 2023-01-01 2023-03-31 0001850119 us-gaap:InProcessResearchAndDevelopmentMember ipsc:EmpiricaAgreementMember 2020-06-09 0001850119 ipsc:TimeBasedVestingMember 2023-03-31 0001850119 ipsc:UnvestedRestrictedStockWithTimeBasedVestingMember 2023-01-01 2023-03-31 0001850119 ipsc:TimeBasedVestingMember 2023-01-01 2023-03-31 0001850119 us-gaap:RestrictedStockUnitsRSUMember 2023-03-31 0001850119 ipsc:FujifilmCellularDynamicsInc.Member 2023-03-31 0001850119 us-gaap:AccruedLiabilitiesMember ipsc:ConsultingArrangementsMember ipsc:ShareholdersOfEquityMethodInvestorMember 2023-03-31 0001850119 ipsc:FcdiCollaborationAgreementMember 2023-03-31 0001850119 us-gaap:AccruedLiabilitiesMember ipsc:ConsultingArrangementsMember ipsc:ShareholdersOfEquityMethodInvestorMember 2022-12-31 0001850119 ipsc:UnvestedRestrictedStockWithTimeBasedVestingMember 2023-03-31 0001850119 ipsc:Next2OfParticipatingEmployeeContributionsMember 2023-01-01 2023-03-31 0001850119 ipsc:First3OfParticipatingEmployeeContributionsMember 2023-01-01 2023-03-31 0001850119 ipsc:ResearchAndDevelopmentServicesMember ipsc:TransactionPriceMember 2023-03-31 0001850119 ipsc:OptionRightsMember ipsc:TransactionPriceMember 2023-03-31 0001850119 ipsc:TransactionPriceMember 2023-03-31 0001850119 ipsc:ResearchAndDevelopmentServicesMember 2023-03-31 0001850119 ipsc:OptionRightsMember 2023-03-31 0001850119 ipsc:ResearchAndDevelopmentServicesMember ipsc:TransactionPriceMember 2022-12-31 0001850119 ipsc:OptionRightsMember ipsc:TransactionPriceMember 2022-12-31 0001850119 ipsc:TransactionPriceMember 2022-12-31 0001850119 ipsc:ResearchAndDevelopmentServicesMember 2022-12-31 0001850119 ipsc:OptionRightsMember 2022-12-31 0001850119 ipsc:TermLoanAgreementWithHerculesCapitalIncMember 2023-01-01 2023-03-31 0001850119 srt:MinimumMember ipsc:TermLoanAgreementWithHerculesCapitalIncMember us-gaap:PrimeRateMember 2020-09-14 2020-09-14 0001850119 ipsc:Tranche3AdvancesMember 2023-03-31 0001850119 ipsc:Tranche2AdvancesMember 2023-03-31 0001850119 ipsc:Tranche1AdvancesMember 2020-09-14 0001850119 ipsc:TermLoanAgreementWithHerculesCapitalIncMember 2020-09-14 0001850119 ipsc:ResearchAndDevelopmentServicesMember ipsc:CumulativeCollaborationRevenueRecognizedMember 2023-01-01 2023-03-31 0001850119 ipsc:CumulativeCollaborationRevenueRecognizedMember 2023-01-01 2023-03-31 0001850119 ipsc:ResearchAndDevelopmentServicesMember ipsc:CumulativeCollaborationRevenueRecognizedMember 2022-01-01 2022-12-31 0001850119 ipsc:CumulativeCollaborationRevenueRecognizedMember 2022-01-01 2022-12-31 0001850119 us-gaap:EmployeeStockMember ipsc:IncentivePlan2021Member 2023-03-31 0001850119 ipsc:IncentivePlan2021Member 2023-03-31 0001850119 2022-03-31 0001850119 2021-12-31 0001850119 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember 2023-03-31 0001850119 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2023-03-31 0001850119 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember 2022-12-31 0001850119 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasurySecuritiesMember 2022-12-31 0001850119 us-gaap:USTreasurySecuritiesMember 2023-03-31 0001850119 us-gaap:USTreasurySecuritiesMember 2022-12-31 0001850119 us-gaap:CorporateBondSecuritiesMember 2023-03-31 0001850119 us-gaap:CorporateBondSecuritiesMember 2022-12-31 0001850119 us-gaap:FairValueInputsLevel2Member 2023-03-31 0001850119 us-gaap:FairValueInputsLevel1Member 2023-03-31 0001850119 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001850119 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001850119 us-gaap:InProcessResearchAndDevelopmentMember ipsc:EmpiricaAgreementMember 2020-06-09 2020-06-09 0001850119 us-gaap:WarrantMember 2023-01-01 2023-03-31 0001850119 us-gaap:StockOptionMember 2023-01-01 2023-03-31 0001850119 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001850119 us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0001850119 ipsc:EarlyExercisedStockOptionsSubjectToFutureVestingMember 2023-01-01 2023-03-31 0001850119 us-gaap:WarrantMember 2022-01-01 2022-03-31 0001850119 us-gaap:StockOptionMember 2022-01-01 2022-03-31 0001850119 us-gaap:RestrictedStockMember 2022-01-01 2022-03-31 0001850119 ipsc:EarlyExercisedStockOptionsSubjectToFutureVestingMember 2022-01-01 2022-03-31 0001850119 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001850119 us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0001850119 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001850119 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0001850119 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001850119 us-gaap:EmployeeStockMember 2023-01-01 2023-03-31 0001850119 us-gaap:RestrictedStockMember 2022-01-01 2022-03-31 0001850119 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001850119 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001850119 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001850119 ipsc:FcdiCollaborationAgreementMember 2022-12-31 0001850119 2023-01-01 2023-01-31 0001850119 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001850119 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001850119 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001850119 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001850119 2022-01-01 2022-12-31 0001850119 ipsc:EmployeeStockOptionsAndRestrictedStockUnitsMember ipsc:IncentivePlan2021Member 2023-03-31 0001850119 us-gaap:InProcessResearchAndDevelopmentMember ipsc:EmpiricaAgreementMember 2023-02-01 2023-02-28 0001850119 us-gaap:InProcessResearchAndDevelopmentMember ipsc:EmpiricaAgreementMember 2022-06-01 2022-06-30 0001850119 us-gaap:InProcessResearchAndDevelopmentMember ipsc:EmpiricaAgreementMember 2021-07-01 2021-07-31 0001850119 ipsc:ConsultingArrangementsMember ipsc:ShareholdersOfEquityMethodInvestorMember 2019-01-01 2019-12-31 0001850119 ipsc:ConsultingArrangementsMember ipsc:ShareholdersOfEquityMethodInvestorMember 2019-12-31 0001850119 ipsc:IncentivePlan2021Member 2023-01-01 2023-03-31 0001850119 ipsc:IncentivePlan2021Member 2022-01-01 2022-12-31 0001850119 ipsc:EmployeeStockPurchasePlan2021Member 2022-01-01 2022-12-31 0001850119 ipsc:IncentivePlan2021Member 2021-01-01 2021-12-31 0001850119 2022-01-01 2022-03-31 0001850119 ipsc:IcellInc.SublicenseAgreementMember 2020-03-31 0001850119 ipsc:TermLoanAgreementWithHerculesCapitalIncMember 2020-09-14 2020-09-14 0001850119 ipsc:LoanAmountsPrepaidDuringInterestOnlyPeriodMember ipsc:TermLoanAgreementWithHerculesCapitalIncMember 2020-09-14 2020-09-14 0001850119 ipsc:LoanAmountsPrepaidAfterInterestOnlyPeriodMember ipsc:TermLoanAgreementWithHerculesCapitalIncMember 2020-09-14 2020-09-14 0001850119 srt:MinimumMember ipsc:TermLoanAgreementWithHerculesCapitalIncMember 2020-09-14 2020-09-14 0001850119 ipsc:BristolMyersSquibbCompanyCollaborationAgreementMember 2022-01-07 2022-01-07 0001850119 srt:MaximumMember ipsc:IcellInc.SublicenseAgreementMember 2020-03-31 0001850119 ipsc:DistributedBioMasterServiceAgreementMember 2019-06-24 0001850119 ipsc:DistributedBioMasterServiceAgreementMember 2023-03-31 0001850119 ipsc:IcellInc.SublicenseAgreementMember 2022-12-31 0001850119 ipsc:IcellInc.SublicenseAgreementMember 2021-12-31 0001850119 ipsc:FcdiCollaborationAgreementMember ipsc:BristolMyersSquibbCompanyCollaborationAgreementMember 2022-01-07 0001850119 ipsc:BristolMyersSquibbCompanyCollaborationAgreementMember 2022-01-07 0001850119 2020-09-14 0001850119 2023-03-31 0001850119 ipsc:AccruedExpensesAndOtherLiabilitiesCurrentMember us-gaap:InProcessResearchAndDevelopmentMember ipsc:EmpiricaAgreementMember 2023-03-31 0001850119 ipsc:AccruedExpensesAndOtherLiabilitiesCurrentMember us-gaap:InProcessResearchAndDevelopmentMember ipsc:EmpiricaAgreementMember 2022-12-31 0001850119 2022-12-31 0001850119 2023-05-01 0001850119 2023-01-01 2023-03-31 shares iso4217:USD ipsc:Program iso4217:USD shares pure ipsc:item ipsc:segment -0.53 -0.66 58610375 57051539 http://www.centurytx.com/20230331#AccruedExpensesAndOtherLiabilitiesCurrent 58610375 57051539 0001850119 false --12-31 2023 Q1 0 0 58473660 59106784 0 P12Y 950000 P5Y http://www.centurytx.com/20230331#AccruedExpensesAndOtherLiabilitiesCurrent -0.53 -0.66 P4Y 10-Q true 2023-03-31 false 001-40498 Century Therapeutics, Inc. DE 84-2040295 3675 Market Street Philadelphia PA 19104 267 817-5790 Common Stock, $0.0001 par value per share IPSC NASDAQ Yes Yes Non-accelerated Filer true true false false 59580817 86832000 84265000 164637000 231233000 220000 4465000 4003000 255934000 319721000 85842000 82785000 28207000 28945000 1979000 1979000 83316000 51854000 950000 1260000 456228000 486544000 3475000 5454000 6531000 9841000 881000 866000 10297000 6502000 6500000 7154000 27684000 29817000 41168000 38698000 433000 718000 109768000 110834000 3739000 179053000 183806000 0.0001 0.0001 10000000 10000000 0 0 0.0001 0.0001 125236190 125236190 59106784 58473660 6000 6000 828806000 824292000 -550362000 -519098000 -1275000 -2462000 277175000 302738000 456228000 486544000 1720000 1058000 24899000 21196000 8902000 7298000 10000000 33801000 38494000 -32081000 -37436000 404000 314000 2623000 253000 194000 2025000 -61000 -30056000 -37497000 1208000 16000 -31264000 -37513000 -0.53 -0.66 58610375 57051539 -31264000 -37513000 1196000 -1986000 -9000 -6000 -30077000 -39505000 58473660 6000 824292000 -519098000 -2462000 302738000 452102 448000 448000 95877 85145 269000 269000 1196000 1196000 -9000 -9000 3797000 3797000 -31264000 -31264000 59106784 6000 828806000 -550362000 -1275000 277175000 55005523 5000 785049000 -388166000 -650000 396238000 2160760 1000 26812000 26813000 85396 65000 65000 161159 173192 673000 673000 2380000 2380000 -1986000 -1986000 -6000 -6000 -37513000 -37513000 57586030 6000 814979000 -425679000 -2642000 386664000 -31264000 -37513000 2908000 1160000 56000 76000 -738000 188000 3797000 2380000 -220000 -125000 160000 -1033000 3842000 -152000 -1720000 122129000 -2954000 -1503000 -3206000 -1170000 -29219000 86753000 4991000 4067000 42829000 103060000 79158000 63090000 31338000 -44037000 448000 65000 26813000 448000 26878000 2567000 69594000 86244000 58162000 88811000 127756000 345000 238000 975000 3796000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;text-align:center;margin:0pt;"><b style="font-style:normal;font-weight:bold;">CENTURY THERAPEUTICS, INC.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;text-align:center;margin:0pt;"><b style="font-style:normal;font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;text-align:center;margin:0pt;"><b style="font-style:normal;font-weight:bold;">(Unaudited)</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;text-align:center;margin:0pt 0pt 20pt 0pt;"><b style="font-style:normal;font-weight:bold;">(in thousands, except share and per share amounts)</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Note 1—Organization and description of the business</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Century Therapeutics, Inc. (the “Company”) is an innovative biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. Since inception, the Company has devoted substantially all of its time and efforts to performing research and development activities, building infrastructure and raising capital. The Company is incorporated in the state of Delaware.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Century Therapeutics Canada ULC (“Century Canada”) is the Company’s wholly owned subsidiary performing research and development activities in Canada.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Principles of Consolidation</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">The consolidated financial statements include the consolidated financial position and consolidated results of operations of the Company and Century Canada. All intercompany balances and transactions have been eliminated in consolidation.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Liquidity</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has limited operating history and its prospects are subject to risks, expenses, and uncertainties frequently encountered by companies in the biotechnology and pharmaceutical industries. These risks include, but are not limited to, the uncertainty of availability of additional financing and the uncertainty of achieving future profitability.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Since inception, the Company has incurred net losses. During the three months ended March 31, 2023, the Company incurred a net loss of $31,264. During the three months ended March 31, 2023, the Company used $29,219 of cash from operations. Cash and cash equivalents and investments were $334,785 at March 31, 2023. Management expects to incur additional losses in the future to fund its operations and conduct product research and preclinical and clinical development and recognizes the need to raise additional capital to fully implement its business plan. The Company believes it has adequate cash and financial resources to operate for at least the next 12 months from the date of issuance of these consolidated financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Reduction in force</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">In January 2023, the Company's Board of Directors approved, and management implemented a new portfolio prioritization and capital allocation strategy. The resulting changes include pausing investment in CNTY-103 for glioblastoma as well as a discovery program in hematologic malignancies. The Company will focus on CNTY-101 and will accelerate key programs, including one follow-on candidate for lymphoma, CNTY-102, and CNTY-107 for Nectin-4+ solid tumors. In addition, the Company will continue its partnered programs with Bristol Myers Squibb. The restructuring plan resulted in a reduction in the Company's workforce of approximately </span>25%<span style="white-space:pre-wrap;">. In addition, lab operations in Seattle and Hamilton, Ontario were closed and research activities were consolidated in Philadelphia.</span></p> -31264000 -29219000 334785000 0.25 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Note 2—Summary of significant accounting policies and basis of presentation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Basis of presentation</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the interim period reporting requirements of Form 10-Q and Article 10 of Regulation S-X. The consolidated balance sheet as of March 31, 2023, the consolidated statements of operations and comprehensive loss, and consolidated statements of changes in stockholders’ equity for the three months ended March 31, 2023 and 2022, and the consolidated statements of cash flows for the three months ended March 31, 2023 and 2022 are unaudited, but, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.  The results for any interim period are not necessarily indicative of results for the year ending December 31, 2023 or for any other subsequent interim period.  The consolidated balance sheet at December 31, 2022 has been derived from the Company’s audited consolidated financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Certain prior year information has been reclassified to conform to the fiscal year 2023 presentation.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Segment information</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages the business as one operating segment.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Use of estimates</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuations supporting stock compensation, the estimation of the incremental borrowing rate for operating leases and standalone selling prices of performance obligations in collaboration agreements. If actual results differ from the Company’s estimates, or to the extent these estimates are adjusted in future periods, the Company’s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Concentration of credit risk and other risks and uncertainties</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist of cash, cash equivalents, U.S. Treasury bills and bonds, as well as corporate bonds. Cash and cash equivalents, as well as short and long-term investments include a checking account and asset management accounts held by a limited number of financial institutions. At times, such deposits may be in excess of insured limits. As of March 31, 2023 and December 31, 2022, the Company has not experienced any losses on its deposits of cash and cash equivalents.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, uncertainty of market acceptance of its products, competition from substitute products and larger companies, protection of proprietary technology, strategic relationships, and dependence on key individuals.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Products developed by the Company require clearances from the U.S. Food and Drug Administration (the “FDA”) or other international regulatory agencies prior to commercial sales. There can be no assurance the Company’s future products will receive the necessary clearances. If the Company was denied clearance, </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">clearance was delayed, or if the Company was unable to maintain clearance, it could have a material adverse impact on the Company.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Fair value of financial instruments</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Level 1</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Level 2</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly, including inputs in markets that are not considered to be active;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Level 3</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Inputs are unobservable in which there is little or no market data available, which require the reporting entity to develop its own assumptions that are unobservable.</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Cash and cash equivalents</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Management considers all highly liquid investments with an insignificant interest rate risk and original maturities of three months or less to be cash equivalents.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Restricted cash</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of March 31, 2023 and December 31, 2022, the Company had $1,979 in cash on deposit to secure certain lease commitments. Restricted cash is recorded separately in the Company’s consolidated balance sheets.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The following provides a reconciliation of the Company’s cash, cash equivalents, and restricted cash as reported in the consolidated balance sheets to the amounts reported in the consolidated statements of cash flows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.4%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:14.48%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">December 31, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:68.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 86,832</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 84,265</p></td></tr><tr><td style="vertical-align:bottom;width:68.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,979</p></td></tr><tr><td style="vertical-align:bottom;width:68.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash, cash equivalents, and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 88,811</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 86,244</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Investments </i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The Company invests in fixed maturity securities including U.S. Treasury bills and bonds as well as corporate bonds. The investments are classified as available-for-sale and reported at fair value. Unrealized gains or losses are determined by comparing the fair market value of the securities with their cost or amortized cost. Realized gains and losses on investments are recorded on the trade date and are included in the statement of operations. Unrealized gains and losses on investments are recorded in other comprehensive income (loss) on the consolidated statements of operations and comprehensive loss. The cost of securities sold is based on the specified identification method. Investment income is recognized as earned and discounts or premiums arising from the purchase of debt securities are recognized in investment income using the interest </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">method over the remaining term of the security. Securities with an original maturity date greater than three months that mature within one year of the balance sheet date are classified as short-term, while investments with a maturity date greater than one year are classified as long-term.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Property and equipment, net </i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which is generally five years<span style="white-space:pre-wrap;">. Leasehold improvements are amortized over the shorter of the asset’s useful life or the remaining term of the lease. Construction in progress includes direct cost related to the construction of leasehold improvements and is stated at original cost. Such costs are not depreciated until the asset is completed and placed into service. Once the asset is placed into service, these capitalized costs will be allocated to leasehold improvements and will be depreciated over the shorter of the asset’s useful life or the remaining term of the lease. Computer software and equipment includes implementation costs for cloud-based software and network equipment.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Expenditures for major additions and improvements are capitalized, while minor replacements, maintenance, and repairs are charged to expense as incurred. When property is retired or otherwise disposed of, the costs and accumulated depreciation are removed from the respective accounts, with any resulting gain or loss recognized concurrently.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Research and development expenses </i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, stock compensation, materials, supplies, rent, depreciation on and maintenance of research equipment with alternative future use, and the cost of services provided by outside contractors. All costs associated with research and development are expensed as incurred.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Clinical trial costs are a component of research and development expenses. The company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Stock-based compensation</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Employees, consultants and members of the board of directors of the Company have received stock options and restricted stock of the Company. The Company recognizes the cost of the stock-based compensation incurred as its employees and board members vest in the awards. The Company accounts for stock-based compensation arrangements in accordance with provisions of Accounting Standards Codification (“ASC”) 718, Compensation—Stock Compensation. ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The Company uses the Black-Scholes option-pricing model (“Black Scholes”) to determine the fair value of options granted. The Company’s stock-based awards are subject to service-based vesting conditions and performance-based vesting conditions. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. For performance-based awards, the Company reassesses at each reporting date whether achievement of the performance condition is probable and accrues compensation expense if and when achievement of the performance condition is probable.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Black-Scholes requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. Due to </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">the lack of a public market for the Company’s common stock prior to its initial public offering (“IPO”) and lack of company-specific historical and implied volatility data, the Company based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be </span>zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. Forfeitures are recognized as they occur.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Warrants</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has issued warrants that have been recognized as equity, and the fair value is recorded into additional paid-in capital in the accompanying consolidated balance sheets. Warrants are accounted for in accordance with applicable accounting guidance provided in ASC Topic 815, Derivatives and Hedging—Contracts in Entity’s Own Equity, as either derivative liabilities or as equity instruments depending on the specific terms of the warrant agreement. The Company’s warrants issued are in connection with its long-term debt and in connection with services provided by consultants, and are equity classified on the accompanying consolidated balance sheets. Equity classified warrants are accounted for at fair value on the issuance date, using Black Scholes, with no changes in fair value recognized after the issuance date.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Foreign currency translation</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The reporting currency of the Company is the U.S. dollar. The functional currency of Century Canada is the Canadian dollar. Assets and liabilities of Century Canada are translated into U.S. dollars based on exchange rates at the end of each reporting period. Expenses are translated at average exchange rates during the reporting period. Gains and losses arising from the translation of assets and liabilities are included as a component of accumulated other comprehensive loss or income on the company’s consolidated balance sheets. Gains and losses resulting from foreign currency transactions are reflected within the Company’s consolidated statements of operations and comprehensive loss. The Company has not utilized any foreign currency hedging strategies to mitigate the effect of its foreign currency exposure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Intercompany payables and receivables are considered to be long-term in nature and any change in balance due to foreign currency fluctuation is included as a component of the Company’s consolidated comprehensive loss and accumulated other comprehensive loss within the Company’s consolidated balance sheets.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Basic and diluted net loss per common shares</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Basic net loss per common share is computed by dividing net loss applicable to common shareholders by the weighted-average number of common shares outstanding during the period. The Company computes diluted net loss per common share by dividing the net loss applicable to common shareholders by the sum of the weighted- average number of common shares outstanding during the period plus the potential dilutive effects of its warrants, restricted stock and stock options to purchase common shares, but such items are excluded if their effect is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there were no differences between the Company’s basic and diluted net loss per common share for the three months ended March 31, 2023 and 2022.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Early exercised options</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The Company allowed certain of its employees and its consultants to exercise options granted under the 2018 Stock Option and Grant Plan (the “2018 Incentive Plan”) (Note 16) prior to vesting and prior to its IPO. The shares related to early exercised stock options are subject to the Company’s repurchase right upon termination of employment or services at the lesser of the original purchase price or fair market value at the time of repurchase. In order to vest, the holders are required to provide continued service to the Company. The early exercise by an employee or consultant of a stock option is not considered to be a substantive </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">exercise for accounting purposes, and therefore, the payment received by the employer for the exercise price is recognized as a liability. For accounting purposes, unvested early exercised shares are not considered issued and outstanding and therefore not reflected as issued and outstanding in the accompanying consolidated balance sheets or the consolidated statements of changes in stockholders’ equity (deficit) until the awards vest. The deposits received are initially recorded in deposit liability. The liabilities are reclassified to common stock and additional paid-in-capital as the repurchase right lapses. At March 31, 2023 and December 31, 2022, there were $1,314 and $1,584, respectively, recorded in deposit liability related to shares held by employees and nonemployees that were subject to repurchase. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">All shares that were early exercised by the executives of the Company are considered legally issued, however, for accounting purposes, only vested shares are considered issued. Below is a reconciliation of shares issued and outstanding:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:16.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.42%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:middle;white-space:nowrap;width:13.43%;border-bottom:1px solid #231f20;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">March 31, 2023</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">    </span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.14%;border-bottom:1px solid #231f20;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">December 31, 2022</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total shares legally outstanding</p></td><td style="vertical-align:bottom;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 59,541,904</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 59,137,491</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Less: unvested early exercised shares</p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (385,655)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (470,800)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Less: unvested restricted stock awards (Note 16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (49,465)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (193,031)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total shares issued and outstanding </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 59,106,784</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 58,473,660</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Income taxes</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations and comprehensive loss. As of March 31, 2023 and December 31, 2022, no accrued interest or penalties are included on the related tax liability line in the consolidated balance sheet.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Collaboration revenue</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company may enter into collaboration and licensing agreements with strategic partners for research and development, manufacturing, and commercialization of its product candidates. Payments under these arrangements may include non-refundable, upfront fees; reimbursement of certain costs; customer option fees for additional goods or services; payments upon the achievement of development, regulatory, and commercial milestones; sales of product at certain agreed-upon amounts; and royalties on product sales.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers, or ASC 606. This standard applies to all contracts with customers. When an agreement falls under the scope of other standards, such as ASC Topic 808, Collaborative Arrangements, or ASC 808, the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606 is recorded as collaboration revenue on the statements of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under a collaboration agreement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations on a relative stand-alone selling price basis; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As part of the accounting for these arrangements, the Company must use its judgment to determine the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price. The estimation of the stand-alone selling price may include such estimates as forecasted revenues and costs, development timelines, discount rates, and probabilities of regulatory and commercial success. The Company also applies significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining when performance obligations have been met, assessing the recognition and future reversal of variable consideration and determining and applying appropriate methods of measuring progress for performance obligations satisfied over time. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, current. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, non-current.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are not determined to represent a material right, no transaction price is allocated to these options and the Company will account for these options at that time they are exercised. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The obligations under the Company’s collaboration agreements may include research and development services to be performed by the Company for or on behalf of the customer. Amounts allocated to these performance obligations are recognized as the Company performs these obligations, and revenue is measured based on an inputs method of costs incurred to date of budgeted costs. Under certain circumstances, the Company may be reimbursed for certain expenses incurred under the research and development services. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the statements of operations in the period of adjustment.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Recent accounting pronouncements</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses of Financial Instruments (ASC 326). The guidance is effective for the Company beginning January 1, 2023 and it changes how entities account for credit losses on the financial assets and other instruments that are not measured at fair value through net income, including available-for-sale debt securities. The adoption of ASC 326 did not have a material impact on the consolidated financial statements<span style="white-space:pre-wrap;">. </span></p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Basis of presentation</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the interim period reporting requirements of Form 10-Q and Article 10 of Regulation S-X. The consolidated balance sheet as of March 31, 2023, the consolidated statements of operations and comprehensive loss, and consolidated statements of changes in stockholders’ equity for the three months ended March 31, 2023 and 2022, and the consolidated statements of cash flows for the three months ended March 31, 2023 and 2022 are unaudited, but, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.  The results for any interim period are not necessarily indicative of results for the year ending December 31, 2023 or for any other subsequent interim period.  The consolidated balance sheet at December 31, 2022 has been derived from the Company’s audited consolidated financial statements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Certain prior year information has been reclassified to conform to the fiscal year 2023 presentation.</p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Segment information</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages the business as one operating segment.</p> 1 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Use of estimates</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuations supporting stock compensation, the estimation of the incremental borrowing rate for operating leases and standalone selling prices of performance obligations in collaboration agreements. If actual results differ from the Company’s estimates, or to the extent these estimates are adjusted in future periods, the Company’s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Concentration of credit risk and other risks and uncertainties</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist of cash, cash equivalents, U.S. Treasury bills and bonds, as well as corporate bonds. Cash and cash equivalents, as well as short and long-term investments include a checking account and asset management accounts held by a limited number of financial institutions. At times, such deposits may be in excess of insured limits. As of March 31, 2023 and December 31, 2022, the Company has not experienced any losses on its deposits of cash and cash equivalents.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, uncertainty of market acceptance of its products, competition from substitute products and larger companies, protection of proprietary technology, strategic relationships, and dependence on key individuals.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Products developed by the Company require clearances from the U.S. Food and Drug Administration (the “FDA”) or other international regulatory agencies prior to commercial sales. There can be no assurance the Company’s future products will receive the necessary clearances. If the Company was denied clearance, </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">clearance was delayed, or if the Company was unable to maintain clearance, it could have a material adverse impact on the Company.</p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Fair value of financial instruments</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Level 1</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Level 2</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly, including inputs in markets that are not considered to be active;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Level 3</p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Inputs are unobservable in which there is little or no market data available, which require the reporting entity to develop its own assumptions that are unobservable.</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Cash and cash equivalents</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Management considers all highly liquid investments with an insignificant interest rate risk and original maturities of three months or less to be cash equivalents.</p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Restricted cash</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of March 31, 2023 and December 31, 2022, the Company had $1,979 in cash on deposit to secure certain lease commitments. Restricted cash is recorded separately in the Company’s consolidated balance sheets.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The following provides a reconciliation of the Company’s cash, cash equivalents, and restricted cash as reported in the consolidated balance sheets to the amounts reported in the consolidated statements of cash flows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.4%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:14.48%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">December 31, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:68.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 86,832</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 84,265</p></td></tr><tr><td style="vertical-align:bottom;width:68.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,979</p></td></tr><tr><td style="vertical-align:bottom;width:68.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash, cash equivalents, and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 88,811</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 86,244</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 1979000 1979000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.4%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:14.48%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">December 31, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:68.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 86,832</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 84,265</p></td></tr><tr><td style="vertical-align:bottom;width:68.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,979</p></td></tr><tr><td style="vertical-align:bottom;width:68.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash, cash equivalents, and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 88,811</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 86,244</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 86832000 84265000 1979000 1979000 88811000 86244000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Investments </i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The Company invests in fixed maturity securities including U.S. Treasury bills and bonds as well as corporate bonds. The investments are classified as available-for-sale and reported at fair value. Unrealized gains or losses are determined by comparing the fair market value of the securities with their cost or amortized cost. Realized gains and losses on investments are recorded on the trade date and are included in the statement of operations. Unrealized gains and losses on investments are recorded in other comprehensive income (loss) on the consolidated statements of operations and comprehensive loss. The cost of securities sold is based on the specified identification method. Investment income is recognized as earned and discounts or premiums arising from the purchase of debt securities are recognized in investment income using the interest </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">method over the remaining term of the security. Securities with an original maturity date greater than three months that mature within one year of the balance sheet date are classified as short-term, while investments with a maturity date greater than one year are classified as long-term.</p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Property and equipment, net </i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which is generally five years<span style="white-space:pre-wrap;">. Leasehold improvements are amortized over the shorter of the asset’s useful life or the remaining term of the lease. Construction in progress includes direct cost related to the construction of leasehold improvements and is stated at original cost. Such costs are not depreciated until the asset is completed and placed into service. Once the asset is placed into service, these capitalized costs will be allocated to leasehold improvements and will be depreciated over the shorter of the asset’s useful life or the remaining term of the lease. Computer software and equipment includes implementation costs for cloud-based software and network equipment.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Expenditures for major additions and improvements are capitalized, while minor replacements, maintenance, and repairs are charged to expense as incurred. When property is retired or otherwise disposed of, the costs and accumulated depreciation are removed from the respective accounts, with any resulting gain or loss recognized concurrently.</p> P5Y <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Research and development expenses </i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, stock compensation, materials, supplies, rent, depreciation on and maintenance of research equipment with alternative future use, and the cost of services provided by outside contractors. All costs associated with research and development are expensed as incurred.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Clinical trial costs are a component of research and development expenses. The company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.</span></p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Stock-based compensation</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Employees, consultants and members of the board of directors of the Company have received stock options and restricted stock of the Company. The Company recognizes the cost of the stock-based compensation incurred as its employees and board members vest in the awards. The Company accounts for stock-based compensation arrangements in accordance with provisions of Accounting Standards Codification (“ASC”) 718, Compensation—Stock Compensation. ASC 718 requires the recognition of compensation expense, using a fair-value based method, for costs related to all share-based payments including stock options. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The Company uses the Black-Scholes option-pricing model (“Black Scholes”) to determine the fair value of options granted. The Company’s stock-based awards are subject to service-based vesting conditions and performance-based vesting conditions. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. For performance-based awards, the Company reassesses at each reporting date whether achievement of the performance condition is probable and accrues compensation expense if and when achievement of the performance condition is probable.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Black-Scholes requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. Due to </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">the lack of a public market for the Company’s common stock prior to its initial public offering (“IPO”) and lack of company-specific historical and implied volatility data, the Company based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be </span>zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. Forfeitures are recognized as they occur.</p> 0 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Warrants</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has issued warrants that have been recognized as equity, and the fair value is recorded into additional paid-in capital in the accompanying consolidated balance sheets. Warrants are accounted for in accordance with applicable accounting guidance provided in ASC Topic 815, Derivatives and Hedging—Contracts in Entity’s Own Equity, as either derivative liabilities or as equity instruments depending on the specific terms of the warrant agreement. The Company’s warrants issued are in connection with its long-term debt and in connection with services provided by consultants, and are equity classified on the accompanying consolidated balance sheets. Equity classified warrants are accounted for at fair value on the issuance date, using Black Scholes, with no changes in fair value recognized after the issuance date.</p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Foreign currency translation</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The reporting currency of the Company is the U.S. dollar. The functional currency of Century Canada is the Canadian dollar. Assets and liabilities of Century Canada are translated into U.S. dollars based on exchange rates at the end of each reporting period. Expenses are translated at average exchange rates during the reporting period. Gains and losses arising from the translation of assets and liabilities are included as a component of accumulated other comprehensive loss or income on the company’s consolidated balance sheets. Gains and losses resulting from foreign currency transactions are reflected within the Company’s consolidated statements of operations and comprehensive loss. The Company has not utilized any foreign currency hedging strategies to mitigate the effect of its foreign currency exposure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Intercompany payables and receivables are considered to be long-term in nature and any change in balance due to foreign currency fluctuation is included as a component of the Company’s consolidated comprehensive loss and accumulated other comprehensive loss within the Company’s consolidated balance sheets.</p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Basic and diluted net loss per common shares</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Basic net loss per common share is computed by dividing net loss applicable to common shareholders by the weighted-average number of common shares outstanding during the period. The Company computes diluted net loss per common share by dividing the net loss applicable to common shareholders by the sum of the weighted- average number of common shares outstanding during the period plus the potential dilutive effects of its warrants, restricted stock and stock options to purchase common shares, but such items are excluded if their effect is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there were no differences between the Company’s basic and diluted net loss per common share for the three months ended March 31, 2023 and 2022.</p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Early exercised options</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The Company allowed certain of its employees and its consultants to exercise options granted under the 2018 Stock Option and Grant Plan (the “2018 Incentive Plan”) (Note 16) prior to vesting and prior to its IPO. The shares related to early exercised stock options are subject to the Company’s repurchase right upon termination of employment or services at the lesser of the original purchase price or fair market value at the time of repurchase. In order to vest, the holders are required to provide continued service to the Company. The early exercise by an employee or consultant of a stock option is not considered to be a substantive </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">exercise for accounting purposes, and therefore, the payment received by the employer for the exercise price is recognized as a liability. For accounting purposes, unvested early exercised shares are not considered issued and outstanding and therefore not reflected as issued and outstanding in the accompanying consolidated balance sheets or the consolidated statements of changes in stockholders’ equity (deficit) until the awards vest. The deposits received are initially recorded in deposit liability. The liabilities are reclassified to common stock and additional paid-in-capital as the repurchase right lapses. At March 31, 2023 and December 31, 2022, there were $1,314 and $1,584, respectively, recorded in deposit liability related to shares held by employees and nonemployees that were subject to repurchase. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">All shares that were early exercised by the executives of the Company are considered legally issued, however, for accounting purposes, only vested shares are considered issued. Below is a reconciliation of shares issued and outstanding:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:16.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.42%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:middle;white-space:nowrap;width:13.43%;border-bottom:1px solid #231f20;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">March 31, 2023</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">    </span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.14%;border-bottom:1px solid #231f20;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">December 31, 2022</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total shares legally outstanding</p></td><td style="vertical-align:bottom;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 59,541,904</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 59,137,491</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Less: unvested early exercised shares</p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (385,655)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (470,800)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Less: unvested restricted stock awards (Note 16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (49,465)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (193,031)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total shares issued and outstanding </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 59,106,784</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 58,473,660</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 1314000 1584000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:66.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:16.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.42%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:middle;white-space:nowrap;width:13.43%;border-bottom:1px solid #231f20;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">March 31, 2023</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">    </span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.14%;border-bottom:1px solid #231f20;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">December 31, 2022</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total shares legally outstanding</p></td><td style="vertical-align:bottom;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 59,541,904</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 59,137,491</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Less: unvested early exercised shares</p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (385,655)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (470,800)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Less: unvested restricted stock awards (Note 16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (49,465)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;"> (193,031)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total shares issued and outstanding </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 59,106,784</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 58,473,660</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 59541904 59137491 385655 470800 49465 193031 59106784 58473660 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Income taxes</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations and comprehensive loss. As of March 31, 2023 and December 31, 2022, no accrued interest or penalties are included on the related tax liability line in the consolidated balance sheet.</p> 0 0 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Collaboration revenue</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company may enter into collaboration and licensing agreements with strategic partners for research and development, manufacturing, and commercialization of its product candidates. Payments under these arrangements may include non-refundable, upfront fees; reimbursement of certain costs; customer option fees for additional goods or services; payments upon the achievement of development, regulatory, and commercial milestones; sales of product at certain agreed-upon amounts; and royalties on product sales.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers, or ASC 606. This standard applies to all contracts with customers. When an agreement falls under the scope of other standards, such as ASC Topic 808, Collaborative Arrangements, or ASC 808, the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606 is recorded as collaboration revenue on the statements of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under a collaboration agreement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations on a relative stand-alone selling price basis; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As part of the accounting for these arrangements, the Company must use its judgment to determine the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price. The estimation of the stand-alone selling price may include such estimates as forecasted revenues and costs, development timelines, discount rates, and probabilities of regulatory and commercial success. The Company also applies significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining when performance obligations have been met, assessing the recognition and future reversal of variable consideration and determining and applying appropriate methods of measuring progress for performance obligations satisfied over time. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, current. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, non-current.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the goods and services underlying the customer options are not considered to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights or options to acquire additional goods or services for free or at a discount. If the customer options are not determined to represent a material right, no transaction price is allocated to these options and the Company will account for these options at that time they are exercised. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The obligations under the Company’s collaboration agreements may include research and development services to be performed by the Company for or on behalf of the customer. Amounts allocated to these performance obligations are recognized as the Company performs these obligations, and revenue is measured based on an inputs method of costs incurred to date of budgeted costs. Under certain circumstances, the Company may be reimbursed for certain expenses incurred under the research and development services. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the statements of operations in the period of adjustment.</p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Recent accounting pronouncements</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses of Financial Instruments (ASC 326). The guidance is effective for the Company beginning January 1, 2023 and it changes how entities account for credit losses on the financial assets and other instruments that are not measured at fair value through net income, including available-for-sale debt securities. The adoption of ASC 326 did not have a material impact on the consolidated financial statements<span style="white-space:pre-wrap;">. </span></p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:12pt;">Note 3—Reduction in force</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">During the three months ended March 31,2023, the Company incurred $2,032<span style="white-space:pre-wrap;"> of cash-based expenses related to employee severances, benefits and related costs. In addition, the Company recorded non-cash stock-based compensation charge of </span>$581<span style="white-space:pre-wrap;"> related to modification of equity awards for employees impacted by the restructuring during the quarter ended March 31, 2023. There were </span>no remaining outstanding liabilities related to the reduction in force during the quarter ended March 31, 2023.</p> 2032000 581000 0 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Note 4—Asset purchase by Century Therapeutics Canada ULC</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On June 9, 2020, Century Canada and the Company entered into an agreement with Empirica Therapeutics, Inc. (“Empirica”), a company focused on the development of adoptive immunotherapies against aggressive and treatment-resistant forms of cancers, including glioblastoma and brain metastasis. Under the terms of the Empirica Agreement, the Company acquired an IPR&amp;D asset. Cash of $4,519 was paid at closing and transaction expenses totaled $203. The Company also deposited $1,506 in escrow (the “Escrow Deposit”). Release of the Escrow Deposit is subject to the terms of a promissory note, which provides for the funds to be released in equal annual installments over a three-year period related to continuing services by certain Empirica shareholders. In July 2021, the first annual installment of $523 was released from the Escrow Deposit. In June 2022, the second annual installment of $517 was released from the Escrow Deposit. In February 2023, the third installment of $494<span style="white-space:pre-wrap;"> was released from Escrow Deposit. As of March 31, 2023 and December 31, 2022, accrued compensation expense on the promissory note was </span>$0 and $220, which is presented within escrow deposits on the consolidated balance sheets. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">​</span></p> 4519000 203000 1506000 523000 517000 494000 0 220000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Note 5—Financial instruments and fair value measurements</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The following table sets forth the Company’s assets that were measured at fair value as of March 31, 2023 by level within the fair value hierarchy:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.23%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Level 1</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.69%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.75%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Level 2</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.69%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.75%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Level 3</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.69%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Total</p></td></tr><tr><td style="vertical-align:bottom;width:38.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 83,187</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 83,187</p></td></tr><tr><td style="vertical-align:bottom;width:38.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">U.S. Treasury</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 65,197</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 65,197</p></td></tr><tr><td style="vertical-align:bottom;width:38.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 182,756</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 182,756</p></td></tr><tr><td style="vertical-align:bottom;width:38.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 148,384</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 182,756</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 331,140</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The following table sets forth the Company’s assets that were measured at fair value as of December 31, 2022, by level within the fair value hierarchy:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.81%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Level 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Level 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.13%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Level 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Total</p></td></tr><tr><td style="vertical-align:bottom;width:56.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 77,736</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 77,736</p></td></tr><tr><td style="vertical-align:bottom;width:56.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">U.S. Treasury</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 86,475</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 86,475</p></td></tr><tr><td style="vertical-align:bottom;width:56.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 196,603</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 196,603</p></td></tr><tr><td style="vertical-align:bottom;width:56.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 164,211</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 196,603</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 360,814</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">There were no transfers between <span style="-sec-ix-hidden:Hidden_sxDfMCcneUWxUid0iaISXA;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">levels</span></span> during the period ended March 31, 2023. The Company uses the services of its investment manager, which uses widely accepted models for assumptions in valuing securities with inputs from major third-party data providers.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company classifies all of its investments in fixed maturity debt securities as available-for-sale and, accordingly, are carried at estimated fair value.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The amortized cost, gross unrealized gains and losses, and fair value of investments in fixed maturity securities are as follows as of March 31, 2023:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.19%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.54%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.46%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Gross </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.31%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Gross</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Unrealized</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> Unrealized </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Amortized Cost</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> Gains</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Losses</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Fair Value</p></td></tr><tr><td style="vertical-align:bottom;width:53.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">U.S. Treasury</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 65,807</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (610)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 65,197</p></td></tr><tr><td style="vertical-align:bottom;width:53.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 183,329</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (660)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 182,756</p></td></tr><tr><td style="vertical-align:bottom;width:53.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 249,136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (1,271)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 247,953</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The amortized cost, gross unrealized gains and losses, and fair value of investments in fixed maturity securities are as follows as of December 31, 2022:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.01%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.54%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Gross </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.46%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Gross </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Unrealized</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Unrealized</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Amortized Cost</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> Gains</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> Losses</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Fair Value</p></td></tr><tr><td style="vertical-align:bottom;width:54.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">U.S. Treasury</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 87,798</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (1,323)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 86,475</p></td></tr><tr><td style="vertical-align:bottom;width:54.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 197,668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (1,067)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 196,603</p></td></tr><tr><td style="vertical-align:bottom;width:54.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 285,466</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (2,390)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 283,078</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The following table provides the maturities of our fixed maturity available-for-sale securities:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">     </p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">     </p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:14.48%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">December 31, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Less than one year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 164,637</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 231,224</p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">One to five years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 83,316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 51,854</p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 247,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 283,078</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company has evaluated the unrealized losses on the fixed maturity securities and determined that they are not attributable to credit risk factors. For fixed maturity securities, losses in fair value are viewed as temporary if the fixed maturity security can be held to maturity and it is reasonable to assume that the issuer will be able to service the debt, both as to principal and interest.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">At March 31, 2023 and December 31, 2022, respectively, the Company had 32 and 42<span style="white-space:pre-wrap;"> available-for-sale investment debt securities in an unrealized loss position without an allowance for credit losses. Unrealized losses on corporate debt securities have not been recognized into income because the issuers’ bonds are of high credit quality (rated BBB+ or higher) and the decline in fair value is largely due to market conditions and or changes in interest rates. Management does not intend to sell and it is likely that management will not be required to sell the securities prior to the anticipated recovery of their amortized cost basis. The issuers </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">continue to make timely payments on the bonds. The fair value is expected to recover as the bond approach maturity.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2023 and December 31, 2022, accrued interest receivable on available-for-sale investment debt securities totaling $855 and $0, respectively, is excluded from the estimate of credit losses and is included in prepaid expenses and other current assets.</p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.23%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Level 1</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.69%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.75%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Level 2</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.69%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.75%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Level 3</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.69%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Total</p></td></tr><tr><td style="vertical-align:bottom;width:38.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 83,187</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 83,187</p></td></tr><tr><td style="vertical-align:bottom;width:38.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">U.S. Treasury</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 65,197</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 65,197</p></td></tr><tr><td style="vertical-align:bottom;width:38.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 182,756</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 182,756</p></td></tr><tr><td style="vertical-align:bottom;width:38.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 148,384</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 182,756</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 331,140</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.81%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Level 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Level 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.13%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Level 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Total</p></td></tr><tr><td style="vertical-align:bottom;width:56.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 77,736</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 77,736</p></td></tr><tr><td style="vertical-align:bottom;width:56.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">U.S. Treasury</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 86,475</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 86,475</p></td></tr><tr><td style="vertical-align:bottom;width:56.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 196,603</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 196,603</p></td></tr><tr><td style="vertical-align:bottom;width:56.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 164,211</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 196,603</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 360,814</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 83187000 83187000 65197000 65197000 182756000 182756000 148384000 182756000 331140000 77736000 77736000 86475000 86475000 196603000 196603000 164211000 196603000 360814000 0 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.19%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.54%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.46%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Gross </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.31%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Gross</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Unrealized</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.31%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> Unrealized </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Amortized Cost</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> Gains</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Losses</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Fair Value</p></td></tr><tr><td style="vertical-align:bottom;width:53.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">U.S. Treasury</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 65,807</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (610)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 65,197</p></td></tr><tr><td style="vertical-align:bottom;width:53.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 183,329</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (660)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 182,756</p></td></tr><tr><td style="vertical-align:bottom;width:53.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 249,136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (1,271)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 247,953</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.01%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.54%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Gross </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.46%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Gross </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.75%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Unrealized</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Unrealized</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Amortized Cost</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> Gains</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:8.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> Losses</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Fair Value</p></td></tr><tr><td style="vertical-align:bottom;width:54.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">U.S. Treasury</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 87,798</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (1,323)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 86,475</p></td></tr><tr><td style="vertical-align:bottom;width:54.01%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 197,668</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (1,067)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 196,603</p></td></tr><tr><td style="vertical-align:bottom;width:54.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 285,466</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (2,390)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 283,078</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 65807000 610000 65197000 183329000 87000 660000 182756000 249136000 87000 1271000 247953000 87798000 1323000 86475000 197668000 2000 1067000 196603000 285466000 2000 2390000 283078000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">     </p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">     </p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:14.48%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">December 31, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Less than one year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 164,637</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 231,224</p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">One to five years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 83,316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 51,854</p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 247,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 283,078</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 164637000 231224000 83316000 51854000 247953000 283078000 32 42 855000 0 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:12pt;">Note 6—Prepaid expenses and other current assets</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The following is a summary of prepaid expenses and other current assets:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:14.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">December 31, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 110</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Prepaid clinical trial related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 791</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 884</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,454</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Software licenses and other </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,417</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Reimbursement receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 780</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Warranties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 242</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accrued interest receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 855</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,465</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,003</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:14.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">December 31, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 110</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Prepaid clinical trial related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 791</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 884</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,454</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Software licenses and other </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,417</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Reimbursement receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 780</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Warranties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 242</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accrued interest receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 855</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,465</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,003</p></td></tr></table> 110000 791000 884000 1454000 1123000 1417000 610000 780000 202000 242000 855000 4465000 4003000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Note 7—Property and equipment, net </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;">The following is a summary of property and equipment, net:</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:14.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">December 31, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28,811</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 49,180</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 48,951</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Construction in progress </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 19,758</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13,998</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Computer software and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,132</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,132</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,548</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,548</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 102,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 96,440</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Less: Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (16,563)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (13,655)</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 85,842</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 82,785</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Depreciation expense was $2,908 and $1,160 for the three months ended March 31, 2023 and 2022, respectively. </p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:14.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">December 31, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Lab equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28,811</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 49,180</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 48,951</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Construction in progress </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 19,758</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13,998</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Computer software and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,132</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,132</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,548</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,548</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 102,405</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 96,440</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Less: Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (16,563)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (13,655)</p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 85,842</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 82,785</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 28787000 28811000 49180000 48951000 19758000 13998000 3132000 3132000 1548000 1548000 102405000 96440000 16563000 13655000 85842000 82785000 2908000 1160000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Note 8—Accrued expenses and other liabilities</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The following is a summary of accrued expenses:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:14.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">December 31, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Payroll and bonuses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,139</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,062</p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 122</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 117</p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accrued clinical trial related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 314</p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Professional and legal fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,432</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,637</p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease liability, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 579</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 475</p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 259</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 236</p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total accrued expenses and other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,531</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,841</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:11.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:14.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">December 31, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Payroll and bonuses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,139</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,062</p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 122</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 117</p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Accrued clinical trial related costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 314</p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Professional and legal fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,432</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,637</p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease liability, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 579</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 475</p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 259</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 236</p></td></tr><tr><td style="vertical-align:bottom;width:69.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total accrued expenses and other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,531</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,841</p></td></tr></table> 3139000 7062000 122000 117000 314000 2432000 1637000 579000 475000 259000 236000 6531000 9841000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Note </span><span style="font-weight:normal;white-space:pre-wrap;">9—Long-term debt </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The following is a summary of the Company’s indebtedness:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.09%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.29%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:14.48%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">December 31, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:69.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Principal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,000</p></td></tr><tr><td style="vertical-align:bottom;width:69.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Plus: End of term fee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 395</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 395</p></td></tr><tr><td style="vertical-align:bottom;width:69.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Less: Debt discount attributable to warrants, net of accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (8)</p></td></tr><tr><td style="vertical-align:bottom;width:69.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Less: Unamortized deferred financing cost and end of term fee, net of accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (90)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (146)</p></td></tr><tr><td style="vertical-align:bottom;width:69.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Long-term debt, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,297</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,241</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On September 14, 2020, the Company entered into a $10,000 Term Loan Agreement (as amended, the “Loan Agreement”) with Hercules Capital, Inc. (“Hercules”). Pursuant to the terms of the Loan Agreement, the Company borrowed $10,000 (the “Tranche 1 Advance”) from the lenders at closing. Beginning January 1, 2021 and upon the achievement of certain development milestones and continuing through September 30, 2021 the Company may borrow an additional $10,000 (the “Tranche 2 Advance”). The remaining $10,000 tranche (“Tranche 3 Advance”) is subject to Hercules’ investment committee’s sole discretion.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Loan Agreement has a four-year term and an interest-only period of up to 30 months. The Company was in compliance with all provisions of the Loan Agreement as of March 31, 2023. Amounts borrowed under the Loan Agreement accrue interest at a floating rate per annum (based on a year of 360 days) equal to (i) the sum of (a) the greater of 6.30% plus (b) the prime rate as reported in <i style="font-style:italic;">The Wall Street Journal </i>on the last business day of the month that immediately precedes the month in which the interest will accrue or (ii) 9.55%. The interest rate as of March 31, 2023 was 14.3%.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company incurred $410 in deferred financing costs. The Company is also required to pay the lenders an end of term fee of 3.95% of loan proceeds upon repayment or prepayment of any loans made under the Loan Agreement. The end of term fee is being recognized as interest expense and accreted over the term of the Loan Agreement using the effective interest method. The Company is also required to pay Hercules a prepayment charge equal to 2.00% of the loan amounts prepaid during the interest-only period and 1.00% thereafter on any loans made under the Loan Agreement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company granted Hercules a lien on substantially all of the Company’s assets, excluding intellectual property.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company issued to Hercules warrants to purchase up to an aggregate of 16,112 shares of common stock. The warrants are exercisable for a period of ten years from the date of the issuance of each warrant at a per share exercise price equal to $13.96, subject to certain adjustments as specified in the warrants. The fair value of the warrants at issuance was $46. The Company accounted for the warrants as equity, and the fair value is recorded in additional paid-in capital. The warrant value is also recorded as a debt discount and classified as a contra- liability on the consolidated balance sheet and amortized to interest expense. If the Company borrows on the remaining two tranche advances outlined above, the Company will be required to issue warrants to Hercules equal to 2.25% of the aggregate amount funded.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Interest expense of the Loan Agreement is as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.65%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.35%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">For the Three Months Ended </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">For the Three Months Ended </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:20.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:20.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 348</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 238</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Amortization of debt issuance costs, including end of term fee accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 404</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 314</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Included in accrued expenses in the accompanying consolidated balance sheets as of March 31, 2023 and December 31, 2022 was $122 and $117 of accrued interest, respectively.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Future principal payments due (including the end of term fee) under the Loan Agreement are as follows (in thousands):</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.73%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">    </span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Principal Payments</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">2023</span></p></td><td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 10,395</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Total future payments</span></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 10,395</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">On May 1, 2023, the Company repaid the loan in its entirety. See Note 18.</p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.09%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.29%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:14.48%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">December 31, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:69.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Principal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,000</p></td></tr><tr><td style="vertical-align:bottom;width:69.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Plus: End of term fee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 395</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 395</p></td></tr><tr><td style="vertical-align:bottom;width:69.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Less: Debt discount attributable to warrants, net of accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (8)</p></td></tr><tr><td style="vertical-align:bottom;width:69.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Less: Unamortized deferred financing cost and end of term fee, net of accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (90)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (146)</p></td></tr><tr><td style="vertical-align:bottom;width:69.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Long-term debt, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,297</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,241</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 10000000 10000000 -395000 -395000 8000 8000 90000 146000 10297000 10241000 10000000 10000000 10000000 10000000 P4Y P30M 0.0630 0.0955 0.143 410000 0.0395 0.0200 0.0100 16112 P10Y 13.96 46000 0.0225 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.65%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.35%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">For the Three Months Ended </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">For the Three Months Ended </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:20.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:20.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 348</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 238</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Amortization of debt issuance costs, including end of term fee accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 404</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 314</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 348000 238000 56000 76000 404000 314000 122000 117000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Future principal payments due (including the end of term fee) under the Loan Agreement are as follows (in thousands):</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:81.73%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">    </span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Principal Payments</p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">2023</span></p></td><td style="vertical-align:bottom;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 10,395</span></p></td></tr><tr><td style="vertical-align:bottom;width:81.73%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Total future payments</span></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="color:#231f20;"> 10,395</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> 10395000 10395000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-size:12pt;font-weight:normal;">Note 10 – Bristol-Myers Squibb Collaboration</span><span style="font-weight:normal;"> </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On January 7, 2022, the Company entered into the Collaboration Agreement with Bristol-Myers Squibb to collaborate on the research, development and commercialization of iNK and iT cell programs for hematologic malignancies and solid tumors (“Collaboration Program,” and each product candidate a “Development Candidate”). The Collaboration Agreement is within the scope of ASC 808, Collaborative Arrangements as both parties are active participants in the arrangement and are exposed to significant risks and rewards. While this arrangement is in the scope of ASC 808, the Company analogizes to ASC 606 for the accounting for the Collaboration Agreement, including for the delivery of goods and services (i.e., units of account). Revenue recognized by analogizing to ASC 606 is recorded as collaboration revenue in the statements of operations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Pursuant to the Collaboration Agreement, the Company and Bristol-Myers Squibb will initially collaborate on two Collaboration Programs focused on acute myeloid leukemia (“AML”) and multiple myeloma (“MM”), and Bristol-Myers Squibb has the option to add up to two additional Collaboration Programs for an additional fee. The Company is responsible for generating Development Candidates for each Collaboration Program, and Bristol-Myers Squibb has the option to elect to exclusively license the Development Candidates for pre-clinical development, clinical development and commercialization on a worldwide basis (“License Option”). Following Bristol-Myers Squibb’s exercise of the License Option, the Company will be responsible for performing IND-enabling studies, supporting Bristol-Myers Squibb’s preparation and submission of an IND, and manufacturing of clinical supplies until completion of a proof of concept clinical trial. Bristol-Myers Squibb will be responsible for all regulatory, clinical, manufacturing (after the proof of concept clinical trial) and commercialization activities for such Development Candidates worldwide. The Company has the option to co-promote Development Candidates generated from certain specified Collaboration Programs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Under the terms of the Collaboration Agreement, Bristol-Myers Squibb made a non-refundable, upfront cash payment of $100,000 and will pay an exercise fee upon the exercise of the License Option (“Licensed Program” and product candidates developed under a Licensed Program, “Licensed Products”). For each Licensed Program, Bristol-Myers Squibb will pay up to $235,000 in milestone payments upon the first achievement of certain development and regulatory milestones and will pay up to $500,000 per Licensed Product in net sales-based milestone payments. Bristol-Myers Squibb will also pay the Company tiered royalties per Licensed Product as a percentage of net sales in the high-single digits to low-teens, subject to reduction for biosimilar competition, compulsory licensing and certain third party license costs. If Century exercises its co-promote option, such royalty percentage will be increased to low-teens to high-teens in respect of the sales of the co-promoted Licensed Products in the United States. The royalty term shall terminate on a Licensed Product-by-Licensed Product and country-by-country basis on the latest of (i) the <span style="-sec-ix-hidden:Hidden_PS7xe1wSFUuD1yqfU-NWNg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">twelve</span></span> (12) year anniversary of the first commercial sale of such Licensed Product in such country, (ii) the expiration of any regulatory exclusivity period that covers such Licensed Product in such country, and (iii) the expiration of the last-to-expire licensed patent of the Company or a jointly owned patent that covers such the Licensed Product in such country. After expiration of the applicable royalty term for a Licensed Product in a </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">country, all licenses granted by the Company to Bristol-Myers Squibb for such Licensed Product in such country will be fully paid-up, royalty- free, perpetual and irrevocable.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the Collaboration Agreement, Bristol-Myers Squibb purchased 2,160,760 shares of the Company’s common stock at a price per share of $23.14, for an aggregate purchase price of $50,000<span style="white-space:pre-wrap;">. In determining the fair value of the common stock issued to Bristol-Myers Squibb, the Company considered the closing price of the common stock on the date of the transaction and included a lack of marketability discount because the shares are subject to certain restrictions. The Company determined the common stock purchase represented a premium of </span>$7.82 per share, or $23,200 in the aggregate (“Equity Premium”), and the remaining $26,800 was recorded as issuance of common stock in stockholders’ equity.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company identified the following commitments under the arrangement: (i) research and development services (“R&amp;D Services”) under each of the two initial Collaboration Programs and (ii) Bristol-Myers Squibb’s License Option to elect to exclusively license the Development Candidates for each of the two initial Collaboration Programs. The Company determined that these four commitments represent distinct performance obligations for purposes of recognizing revenue and will recognize revenue as the Company fulfills each performance obligation.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company determined that the upfront payment and Equity Premium constitute the transaction price at the inception of the Collaboration Agreement. The future potential development and regulatory milestone payments were fully constrained at contract inception as the risk of significant revenue reversal related to these amounts has not yet been resolved. The achievement of the future potential milestones is not within the Company’s control and is subject to certain research and development success and therefore carries significant uncertainty. The Company will reevaluate the likelihood of achieving these milestones at the end of each reporting period and adjust the transaction price in the period the risk is resolved. In addition, the Company will recognize any consideration related to sales-based milestones and royalties when the subsequent sales occur.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">At March 31, 2023, the total transaction price of $123,187 is allocated to the performance obligations based on their estimated standalone selling price. The stand-alone selling price of the research and development services was estimated using the expected cost-plus margin approach, and the stand-alone selling price of the License Options was based on a discounted cash flow approach and considered several factors including, but not limited to, discount rate, development timeline, regulatory risks, estimated market demand, and future revenue potential using an adjusted market approach. The allocated transaction price is recognized as revenue in one of two ways:</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Research and development services: The Company recognizes the portion of the transaction price allocated to each of the research and development performance obligations as the research and development services are provided, using an inputs method, in proportion to costs incurred to date for each research development target as compared to total costs incurred and expected to be incurred in the future to satisfy the underlying obligation related to each research and development target. The transfer of control occurs over this period and, in management’s judgment, is the best measure of progress towards satisfying the performance obligation.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">License option rights: The transaction price allocated to the license options rights, which are considered material rights to license and commercialize the underlying research and development target, are deferred until the period that Bristol-Myers Squibb elects to exercise or elects to not exercise its option or when the option to exercise expires.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">The following table summarizes the allocation of the total transaction price to the identified performance obligations under the arrangement, and the amount of the transaction price unsatisfied as of March 31, 2023: </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">Cumulative collaboration</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:20.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">Deferred</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Performance obligations:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">Transaction price</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">revenue recognized</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:20.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">collaboration revenue</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Option rights</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> 109,164</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> -</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> 109,164</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Research and development services</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Helvecta';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> 14,023</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Helvecta';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Helvecta';"> (6,919)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Helvecta';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> 7,104</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> 123,187</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Helvecta';"> (6,919)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> 116,268</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Less current portion of deferred revenue</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> -</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> -</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Helvecta';"> (6,500)</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Total long-term deferred revenue</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> 123,187</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Helvecta';"> (6,919)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> 109,768</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">The following table summarizes the allocation of the total transaction price to the identified performance obligations under the arrangement, and the amount of the transaction price unsatisfied as of December 31, 2022: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">Cumulative collaboration</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:20.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">Deferred</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Performance obligations:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">Transaction price</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">revenue recognized</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:20.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">collaboration revenue</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Option rights</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> 109,164</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> -</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> 109,164</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Research and development services</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Helvecta';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> 14,023</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Helvecta';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Helvecta';"> (5,199)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Helvecta';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> 8,824</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> 123,187</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Helvecta';"> (5,199)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> 117,988</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Less current portion of deferred revenue</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> -</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> -</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Helvecta';"> (7,154)</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Total long-term deferred revenue</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> 123,187</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Helvecta';"> (5,199)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> 110,834</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As a direct result of the execution of the Collaboration Agreement, the Company incurred $10,000<span style="white-space:pre-wrap;"> in fees to amend the FCDI agreement to gain access to the territory rights of Japan. This is recorded as in-process research and development expenses in the consolidated statement of operations and comprehensive loss for the three months ended March 31, 2022. </span></p> 2 2 100000000 235000000 500000000 2160760 23.14 50000000 7.82 23200000 26800000 2 2 4 123187000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">Cumulative collaboration</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:20.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">Deferred</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Performance obligations:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">Transaction price</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">revenue recognized</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:20.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="color:#231f20;">collaboration revenue</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Option rights</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> 109,164</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> -</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> 109,164</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Research and development services</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Helvecta';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> 14,023</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Helvecta';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Helvecta';"> (6,919)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Helvecta';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> 7,104</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Total</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> 123,187</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Helvecta';"> (6,919)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> 116,268</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Less current portion of deferred revenue</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> -</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> -</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Helvecta';"> (6,500)</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="color:#231f20;">Total long-term deferred revenue</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> 123,187</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Helvecta';"> (6,919)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="font-family:'Helvecta';"> 109,768</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 109164000 109164000 14023000 6919000 7104000 123187000 6919000 116268000 6500000 123187000 6919000 109768000 109164000 109164000 14023000 5199000 8824000 123187000 5199000 117988000 7154000 123187000 5199000 110834000 10000000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">N</span><span style="font-weight:normal;">ote 11—Commitments and contingencies</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when future expenditures are probable and such expenditures can be reasonably estimated.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Distributed Bio Master Service Agreement</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On July 24, 2019, the Company entered into a Master Service Agreement with Distributed Bio, Inc (“DBio”), whereby DBio will screen for protein binders that bind to specific therapeutic targets. The Company pays for such services according to a payment schedule, and if the Company brings the protein binders into the clinic for further development, DBio will receive milestone payments of up to $16,100 in total for each product as the products move through the clinical development and regulatory approval processes. No milestone payments were due since the inception of the agreement. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company had $27 within accounts payable as of March 31, 2023 and $110 as of December 31, 2022, in its consolidated balance sheets related to the Master Service Agreement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">iCELL Inc. Sublicense Agreement</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In March 2020, the Company entered into a Sublicense Agreement with iCELL Inc (“iCELL”) whereby iCELL granted the Company a license of certain patents and technology. The Company will pay iCELL royalties in the low single digits on net sales of the licensed product. In addition to the earned royalties, the Company will pay sales milestones, not to exceed $70,000, for the sales of the licensed product. iCELL is also eligible to </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">receive payments of up to $4,250 in development and regulatory approval milestone payments. No milestones or royalties were due in 2022 or 2021. </p> 16100000 0 27000 110000 70000000 4250000 0 0 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Note 12—Leases</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company has commitments under operating leases for certain facilities used in its operations. The Company maintains security deposits on certain leases in the amounts of <span style="-sec-ix-hidden:Hidden_LDxQlWuc_kivqGHAHiI7Eg;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$950</span></span> and $1,260 within security deposits in its consolidated balance sheets at March 31, 2023 and December 31, 2022, respectively. The Company’s leases have initial lease terms ranging from <span style="-sec-ix-hidden:Hidden_kR9uSBXjwEquPz2BPZdcuw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">5</span></span> to 16 years. Certain lease agreements contain provisions for future rent increases.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The following table reflects the components of lease expense:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:26.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:28.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:28.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:28.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">For the Three Months Ended </p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:28.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">For the Three Months Ended </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:28.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:28.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease expense:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:37.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fixed lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,395</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 597</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 297</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Short term lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 594</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 649</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total operating lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,543</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The following table reflects supplemental balance sheet information related to leases:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.55%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:35.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.67%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:11.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">As of </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">As of </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">December 31, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Location in Balance Sheet</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease right-of-use asset, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28,207</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28,945</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease liability, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_08yF4XVw9kq8gguAcVMQ1w;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Accrued expenses and other liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 579</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 475</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease liability, long-term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease liability, long-term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 41,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 38,698</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 41,747</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 39,173</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The following table reflects supplement lease term and discount rate information related to leases:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:19.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.17%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">As of March 31, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.38%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td style="vertical-align:middle;white-space:nowrap;width:19.39%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">As of December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:58.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease terms - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">9.1 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">9.4 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Weighted-average discount rate - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The following table reflects supplemental cash flow information related to leases as of the periods indicated:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;width:11.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">For the Three Months Ended </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;width:12.46%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">For the Three Months Ended </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (31)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (152)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The following table reflects future minimum lease payments under noncancelable leases as of March 31, 2023:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Operating Leases</p></td></tr><tr><td style="vertical-align:bottom;width:83.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,306</p></td></tr><tr><td style="vertical-align:bottom;width:83.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,079</p></td></tr><tr><td style="vertical-align:bottom;width:83.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,588</p></td></tr><tr><td style="vertical-align:bottom;width:83.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,727</p></td></tr><tr><td style="vertical-align:bottom;width:83.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,905</p></td></tr><tr><td style="vertical-align:bottom;width:83.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 53,073</p></td></tr><tr><td style="vertical-align:bottom;width:83.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 91,678</p></td></tr><tr><td style="vertical-align:bottom;width:83.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (46,097)</p></td></tr><tr><td style="vertical-align:bottom;width:83.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Tenant incentive receivable </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,834)</p></td></tr><tr><td style="vertical-align:bottom;width:83.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 41,747</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">​</span></p> 1260000 P16Y <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:26.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:28.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:28.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:28.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">For the Three Months Ended </p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:28.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">For the Three Months Ended </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:28.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:28.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease expense:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:37.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fixed lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,395</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 597</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 297</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Short term lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 594</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 649</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total operating lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,543</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 1395000 597000 125000 297000 594000 649000 2114000 1543000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The following table reflects supplemental balance sheet information related to leases:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.55%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:35.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.67%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:11.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">As of </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">As of </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">December 31, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Location in Balance Sheet</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease right-of-use asset, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28,207</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28,945</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease liability, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_08yF4XVw9kq8gguAcVMQ1w;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Accrued expenses and other liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 579</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 475</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease liability, long-term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating lease liability, long-term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 41,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 38,698</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 41,747</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 39,173</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 28207000 28945000 579000 475000 41168000 38698000 41747000 39173000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The following table reflects supplement lease term and discount rate information related to leases:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:19.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.17%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">As of March 31, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.38%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td style="vertical-align:middle;white-space:nowrap;width:19.39%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">As of December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:58.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease terms - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">9.1 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">9.4 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Weighted-average discount rate - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.39%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> P9Y1M6D P9Y4M24D 0.090 0.090 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The following table reflects supplemental cash flow information related to leases as of the periods indicated:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;width:11.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">For the Three Months Ended </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;width:12.46%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">For the Three Months Ended </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">     </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (31)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (152)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 31000 152000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Operating Leases</p></td></tr><tr><td style="vertical-align:bottom;width:83.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,306</p></td></tr><tr><td style="vertical-align:bottom;width:83.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,079</p></td></tr><tr><td style="vertical-align:bottom;width:83.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,588</p></td></tr><tr><td style="vertical-align:bottom;width:83.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,727</p></td></tr><tr><td style="vertical-align:bottom;width:83.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8,905</p></td></tr><tr><td style="vertical-align:bottom;width:83.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 53,073</p></td></tr><tr><td style="vertical-align:bottom;width:83.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 91,678</p></td></tr><tr><td style="vertical-align:bottom;width:83.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (46,097)</p></td></tr><tr><td style="vertical-align:bottom;width:83.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Tenant incentive receivable </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,834)</p></td></tr><tr><td style="vertical-align:bottom;width:83.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 41,747</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">​</span></p> 4306000 8079000 8588000 8727000 8905000 53073000 91678000 46097000 3834000 41747000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:12pt;">Note 13—Income taxes</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the three months ended March 31, 2023, the Company recorded income tax expense of $1,208, which includes a tax provision of $13<span style="white-space:pre-wrap;"> related to its income tax obligations of its operating company in Canada. The Company is projecting taxable income for tax year 2023, due primarily to revenue recognition for tax purposes from the Company's Research Collaboration and Collaboration Agreement entered into with Bristol-Myers Squibb Company in 2022.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company’s tax provision and the resulting effective tax rate for interim periods is determined based upon its estimated annual effective tax rate (“AETR”), adjusted for the effect of discrete items arising in that quarter. The impact of such inclusions could result in a higher or lower effective tax rate during a particular quarter, based upon the mix and timing of actual earnings or losses versus annual projections. In each quarter, the Company updates its estimate of the annual effective tax rate, and if the estimated annual tax rate changes, a cumulative adjustment is made in that quarter. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has evaluated the positive and negative evidence bearing upon its ability to realize its deferred tax assets, which primarily consist of net operating loss carryforwards. While the Company anticipates utilizing a portion of its existing net operating loss carryforwards during tax year 2023, the Company has considered its history of cumulative net losses in the U.S., estimated future taxable income and prudent and feasible tax planning strategies and has concluded that it is more likely than not that the Company will not realize the benefits of its U.S. deferred tax assets. As a result, as of March 31, 2023, the Company has recorded a full valuation allowance against its net deferred tax assets in the U.S.</p> 1208000 13000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Note 14—Basic and diluted net loss per common share</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Basic and diluted net loss per common share is calculated as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Three Months Ended </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Three Months Ended </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Numerator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (31,264)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (37,513)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Denominator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average common shares for basic and diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 58,610,375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 57,051,539</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Basic and diluted net loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_HL6whsV3jke4w_Sl7dO28Q;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (0.53)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_C0N3OWiqdEWJWGpuVY3NnQ;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (0.66)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The Company’s potentially dilutive securities, which include restricted stock, warrants, early exercised stock options and stock options to purchase shares of the Company’s common stock, have been excluded from the computation of dilutive net loss per share as the effect would be antidilutive. Therefore, the weighted- average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential shares of common stock presented based on amounts outstanding at each stated period end, from the computation of diluted net loss per share for the three months ended March 31, 2023 and 2022 because including them would have had an anti-dilutive effect.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.041217804%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.54%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:15.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Three Months Ended </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:15.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Three Months Ended </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:middle;white-space:nowrap;width:15.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:middle;white-space:nowrap;width:15.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stock options to purchase common stock </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,370,402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,424,538</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Early exercised stock options subject to future vesting </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 385,655</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 773,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted stock award subject to future vesting </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 49,465</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 520,630</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 544,650</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 32,009</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 32,009</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,382,181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,750,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Three Months Ended </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Three Months Ended </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, </p></td><td style="vertical-align:middle;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Numerator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (31,264)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (37,513)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Denominator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average common shares for basic and diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 58,610,375</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 57,051,539</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Basic and diluted net loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_HL6whsV3jke4w_Sl7dO28Q;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (0.53)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_C0N3OWiqdEWJWGpuVY3NnQ;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (0.66)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> -31264000 -37513000 58610375 57051539 -0.53 -0.66 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.041217804%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.54%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:15.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Three Months Ended </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:15.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Three Months Ended </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:middle;white-space:nowrap;width:15.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:middle;white-space:nowrap;width:15.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Stock options to purchase common stock </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,370,402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,424,538</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Early exercised stock options subject to future vesting </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 385,655</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 773,394</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Restricted stock award subject to future vesting </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 49,465</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 520,630</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 544,650</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 32,009</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 32,009</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,382,181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,750,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 10370402 7424538 385655 773394 49465 520630 544650 32009 32009 11382181 8750571 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Note 15—Defined contribution plan</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The Company has a 401(k) Employee Savings Plan (“401(k) Plan”) that is available to all employees of the Company. The Company has elected a Safe-Harbor provision for the 401(k) Plan in which participants are always fully vested in their employer contributions. The Company matches 100% of the first 3% of participating employee contributions and 50% of the next 2% of participating employee contributions. Contributions are made in cash. Contributions were approximately $384 and $158 for the three months ended March 31, 2023 and 2022, respectively. Such contribution expense has been recognized in the consolidated statement of operations for each period.</p> 1 0.03 0.50 0.02 384000 158000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Note 16—Stock-based compensation</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On June 17, 2021, the Company adopted the Century Therapeutics, Inc. 2021 Equity Incentive Plan (the “2021 Incentive Plan”) which superseded the 2018 Incentive Plan and from that date forward all issuances of incentive awards will be governed by the 2021 Incentive Plan.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The 2021 Incentive Plan provides for the Company to sell or issue common stock or restricted common stock, restricted stock units (“RSU”), or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the Board of Directors, and consultants of the Company under terms and provisions established by the Board of Directors. Under the terms of the 2021 Incentive Plan, options may be granted at an exercise price not less than fair market value. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Upon adoption of the 2021 Incentive Plan, the Company was authorized to issue 5,481,735 shares of Common Stock under the 2021 Incentive Plan (which represents 5,640,711 shares of Common Stock initially available for grant under the 2021 Incentive Plan less 158,976 shares of Common Stock reserved for issuance upon the exercise of previously granted stock options that remain outstanding under the 2018 Incentive Plan). The number of shares of common stock initially reserved for issuance under the 2021 Incentive Plan shall be increased, upon approval by the board of directors, on January 1, 2022 and each January 1 thereafter, in an amount equal to the least of, (i) five percent (5%)<span style="white-space:pre-wrap;"> of the outstanding common stock on the immediately preceding December 31, or (ii) such number of common stock determined by the board of directors no later than the immediately preceding December 31. For 2022, the 2021 Incentive Plan reserved shares were increased under clause (i) by </span>2,750,276 shares, effective as of January 1, 2022. For 2023, the 2021 Incentive Plan reserved shares were increased under clause (i) by 2,954,788 shares, effective as of January 1, 2023. As of March 31, 2023, there were 4,863,670 shares available for issuance under the 2021 Incentive Plan.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company’s stock-based awards are subject to service-based vesting conditions. Compensation expense related to awards to employees and directors with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Stock awards granted typically vest over a four-year<span style="white-space:pre-wrap;"> period but may be granted with different vesting terms. The Company may also issue awards with performance-based vesting conditions. For performance-based awards, the Company would reassess at each reporting date whether achievement of the performance condition is probable and accrue compensation expense if and when the achievement of the performance condition is probable.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company recognizes the costs of the stock-based payments as the employees vest in the awards.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of March 31, 2023, the Company had reserved shares of common stock for issuance as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:18.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">    </span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Shares</p></td></tr><tr><td style="vertical-align:bottom;width:78.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Options and RSUs issued and outstanding</p></td><td style="vertical-align:bottom;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,915,052</p></td></tr><tr><td style="vertical-align:bottom;width:78.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Shares available for future stock option and RSU grants</p></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,863,670</p></td></tr><tr><td style="vertical-align:bottom;width:78.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Shares available for employee stock purchase plan</p></td><td style="vertical-align:bottom;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,114,126</p></td></tr><tr><td style="vertical-align:bottom;width:78.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,892,848</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The shares of Common Stock available under the 2021 Incentive Plan as of March 31, 2023 are as follows</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:18.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">    </span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Shares</p></td></tr><tr><td style="vertical-align:bottom;width:78.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance, December 31, 2022</b></p></td><td style="vertical-align:bottom;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,786,358</p></td></tr><tr><td style="vertical-align:bottom;width:78.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Shares reserved for issuance</p></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,954,788</p></td></tr><tr><td style="vertical-align:bottom;width:78.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Options granted</p></td><td style="vertical-align:bottom;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (3,770,399)</p></td></tr><tr><td style="vertical-align:bottom;width:78.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">RSU’s granted</p></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (546,795)</p></td></tr><tr><td style="vertical-align:bottom;width:78.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Options and RSUs forfeited / cancelled</p></td><td style="vertical-align:bottom;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 439,718</p></td></tr><tr><td style="vertical-align:bottom;width:78.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance March 31, 2023</b></p></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,863,670</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Stock Options</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The following table summarizes stock option activity for the three month period ended March 31, 2023:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.82%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Weighted Average </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Remaining</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Aggregate</p></td></tr><tr><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Contractual</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Intrinsic</p></td></tr><tr><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Value</p></td></tr><tr><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:middle;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Exercise Price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:middle;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">(years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">(in thousands)</p></td></tr><tr><td style="vertical-align:bottom;width:52.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Outstanding January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,489,678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,991</p></td></tr><tr><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,770,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:52.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (452,102)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (437,573)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:52.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding, March 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,370,402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">4.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,952</p></td></tr><tr><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exercisable at March 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,145,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,262</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The weighted average grant date fair value of awards for options granted during the three months ended March 31, 2023 was $4.65. As of March 31, 2023, there was $38,428 of total unrecognized compensation expense related to unvested stock options with time-based vesting terms, which is expected to be recognized over a weighted average period of 3.13 years.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The Company estimates the fair value of its option awards to employees and directors using Black-Scholes. Due to the lack of substantial company-specific historical and implied volatility data of its common stock, the Company has based its estimate of expected volatility on the historical volatility of a group of similar public </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">companies. The Company has never paid dividends and does not expect to in the foreseeable future. The expected term of the options granted to employees is derived from the “simplified” method as described in Staff Accounting Bulletin 107 relating to stock-based compensation. The risk-free interest rates for periods within the expected term of the option are based on the U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The Company will account for actual forfeitures as they occur.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The weighted-average assumptions used to calculate the fair value of stock options granted are as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected dividend rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected option term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 79.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 69.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;">Stock-based compensation expense recorded under ASC 718 related to stock options granted and common stock issued under the 2021 Employee Stock Purchase Plan (the “ESPP”) were allocated to research and development and general and administrative expense as follows:</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:69.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Three Months Ended </p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Three Months Ended </p></td></tr><tr><td style="vertical-align:middle;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 31, </p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 31, </p></td></tr><tr><td style="vertical-align:middle;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2022</p></td></tr><tr><td style="vertical-align:middle;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,112</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,309</p></td></tr><tr><td style="vertical-align:middle;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,685</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,071</p></td></tr><tr><td style="vertical-align:middle;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total stock-based compensation</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,797</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,380</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;background:#ffff00;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Stock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:69.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Three Months Ended </p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Three Months Ended </p></td></tr><tr><td style="vertical-align:middle;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 31, </p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 31, </p></td></tr><tr><td style="vertical-align:middle;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2022</p></td></tr><tr><td style="vertical-align:middle;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,546</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,108</p></td></tr><tr><td style="vertical-align:middle;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 97</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:middle;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock awards</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 93</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 272</p></td></tr><tr><td style="vertical-align:middle;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee stock purchase plan</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 61</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:middle;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total stock-based compensation</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,797</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,380</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;background:#ffff00;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Restricted Stock Units</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The following table summarizes RSU activity for the quarter ended March 31, 2023:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Weighted Average</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:16.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Grant Date Fair Value</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Unvested December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 546,795</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.64</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,145)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.64</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Unvested March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 544,650</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.64</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of March 31, 2023, there was $2,428 of total unrecognized compensation expense related to the unvested restricted stock with time-based vesting terms, which is expected to be recognized over a weighted average period of 3.85 years. All restricted stock units vest over a four-year period.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Restricted Stock Awards</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The following table summarizes restricted stock activity as of March 31, 2023 and December 31, 2022:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.35%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:16.55%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Weighted Average</p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Shares</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:16.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Grant Date Fair Value</p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total Unvested December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 193,031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8.41</p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (47,689)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (95,877)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2.50</p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total Unvested March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 49,465</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.27</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Pursuant to certain stock purchase agreements containing vesting and other provisions, the Company has the right to repurchase unvested shares.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As of March 31, 2023, there was $356 of total unrecognized compensation expense related to the unvested restricted stock with time-based vesting terms, which is expected to be recognized over a weighted average period of 1.98 years. All restricted stock vests over a <span style="-sec-ix-hidden:Hidden_7vX1pmn4MUOkHL6CNZgmrw;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">four-year</span></span> period.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Early-Exercise of Unvested Equity Awards</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Certain equity award holders early exercised unvested equity awards. The cash received upon early exercise of options of $1,314 was recorded as a deposit liability on the Company’s balance sheet as of March 31, 2023.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Employee Stock Purchase Plan</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The ESPP was adopted by the Board of Directors in May 2021. A total of 564,071 shares of common stock were initially reserved for issuance under this plan, which shall be increased, upon approval by the board of directors, on January 1, 2022 and each January 1 thereafter, to the lesser of (i) one percent (1%) of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (ii) an amount determined by the board of directors no later than the last day of the immediately preceding fiscal year. For 2022, the ESPP reserved shares were increased under clause (i) by 550,055<span style="white-space:pre-wrap;"> shares, effective as of January 1, 2022. For 2023, the board waived the annual increase to the shares reserved under the ESPP. As of March 31, 2023, there were </span>1,114,126 shares available for issuance, under the ESPP.</p> 5481735 5640711 158976 -0.05 2750276 2750276 2954788 4863670 P4Y <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:18.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">    </span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Shares</p></td></tr><tr><td style="vertical-align:bottom;width:78.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Options and RSUs issued and outstanding</p></td><td style="vertical-align:bottom;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,915,052</p></td></tr><tr><td style="vertical-align:bottom;width:78.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Shares available for future stock option and RSU grants</p></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,863,670</p></td></tr><tr><td style="vertical-align:bottom;width:78.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Shares available for employee stock purchase plan</p></td><td style="vertical-align:bottom;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,114,126</p></td></tr><tr><td style="vertical-align:bottom;width:78.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,892,848</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p> 10915052 4863670 1114126 16892848 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:18.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">    </span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Shares</p></td></tr><tr><td style="vertical-align:bottom;width:78.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance, December 31, 2022</b></p></td><td style="vertical-align:bottom;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,786,358</p></td></tr><tr><td style="vertical-align:bottom;width:78.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Shares reserved for issuance</p></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,954,788</p></td></tr><tr><td style="vertical-align:bottom;width:78.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Options granted</p></td><td style="vertical-align:bottom;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (3,770,399)</p></td></tr><tr><td style="vertical-align:bottom;width:78.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">RSU’s granted</p></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (546,795)</p></td></tr><tr><td style="vertical-align:bottom;width:78.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Options and RSUs forfeited / cancelled</p></td><td style="vertical-align:bottom;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 439,718</p></td></tr><tr><td style="vertical-align:bottom;width:78.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance March 31, 2023</b></p></td><td style="vertical-align:bottom;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,863,670</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p> 5786358 2954788 3770399 546795 439718 4863670 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.82%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Weighted Average </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Remaining</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Aggregate</p></td></tr><tr><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Contractual</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Intrinsic</p></td></tr><tr><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Value</p></td></tr><tr><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:middle;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Exercise Price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:middle;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">(years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">(in thousands)</p></td></tr><tr><td style="vertical-align:bottom;width:52.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Outstanding January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,489,678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,991</p></td></tr><tr><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,770,399</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:52.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (452,102)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 0.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (437,573)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:52.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding, March 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,370,402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">4.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,952</p></td></tr><tr><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exercisable at March 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,145,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,262</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 7489678 7.77 P7Y10M2D 8991000 3770399 4.66 452102 0.99 437573 10.39 10370402 5.28 P4Y6M18D 3952000 3145362 6.45 P6Y11M4D 3262000 4.65 38428000 P3Y1M17D <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">March 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected dividend rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected option term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 79.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 69.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.87%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.44%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1.08</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> P6Y29D P6Y1M2D 0.7915 0.6973 0.0365 0.0108 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:69.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Three Months Ended </p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Three Months Ended </p></td></tr><tr><td style="vertical-align:middle;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 31, </p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 31, </p></td></tr><tr><td style="vertical-align:middle;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2022</p></td></tr><tr><td style="vertical-align:middle;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,112</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,309</p></td></tr><tr><td style="vertical-align:middle;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,685</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,071</p></td></tr><tr><td style="vertical-align:middle;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total stock-based compensation</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,797</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,380</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;background:#ffff00;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Stock-based compensation expense by award type included within the condensed consolidated statements of operations is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:69.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Three Months Ended </p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Three Months Ended </p></td></tr><tr><td style="vertical-align:middle;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 31, </p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.4%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 31, </p></td></tr><tr><td style="vertical-align:middle;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2022</p></td></tr><tr><td style="vertical-align:middle;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,546</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,108</p></td></tr><tr><td style="vertical-align:middle;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 97</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:middle;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock awards</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 93</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 272</p></td></tr><tr><td style="vertical-align:middle;width:69.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee stock purchase plan</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 61</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:middle;width:69.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total stock-based compensation</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,797</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,380</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;background:#ffff00;">​</span></p> 2112000 1309000 1685000 1071000 3797000 2380000 3546000 2108000 97000 93000 272000 61000 3797000 2380000 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:16.04%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Weighted Average</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:16.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Grant Date Fair Value</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Unvested December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 546,795</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.64</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,145)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.64</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Unvested March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 544,650</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.64</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">​</span></p> 546795 4.64 2145 4.64 544650 4.64 2428000 P3Y10M6D P4Y <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.35%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:16.55%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Weighted Average</p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Shares</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:16.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">Grant Date Fair Value</p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total Unvested December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 193,031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8.41</p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (47,689)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (95,877)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2.50</p></td></tr><tr><td style="vertical-align:bottom;width:68.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total Unvested March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 49,465</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7.27</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 193031 8.41 47689 95877 2.50 49465 7.27 356000 P1Y11M23D 1314000 564071 -0.01 550055 1114126 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">Note 17—Related party transactions</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">License Agreements and Collaborative Agreements with Shareholder</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company owns licenses and other contracts with FUJIFILM Cellular Dynamics, Inc. (“FCDI”). FCDI is a shareholder of Century. The acquired licenses and other contracts with FCDI are as follows:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">FCDI Licenses</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company owns a non-exclusive license agreement with FCDI. The license provides the Company with certain patents and know-how related to the reprogramming of human somatic cells to induce pluripotent stem cells (“iPSCs”) (“License Agreement”). Under this agreement, the Company is required to make certain developmental and regulatory milestone payments as well as royalty payments upon commercialization. Royalties are in the low single digits on the sale of all licensed products.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company also owns an exclusive license agreement with FCDI. The license provides the Company with patents and know-how related to human iPSC exclusively manufactured by FCDI.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The potential development and regulatory milestone payments to be paid by the Company to FCDI are $6,000.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">FCDI Collaboration Agreement</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In October <span style="white-space:pre-wrap;">2019, the Company entered into the Master Collaboration Agreement with FCDI, whereby FCDI will provide certain services to the Company to develop and manufacture iPSCs and immune cells derived therefrom. FCDI will provide services in accordance with the approved research plan and related research budget. The initial research plan covers the period from October 2019 through March 31, 2022. On July 29, 2022 the Company amended it’s Master Collaboration Agreement to extend the term through September 30, 2025.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On March 23, 2021, the Company entered into a Manufacturing Agreement with FCDI, or the Manufacturing Agreement, pursuant to which FCDI will provide certain agreed upon technology transfer, process development, analytical testing and cGMP manufacturing services to the company.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">On January 7, 2022, the Company and FCDI entered into a letter agreement (the “Letter Agreement”), which amends each of the FCDI agreements pursuant to the Company’s Research Collaboration and License Agreement with Bristol-Myers Squibb. Pursuant to the Letter Agreement, and in consideration for amending the FCDI Agreements, the Company will pay to FCDI (i) an upfront payment of </span>$10,000, (ii) a percentage of any milestone payments received by the Company under the FCDI Collaboration Agreement in respect of achievement of development or regulatory milestones specific to Japan, and (iii) a percentage of all royalties received by the Company under the FCDI Collaboration Agreement in respect of sales of products in Japan.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">During the three months ended March 31, 2023, the Company made payments of $12 and incurred research and development expenses of $32 and legal fees of $33, recorded within general and administrative expenses in its consolidated statements of operations and comprehensive loss. As of March 31, 2023, there was $21 in accrued expenses related to this agreement on the consolidated balance sheets. As of December 31, 2022, there was $0 in accrued expenses on the consolidated balance sheets.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">During the three months ended March 31, 2022, the Company made payments of $3,003 and incurred research and development expenses of $1,445, and legal fees of $30, recorded within general and administrative expenses in its consolidated statements of operations and comprehensive loss. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Bayer Option Agreement</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Bayer Health, LLC (“Bayer”) has the right of first refusal to acquire certain products researched and developed by the Company. Subject to certain exceptions, Bayer’s right of first refusal is exercisable with respect to up to four products and may only exercise these option rights in a non-sequential and alternating manner, and such rights are subject to additional limitations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"><i style="white-space:pre-wrap;">Consulting Arrangements with Shareholders </i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In 2019, the Company entered into arrangements with two shareholders of the Company, wherein the shareholders provide consulting services to the Company. As compensation for the consulting services, the shareholders are entitled to an annual retainer fee of $125 payable quarterly, along with payment of reasonable expenses associated with providing the consulting services. The Company incurred $0 related to these consulting arrangements that were included in research and development expenses in the consolidated statements of operations and comprehensive loss for the three  months ended March 31, 2023. The Company incurred $19 related to these consulting arrangements that were included in research and development expenses in the consolidated statements of operations and comprehensive loss for the three months ended March 31, 2022. As of March 31, 2023 and December 31, 2022, there was $0 in accrued </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">expenses related to this agreement on the consolidated balance sheets. This agreement was terminated in January 2023.</span></p> 6000000 10000000 12000 32000 33000 21000 0 3003000 1445000 30000 2 125000 0 19000 0 0 <p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:12pt;">Note 18—Subsequent Events</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">The Company has evaluated subsequent events through the filing of this Quarterly Report on Form 10-Q, and determined that there have been no events that have occurred that would require adjustments to our disclosures in the consolidated financial statements. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:10pt;visibility:hidden;background:#ffffff;">​</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;background:#ffffff;">On May 1, 2023 the Company repaid the Loan Agreement with Hercules in full. The total repayment was </span><span style="background:#ffffff;">$10,617</span><span style="background:#ffffff;">, which included principal, interest, and end of term and prepayment charge.</span></p> 10617000 EXCEL 90 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 91 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 92 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 93 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 160 335 1 false 59 0 false 7 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.centurytx.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.centurytx.com/role/StatementConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) Sheet http://www.centurytx.com/role/StatementConsolidatedBalanceSheetsParentheticals CONSOLIDATED BALANCE SHEETS (Parentheticals) Statements 3 false false R4.htm 00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 4 false false R5.htm 00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Sheet http://www.centurytx.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 10101 - Disclosure - Organization and description of the business Sheet http://www.centurytx.com/role/DisclosureOrganizationAndDescriptionOfBusiness Organization and description of the business Notes 7 false false R8.htm 10201 - Disclosure - Summary of significant accounting policies and basis of presentation Sheet http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation Summary of significant accounting policies and basis of presentation Notes 8 false false R9.htm 10301 - Disclosure - Reduction in force Sheet http://www.centurytx.com/role/DisclosureReductionInForce Reduction in force Notes 9 false false R10.htm 10401 - Disclosure - Asset purchase by Century Therapeutics Canada ULC Sheet http://www.centurytx.com/role/DisclosureAssetPurchaseByCenturyTherapeuticsCanadaUlc Asset purchase by Century Therapeutics Canada ULC Notes 10 false false R11.htm 10501 - Disclosure - Financial instruments and fair value measurements Sheet http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements Financial instruments and fair value measurements Notes 11 false false R12.htm 10601 - Disclosure - Prepaid expenses and other current assets Sheet http://www.centurytx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets Prepaid expenses and other current assets Notes 12 false false R13.htm 10701 - Disclosure - Property and equipment, net Sheet http://www.centurytx.com/role/DisclosurePropertyAndEquipmentNet Property and equipment, net Notes 13 false false R14.htm 10801 - Disclosure - Accrued expenses and other liabilities Sheet http://www.centurytx.com/role/DisclosureAccruedExpensesAndOtherLiabilities Accrued expenses and other liabilities Notes 14 false false R15.htm 10901 - Disclosure - Long-term debt Sheet http://www.centurytx.com/role/DisclosureLongTermDebt Long-term debt Notes 15 false false R16.htm 11001 - Disclosure - Bristol-Myers Squibb Collaboration Sheet http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaboration Bristol-Myers Squibb Collaboration Notes 16 false false R17.htm 11101 - Disclosure - Commitments and Contingencies Sheet http://www.centurytx.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 11201 - Disclosure - Leases Sheet http://www.centurytx.com/role/DisclosureLeases Leases Notes 18 false false R19.htm 11301 - Disclosure - Income taxes Sheet http://www.centurytx.com/role/DisclosureIncomeTaxes Income taxes Notes 19 false false R20.htm 11401 - Disclosure - Basic and diluted net loss per common share Sheet http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShare Basic and diluted net loss per common share Notes 20 false false R21.htm 11501 - Disclosure - Defined contribution plan Sheet http://www.centurytx.com/role/DisclosureDefinedContributionPlan Defined contribution plan Notes 21 false false R22.htm 11601 - Disclosure - Stock based compensation Sheet http://www.centurytx.com/role/DisclosureStockBasedCompensation Stock based compensation Notes 22 false false R23.htm 11701 - Disclosure - Related party transactions Sheet http://www.centurytx.com/role/DisclosureRelatedPartyTransactions Related party transactions Notes 23 false false R24.htm 11801 - Disclosure - Subsequent Events Sheet http://www.centurytx.com/role/DisclosureSubsequentEvents Subsequent Events Notes 24 false false R25.htm 20202 - Disclosure - Summary of significant accounting policies and basis of presentation (Policies) Sheet http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies Summary of significant accounting policies and basis of presentation (Policies) Policies 25 false false R26.htm 30203 - Disclosure - Summary of significant accounting policies and basis of presentation (Tables) Sheet http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationTables Summary of significant accounting policies and basis of presentation (Tables) Tables http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation 26 false false R27.htm 30503 - Disclosure - Financial instruments and fair value measurements (Tables) Sheet http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables Financial instruments and fair value measurements (Tables) Tables http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements 27 false false R28.htm 30603 - Disclosure - Prepaid expenses and other current assets (Tables) Sheet http://www.centurytx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables Prepaid expenses and other current assets (Tables) Tables http://www.centurytx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets 28 false false R29.htm 30703 - Disclosure - Property and equipment, net (Tables) Sheet http://www.centurytx.com/role/DisclosurePropertyAndEquipmentNetTables Property and equipment, net (Tables) Tables http://www.centurytx.com/role/DisclosurePropertyAndEquipmentNet 29 false false R30.htm 30803 - Disclosure - Accrued expenses and other liabilities (Tables) Sheet http://www.centurytx.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesTables Accrued expenses and other liabilities (Tables) Tables http://www.centurytx.com/role/DisclosureAccruedExpensesAndOtherLiabilities 30 false false R31.htm 30903 - Disclosure - Long-term debt (Tables) Sheet http://www.centurytx.com/role/DisclosureLongTermDebtTables Long-term debt (Tables) Tables http://www.centurytx.com/role/DisclosureLongTermDebt 31 false false R32.htm 31003 - Disclosure - Bristol-Myers Squibb Collaboration (Tables) Sheet http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationTables Bristol-Myers Squibb Collaboration (Tables) Tables http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaboration 32 false false R33.htm 31203 - Disclosure - Leases (Tables) Sheet http://www.centurytx.com/role/DisclosureLeasesTables Leases (Tables) Tables http://www.centurytx.com/role/DisclosureLeases 33 false false R34.htm 31403 - Disclosure - Basic and diluted net loss per common share (Tables) Sheet http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareTables Basic and diluted net loss per common share (Tables) Tables http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShare 34 false false R35.htm 31603 - Disclosure - Stock based compensation (Tables) Sheet http://www.centurytx.com/role/DisclosureStockBasedCompensationTables Stock based compensation (Tables) Tables http://www.centurytx.com/role/DisclosureStockBasedCompensation 35 false false R36.htm 40101 - Disclosure - Organization and description of the business - Going concern and liquidity (Details) Sheet http://www.centurytx.com/role/DisclosureOrganizationAndDescriptionOfBusinessGoingConcernAndLiquidityDetails Organization and description of the business - Going concern and liquidity (Details) Details 36 false false R37.htm 40201 - Disclosure - Summary of significant accounting policies and basis of presentation (Details) Sheet http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationDetails Summary of significant accounting policies and basis of presentation (Details) Details http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationTables 37 false false R38.htm 40202 - Disclosure - Summary of significant accounting policies and basis of presentation - Restricted cash (Details) Sheet http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationRestrictedCashDetails Summary of significant accounting policies and basis of presentation - Restricted cash (Details) Details 38 false false R39.htm 40203 - Disclosure - Summary of significant accounting policies and basis of presentation - Property and equipment and Stock-based compensation (Details) Sheet http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPropertyAndEquipmentAndStockBasedCompensationDetails Summary of significant accounting policies and basis of presentation - Property and equipment and Stock-based compensation (Details) Details 39 false false R40.htm 40204 - Disclosure - Summary of significant accounting policies and basis of presentation - Early exercised options (Details) Sheet http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationEarlyExercisedOptionsDetails Summary of significant accounting policies and basis of presentation - Early exercised options (Details) Details 40 false false R41.htm 40205 - Disclosure - Summary of significant accounting policies and basis of presentation - Income taxes (Details) Sheet http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationIncomeTaxesDetails Summary of significant accounting policies and basis of presentation - Income taxes (Details) Details http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationTables 41 false false R42.htm 40301 - Disclosure - Reduction in force (Details) Sheet http://www.centurytx.com/role/DisclosureReductionInForceDetails Reduction in force (Details) Details http://www.centurytx.com/role/DisclosureReductionInForce 42 false false R43.htm 40401 - Disclosure - Asset purchase by Century Therapeutics Canada ULC (Details) Sheet http://www.centurytx.com/role/DisclosureAssetPurchaseByCenturyTherapeuticsCanadaUlcDetails Asset purchase by Century Therapeutics Canada ULC (Details) Details http://www.centurytx.com/role/DisclosureAssetPurchaseByCenturyTherapeuticsCanadaUlc 43 false false R44.htm 40501 - Disclosure - Financial instruments and fair value measurements - Assets measured at fair value (Details) Sheet http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAssetsMeasuredAtFairValueDetails Financial instruments and fair value measurements - Assets measured at fair value (Details) Details 44 false false R45.htm 40502 - Disclosure - Financial instruments and fair value measurements - Transfers between levels (Details) Sheet http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTransfersBetweenLevelsDetails Financial instruments and fair value measurements - Transfers between levels (Details) Details 45 false false R46.htm 40503 - Disclosure - Financial instruments and fair value measurements - Investments in fixed maturity securities (Details) Sheet http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsInvestmentsInFixedMaturitySecuritiesDetails Financial instruments and fair value measurements - Investments in fixed maturity securities (Details) Details 46 false false R47.htm 40504 - Disclosure - Financial instruments and fair value measurements - Maturities of fixed maturity available-for-sale securities (Details) Sheet http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsMaturitiesOfFixedMaturityAvailableForSaleSecuritiesDetails Financial instruments and fair value measurements - Maturities of fixed maturity available-for-sale securities (Details) Details 47 false false R48.htm 40601 - Disclosure - Prepaid expenses and other current assets - Summary of prepaid expenses and other current assets (Details) Sheet http://www.centurytx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails Prepaid expenses and other current assets - Summary of prepaid expenses and other current assets (Details) Details 48 false false R49.htm 40701 - Disclosure - Property and equipment, net (Details) Sheet http://www.centurytx.com/role/DisclosurePropertyAndEquipmentNetDetails Property and equipment, net (Details) Details http://www.centurytx.com/role/DisclosurePropertyAndEquipmentNetTables 49 false false R50.htm 40801 - Disclosure - Accrued expenses and other liabilities - Summary of accrued expenses (Details) Sheet http://www.centurytx.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesSummaryOfAccruedExpensesDetails Accrued expenses and other liabilities - Summary of accrued expenses (Details) Details 50 false false R51.htm 40901 - Disclosure - Long-term debt (Details) Sheet http://www.centurytx.com/role/DisclosureLongTermDebtDetails Long-term debt (Details) Details http://www.centurytx.com/role/DisclosureLongTermDebtTables 51 false false R52.htm 40902 - Disclosure - Long-term debt - Term Loan Agreement (Details) Sheet http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails Long-term debt - Term Loan Agreement (Details) Details 52 false false R53.htm 40903 - Disclosure - Long-term debt - Interest Expenses (Details) Sheet http://www.centurytx.com/role/DisclosureLongTermDebtInterestExpensesDetails Long-term debt - Interest Expenses (Details) Details 53 false false R54.htm 40904 - Disclosure - Long-term debt - Future principal payments due (Details) Sheet http://www.centurytx.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDueDetails Long-term debt - Future principal payments due (Details) Details 54 false false R55.htm 41001 - Disclosure - Bristol-Myers Squibb Collaboration (Details) Sheet http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationDetails Bristol-Myers Squibb Collaboration (Details) Details http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationTables 55 false false R56.htm 41002 - Disclosure - Bristol-Myers Squibb Collaboration - Total transaction price (Details) Sheet http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationTotalTransactionPriceDetails Bristol-Myers Squibb Collaboration - Total transaction price (Details) Details 56 false false R57.htm 41101 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.centurytx.com/role/DisclosureCommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.centurytx.com/role/DisclosureCommitmentsAndContingencies 57 false false R58.htm 41201 - Disclosure - Leases - Components of lease expenses (Details) Sheet http://www.centurytx.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails Leases - Components of lease expenses (Details) Details 58 false false R59.htm 41202 - Disclosure - Leases - Other information (Details) Sheet http://www.centurytx.com/role/DisclosureLeasesOtherInformationDetails Leases - Other information (Details) Details 59 false false R60.htm 41203 - Disclosure - Leases - Operating lease - Other information (Details) Sheet http://www.centurytx.com/role/DisclosureLeasesOperatingLeaseOtherInformationDetails Leases - Operating lease - Other information (Details) Details 60 false false R61.htm 41204 - Disclosure - Leases - Supplemental cash flow information (Details) Sheet http://www.centurytx.com/role/DisclosureLeasesSupplementalCashFlowInformationDetails Leases - Supplemental cash flow information (Details) Details 61 false false R62.htm 41205 - Disclosure - Leases - Future minimum lease payments (Details) Sheet http://www.centurytx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails Leases - Future minimum lease payments (Details) Details 62 false false R63.htm 41301 - Disclosure - Income taxes (Details) Sheet http://www.centurytx.com/role/DisclosureIncomeTaxesDetails Income taxes (Details) Details http://www.centurytx.com/role/DisclosureIncomeTaxes 63 false false R64.htm 41401 - Disclosure - Basic and diluted net loss per common share (Details) Sheet http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareDetails Basic and diluted net loss per common share (Details) Details http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareTables 64 false false R65.htm 41402 - Disclosure - Basic and diluted net loss per common share - Schedule of potential shares of common stock excluded from computation (Details) Sheet http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareScheduleOfPotentialSharesOfCommonStockExcludedFromComputationDetails Basic and diluted net loss per common share - Schedule of potential shares of common stock excluded from computation (Details) Details 65 false false R66.htm 41501 - Disclosure - Defined contribution plan (Details) Sheet http://www.centurytx.com/role/DisclosureDefinedContributionPlanDetails Defined contribution plan (Details) Details http://www.centurytx.com/role/DisclosureDefinedContributionPlan 66 false false R67.htm 41601 - Disclosure - Stock based compensation (Details) Sheet http://www.centurytx.com/role/DisclosureStockBasedCompensationDetails Stock based compensation (Details) Details http://www.centurytx.com/role/DisclosureStockBasedCompensationTables 67 false false R68.htm 41602 - Disclosure - Stock based compensation - Reserved shares of common stock (Details) Sheet http://www.centurytx.com/role/DisclosureStockBasedCompensationReservedSharesOfCommonStockDetails Stock based compensation - Reserved shares of common stock (Details) Details 68 false false R69.htm 41603 - Disclosure - Stock based compensation - Common stock available under 2021 Incentive Plan (Details) Sheet http://www.centurytx.com/role/DisclosureStockBasedCompensationCommonStockAvailableUnder2021IncentivePlanDetails Stock based compensation - Common stock available under 2021 Incentive Plan (Details) Details 69 false false R70.htm 41604 - Disclosure - Stock based compensation - Stock option activity (Details) Sheet http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails Stock based compensation - Stock option activity (Details) Details 70 false false R71.htm 41605 - Disclosure - Stock based compensation - Stock option weighted-average assumptions (Details) Sheet http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionWeightedAverageAssumptionsDetails Stock based compensation - Stock option weighted-average assumptions (Details) Details 71 false false R72.htm 41606 - Disclosure - Stock based compensation - Stock-based compensation expense and by award type (Details) Sheet http://www.centurytx.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseAndByAwardTypeDetails Stock based compensation - Stock-based compensation expense and by award type (Details) Details 72 false false R73.htm 41607 - Disclosure - Stock based compensation - Restricted stock (Details) Sheet http://www.centurytx.com/role/DisclosureStockBasedCompensationRestrictedStockDetails Stock based compensation - Restricted stock (Details) Details 73 false false R74.htm 41608 - Disclosure - Stock based compensation - Employee Stock Purchase Plan (Details) Sheet http://www.centurytx.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails Stock based compensation - Employee Stock Purchase Plan (Details) Details 74 false false R75.htm 41701 - Disclosure - Related party transactions (Details) Sheet http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails Related party transactions (Details) Details http://www.centurytx.com/role/DisclosureRelatedPartyTransactions 75 false false R76.htm 41801 - Disclosure - Subsequent Events (Details) Sheet http://www.centurytx.com/role/DisclosureSubsequentEventsDetails Subsequent Events (Details) Details http://www.centurytx.com/role/DisclosureSubsequentEvents 76 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept ResearchAndDevelopmentInProcess in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. ipsc-20230331x10q.htm 15 [dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrentAndNoncurrent in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. ipsc-20230331x10q.htm 38 [dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrent in us-gaap/2022 used in 3 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. ipsc-20230331x10q.htm 38 [dq-0542-Deprecated-Concept] Concept AccountsPayableRelatedPartiesCurrent in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. ipsc-20230331x10q.htm 38 [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 17 fact(s) appearing in ix:hidden were eligible for transformation: ipsc:FairValueAssetsLevel2ToLevel1TransfersAmountOne, ipsc:TerminationOfRoyaltyTerm, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:DepositsAssetsNoncurrent, us-gaap:EarningsPerShareDiluted, us-gaap:LessorOperatingLeaseTermOfContract, us-gaap:PreferredStockSharesOutstanding, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding - ipsc-20230331x10q.htm 9 [ix-0514-Hidden-Fact-Not-Referenced] WARN: 3 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies, us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList - ipsc-20230331x10q.htm 9 ipsc-20230331x10q.htm ipsc-20230331.xsd ipsc-20230331_cal.xml ipsc-20230331_def.xml ipsc-20230331_lab.xml ipsc-20230331_pre.xml ipsc-20230331xex10d1.htm ipsc-20230331xex10d2.htm ipsc-20230331xex31d1.htm ipsc-20230331xex31d2.htm ipsc-20230331xex32d1.htm ipsc-20230331xex32d2.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 96 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ipsc-20230331x10q.htm": { "axisCustom": 0, "axisStandard": 24, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 576, "http://xbrl.sec.gov/dei/2022": 30 }, "contextCount": 160, "dts": { "calculationLink": { "local": [ "ipsc-20230331_cal.xml" ] }, "definitionLink": { "local": [ "ipsc-20230331_def.xml" ] }, "inline": { "local": [ "ipsc-20230331x10q.htm" ] }, "labelLink": { "local": [ "ipsc-20230331_lab.xml" ] }, "presentationLink": { "local": [ "ipsc-20230331_pre.xml" ] }, "schema": { "local": [ "ipsc-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 526, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 21, "http://www.centurytx.com/20230331": 2, "http://xbrl.sec.gov/dei/2022": 5, "total": 28 }, "keyCustom": 61, "keyStandard": 274, "memberCustom": 28, "memberStandard": 29, "nsprefix": "ipsc", "nsuri": "http://www.centurytx.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AssetAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Asset purchase by Century Therapeutics Canada ULC", "menuCat": "Notes", "order": "10", "role": "http://www.centurytx.com/role/DisclosureAssetPurchaseByCenturyTherapeuticsCanadaUlc", "shortName": "Asset purchase by Century Therapeutics Canada ULC", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AssetAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Financial instruments and fair value measurements", "menuCat": "Notes", "order": "11", "role": "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements", "shortName": "Financial instruments and fair value measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "ipsc:PrepaidExpenseAndOtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Prepaid expenses and other current assets", "menuCat": "Notes", "order": "12", "role": "http://www.centurytx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets", "shortName": "Prepaid expenses and other current assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "ipsc:PrepaidExpenseAndOtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Property and equipment, net", "menuCat": "Notes", "order": "13", "role": "http://www.centurytx.com/role/DisclosurePropertyAndEquipmentNet", "shortName": "Property and equipment, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Accrued expenses and other liabilities", "menuCat": "Notes", "order": "14", "role": "http://www.centurytx.com/role/DisclosureAccruedExpensesAndOtherLiabilities", "shortName": "Accrued expenses and other liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Long-term debt", "menuCat": "Notes", "order": "15", "role": "http://www.centurytx.com/role/DisclosureLongTermDebt", "shortName": "Long-term debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Bristol-Myers Squibb Collaboration", "menuCat": "Notes", "order": "16", "role": "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaboration", "shortName": "Bristol-Myers Squibb Collaboration", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "17", "role": "http://www.centurytx.com/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - Leases", "menuCat": "Notes", "order": "18", "role": "http://www.centurytx.com/role/DisclosureLeases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - Income taxes", "menuCat": "Notes", "order": "19", "role": "http://www.centurytx.com/role/DisclosureIncomeTaxes", "shortName": "Income taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "lang": null, "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11401 - Disclosure - Basic and diluted net loss per common share", "menuCat": "Notes", "order": "20", "role": "http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShare", "shortName": "Basic and diluted net loss per common share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11501 - Disclosure - Defined contribution plan", "menuCat": "Notes", "order": "21", "role": "http://www.centurytx.com/role/DisclosureDefinedContributionPlan", "shortName": "Defined contribution plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11601 - Disclosure - Stock based compensation", "menuCat": "Notes", "order": "22", "role": "http://www.centurytx.com/role/DisclosureStockBasedCompensation", "shortName": "Stock based compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11701 - Disclosure - Related party transactions", "menuCat": "Notes", "order": "23", "role": "http://www.centurytx.com/role/DisclosureRelatedPartyTransactions", "shortName": "Related party transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11801 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "24", "role": "http://www.centurytx.com/role/DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20202 - Disclosure - Summary of significant accounting policies and basis of presentation (Policies)", "menuCat": "Policies", "order": "25", "role": "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies", "shortName": "Summary of significant accounting policies and basis of presentation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30203 - Disclosure - Summary of significant accounting policies and basis of presentation (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationTables", "shortName": "Summary of significant accounting policies and basis of presentation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Financial instruments and fair value measurements (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables", "shortName": "Financial instruments and fair value measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ipsc:PrepaidExpenseAndOtherCurrentAssetsTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "ipsc:PrepaidAndOtherCurrentAssetsDisclosureTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - Prepaid expenses and other current assets (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.centurytx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables", "shortName": "Prepaid expenses and other current assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ipsc:PrepaidExpenseAndOtherCurrentAssetsTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "ipsc:PrepaidAndOtherCurrentAssetsDisclosureTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - Property and equipment, net (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.centurytx.com/role/DisclosurePropertyAndEquipmentNetTables", "shortName": "Property and equipment, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_-w5ZispvCU6gFoXIOKgppw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)", "menuCat": "Statements", "order": "3", "role": "http://www.centurytx.com/role/StatementConsolidatedBalanceSheetsParentheticals", "shortName": "CONSOLIDATED BALANCE SHEETS (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_-w5ZispvCU6gFoXIOKgppw", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30803 - Disclosure - Accrued expenses and other liabilities (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.centurytx.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesTables", "shortName": "Accrued expenses and other liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - Long-term debt (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.centurytx.com/role/DisclosureLongTermDebtTables", "shortName": "Long-term debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "ipsc:TotalTransactionPriceToIdentifiedPerformanceObligationsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31003 - Disclosure - Bristol-Myers Squibb Collaboration (Tables)", "menuCat": "Tables", "order": "32", "role": "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationTables", "shortName": "Bristol-Myers Squibb Collaboration (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "ipsc:TotalTransactionPriceToIdentifiedPerformanceObligationsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31203 - Disclosure - Leases (Tables)", "menuCat": "Tables", "order": "33", "role": "http://www.centurytx.com/role/DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31403 - Disclosure - Basic and diluted net loss per common share (Tables)", "menuCat": "Tables", "order": "34", "role": "http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareTables", "shortName": "Basic and diluted net loss per common share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "ipsc:ShareBasedPaymentArrangementSharesReservedForIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31603 - Disclosure - Stock based compensation (Tables)", "menuCat": "Tables", "order": "35", "role": "http://www.centurytx.com/role/DisclosureStockBasedCompensationTables", "shortName": "Stock based compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "ipsc:ShareBasedPaymentArrangementSharesReservedForIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - Organization and description of the business - Going concern and liquidity (Details)", "menuCat": "Details", "order": "36", "role": "http://www.centurytx.com/role/DisclosureOrganizationAndDescriptionOfBusinessGoingConcernAndLiquidityDetails", "shortName": "Organization and description of the business - Going concern and liquidity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "lang": null, "name": "ipsc:CashAndCashEquivalentsShortAndLongTermInvestments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_segment_G2DOoklEHkiEuEk-8AcbHg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - Summary of significant accounting policies and basis of presentation (Details)", "menuCat": "Details", "order": "37", "role": "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationDetails", "shortName": "Summary of significant accounting policies and basis of presentation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_segment_G2DOoklEHkiEuEk-8AcbHg", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestrictedCashNoncurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40202 - Disclosure - Summary of significant accounting policies and basis of presentation - Restricted cash (Details)", "menuCat": "Details", "order": "38", "role": "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationRestrictedCashDetails", "shortName": "Summary of significant accounting policies and basis of presentation - Restricted cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "lang": null, "name": "us-gaap:RestrictedCash", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40203 - Disclosure - Summary of significant accounting policies and basis of presentation - Property and equipment and Stock-based compensation (Details)", "menuCat": "Details", "order": "39", "role": "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPropertyAndEquipmentAndStockBasedCompensationDetails", "shortName": "Summary of significant accounting policies and basis of presentation - Property and equipment and Stock-based compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "menuCat": "Statements", "order": "4", "role": "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeStockOwnershipPlanESOPFairValueOfSharesSubjectToRepurchaseObligation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40204 - Disclosure - Summary of significant accounting policies and basis of presentation - Early exercised options (Details)", "menuCat": "Details", "order": "40", "role": "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationEarlyExercisedOptionsDetails", "shortName": "Summary of significant accounting policies and basis of presentation - Early exercised options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeStockOwnershipPlanESOPFairValueOfSharesSubjectToRepurchaseObligation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40205 - Disclosure - Summary of significant accounting policies and basis of presentation - Income taxes (Details)", "menuCat": "Details", "order": "41", "role": "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationIncomeTaxesDetails", "shortName": "Summary of significant accounting policies and basis of presentation - Income taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_3e3lnXvieUKSbgkuELUQ-A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsForRestructuring", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Reduction in force (Details)", "menuCat": "Details", "order": "42", "role": "http://www.centurytx.com/role/DisclosureReductionInForceDetails", "shortName": "Reduction in force (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember_3e3lnXvieUKSbgkuELUQ-A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsForRestructuring", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "us-gaap:AssetAcquisitionTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_6_9_2020_To_6_9_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_TypeOfArrangementAxis_ipsc_EmpiricaAgreementMember_qsjpjdrkPEysji5hFmcHpQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Asset purchase by Century Therapeutics Canada ULC (Details)", "menuCat": "Details", "order": "43", "role": "http://www.centurytx.com/role/DisclosureAssetPurchaseByCenturyTherapeuticsCanadaUlcDetails", "shortName": "Asset purchase by Century Therapeutics Canada ULC (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:AssetAcquisitionTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_6_9_2020_To_6_9_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_TypeOfArrangementAxis_ipsc_EmpiricaAgreementMember_qsjpjdrkPEysji5hFmcHpQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Financial instruments and fair value measurements - Assets measured at fair value (Details)", "menuCat": "Details", "order": "44", "role": "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAssetsMeasuredAtFairValueDetails", "shortName": "Financial instruments and fair value measurements - Assets measured at fair value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "first": true, "lang": null, "name": "ipsc:FairValueAssetsLevel1ToLevel2TransfersAmountOne", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40502 - Disclosure - Financial instruments and fair value measurements - Transfers between levels (Details)", "menuCat": "Details", "order": "45", "role": "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTransfersBetweenLevelsDetails", "shortName": "Financial instruments and fair value measurements - Transfers between levels (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "first": true, "lang": null, "name": "ipsc:FairValueAssetsLevel1ToLevel2TransfersAmountOne", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40503 - Disclosure - Financial instruments and fair value measurements - Investments in fixed maturity securities (Details)", "menuCat": "Details", "order": "46", "role": "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsInvestmentsInFixedMaturitySecuritiesDetails", "shortName": "Financial instruments and fair value measurements - Investments in fixed maturity securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40504 - Disclosure - Financial instruments and fair value measurements - Maturities of fixed maturity available-for-sale securities (Details)", "menuCat": "Details", "order": "47", "role": "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsMaturitiesOfFixedMaturityAvailableForSaleSecuritiesDetails", "shortName": "Financial instruments and fair value measurements - Maturities of fixed maturity available-for-sale securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ipsc:PrepaidAndOtherCurrentAssetsDisclosureTableTextBlock", "ipsc:PrepaidExpenseAndOtherCurrentAssetsTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_12_31_2022_JDWKm09os0OxxoeVORlkkQ", "decimals": "-3", "first": true, "lang": null, "name": "ipsc:PrepaidResearchAndDevelopment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Prepaid expenses and other current assets - Summary of prepaid expenses and other current assets (Details)", "menuCat": "Details", "order": "48", "role": "http://www.centurytx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails", "shortName": "Prepaid expenses and other current assets - Summary of prepaid expenses and other current assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ipsc:PrepaidAndOtherCurrentAssetsDisclosureTableTextBlock", "ipsc:PrepaidExpenseAndOtherCurrentAssetsTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_12_31_2022_JDWKm09os0OxxoeVORlkkQ", "decimals": "-3", "first": true, "lang": null, "name": "ipsc:PrepaidResearchAndDevelopment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Property and equipment, net (Details)", "menuCat": "Details", "order": "49", "role": "http://www.centurytx.com/role/DisclosurePropertyAndEquipmentNetDetails", "shortName": "Property and equipment, net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RYx6qGUSOUqsBUIKRvMqYg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "menuCat": "Statements", "order": "5", "role": "http://www.centurytx.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_RYx6qGUSOUqsBUIKRvMqYg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Accrued expenses and other liabilities - Summary of accrued expenses (Details)", "menuCat": "Details", "order": "50", "role": "http://www.centurytx.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesSummaryOfAccruedExpensesDetails", "shortName": "Accrued expenses and other liabilities - Summary of accrued expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Long-term debt (Details)", "menuCat": "Details", "order": "51", "role": "http://www.centurytx.com/role/DisclosureLongTermDebtDetails", "shortName": "Long-term debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40902 - Disclosure - Long-term debt - Term Loan Agreement (Details)", "menuCat": "Details", "order": "52", "role": "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails", "shortName": "Long-term debt - Term Loan Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_9_14_2020_O5H9D1agA0ix2zcuFZhd1A", "decimals": "INF", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_d4paCXEnnkyHaHDwXegojQ", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ipsc:ScheduleOfInterestExpensesOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpenseDebt", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40903 - Disclosure - Long-term debt - Interest Expenses (Details)", "menuCat": "Details", "order": "53", "role": "http://www.centurytx.com/role/DisclosureLongTermDebtInterestExpensesDetails", "shortName": "Long-term debt - Interest Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ipsc:ScheduleOfInterestExpensesOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpenseDebt", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40904 - Disclosure - Long-term debt - Future principal payments due (Details)", "menuCat": "Details", "order": "54", "role": "http://www.centurytx.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDueDetails", "shortName": "Long-term debt - Future principal payments due (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_-w5ZispvCU6gFoXIOKgppw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Bristol-Myers Squibb Collaboration (Details)", "menuCat": "Details", "order": "55", "role": "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationDetails", "shortName": "Bristol-Myers Squibb Collaboration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ipsc:TotalTransactionPriceToIdentifiedPerformanceObligationsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredRevenue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41002 - Disclosure - Bristol-Myers Squibb Collaboration - Total transaction price (Details)", "menuCat": "Details", "order": "56", "role": "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationTotalTransactionPriceDetails", "shortName": "Bristol-Myers Squibb Collaboration - Total transaction price (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ipsc:TotalTransactionPriceToIdentifiedPerformanceObligationsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredRevenue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_6_24_2019_us-gaap_OtherCommitmentsAxis_ipsc_DistributedBioMasterServiceAgreementMember_HulgEjFHu0e8Ax7qIzwOOQ", "decimals": "-3", "first": true, "lang": null, "name": "ipsc:CommitmentMilestonePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Commitments and Contingencies (Details)", "menuCat": "Details", "order": "57", "role": "http://www.centurytx.com/role/DisclosureCommitmentsAndContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_6_24_2019_us-gaap_OtherCommitmentsAxis_ipsc_DistributedBioMasterServiceAgreementMember_HulgEjFHu0e8Ax7qIzwOOQ", "decimals": "-3", "first": true, "lang": null, "name": "ipsc:CommitmentMilestonePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_12_31_2022_JDWKm09os0OxxoeVORlkkQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DepositsAssetsNoncurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - Leases - Components of lease expenses (Details)", "menuCat": "Details", "order": "58", "role": "http://www.centurytx.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails", "shortName": "Leases - Components of lease expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": "-3", "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41202 - Disclosure - Leases - Other information (Details)", "menuCat": "Details", "order": "59", "role": "http://www.centurytx.com/role/DisclosureLeasesOtherInformationDetails", "shortName": "Leases - Other information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "6", "role": "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ipsc:ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41203 - Disclosure - Leases - Operating lease - Other information (Details)", "menuCat": "Details", "order": "60", "role": "http://www.centurytx.com/role/DisclosureLeasesOperatingLeaseOtherInformationDetails", "shortName": "Leases - Operating lease - Other information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ipsc:ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ipsc:ScheduleOfSupplementalCashFlowInformationRelatedToLeases", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromLeasePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41204 - Disclosure - Leases - Supplemental cash flow information (Details)", "menuCat": "Details", "order": "61", "role": "http://www.centurytx.com/role/DisclosureLeasesSupplementalCashFlowInformationDetails", "shortName": "Leases - Supplemental cash flow information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ipsc:ScheduleOfSupplementalCashFlowInformationRelatedToLeases", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromLeasePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41205 - Disclosure - Leases - Future minimum lease payments (Details)", "menuCat": "Details", "order": "62", "role": "http://www.centurytx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails", "shortName": "Leases - Future minimum lease payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_VhM7A0sdN0OesB12iIMiGQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - Income taxes (Details)", "menuCat": "Details", "order": "63", "role": "http://www.centurytx.com/role/DisclosureIncomeTaxesDetails", "shortName": "Income taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_CanadaRevenueAgencyMember_RQ1IJLWgY0mb7oRVrywG6A", "decimals": "-3", "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41401 - Disclosure - Basic and diluted net loss per common share (Details)", "menuCat": "Details", "order": "64", "role": "http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareDetails", "shortName": "Basic and diluted net loss per common share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R65": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_d4paCXEnnkyHaHDwXegojQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41402 - Disclosure - Basic and diluted net loss per common share - Schedule of potential shares of common stock excluded from computation (Details)", "menuCat": "Details", "order": "65", "role": "http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareScheduleOfPotentialSharesOfCommonStockExcludedFromComputationDetails", "shortName": "Basic and diluted net loss per common share - Schedule of potential shares of common stock excluded from computation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_d4paCXEnnkyHaHDwXegojQ", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DefinedContributionPlanTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanCostRecognized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41501 - Disclosure - Defined contribution plan (Details)", "menuCat": "Details", "order": "66", "role": "http://www.centurytx.com/role/DisclosureDefinedContributionPlanDetails", "shortName": "Defined contribution plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DefinedContributionPlanTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanCostRecognized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4tMikzozL0eEjej9TDhq3A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41601 - Disclosure - Stock based compensation (Details)", "menuCat": "Details", "order": "67", "role": "http://www.centurytx.com/role/DisclosureStockBasedCompensationDetails", "shortName": "Stock based compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4tMikzozL0eEjej9TDhq3A", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ipsc:ShareBasedPaymentArrangementSharesReservedForIssuanceTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_us-gaap_PlanNameAxis_ipsc_IncentivePlan2021Member_rpIee-F9GkuBCpL-_VEMrQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_d4paCXEnnkyHaHDwXegojQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41602 - Disclosure - Stock based compensation - Reserved shares of common stock (Details)", "menuCat": "Details", "order": "68", "role": "http://www.centurytx.com/role/DisclosureStockBasedCompensationReservedSharesOfCommonStockDetails", "shortName": "Stock based compensation - Reserved shares of common stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ipsc:ShareBasedPaymentArrangementSharesReservedForIssuanceTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_us-gaap_PlanNameAxis_ipsc_IncentivePlan2021Member_rpIee-F9GkuBCpL-_VEMrQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_d4paCXEnnkyHaHDwXegojQ", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4tMikzozL0eEjej9TDhq3A", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "Unit_Standard_shares_d4paCXEnnkyHaHDwXegojQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41603 - Disclosure - Stock based compensation - Common stock available under 2021 Incentive Plan (Details)", "menuCat": "Details", "order": "69", "role": "http://www.centurytx.com/role/DisclosureStockBasedCompensationCommonStockAvailableUnder2021IncentivePlanDetails", "shortName": "Stock based compensation - Common stock available under 2021 Incentive Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ipsc:ShareBasedPaymentArrangementSharesAvailableForGrantTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_PlanNameAxis_ipsc_IncentivePlan2021Member_SVTuFkGm9EOLR1odzTWI4Q", "decimals": "INF", "lang": null, "name": "ipsc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsForfeituresInPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_d4paCXEnnkyHaHDwXegojQ", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Organization and description of the business", "menuCat": "Notes", "order": "7", "role": "http://www.centurytx.com/role/DisclosureOrganizationAndDescriptionOfBusiness", "shortName": "Organization and description of the business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": "INF", "first": true, "lang": null, "name": "ipsc:StockIssuedDuringPeriodSharesStockOptionsExercisedUnvested", "reportCount": 1, "unitRef": "Unit_Standard_shares_d4paCXEnnkyHaHDwXegojQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41604 - Disclosure - Stock based compensation - Stock option activity (Details)", "menuCat": "Details", "order": "70", "role": "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "shortName": "Stock based compensation - Stock option activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_4tMikzozL0eEjej9TDhq3A", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_d4paCXEnnkyHaHDwXegojQ", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unitRef": "Unit_Standard_pure_D3HhtG4UzEek5XeWdrrLKg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41605 - Disclosure - Stock based compensation - Stock option weighted-average assumptions (Details)", "menuCat": "Details", "order": "71", "role": "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionWeightedAverageAssumptionsDetails", "shortName": "Stock based compensation - Stock option weighted-average assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_S7KIhz0-LU2Np3I1UsjW1Q", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41606 - Disclosure - Stock based compensation - Stock-based compensation expense and by award type (Details)", "menuCat": "Details", "order": "72", "role": "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseAndByAwardTypeDetails", "shortName": "Stock based compensation - Stock-based compensation expense and by award type (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_12_31_2022_JDWKm09os0OxxoeVORlkkQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares_d4paCXEnnkyHaHDwXegojQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41607 - Disclosure - Stock based compensation - Restricted stock (Details)", "menuCat": "Details", "order": "73", "role": "http://www.centurytx.com/role/DisclosureStockBasedCompensationRestrictedStockDetails", "shortName": "Stock based compensation - Restricted stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_12_31_2022_us-gaap_AwardTypeAxis_ipsc_UnvestedRestrictedStockWithTimeBasedVestingMember_Pq4LwkIQgUKZE7MFu0Xg5Q", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_d4paCXEnnkyHaHDwXegojQ", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_12_31_2022_us-gaap_PlanNameAxis_ipsc_EmployeeStockPurchasePlan2021Member_FoSdG6eN6EaPnGsRA4DZJg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_d4paCXEnnkyHaHDwXegojQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41608 - Disclosure - Stock based compensation - Employee Stock Purchase Plan (Details)", "menuCat": "Details", "order": "74", "role": "http://www.centurytx.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails", "shortName": "Stock based compensation - Employee Stock Purchase Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_12_31_2022_us-gaap_PlanNameAxis_ipsc_EmployeeStockPurchasePlan2021Member_FoSdG6eN6EaPnGsRA4DZJg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_d4paCXEnnkyHaHDwXegojQ", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "As_Of_1_7_2022_us-gaap_TypeOfArrangementAxis_ipsc_BristolMyersSquibbCompanyCollaborationAgreementMember_0KNLoduoNEOyru5z-jmQHw", "decimals": "-3", "first": true, "lang": null, "name": "ipsc:CollaborationAgreementUpfrontCashPaymentReceivable", "reportCount": 1, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41701 - Disclosure - Related party transactions (Details)", "menuCat": "Details", "order": "75", "role": "http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails", "shortName": "Related party transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_RelatedPartyTransactionAxis_ipsc_FcdiCollaborationAgreementMember_nwpfnIsNNkK8lEiFIDCMQA", "decimals": "-3", "lang": null, "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_5_1_2023_To_5_1_2023_us-gaap_DebtInstrumentAxis_ipsc_TermLoanAgreementWithHerculesCapitalIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_efpkTvmBoE6BENW5P1DGVA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RepaymentsOfDebt", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41801 - Disclosure - Subsequent Events (Details)", "menuCat": "Details", "order": "76", "role": "http://www.centurytx.com/role/DisclosureSubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_5_1_2023_To_5_1_2023_us-gaap_DebtInstrumentAxis_ipsc_TermLoanAgreementWithHerculesCapitalIncMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_efpkTvmBoE6BENW5P1DGVA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RepaymentsOfDebt", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_mvLIty94CESxhqZd-Bk6YQ", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Summary of significant accounting policies and basis of presentation", "menuCat": "Notes", "order": "8", "role": "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation", "shortName": "Summary of significant accounting policies and basis of presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Reduction in force", "menuCat": "Notes", "order": "9", "role": "http://www.centurytx.com/role/DisclosureReductionInForce", "shortName": "Reduction in force", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ipsc-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_dTCRPGOvPEqIa_devLkH_Q", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 59, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r579" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r581" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r575" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r577" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.centurytx.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "ipsc_AccruedClinicalTrialRelatedCosts": { "auth_ref": [], "calculation": { "http://www.centurytx.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesSummaryOfAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date for A\\accrued clinical trial related costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued clinical trial related costs", "terseLabel": "Accrued clinical trial related costs" } } }, "localname": "AccruedClinicalTrialRelatedCosts", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesSummaryOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ipsc_AccruedCompensationExpenseCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for compensation expense. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Compensation Expense, Current", "terseLabel": "Accrued compensation expense" } } }, "localname": "AccruedCompensationExpenseCurrent", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureAssetPurchaseByCenturyTherapeuticsCanadaUlcDetails" ], "xbrltype": "monetaryItemType" }, "ipsc_AccruedExpensesAndOtherLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)", "label": "Accrued Expenses And Other Liabilities, Current", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "AccruedExpensesAndOtherLiabilitiesCurrent", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ipsc_AccruedExpensesAndOtherLiabilitiesCurrentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing accrued and other liabilities.", "label": "Accrued expenses and other liabilities" } } }, "localname": "AccruedExpensesAndOtherLiabilitiesCurrentMember", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureAssetPurchaseByCenturyTherapeuticsCanadaUlcDetails", "http://www.centurytx.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.centurytx.com/role/DisclosureLongTermDebtInterestExpensesDetails" ], "xbrltype": "domainItemType" }, "ipsc_BristolMyersSquibbCompanyCollaborationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Bristol Myers Squibb Company Collaboration Agreement.", "label": "Collaboration Agreement" } } }, "localname": "BristolMyersSquibbCompanyCollaborationAgreementMember", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationDetails", "http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "ipsc_CashAndCashEquivalentsShortAndLongTermInvestments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents on short and long term investments.", "label": "Cash And Cash Equivalents Short And Long Term Investments", "terseLabel": "Amount of cash and cash equivalents on short and long term investments" } } }, "localname": "CashAndCashEquivalentsShortAndLongTermInvestments", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureOrganizationAndDescriptionOfBusinessGoingConcernAndLiquidityDetails" ], "xbrltype": "monetaryItemType" }, "ipsc_ClassOfWarrantOrRightFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of warrants or rights at the issuance.", "label": "Class of Warrant or Right, Fair Value", "terseLabel": "Fair value of the warrants at issuance" } } }, "localname": "ClassOfWarrantOrRightFairValue", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails" ], "xbrltype": "monetaryItemType" }, "ipsc_CollaborationAgreementAdditionalNumberOfCollaborationPrograms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional collaboration programs under the collaboration agreement.", "label": "Collaboration Agreement, Additional Number of Collaboration Programs", "terseLabel": "Additional number of collaboration programs" } } }, "localname": "CollaborationAgreementAdditionalNumberOfCollaborationPrograms", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationDetails" ], "xbrltype": "integerItemType" }, "ipsc_CollaborationAgreementMilestonePaymentsReceivableUponAchievementOfCertainDevelopmentAndRegulatoryMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of milestone payments receivable upon achievement of certain development and regulatory milestones.", "label": "Collaboration Agreement, Milestone Payments Receivable upon Achievement of Certain Development and Regulatory Milestones", "terseLabel": "Milestone payments receivable upon achievement of certain development and regulatory milestones" } } }, "localname": "CollaborationAgreementMilestonePaymentsReceivableUponAchievementOfCertainDevelopmentAndRegulatoryMilestones", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationDetails" ], "xbrltype": "monetaryItemType" }, "ipsc_CollaborationAgreementNumberOfCollaborationPrograms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of collaboration programs under the collaboration agreement.", "label": "Collaboration Agreement, Number of Collaboration Programs", "terseLabel": "Number of collaboration programs" } } }, "localname": "CollaborationAgreementNumberOfCollaborationPrograms", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationDetails" ], "xbrltype": "integerItemType" }, "ipsc_CollaborationAgreementSalesBasedMilestonePaymentsReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of sales-based milestone payments receivable under the collaboration agreement.", "label": "Collaboration Agreement, Sales Based Milestone Payments Receivable", "terseLabel": "Sales-based milestone payments" } } }, "localname": "CollaborationAgreementSalesBasedMilestonePaymentsReceivable", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationDetails" ], "xbrltype": "monetaryItemType" }, "ipsc_CollaborationAgreementUpfrontCashPaymentReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of upfront cash payment receivable under the collaboration agreement.", "label": "Collaboration Agreement, Upfront Cash Payment, Receivable", "terseLabel": "Upfront cash payment receivable" } } }, "localname": "CollaborationAgreementUpfrontCashPaymentReceivable", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationDetails", "http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "ipsc_CollaborativeArrangementMilestonePaymentsPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of milestone payments due in collaborative arrangement.", "label": "Collaborative Arrangement, Milestone Payments, Payable", "terseLabel": "Milestone payments due" } } }, "localname": "CollaborativeArrangementMilestonePaymentsPayable", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "ipsc_CommitmentMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of milestone payment.", "label": "Commitment, Milestone Payments", "terseLabel": "Milestone payments" } } }, "localname": "CommitmentMilestonePayments", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "ipsc_CommonStockPremiumValuePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Premium value per share of common stock.", "label": "Common Stock, Premium Value Per Share", "terseLabel": "Common stock, premium per share" } } }, "localname": "CommonStockPremiumValuePerShare", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationDetails" ], "xbrltype": "perShareItemType" }, "ipsc_CommonStockSharesIssuedAndOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount of common shares issued and outstanding.", "label": "Common Stock Shares Issued and Outstanding", "terseLabel": "Total shares issued and outstanding" } } }, "localname": "CommonStockSharesIssuedAndOutstanding", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationEarlyExercisedOptionsDetails" ], "xbrltype": "sharesItemType" }, "ipsc_CommonStockSharesLegallyOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount of all shares legally outstanding.", "label": "Common Stock Shares Legally Outstanding", "terseLabel": "Total shares legally outstanding" } } }, "localname": "CommonStockSharesLegallyOutstanding", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationEarlyExercisedOptionsDetails" ], "xbrltype": "sharesItemType" }, "ipsc_CommonStockValuePremium": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of common stock premium.", "label": "Common Stock, Value, Premium", "terseLabel": "Premium amount of common stock" } } }, "localname": "CommonStockValuePremium", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationDetails" ], "xbrltype": "monetaryItemType" }, "ipsc_ConsultingArrangementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to consulting arrangements.", "label": "Consulting Arrangements" } } }, "localname": "ConsultingArrangementsMember", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "ipsc_CumulativeCollaborationRevenueRecognizedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Cumulative collaboration revenue recognized", "label": "Cumulative collaboration revenue recognized" } } }, "localname": "CumulativeCollaborationRevenueRecognizedMember", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationTotalTransactionPriceDetails" ], "xbrltype": "domainItemType" }, "ipsc_DebtInstrumentEndOfTermFee": { "auth_ref": [], "calculation": { "http://www.centurytx.com/role/DisclosureLongTermDebtDetails": { "order": 4.0, "parentTag": "us-gaap_DebtAndCapitalLeaseObligations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of end of term fee of debt.", "label": "Debt Instrument, End of Term Fee", "negatedLabel": "Plus: End of term fee" } } }, "localname": "DebtInstrumentEndOfTermFee", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "ipsc_DebtInstrumentInterestOnlyPaymentPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of interest only payment, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Interest Only Payment Period", "terseLabel": "Interest only payment period" } } }, "localname": "DebtInstrumentInterestOnlyPaymentPeriod", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails" ], "xbrltype": "durationItemType" }, "ipsc_DebtInstrumentPrepaymentChargesPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of prepayment charges under the loan agreement.", "label": "Debt Instrument, Prepayment Charges, Percentage", "terseLabel": "Prepayment charges percentage" } } }, "localname": "DebtInstrumentPrepaymentChargesPercentage", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails" ], "xbrltype": "percentItemType" }, "ipsc_DebtInstrumentTermFeesPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of term fees payable to lender for loan proceeds upon repayment or prepayment of any loans made under the loan agreement.", "label": "Debt Instrument, Term Fees, Percentage", "terseLabel": "Percentage of term fee" } } }, "localname": "DebtInstrumentTermFeesPercentage", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails" ], "xbrltype": "percentItemType" }, "ipsc_DepositLiabilityNoncurrent": { "auth_ref": [], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The non-current portion, due after one year or beyond the normal operating cycle, if longer, of deposits held other than customer deposits.", "label": "Deposit Liability, Noncurrent", "verboseLabel": "Deposit liability, non-current" } } }, "localname": "DepositLiabilityNoncurrent", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ipsc_DevelopmentAndRegulatoryApprovalMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of development and regulatory approval milestone payments.", "label": "Development And Regulatory Approval Milestone Payments", "terseLabel": "Development and regulatory approval milestone payments" } } }, "localname": "DevelopmentAndRegulatoryApprovalMilestonePayments", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "ipsc_DistributedBioMasterServiceAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Distributed bio master agreement.", "label": "Distributed Bio Master Service Agreement" } } }, "localname": "DistributedBioMasterServiceAgreementMember", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "ipsc_EarlyExercisedStockOptionsSubjectToFutureVestingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to early exercised stock options subject to future vesting.", "label": "Early exercised stock options subject to future vesting" } } }, "localname": "EarlyExercisedStockOptionsSubjectToFutureVestingMember", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareScheduleOfPotentialSharesOfCommonStockExcludedFromComputationDetails" ], "xbrltype": "domainItemType" }, "ipsc_EmpiricaAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to agreement entered with Empirica.", "label": "Empirica Agreement" } } }, "localname": "EmpiricaAgreementMember", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureAssetPurchaseByCenturyTherapeuticsCanadaUlcDetails" ], "xbrltype": "domainItemType" }, "ipsc_EmployeeStockOptionsAndRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to employee stock options and restricted stock units.", "label": "Employee Stock Options and Restricted Stock Units [Member]", "terseLabel": "Options and RSUs" } } }, "localname": "EmployeeStockOptionsAndRestrictedStockUnitsMember", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationReservedSharesOfCommonStockDetails" ], "xbrltype": "domainItemType" }, "ipsc_EmployeeStockPurchasePlan2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to the 2021 Employee Stock Purchase Plan", "label": "Employee Stock Purchase Plan 2021" } } }, "localname": "EmployeeStockPurchasePlan2021Member", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails" ], "xbrltype": "domainItemType" }, "ipsc_EscrowDepositsCurrent": { "auth_ref": [], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of escrow deposits that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.", "label": "Escrow Deposits, Current", "terseLabel": "Escrow deposits, current" } } }, "localname": "EscrowDepositsCurrent", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ipsc_FairValueAssetsLevel1ToLevel2TransfersAmountOne": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.", "label": "Fair Value, Assets, Level 1 to Level 2 Transfers, Amount One", "terseLabel": "Transfer of assets from level 1 to level 2" } } }, "localname": "FairValueAssetsLevel1ToLevel2TransfersAmountOne", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTransfersBetweenLevelsDetails" ], "xbrltype": "monetaryItemType" }, "ipsc_FairValueAssetsLevel2ToLevel1TransfersAmountOne": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.", "label": "Fair Value, Assets, Level 2 to Level 1 Transfers, Amount One", "terseLabel": "Transfer of assets from level 2 to level 1" } } }, "localname": "FairValueAssetsLevel2ToLevel1TransfersAmountOne", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTransfersBetweenLevelsDetails" ], "xbrltype": "monetaryItemType" }, "ipsc_FcdiCollaborationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to FCDI Collaboration Agreement.", "label": "FCDI Collaboration Agreement" } } }, "localname": "FcdiCollaborationAgreementMember", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationDetails", "http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "ipsc_First3OfParticipatingEmployeeContributionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to first 3% of participating employee contributions", "label": "First 3% of participating employee contributions" } } }, "localname": "First3OfParticipatingEmployeeContributionsMember", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureDefinedContributionPlanDetails" ], "xbrltype": "domainItemType" }, "ipsc_FixedMaturitySecuritiesPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fixed maturity securities.", "label": "Fixed Maturity Securities Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "FixedMaturitySecuritiesPolicyPolicyTextBlock", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "ipsc_FujifilmCellularDynamicsInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to FUJIFILM Cellular Dynamics, Inc.", "label": "FUJIFILM Cellular Dynamics, Inc." } } }, "localname": "FujifilmCellularDynamicsInc.Member", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "ipsc_IcellInc.SublicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to ICell?Inc. Sublicense Agreement.", "label": "ICell Inc. Sublicense Agreement" } } }, "localname": "IcellInc.SublicenseAgreementMember", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "ipsc_IncentivePlan2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to the 2021 Incentive Plan", "label": "2021 Incentive Plan" } } }, "localname": "IncentivePlan2021Member", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationCommonStockAvailableUnder2021IncentivePlanDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationReservedSharesOfCommonStockDetails" ], "xbrltype": "domainItemType" }, "ipsc_IncreaseDecreaseInEscrowDeposit": { "auth_ref": [], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in escrow deposits.", "label": "Increase (Decrease) in Escrow Deposit", "negatedLabel": "Escrow deposit" } } }, "localname": "IncreaseDecreaseInEscrowDeposit", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ipsc_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase in aggregate number of common shares reserved for issuance.", "label": "Increase in Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Increase in common stock reserved", "verboseLabel": "Shares reserved for issuance" } } }, "localname": "IncreaseInCommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationCommonStockAvailableUnder2021IncentivePlanDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "ipsc_LabEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to lab equipment.", "label": "Lab equipment" } } }, "localname": "LabEquipmentMember", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "ipsc_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://www.centurytx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "ipsc_LesseeTenantIncentiveReceivable": { "auth_ref": [], "calculation": { "http://www.centurytx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailsCalc2": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee tenant incentive receivable.", "label": "Lessee Tenant Incentive Receivable", "negatedLabel": "Less: Tenant incentive receivable" } } }, "localname": "LesseeTenantIncentiveReceivable", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "ipsc_LoanAmountsPrepaidAfterInterestOnlyPeriodMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the scenario for prepayment fees charges, if loan amounts prepaid after the interest-only period.", "label": "Loan amounts prepaid after the interest-only period" } } }, "localname": "LoanAmountsPrepaidAfterInterestOnlyPeriodMember", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails" ], "xbrltype": "domainItemType" }, "ipsc_LoanAmountsPrepaidDuringInterestOnlyPeriodMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the scenario for prepayment fees charges, if loan amounts prepaid during the interest-only period.", "label": "Loan amounts prepaid during the interest-only period" } } }, "localname": "LoanAmountsPrepaidDuringInterestOnlyPeriodMember", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails" ], "xbrltype": "domainItemType" }, "ipsc_MinimumPercentageOfWarrantsAndRightsToBeIssuedOfAggregateAmountFunded": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum percentage of warrants to be issued of the aggregate amount funded.", "label": "Minimum Percentage of Warrants and Rights To Be Issued of Aggregate Amount Funded", "terseLabel": "Warrants to be issued percentage" } } }, "localname": "MinimumPercentageOfWarrantsAndRightsToBeIssuedOfAggregateAmountFunded", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails" ], "xbrltype": "percentItemType" }, "ipsc_Next2OfParticipatingEmployeeContributionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to next 2% of participating employee contributions", "label": "Next 2% of participating employee contributions" } } }, "localname": "Next2OfParticipatingEmployeeContributionsMember", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureDefinedContributionPlanDetails" ], "xbrltype": "domainItemType" }, "ipsc_NonCashOperatingLeaseExpense": { "auth_ref": [], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents amount of non-cash operating lease expense.", "label": "Non Cash Operating Lease Expense", "terseLabel": "Non-cash operating lease expense" } } }, "localname": "NonCashOperatingLeaseExpense", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ipsc_NumberOfCommitments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of commitments represent distinct performance .", "label": "Number of Commitments", "terseLabel": "Number of Commitments" } } }, "localname": "NumberOfCommitments", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationDetails" ], "xbrltype": "integerItemType" }, "ipsc_OptionRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member standards for option rights", "label": "Option rights" } } }, "localname": "OptionRightsMember", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationTotalTransactionPriceDetails" ], "xbrltype": "domainItemType" }, "ipsc_PaymentInAdvanceToRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of payments recorded as prepaid expenses and other current assets.", "label": "Payment In Advance to Related Party", "terseLabel": "Pre payments to related party" } } }, "localname": "PaymentInAdvanceToRelatedParty", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "ipsc_PrepaidAndOtherCurrentAssetsDisclosureTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets classified as other, not separately presented elsewhere in the balance sheet.", "label": "Prepaid and Other Current Assets Disclosure [Table Text Block]", "terseLabel": "Schedule of summary of prepaid expenses and other current assets" } } }, "localname": "PrepaidAndOtherCurrentAssetsDisclosureTableTextBlock", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "ipsc_PrepaidClinicalTrialRelatedCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for clinical trial and related costs that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid clinical trial related costs", "terseLabel": "Prepaid clinical trial related costs" } } }, "localname": "PrepaidClinicalTrialRelatedCosts", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ipsc_PrepaidExpenseAndOtherCurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for prepaid expenses and other current assets.", "label": "Prepaid Expense and Other Current Assets [Text Block]", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherCurrentAssetsTextBlock", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "ipsc_PrepaidMiscellaneousReceivables": { "auth_ref": [], "calculation": { "http://www.centurytx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for miscellaneous receivables that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Miscellaneous Receivables", "terseLabel": "Reimbursement receivable" } } }, "localname": "PrepaidMiscellaneousReceivables", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ipsc_PrepaidResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://www.centurytx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for research and development that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Research and Development", "terseLabel": "Research and development" } } }, "localname": "PrepaidResearchAndDevelopment", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ipsc_PrepaidSoftwareLicensesAndOther": { "auth_ref": [], "calculation": { "http://www.centurytx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for software licenses and other that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Software Licenses and Other", "terseLabel": "Software licenses and other" } } }, "localname": "PrepaidSoftwareLicensesAndOther", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ipsc_PrepaidWarranties": { "auth_ref": [], "calculation": { "http://www.centurytx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for warranties that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Warranties", "terseLabel": "Warranties" } } }, "localname": "PrepaidWarranties", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ipsc_RelatedPartyTransactionNumberOfRelatedParties": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of related parties in the transaction.", "label": "Related Party Transaction, Number of Related Parties", "terseLabel": "Number of related parties" } } }, "localname": "RelatedPartyTransactionNumberOfRelatedParties", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "integerItemType" }, "ipsc_ReleaseOfEscrowDeposit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Release of escrow deposit.", "label": "Release Of Escrow Deposit", "terseLabel": "Release of escrow deposit" } } }, "localname": "ReleaseOfEscrowDeposit", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureAssetPurchaseByCenturyTherapeuticsCanadaUlcDetails", "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ipsc_ResearchAndDevelopmentServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for research and development services", "label": "Research and development services" } } }, "localname": "ResearchAndDevelopmentServicesMember", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationTotalTransactionPriceDetails" ], "xbrltype": "domainItemType" }, "ipsc_ScheduleOfInterestExpensesOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of debt interest expenses.", "label": "Schedule of Interest Expenses Of Debt [Table Text Block]", "terseLabel": "Schedule of interest expense of the Loan Agreement" } } }, "localname": "ScheduleOfInterestExpensesOfDebtTableTextBlock", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "ipsc_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of supplemental balance sheet information related to leases.", "label": "Schedule of Supplemental Balance Sheet Information related to leases" } } }, "localname": "ScheduleOfSupplementalBalanceSheetInformationRelatedToLeases", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "ipsc_ScheduleOfSupplementalCashFlowInformationRelatedToLeases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of supplemental cash flow information related to leases.", "label": "Schedule of Supplemental Cash Flow Information Related to Leases", "terseLabel": "Schedule of supplemental cash flow information related to leases" } } }, "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeases", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "ipsc_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental information related to leases.", "label": "Schedule of Supplemental Information Related to Leases [Table Text Block]", "terseLabel": "Schedule of supplemental lease term and discount rate information related to leases" } } }, "localname": "ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "ipsc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsPercentOfOutstandingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional shares authorized for issuance under share-based payment arrangement as percent of shares outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Additional Shares Authorized as Percent of Outstanding Shares", "terseLabel": "Percentage of common stock outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedAsPercentOfOutstandingShares", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails" ], "xbrltype": "percentItemType" }, "ipsc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsForfeituresInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares under options and equity-based payment instruments other than stock options, that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options and Equity Instruments Other than Options, Forfeitures in Period", "terseLabel": "Options and RSUs forfeited / cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsForfeituresInPeriod", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationCommonStockAvailableUnder2021IncentivePlanDetails" ], "xbrltype": "sharesItemType" }, "ipsc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares under options and equity-based payment instruments other than stock options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options and Equity Instruments Other than Options, Outstanding", "terseLabel": "Options and RSUs issued and outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationReservedSharesOfCommonStockDetails" ], "xbrltype": "sharesItemType" }, "ipsc_ShareBasedPaymentArrangementSharesAvailableForGrantTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of shares available for grant for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Shares Available for Grant [Table Text Block]", "terseLabel": "Schedule of common stock available under 2021 Incentive Plan" } } }, "localname": "ShareBasedPaymentArrangementSharesAvailableForGrantTableTextBlock", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "ipsc_ShareBasedPaymentArrangementSharesReservedForIssuanceTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of shares reserved for issuance under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Shares Reserved for Issuance [Table Text Block]", "terseLabel": "Schedule of reserved shares of common stock" } } }, "localname": "ShareBasedPaymentArrangementSharesReservedForIssuanceTableTextBlock", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "ipsc_ShareholdersOfEquityMethodInvestorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Shareholders of Equity Method Investor.", "label": "Shareholders of Equity Method Investor" } } }, "localname": "ShareholdersOfEquityMethodInvestorMember", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "ipsc_StockIssuedDuringPeriodSharesStockOptionsExercisedUnvested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised unvested during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised, Unvested", "negatedLabel": "Less: unvested early exercised shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercisedUnvested", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationEarlyExercisedOptionsDetails" ], "xbrltype": "sharesItemType" }, "ipsc_StockIssuedDuringPeriodSharesVestingOfEarlyExerciseStockOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of stock issued as a result of the vesting of early exercise of stock options.", "label": "Stock Issued During Period, Shares, Vesting of Early Exercise Stock Options", "terseLabel": "Vesting of early exercise stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesVestingOfEarlyExerciseStockOptions", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "ipsc_StockIssuedDuringPeriodToCollaborationPartner": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued to collaboration partner.", "label": "Stock Issued During Period to Collaboration Partner", "terseLabel": "Issuance of stock to collaboration partner" } } }, "localname": "StockIssuedDuringPeriodToCollaborationPartner", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "ipsc_StockIssuedDuringPeriodToCollaborationPartnerShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued to collaboration partner.", "label": "Stock Issued During Period to Collaboration Partner, Shares", "terseLabel": "Issuance of stock to collaboration partner (in shares)" } } }, "localname": "StockIssuedDuringPeriodToCollaborationPartnerShares", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "ipsc_StockIssuedDuringPeriodValueVestingOfEarlyExerciseStockOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the vesting of early exercise of stock options", "label": "Stock Issued During Period, Value, Vesting of Early Exercise Stock Options", "terseLabel": "Vesting of early exercise stock options" } } }, "localname": "StockIssuedDuringPeriodValueVestingOfEarlyExerciseStockOptions", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "ipsc_TermLoanAgreementWithHerculesCapitalIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Term Loan Agreement with Hercules Capital, Inc.", "label": "Loan Agreement" } } }, "localname": "TermLoanAgreementWithHerculesCapitalIncMember", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails", "http://www.centurytx.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "ipsc_TerminationOfRoyaltyTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination of royalty term from the anniversary of first commercial sale .", "label": "Termination of Royalty Term", "terseLabel": "Termination of Royalty term" } } }, "localname": "TerminationOfRoyaltyTerm", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationDetails" ], "xbrltype": "durationItemType" }, "ipsc_TimeBasedVestingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to time based vesting.", "label": "Time Based Vesting" } } }, "localname": "TimeBasedVestingMember", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "domainItemType" }, "ipsc_TotalTransactionPriceToIdentifiedPerformanceObligationsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Entire disclosure of total transaction price to the identified performance obligations", "label": "Total Transaction Price to The Identified Performance Obligations [Table text block]", "terseLabel": "Schedule of transaction price unsatisfied" } } }, "localname": "TotalTransactionPriceToIdentifiedPerformanceObligationsTableTextBlock", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationTables" ], "xbrltype": "textBlockItemType" }, "ipsc_Tranche1AdvancesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Term Loan Agreement tranche 1", "label": "Tranche 1" } } }, "localname": "Tranche1AdvancesMember", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails" ], "xbrltype": "domainItemType" }, "ipsc_Tranche2AdvancesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Term Loan Agreement tranche 2.", "label": "Tranche 2" } } }, "localname": "Tranche2AdvancesMember", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails" ], "xbrltype": "domainItemType" }, "ipsc_Tranche3AdvancesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Term Loan Agreement tranche 3.", "label": "Tranche 3" } } }, "localname": "Tranche3AdvancesMember", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails" ], "xbrltype": "domainItemType" }, "ipsc_TransactionPriceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for transaction price", "label": "Transaction price" } } }, "localname": "TransactionPriceMember", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationTotalTransactionPriceDetails" ], "xbrltype": "domainItemType" }, "ipsc_UnvestedRestrictedStockWithTimeBasedVestingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to unvested restricted stock with time based vesting.", "label": "Unvested restricted stock with time-based vesting" } } }, "localname": "UnvestedRestrictedStockWithTimeBasedVestingMember", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "ipsc_WarrantsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for warrants.", "label": "Warrants Policy [Policy Text block]", "terseLabel": "Warrants" } } }, "localname": "WarrantsPolicyPolicyTextBlock", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "ipsc_WorkplaceReductionRestructuringPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The rate of restructuring plan resulted in a reduction in the Company's workforce.", "label": "Workplace Reduction Restructuring Percentage", "terseLabel": "Reduction percenatge" } } }, "localname": "WorkplaceReductionRestructuringPercentage", "nsuri": "http://www.centurytx.com/20230331", "presentation": [ "http://www.centurytx.com/role/DisclosureOrganizationAndDescriptionOfBusinessGoingConcernAndLiquidityDetails" ], "xbrltype": "percentItemType" }, "srt_MaximumMember": { "auth_ref": [ "r278", "r279", "r280", "r281", "r351", "r496", "r523", "r536", "r537", "r554", "r565", "r574", "r623", "r668", "r669", "r670", "r671", "r672", "r673" ], "lang": { "en-us": { "role": { "label": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.centurytx.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r278", "r279", "r280", "r281", "r351", "r496", "r523", "r536", "r537", "r554", "r565", "r574", "r623", "r668", "r669", "r670", "r671", "r672", "r673" ], "lang": { "en-us": { "role": { "label": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails", "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r235", "r497", "r555", "r573", "r618", "r619", "r625", "r678" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationTotalTransactionPriceDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r235", "r497", "r555", "r573", "r618", "r619", "r625", "r678" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationTotalTransactionPriceDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r278", "r279", "r280", "r281", "r341", "r351", "r382", "r383", "r384", "r472", "r496", "r523", "r536", "r537", "r554", "r565", "r574", "r613", "r623", "r669", "r670", "r671", "r672", "r673" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.centurytx.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails", "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r278", "r279", "r280", "r281", "r341", "r351", "r382", "r383", "r384", "r472", "r496", "r523", "r536", "r537", "r554", "r565", "r574", "r613", "r623", "r669", "r670", "r671", "r672", "r673" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.centurytx.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails", "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r197", "r352", "r582", "r605" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureDefinedContributionPlanDetails", "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r197", "r352", "r582", "r583", "r605" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureDefinedContributionPlanDetails", "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of significant accounting policies and basis of presentation" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureAccruedExpensesAndOtherLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r11", "r572" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrent": { "auth_ref": [ "r11", "r112", "r113", "r601" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Related Parties, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.centurytx.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesSummaryOfAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued Liabilities and Other Liabilities", "totalLabel": "Total accrued expenses and other liabilities" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesSummaryOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued expenses and other liabilities." } } }, "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccruedLiabilitiesMember": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.", "label": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://www.centurytx.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesSummaryOfAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Professional and legal fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesSummaryOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r64", "r153" ], "calculation": { "http://www.centurytx.com/role/DisclosurePropertyAndEquipmentNetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r21", "r22", "r23", "r156", "r519", "r528", "r529" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r20", "r23", "r97", "r456", "r524", "r525", "r591", "r592", "r593", "r602", "r603", "r604" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r6" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Members' Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r391", "r392", "r393", "r602", "r603", "r604", "r658" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r88", "r89", "r354" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r386" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "verboseLabel": "Total stock-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseAndByAwardTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r28", "r315", "r440", "r597" ], "calculation": { "http://www.centurytx.com/role/DisclosureLongTermDebtInterestExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_InterestExpense", "weight": 1.0 }, "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of deferred financing cost", "terseLabel": "Amortization of debt issuance costs, including end of term fee accretion" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtInterestExpensesDetails", "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Securities excluded from the computation of diluted net loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareScheduleOfPotentialSharesOfCommonStockExcludedFromComputationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareScheduleOfPotentialSharesOfCommonStockExcludedFromComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Basic and diluted net loss per common share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareScheduleOfPotentialSharesOfCommonStockExcludedFromComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareScheduleOfPotentialSharesOfCommonStockExcludedFromComputationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureAssetPurchaseByCenturyTherapeuticsCanadaUlcDetails", "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationDetails", "http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asset purchase by Century Therapeutics Canada ULC" } } }, "localname": "AssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "auth_ref": [ "r568", "r654", "r655", "r656" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.", "label": "Asset Acquisition, Consideration Transferred", "terseLabel": "Total consideration transferred" } } }, "localname": "AssetAcquisitionConsiderationTransferred", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureAssetPurchaseByCenturyTherapeuticsCanadaUlcDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": { "auth_ref": [ "r568", "r654", "r655", "r656" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition.", "label": "Asset Acquisition, Consideration Transferred, Transaction Cost", "verboseLabel": "Buyer transaction expenses" } } }, "localname": "AssetAcquisitionConsiderationTransferredTransactionCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureAssetPurchaseByCenturyTherapeuticsCanadaUlcDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Asset Acquisition [Line Items]" } } }, "localname": "AssetAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureAssetPurchaseByCenturyTherapeuticsCanadaUlcDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionTable": { "auth_ref": [ "r653" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset acquisition.", "label": "Asset Acquisition [Table]" } } }, "localname": "AssetAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureAssetPurchaseByCenturyTherapeuticsCanadaUlcDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionTextBlock": { "auth_ref": [ "r653" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for asset acquisition.", "label": "Asset Acquisition [Text Block]", "terseLabel": "Asset purchase by Century Therapeutics Canada ULC" } } }, "localname": "AssetAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureAssetPurchaseByCenturyTherapeuticsCanadaUlc" ], "xbrltype": "textBlockItemType" }, "us-gaap_Assets": { "auth_ref": [ "r116", "r134", "r154", "r180", "r220", "r229", "r233", "r247", "r282", "r283", "r285", "r286", "r287", "r288", "r289", "r291", "r292", "r416", "r420", "r430", "r572", "r621", "r622", "r666" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r148", "r157", "r180", "r247", "r282", "r283", "r285", "r286", "r287", "r288", "r289", "r291", "r292", "r416", "r420", "r430", "r572", "r621", "r622", "r666" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r101" ], "calculation": { "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAssetsMeasuredAtFairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r57" ], "calculation": { "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsInvestmentsInFixedMaturitySecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsInvestmentsInFixedMaturitySecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r58" ], "calculation": { "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsInvestmentsInFixedMaturitySecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsInvestmentsInFixedMaturitySecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r239", "r254" ], "calculation": { "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsInvestmentsInFixedMaturitySecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsInvestmentsInFixedMaturitySecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r59", "r241", "r517" ], "calculation": { "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsMaturitiesOfFixedMaturityAvailableForSaleSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "terseLabel": "One to five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsMaturitiesOfFixedMaturityAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r59", "r240", "r516" ], "calculation": { "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsMaturitiesOfFixedMaturityAvailableForSaleSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Less than one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsMaturitiesOfFixedMaturityAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r56", "r238", "r254", "r512" ], "calculation": { "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAssetsMeasuredAtFairValueDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsInvestmentsInFixedMaturitySecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 }, "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsMaturitiesOfFixedMaturityAvailableForSaleSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Debt securities", "totalLabel": "Fair Value", "verboseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAssetsMeasuredAtFairValueDetails", "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsInvestmentsInFixedMaturitySecuritiesDetails", "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsMaturitiesOfFixedMaturityAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r357", "r358", "r359", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r381", "r382", "r383", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationCommonStockAvailableUnder2021IncentivePlanDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationReservedSharesOfCommonStockDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationRestrictedStockDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseAndByAwardTypeDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionWeightedAverageAssumptionsDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationTables", "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureAssetPurchaseByCenturyTherapeuticsCanadaUlcDetails", "http://www.centurytx.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.centurytx.com/role/DisclosureLongTermDebtInterestExpensesDetails", "http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r99", "r100" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureAssetPurchaseByCenturyTherapeuticsCanadaUlcDetails", "http://www.centurytx.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.centurytx.com/role/DisclosureLongTermDebtInterestExpensesDetails", "http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Summary of significant accounting policies and basis of presentation" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CanadaRevenueAgencyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of Canada.", "label": "Canada Revenue Agency [Member]", "terseLabel": "Canada Revenue Agency" } } }, "localname": "CanadaRevenueAgencyMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r44", "r45", "r46" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchase of property and equipment, accrued and unpaid" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r42", "r150", "r538" ], "calculation": { "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationRestrictedCashDetails", "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAssetsMeasuredAtFairValueDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r43", "r115" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r37", "r42", "r47" ], "calculation": { "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "totalLabel": "Cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationRestrictedCashDetails", "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r37", "r106" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information" } } }, "localname": "CashFlowOperatingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrants exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrants to purchase units" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r17", "r126", "r139" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 11)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies." } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r67", "r275", "r276", "r531", "r620" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Reserved shares of common stock for issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationReservedSharesOfCommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r602", "r603", "r658" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationDetails", "http://www.centurytx.com/role/StatementConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r5", "r72" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r5", "r572" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Unit, Issuance Value", "terseLabel": "Common stock, $0.0001 par value, 125,236,190 shares authorized; 59,106,784 and 58,473,660 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined contribution plan" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r24", "r162", "r164", "r170", "r513", "r520" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r131", "r213" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of credit risk and other risks and uncertainties" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerBasisOfPricingAxis": { "auth_ref": [ "r558", "r625" ], "lang": { "en-us": { "role": { "documentation": "Information by basis of pricing for contract representing right to consideration in exchange for good or service transferred to customer.", "label": "Contract with Customer, Basis of Pricing [Axis]" } } }, "localname": "ContractWithCustomerBasisOfPricingAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationTotalTransactionPriceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerBasisOfPricingDomain": { "auth_ref": [ "r558", "r625" ], "lang": { "en-us": { "role": { "documentation": "Basis of pricing for contract with customer. Includes, but is not limited to, fixed-price and time-and-materials contracts.", "label": "Contract with Customer, Basis of Pricing [Domain]" } } }, "localname": "ContractWithCustomerBasisOfPricingDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationTotalTransactionPriceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r338" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "negatedLabel": "Cumulative collaboration revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationTotalTransactionPriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateBondSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).", "label": "Corporate bonds" } } }, "localname": "CorporateBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAssetsMeasuredAtFairValueDetails", "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsInvestmentsInFixedMaturitySecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtAndCapitalLeaseObligations": { "auth_ref": [ "r123", "r140" ], "calculation": { "http://www.centurytx.com/role/DisclosureLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term and long-term debt and lease obligation.", "label": "Debt and Lease Obligation", "totalLabel": "Long-term debt, net" } } }, "localname": "DebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term debt" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r71", "r179", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r309", "r316", "r317", "r319" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Long-term debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r1", "r2", "r3", "r117", "r118", "r132", "r183", "r293", "r294", "r295", "r296", "r297", "r299", "r305", "r306", "r307", "r308", "r310", "r311", "r312", "r313", "r314", "r315", "r441", "r549", "r550", "r551", "r552", "r553", "r599" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails", "http://www.centurytx.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r3", "r118", "r132", "r320" ], "calculation": { "http://www.centurytx.com/role/DisclosureLongTermDebtDetails": { "order": 3.0, "parentTag": "us-gaap_DebtAndCapitalLeaseObligations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Principal" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r108", "r111", "r293", "r441", "r550", "r551" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Loan amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet": { "auth_ref": [ "r599" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net increase or decrease in the carrying amount of the debt instrument for the period.", "label": "Debt Instrument, Increase (Decrease), Net", "terseLabel": "Amount of accrued interest receivable on available-for-sale investment debt securities" } } }, "localname": "DebtInstrumentIncreaseDecreaseForPeriodNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsMaturitiesOfFixedMaturityAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r15", "r108", "r312" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt Instrument, Interest Rate During Period", "terseLabel": "Debt interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Long-term debt" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtInterestExpensesDetails", "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r16", "r183", "r293", "r294", "r295", "r296", "r297", "r299", "r305", "r306", "r307", "r308", "r310", "r311", "r312", "r313", "r314", "r315", "r441", "r549", "r550", "r551", "r552", "r553", "r599" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails", "http://www.centurytx.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r16", "r73", "r74", "r75", "r76", "r107", "r108", "r111", "r130", "r183", "r293", "r294", "r295", "r296", "r297", "r299", "r305", "r306", "r307", "r308", "r310", "r311", "r312", "r313", "r314", "r315", "r318", "r441", "r549", "r550", "r551", "r552", "r553", "r599" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtInterestExpensesDetails", "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "auth_ref": [ "r107", "r108", "r109", "r110", "r111", "r624" ], "calculation": { "http://www.centurytx.com/role/DisclosureLongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_DebtAndCapitalLeaseObligations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount (premium).", "label": "Debt Instrument, Unamortized Discount (Premium), Net", "negatedLabel": "Less: Debt discount attributable to warrants, net of accretion" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsInvestmentsInFixedMaturitySecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": { "auth_ref": [ "r244", "r255" ], "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions", "terseLabel": "Number of available-for-sale investment debt securities" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsMaturitiesOfFixedMaturityAvailableForSaleSecuritiesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r109", "r624" ], "calculation": { "http://www.centurytx.com/role/DisclosureLongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_DebtAndCapitalLeaseObligations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedLabel": "Less: Unamortized deferred financing cost, net of accretion", "terseLabel": "Deferred financing costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtDetails", "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r587" ], "calculation": { "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationTotalTransactionPriceDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue", "totalLabel": "Total" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationTotalTransactionPriceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r586" ], "calculation": { "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationTotalTransactionPriceDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredRevenue", "weight": 1.0 }, "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "negatedLabel": "Less current portion of deferred revenue", "terseLabel": "Deferred revenue, current" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationTotalTransactionPriceDetails", "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueNoncurrent": { "auth_ref": [ "r587" ], "calculation": { "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationTotalTransactionPriceDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredRevenue", "weight": 1.0 }, "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred Revenue, Noncurrent", "terseLabel": "Deferred revenue, non-current", "verboseLabel": "Total long-term deferred revenue" } } }, "localname": "DeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationTotalTransactionPriceDetails", "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r349" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Defined contributions" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureDefinedContributionPlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Contribution Plan Disclosure [Line Items]", "terseLabel": "Defined contribution plan" } } }, "localname": "DefinedContributionPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureDefinedContributionPlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "terseLabel": "Employer contribution matching percentage" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureDefinedContributionPlanDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent", "terseLabel": "Employee contribution" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureDefinedContributionPlanDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanTable": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.", "label": "Defined Contribution Plan [Table]" } } }, "localname": "DefinedContributionPlanTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureDefinedContributionPlanDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanTextBlock": { "auth_ref": [ "r349", "r350" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for defined contribution plan.", "label": "Defined Contribution Plan [Text Block]", "terseLabel": "Defined contribution plan" } } }, "localname": "DefinedContributionPlanTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureDefinedContributionPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_DepositLiabilityCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The current portion, due within one year or one operating cycle, if longer, of deposits held other than customer deposits.", "label": "Deposit Liability, Current", "terseLabel": "Deposit liability" } } }, "localname": "DepositLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationRestrictedStockDetails", "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r585" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Deposits Assets, Noncurrent", "terseLabel": "Security deposits", "verboseLabel": "Lease deposit" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails", "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r40", "r62" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Bristol-Myers Squibb Collaboration" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationTotalTransactionPriceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r337", "r555", "r556", "r557", "r558", "r559", "r560", "r561" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationTotalTransactionPriceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r356", "r387", "r388", "r390", "r395", "r566" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock based compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock based compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r11", "r284", "r285", "r286", "r290", "r291", "r292", "r460", "r601" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "verboseLabel": "Accrued expenses" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r124", "r141", "r284", "r285", "r286", "r290", "r291", "r292", "r460", "r601" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to Related Parties", "terseLabel": "Development and regulatory milestone payments" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and diluted net loss per common share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r171", "r189", "r190", "r191", "r192", "r193", "r198", "r200", "r202", "r203", "r204", "r208", "r424", "r425", "r514", "r521", "r544" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per common share Basic (in dollars per share)", "verboseLabel": "Basic net loss per common share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareDetails", "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r171", "r189", "r190", "r191", "r192", "r193", "r200", "r202", "r203", "r204", "r208", "r424", "r425", "r514", "r521", "r544" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per common share Diluted (in dollars per share)", "verboseLabel": "Diluted net loss per common share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareDetails", "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r49", "r50" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Basic and diluted net loss per common shares" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r205", "r206", "r207", "r209" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Basic and diluted net loss per common share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://www.centurytx.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesSummaryOfAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Payroll and bonuses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesSummaryOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Stock based compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseAndByAwardTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r389" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized compensation expense expected to be recognized over a weighted average period", "verboseLabel": "Unrecognized compensation expense expected to be recognized over a weighted average period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationRestrictedStockDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r652" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureReductionInForceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee stock purchase plan", "terseLabel": "Employee stock purchase plan" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationReservedSharesOfCommonStockDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseAndByAwardTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Stock Options", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationCommonStockAvailableUnder2021IncentivePlanDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseAndByAwardTypeDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionWeightedAverageAssumptionsDetails", "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOwnershipPlanESOPFairValueOfSharesSubjectToRepurchaseObligation": { "auth_ref": [ "r90" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of the shares allocated that are subject to a repurchase obligation.", "label": "Employee Stock Ownership Plan (ESOP), Fair Value of Shares Subject to Repurchase Obligation", "terseLabel": "Amount of deposit liability related to shares held by employees and nonemployees that were subject to repurchase" } } }, "localname": "EmployeeStockOwnershipPlanESOPFairValueOfSharesSubjectToRepurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationEarlyExercisedOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r72", "r146", "r166", "r167", "r168", "r184", "r185", "r186", "r188", "r194", "r196", "r210", "r248", "r326", "r391", "r392", "r393", "r406", "r407", "r423", "r431", "r432", "r433", "r434", "r435", "r436", "r456", "r524", "r525", "r526" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EscrowDeposit": { "auth_ref": [ "r122", "r532" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.", "label": "Escrow Deposit", "terseLabel": "Escrow deposit" } } }, "localname": "EscrowDeposit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureAssetPurchaseByCenturyTherapeuticsCanadaUlcDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Financial instruments and fair value measurements" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r426", "r427", "r429" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r101", "r102", "r103", "r104", "r105" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "terseLabel": "Schedule of assets measured at fair value by level within the fair value hierarchy" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r307", "r342", "r343", "r344", "r345", "r346", "r347", "r427", "r469", "r470", "r471", "r550", "r551", "r562", "r563", "r564" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial instruments and fair value measurements" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Financial instruments and fair value measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r307", "r342", "r347", "r427", "r469", "r562", "r563", "r564" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r307", "r342", "r347", "r427", "r470", "r550", "r551", "r562", "r563", "r564" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair value of financial instruments" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r307", "r342", "r343", "r344", "r345", "r346", "r347", "r469", "r470", "r471", "r550", "r551", "r562", "r563", "r564" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAssetsMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r242", "r243", "r249", "r250", "r251", "r252", "r253", "r256", "r257", "r258", "r318", "r324", "r422", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r547", "r608", "r609", "r610", "r679", "r680", "r681", "r682", "r683", "r684", "r685" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAssetsMeasuredAtFairValueDetails", "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsInvestmentsInFixedMaturitySecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r259", "r260", "r261", "r262", "r498", "r499" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureAssetPurchaseByCenturyTherapeuticsCanadaUlcDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r60", "r61" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureAssetPurchaseByCenturyTherapeuticsCanadaUlcDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign Tax Authority" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign currency translation" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r30" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense.", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and administrative expense" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseAndByAwardTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In-process research and development (IPR&D) asset" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureAssetPurchaseByCenturyTherapeuticsCanadaUlcDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r25", "r114", "r127", "r143", "r220", "r228", "r232", "r234", "r515", "r546" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r263", "r267" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseAndByAwardTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseAndByAwardTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income taxes" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r181", "r399", "r401", "r404", "r408", "r410", "r412", "r413", "r414" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Examination [Line Items]", "terseLabel": "Income Tax" } } }, "localname": "IncomeTaxExaminationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExaminationTable": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.", "label": "Income Tax Examination [Table]" } } }, "localname": "IncomeTaxExaminationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r182", "r195", "r196", "r219", "r398", "r409", "r411", "r522" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureIncomeTaxesDetails", "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r165", "r396", "r397", "r401", "r402", "r403", "r405" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r39" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r596" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r540" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Change in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r596", "r661" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liability" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r39" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r109", "r129", "r169", "r218", "r439" ], "calculation": { "http://www.centurytx.com/role/DisclosureLongTermDebtInterestExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense", "totalLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtInterestExpensesDetails", "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r31", "r313", "r322", "r552", "r553" ], "calculation": { "http://www.centurytx.com/role/DisclosureLongTermDebtInterestExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_InterestExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtInterestExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r174", "r177", "r178" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://www.centurytx.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesSummaryOfAccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Accrued interest", "verboseLabel": "Interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesSummaryOfAccruedExpensesDetails", "http://www.centurytx.com/role/DisclosureLongTermDebtInterestExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivable": { "auth_ref": [ "r588" ], "calculation": { "http://www.centurytx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 6.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.", "label": "Interest Receivable", "terseLabel": "Accrued interest receivable" } } }, "localname": "InterestReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "terseLabel": "Schedule of maturities of fixed maturity available-for-sale securities" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r451", "r571" ], "calculation": { "http://www.centurytx.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total operating lease expense" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Operating lease expense:" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r662" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of components of lease expenses" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r29" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "Legal Fees", "terseLabel": "Legal fees" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r663" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Future minimum lease payments of operating leases" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r452" ], "calculation": { "http://www.centurytx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.centurytx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r452" ], "calculation": { "http://www.centurytx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r452" ], "calculation": { "http://www.centurytx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r452" ], "calculation": { "http://www.centurytx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r452" ], "calculation": { "http://www.centurytx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r663" ], "calculation": { "http://www.centurytx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r452" ], "calculation": { "http://www.centurytx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed Interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Leases of Lessee Disclosure [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeaseTermOfContract": { "auth_ref": [ "r664" ], "lang": { "en-us": { "role": { "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessor, Operating Lease, Term of Contract", "terseLabel": "Initial lease terms" } } }, "localname": "LessorOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r12", "r180", "r247", "r282", "r283", "r285", "r286", "r287", "r288", "r289", "r291", "r292", "r417", "r420", "r421", "r430", "r545", "r621", "r666", "r667" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r10", "r119", "r137", "r572", "r600", "r611", "r660" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities, convertible preferred stock, and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r14", "r149", "r180", "r247", "r282", "r283", "r285", "r286", "r287", "r288", "r289", "r291", "r292", "r417", "r420", "r421", "r430", "r572", "r621", "r666", "r667" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r3", "r118", "r135", "r306", "r321", "r550", "r551" ], "calculation": { "http://www.centurytx.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-term Debt.", "totalLabel": "Total future payments" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt and lease obligation, classified as current.", "label": "Long-term Debt and Lease Obligation, Current", "terseLabel": "Long-term debt, current" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtByMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term Debt, Fiscal Year Maturity [Abstract]", "terseLabel": "Future principal payments due" } } }, "localname": "LongTermDebtByMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r70", "r183", "r311" ], "calculation": { "http://www.centurytx.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDueDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtFuturePrincipalPaymentsDueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r155" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt, net" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r151" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-term Investments", "terseLabel": "Long-term investments" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r68", "r69", "r277", "r278", "r279", "r616", "r617" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r176" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r176" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r37", "r38", "r41" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "terseLabel": "Cash used in operations", "totalLabel": "Net cash (used in) provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureOrganizationAndDescriptionOfBusinessGoingConcernAndLiquidityDetails", "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r26", "r41", "r128", "r142", "r147", "r161", "r163", "r168", "r180", "r187", "r189", "r190", "r191", "r192", "r195", "r196", "r201", "r220", "r228", "r232", "r234", "r247", "r282", "r283", "r285", "r286", "r287", "r288", "r289", "r291", "r292", "r425", "r430", "r546", "r621" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareDetails", "http://www.centurytx.com/role/DisclosureOrganizationAndDescriptionOfBusinessGoingConcernAndLiquidityDetails", "http://www.centurytx.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Numerator" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent accounting pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of non-cash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r607" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segment" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses.", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r220", "r228", "r232", "r234", "r546" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r446", "r571" ], "calculation": { "http://www.centurytx.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Fixed lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Operating Leases" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r443" ], "calculation": { "http://www.centurytx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.centurytx.com/role/DisclosureLeasesOtherInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total", "totalLabel": "Total operating lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails", "http://www.centurytx.com/role/DisclosureLeasesOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r443" ], "calculation": { "http://www.centurytx.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesSummaryOfAccruedExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 }, "http://www.centurytx.com/role/DisclosureLeasesOtherInformationDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liability, current", "verboseLabel": "Operating lease liability, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesSummaryOfAccruedExpensesDetails", "http://www.centurytx.com/role/DisclosureLeasesOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesSummaryOfAccruedExpensesDetails", "http://www.centurytx.com/role/DisclosureLeasesOtherInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r443" ], "calculation": { "http://www.centurytx.com/role/DisclosureLeasesOtherInformationDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liability, long term" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesOtherInformationDetails", "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r442" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets", "verboseLabel": "Operating lease right-of-use asset, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesOtherInformationDetails", "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r450", "r571" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesOperatingLeaseOtherInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r449", "r571" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease terms (years) - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesOperatingLeaseOtherInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization and description of the business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r98" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization and description of the business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureOrganizationAndDescriptionOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.", "label": "Other Commitment", "verboseLabel": "Accrued expenses" } } }, "localname": "OtherCommitment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of other commitment.", "label": "Other Commitments [Axis]" } } }, "localname": "OtherCommitmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other future obligation.", "label": "Other Commitments [Domain]" } } }, "localname": "OtherCommitmentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r94", "r95", "r96" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation", "verboseLabel": "Foreign currency translation" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax": { "auth_ref": [ "r158", "r159", "r160" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax", "verboseLabel": "Unrealized gain (loss) on investments" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": { "auth_ref": [ "r158", "r160", "r245" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax", "terseLabel": "Unrealized gain on short-term investments" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilities": { "auth_ref": [ "r125" ], "calculation": { "http://www.centurytx.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesSummaryOfAccruedExpensesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other.", "label": "Other Liabilities", "terseLabel": "Other" } } }, "localname": "OtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesSummaryOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingExpense": { "auth_ref": [ "r32" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to nonoperating activities, classified as other.", "label": "Other Nonoperating Expense", "negatedLabel": "Other expense, net" } } }, "localname": "OtherNonoperatingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncome": { "auth_ref": [ "r172" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income", "terseLabel": "Interest income" } } }, "localname": "OtherNonoperatingIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r32" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r266", "r595" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "terseLabel": "Amount of cash-based expenses" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureReductionInForceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r34", "r55", "r173" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-sale", "negatedLabel": "Acquisition of fixed maturity securities, available for sale" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r35" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Acquisition of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationCommonStockAvailableUnder2021IncentivePlanDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationReservedSharesOfCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationCommonStockAvailableUnder2021IncentivePlanDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationReservedSharesOfCommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r4", "r323" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r4", "r323" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r4", "r572" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $ 0.0001 par value, 10,000,000 shares authorized and 0 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r590" ], "calculation": { "http://www.centurytx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails", "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets." } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r539", "r548", "r612" ], "calculation": { "http://www.centurytx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrimeRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.", "label": "Prime Rate [Member]" } } }, "localname": "PrimeRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits": { "auth_ref": [ "r36" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common limited partners units during the period.", "label": "Proceeds from Issuance of Common Limited Partners Units", "terseLabel": "Proceeds from issuance of shares to collaboration partner" } } }, "localname": "ProceedsFromIssuanceOfCommonLimitedPartnersUnits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r36" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock", "verboseLabel": "Aggregate purchase price" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationDetails", "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLeasePayments": { "auth_ref": [ "r454", "r455" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from lease payment, classified as operating activity.", "label": "Proceeds from Lease Payment, Operating Activity", "negatedLabel": "Operating cash flows from operating leases" } } }, "localname": "ProceedsFromLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r33", "r55", "r173" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale of Debt Securities, Available-for-sale", "terseLabel": "Sale of fixed maturity securities, available for sale" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r147", "r161", "r163", "r175", "r180", "r187", "r195", "r196", "r220", "r228", "r232", "r234", "r247", "r282", "r283", "r285", "r286", "r287", "r288", "r289", "r291", "r292", "r415", "r418", "r419", "r425", "r430", "r515", "r546", "r569", "r570", "r593", "r621" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r66", "r533", "r534", "r535" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosurePropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r63", "r152" ], "calculation": { "http://www.centurytx.com/role/DisclosurePropertyAndEquipmentNetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Gross total" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r65", "r138", "r518", "r572" ], "calculation": { "http://www.centurytx.com/role/DisclosurePropertyAndEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r65", "r533", "r534" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of summary of property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosurePropertyAndEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful lives of the assets" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPropertyAndEquipmentAndStockBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r348", "r459", "r460" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r113", "r459" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction, Amounts of Transaction", "verboseLabel": "Payment to related party" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r145", "r459", "r460", "r665" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationDetails", "http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationDetails", "http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related party transactions" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related party transactions" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r348", "r459", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r665" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r457", "r458", "r460", "r461", "r462" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related party transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r594" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "terseLabel": "Total repayment, principal interest" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r91", "r144", "r674" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r91" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseAndByAwardTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentInProcess": { "auth_ref": [], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.", "label": "Research and Development in Process", "terseLabel": "In-process research and development" } } }, "localname": "ResearchAndDevelopmentInProcess", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r584", "r598", "r675", "r677" ], "calculation": { "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r530", "r585", "r598" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash", "verboseLabel": "Cash on deposit" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationRestrictedCashDetails", "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted stock", "terseLabel": "Restricted stock award subject to future vesting", "verboseLabel": "Restricted stock awards" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareScheduleOfPotentialSharesOfCommonStockExcludedFromComputationDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationRestrictedStockDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseAndByAwardTypeDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted stock units", "terseLabel": "Restricted stock units", "verboseLabel": "Unvested restricted stock units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareScheduleOfPotentialSharesOfCommonStockExcludedFromComputationDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationCommonStockAvailableUnder2021IncentivePlanDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationRestrictedStockDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseAndByAwardTypeDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reduction in force" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r264", "r266", "r269", "r273", "r274" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Reduction in force" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureReductionInForce" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "auth_ref": [ "r265", "r268", "r270", "r272" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.", "label": "Restructuring and Related Cost, Expected Cost", "terseLabel": "Amount of remaining outstanding liabilities related to the reduction" } } }, "localname": "RestructuringAndRelatedCostExpectedCost1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureReductionInForceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [ "r265", "r266", "r270", "r271" ], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureReductionInForceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Reduction in force" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureReductionInForceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserveCurrent": { "auth_ref": [ "r586", "r614", "r615" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.", "label": "Restructuring Reserve, Current", "terseLabel": "Amount of non-cash stock-based compensation charge" } } }, "localname": "RestructuringReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureReductionInForceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r7", "r77", "r136", "r527", "r529", "r572" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r146", "r184", "r185", "r186", "r188", "r194", "r196", "r248", "r391", "r392", "r393", "r406", "r407", "r423", "r524", "r526" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Bristol-Myers Squibb Collaboration" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r216", "r217", "r227", "r230", "r231", "r235", "r236", "r237", "r336", "r337", "r497" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Collaboration revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r327", "r328", "r329", "r330", "r331", "r332", "r334", "r335", "r339", "r340" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Bristol-Myers Squibb Collaboration" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaboration" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r541", "r542" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Collaboration Revenue" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r333" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Total transaction price", "terseLabel": "Total transaction price" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of summary of accrued expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareScheduleOfPotentialSharesOfCommonStockExcludedFromComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of potential shares of common stock excluded" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Financial instruments and fair value measurements" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsInvestmentsInFixedMaturitySecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]", "terseLabel": "Schedule of investments in fixed maturity securities" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of reconciliation of the Company's cash, cash equivalents, and restricted cash" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Summary of the Company's indebtedness" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r606" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of basic and diluted net loss per shares of common stock" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r85", "r87" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseAndByAwardTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of stock-based compensation expense and by award type" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of future principal payments due" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r112", "r113" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r265", "r266", "r267", "r268", "r270", "r271", "r272" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureReductionInForceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r79", "r81", "r82" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Activity [Table Text Block]", "terseLabel": "Reconciliation of shares issued and outstanding" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r353", "r355", "r357", "r358", "r359", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r381", "r382", "r383", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationCommonStockAvailableUnder2021IncentivePlanDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationReservedSharesOfCommonStockDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationRestrictedStockDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionWeightedAverageAssumptionsDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of restricted stock activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r78", "r81", "r82" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of weighted-average assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r221", "r222", "r223", "r224", "r225", "r226", "r236" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r39" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r566" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Stock awards vesting period", "verboseLabel": "Restricted stock vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "negatedLabel": "RSU's granted", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationCommonStockAvailableUnder2021IncentivePlanDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r369", "r370" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "negatedLabel": "Less: unvested restricted stock awards (Note 16)", "periodEndLabel": "Total Unvested", "periodStartLabel": "Total Unvested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationRestrictedStockDetails", "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationEarlyExercisedOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r369", "r370" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Total Unvested", "periodStartLabel": "Total Unvested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "weighted-average assumptions fair value of stock option granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionWeightedAverageAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionWeightedAverageAssumptionsDetails", "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPropertyAndEquipmentAndStockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Stock based compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationCommonStockAvailableUnder2021IncentivePlanDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationReservedSharesOfCommonStockDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationRestrictedStockDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionWeightedAverageAssumptionsDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r567" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Shares authorized for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "verboseLabel": "Shares available for grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationCommonStockAvailableUnder2021IncentivePlanDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted Average Remaining Contractual Term (years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "negatedLabel": "Options granted", "terseLabel": "Granted", "verboseLabel": "Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationCommonStockAvailableUnder2021IncentivePlanDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r361", "r362" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, ending (in shares)", "periodStartLabel": "Outstanding, beginning (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r361", "r362" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, ending", "periodStartLabel": "Outstanding, beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r378" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r377" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "periodEndLabel": "Outstanding, ending", "periodStartLabel": "Outstanding, beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r357", "r358", "r359", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r381", "r382", "r383", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationCommonStockAvailableUnder2021IncentivePlanDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationReservedSharesOfCommonStockDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationRestrictedStockDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseAndByAwardTypeDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionWeightedAverageAssumptionsDetails", "http://www.centurytx.com/role/DisclosureStockBasedCompensationTables", "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "verboseLabel": "Exercised - vested" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r360", "r379", "r380", "r381", "r382", "r385", "r394", "r395" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock based compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "verboseLabel": "Stock reserved for issuance upon the exercise of previously granted stock options" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected option term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionWeightedAverageAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r83" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r120", "r121", "r133", "r589" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r447", "r571" ], "calculation": { "http://www.centurytx.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short term lease expense" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SoftwareDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Internally developed software for sale, licensing or long-term internal use.", "label": "Computer software and equipment" } } }, "localname": "SoftwareDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r19", "r72", "r146", "r166", "r167", "r168", "r184", "r185", "r186", "r188", "r194", "r196", "r210", "r248", "r326", "r391", "r392", "r393", "r406", "r407", "r423", "r431", "r432", "r433", "r434", "r435", "r436", "r456", "r524", "r525", "r526" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Bristol-Myers Squibb Collaboration" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationDetails", "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies", "http://www.centurytx.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r184", "r185", "r186", "r210", "r497" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationDetails", "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies", "http://www.centurytx.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r4", "r5", "r72", "r77" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock upon initial public offering, net of underwriting discounts and commissions and other issuance cost (in shares)", "verboseLabel": "Common stock issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationDetails", "http://www.centurytx.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r72", "r77" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "verboseLabel": "Vesting of restricted stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r4", "r5", "r72", "r77", "r366" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised - vested", "verboseLabel": "Issuance of common stock upon the exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.centurytx.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r4", "r5", "r72", "r77" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "positiveLabel": "Aggregate purchase price excluding premium", "terseLabel": "Issuance of common stock upon initial public offering, net of underwriting discounts and commissions and other issuance cost" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationDetails", "http://www.centurytx.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r4", "r5", "r72", "r77" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Vesting of restricted stock" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r19", "r72", "r77" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock upon the exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Stock options to purchase common stock" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareScheduleOfPotentialSharesOfCommonStockExcludedFromComputationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r5", "r8", "r9", "r54", "r572", "r600", "r611", "r660" ], "calculation": { "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets", "http://www.centurytx.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Members' equity:", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r437", "r464" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r437", "r464" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r437", "r464" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r437", "r464" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r463", "r465" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash and non-cash operating activities:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r242", "r243", "r318", "r324", "r422", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r608", "r609", "r610", "r679", "r680", "r681", "r682", "r683", "r684", "r685" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAssetsMeasuredAtFairValueDetails", "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsInvestmentsInFixedMaturitySecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r657" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureAssetPurchaseByCenturyTherapeuticsCanadaUlcDetails", "http://www.centurytx.com/role/DisclosureBristolMyersSquibbCollaborationDetails", "http://www.centurytx.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [ "r265", "r266", "r270", "r271" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureReductionInForceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r543", "r562", "r564", "r676" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "U.S. Treasury" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsAssetsMeasuredAtFairValueDetails", "http://www.centurytx.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementsInvestmentsInFixedMaturitySecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r400" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Accrued interest or penalties on unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r51", "r52", "r53", "r211", "r212", "r214", "r215" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAndBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r448", "r571" ], "calculation": { "http://www.centurytx.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLeasesComponentsOfLeaseExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareScheduleOfPotentialSharesOfCommonStockExcludedFromComputationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r659" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrants term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureLongTermDebtTermLoanAgreementDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r199", "r204" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average common shares for diluted net loss per share", "verboseLabel": "Weighted average common shares outstanding Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareDetails", "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Denominator" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r198", "r204" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares outstanding Basic (in shares)", "verboseLabel": "Weighted-average common shares for basic net loss per share" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.centurytx.com/role/DisclosureBasicAndDilutedNetLossPerCommonShareDetails", "http://www.centurytx.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28567-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.13,16)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.16)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(e))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "https://asc.fasb.org/topic&trid=2175745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/subtopic&trid=2235116", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123420820&loc=SL77919320-209978", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123420820&loc=SL77919327-209978", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(d)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r575": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r576": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r577": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r578": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r579": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r581": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r66": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r67": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r679": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r681": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r682": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r683": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r684": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r685": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 97 0001558370-23-009262-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-23-009262-xbrl.zip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end